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Abstract 
Ubiquitylation is a post-translational modification of proteins with a broad 
range of downstream effects, ranging from protein turnover to transcriptional 
regulation, membrane trafficking and DNA damage repair. The conjugation of 
ubiquitin to its substrate is a sequential process mediated by three enzymes, 
termed the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating 
enzyme and the E3 ubiquitin ligase. Conversely, the removal of ubiquitin is 
mediated by deubiquitylases (DUBs). My project aims to identify DUBs that 
are involved in the selective removal of mitochondria via autophagy 
(mitophagy), a process that is regulated by a serine/threonine kinase, PINK1, 
and an E3 ligase, Parkin. Loss-of-function mutations in both PINK1 and 
Parkin have been reported to cause autosomal recessive-juvenile 
Parkinsonism (AR-JP), a form of early onset Parkinson’s Disease (PD).  
 
During mitochondrial depolarisation, PINK1 is stabilized at the outer 
mitochondrial membrane (OMM) where it recruits and activates Parkin. 
Subsequently, Parkin ubiquitylates a range of OMM proteins either for their 
proteasomal degradation or for the recruitment of the autophagic machinery. 
I first characterised this process in two different cell lines expressing either 
low endogenous levels of Parkin (SH-SY5Y neuroblastoma cells) or high 
exogenous levels of YFP-Parkin (hTERT-RPE1-YFP-Parkin, retinal pigment 
epithelial cells). I developed two different assays to assess Parkin-mediated 
mitophagy: (1) real time monitoring of YFP-Parkin by live-cell imaging (only in 
hTERT-RPE1-YFP-Parkin cells), and (2) western blot analysis of the 
cleavage, ubiquitylation and loss of proteins during mitophagy (in both 
hTERT-RPE1-YFP-Parkin and SH-SY5Y cells). I used these two assays to 
perform siRNA screens to identify DUBs, for which depletion resulted in 
altered Parkin recruitment and/or ubiquitylation and degradation of Parkin 
 III 
substrates. I identified several DUBs, including USP10, USP30, USP38, 
USP42, USP43, USP49, BAP1, OTUD4 and TRABID, for which siRNA 
depletion resulted in delayed Parkin recruitment to the mitochondria. Further 
characterisation of the effects of USP42 and USP43 siRNA depletions 
suggests that the loss of these DUBs could either desensitize the cells or 
affect the cellular response towards mitochondrial depolarisation. Depletion 
of another DUB, USP31, partially inhibited the later stages of mitophagy, i.e. 
the degradation of mitochondria via the lysosomal pathway.   
 
I discovered by chance that high expression levels of Parkin resulted in a 
small percentage of mitophagic cell death that was dependent on both PINK1 
and Parkin. This cell death was prevented or delayed by inhibiting the 
proteasome. Interestingly, depletion of USP30 exacerbated this mitophagic 
cell death. This effect of USP30 depletion is of particular interest as USP30 is 
the only mitochondria-localised DUB. Further characterisation revealed that 
USP30 opposes TOM20 ubiquitylation and degradation, a previously 
described Parkin substrate. I speculate that USP30 counteracts 
disproportionate Parkin-dependent ubiquitylation and proteasomal 
degradation of outer mitochondrial membrane proteins, and its depletion 
enhances apoptosis by promoting Cytochome-C release from damaged 
mitochondria. Importantly, USP30 depletion also enhances apoptosis 
induced by BH3-mimetics ABT-737 and ABT-263, suggesting a more general 
role for USP30 in determining the threshold for mitochondrial cell death. 
 
As USP30 depletion enhances the degradation of Parkin substrate and 
sensitize cells to apoptosis, this data suggest that USP30 is a potential drug 
target not only in Parkinson’s Disease but also in cancer. 
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Chapter 1: Introduction 
1.1 Intracellular protein degradation 
Nowadays, it is a fundamental understanding in cell biology that proteins are 
selectively targeted for degradation. This process ensures that damaged 
proteins are not only cleared away but also spatially and temporally regulated 
for different cellular functions. However, back-track to the early 20th century 
and intracellular proteins were thought to be long-lived, static constituents of 
the body whereas the fuel for energy was thought to be derived from dietary 
sources. It was not until 1939 that Rudolf Schoenheimer and his colleagues 
challenged this paradigm. With the use of heavy isotope labeling, they 
discovered that rats fed with 15N-labelled tyrosine only excreted 50% of the 
isotopic amino acids in their urine while the remainder was incorporated into 
tissue proteins (Schoenheimer et al. 1939). This provided the first evidence 
that intracellular proteins exist in a dynamic equilibrium of synthesis and 
degradation.  
 
In the mid 1950s, Christian de Duve and his colleagues pioneered the 
technique of differential centrifugation for cell fractionation and 
serendipitously identified a single membrane-bound vesicle that encloses 
acid phosphatase and other hydrolases in rat liver (Duve et al. 1953, De 
Duve and Wattiaux 1966). The term lysosome was chosen to describe these 
relatively fragile vesicles that engulf macromolecules, endocytosed 
membrane proteins, worn-out organelles and certain cytosolic proteins for 
degradation (Pillay et al. 2002). This discovery provided the first insight into 
the cellular proteolytic machinery.   
 
1.2 Discovery of the proteasomal degradation system 
It soon became apparent that lysosomal degradation does not account for all 
protein degradation. Firstly, while the inhibition of the lysosomal hydrolases 
(using weak bases) prevented the degradation of extracellular proteins, the 
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degradation of most intracellular proteins was unaffected (Poole et al. 1977). 
Secondly, it was reported that the degradation of haemoglobin occurs in 
immature rabbit reticulocytes that do not contain lysosomes (Rabinovitz and 
Fisher 1964). Etlinger and Goldberg further demonstrated, using lysates from 
the immature rabbit reticulocytes, that the degradation of abnormal 
haemoglobin is ATP-dependent and occurs at neutral rather than acidic pH, 
strongly indicating the existence of an alternative non-lysosomal degradation 
pathway (Etlinger and Goldberg 1977, Ciechanover 2005).  
 
Around the same time, Ciechanover and Hershko discovered that ATP is 
required for the covalent conjugation of a low molecular weight protein to 
proteins that were subsequently degraded by an unknown ATP-dependent 
proteolytic machinery in reticulocyte lysates (Hershko et al. 1979, 
Ciechanover et al. 2012). This protein was appropriately named ATP-
dependent proteolysis factor 1 (APF-1).  
 
Independent of their discovery, Goldstein and colleagues discovered a small 
molecular weight protein that is universally expressed and highly conserved 
(Schlesinger and Goldstein 1975, Schlesinger et al. 1975, Goldstein et al. 
1975). This protein was named ‘ubiquitin’ owing to its ubiquitous expression 
in cells. Ubiquitin was reported as a DNA-associated protein that was joined 
through its C-terminus to an internal lysine of histone H2A (Goldknopf and 
Busch 1977, Goldknopf et al. 1975, Hunt and Dayhoff 1977). Whilst the 
physiological context of APF-1 and ubiquitin conjugations appeared to be 
different, the strikingly similar fashion in which the two were conjugated to 
target substrates raised the interest of Wilkinson and colleagues, who then 
showed by sequence analysis that the two are indeed the same protein 
(Wilkinson et al. 1980). 
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1.2.1 Discovery of the ubiquitin proteasome system (UPS) 
Based on the work by Tanaka and colleagues in reticulocyte lysates, it was 
known that while the presence of ubiquitin and ATP promoted protein 
degradation, selective removal of ubiquitin by ion exchange chromatography 
from the lysates did not fully prevent ATP-dependent protein degradation 
although it slowed down the process. This indicated that there are two ATP-
requiring steps in ubiquitin-mediated proteolysis (Tanaka et al. 1983). An 
important breakthrough was made when Hough and colleagues purified a 
high-molecular-mass proteolytic complex that degraded ubiquitylated 
lysozyme in an ATP-dependent manner, which they termed the proteasome 
(Hough et al. 1986, Hough and Rechsteiner 1986).  
 
The proteasome is a 2.5MDa multicomponent protease that consists of two 
sub-complexes: the 20S proteolytic core particle (~700kDa) and the 19S 
regulatory particle (~900kDa) (Figure 1.1A) (Groll and Clausen 2003, Pickart 
and Cohen 2004, Goldberg 2012). The core particle consists of 2 copies 
each of 7 different α- and β-subunits (α1-7 and β1-7), which are arranged 
into four seven-membered rings (2 α- and 2 β-rings) with the two α-rings 
sandwiching the two β-rings, forming a barrel-like structure (reviewed in 
(Voges et al. 1999). The two middle β-rings contain three proteolytic subunits 
each (2 copies each of β1, 2 and 5), forming the catalytic chamber where the 
degradation of proteins occurs (Figure 1.1B). The α-rings serve as a narrow 
gate to regulate the translocation of substrates into and out of the 
proteasome. The inner compartment of the 20S core particle is only a few 
nanometers in diameter (Groll et al. 2000, Whitby et al. 2000). Therefore, 
access into the catalytic sites is restricted to unfolded proteins only, 
preventing non-specific degradation of cytosolic proteins (reviewed in (Voges 
et al. 1999). The ability of the proteasome to recognise, unfold and 
translocate targeted proteins into the 20S core particle lies in the 19S 
regulatory particle, which caps either one or both ends of the 20S core 
particle (Peters et al. 1993).  
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The 19S regulatory particle is made up of 19 subunits, including six AAA-
ATPases (ATPases associated with a variety of cellular activities; Rpt1-6) 
and 13 non-ATPase subunits (Rpn1-3, Rpn5-13 and Rpn15). Two of the non-
ATPase subunits, Rpn10 (also known as PSME4/S5A/MCB1) and Rpn13 
(also known as ADRM1) have been shown to bind polyubiquitin chains (van 
Nocker et al. 1996, Husnjak et al. 2008, Sledz et al. 2013b, Sledz et al. 
2013a). In addition, three so-called ‘shuttle’ proteins that are not integral 
subunits of the proteasome, Rad23, Dsk2 and Ddi1 bind and recruit 
polyubiquitylated proteins to the proteasome (Zhang et al. 2009, Elsasser et 
al. 2004, Verma et al. 2004, Finley 2009, Schauber et al. 1998, Chen and 
Madura 2002). Importantly, three deubiquitylating enzymes (DUBs; enzymes 
that cleave ubiquitin either from ubiquitin chains or from target substrates, 
discussed in section 1.4), Rpn11 and Ubp6 (POH1/PSMD14, and USP14, as 
well as a third activity, UCH37/UCHL5 in human) are also associated with the 
proteasome. Rpn11/POH1 is an integral subunit of the regulatory particle and 
removes whole ubiquitin chains at once from substrates prior to their 
degradation (Yao and Cohen 2002). In contrast to Rpn11, Uch37 and 
Ubp6/USP14 bind to the proteasome via Rpn13-Rpn2 and Rpn1, 
respectively, and serve to trim ubiquitin chains, thus rescuing proteins from 
proteasomal degradation (Yao et al. 2006, Hamazaki et al. 2006, Qiu et al. 
2006).  
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Figure 1.1 Simplified cartoon of the cross section of eukaryotic 26S proteasome and 
the mechanism of protein degradation.  
(A) The eukaryotic 26S proteasome consists of a 20S core particle capped by two 
19S regulatory particles. The core particle is further composed of two identical α and 
two identical β rings, each made up of seven distinct subunits. Ubiquitylated proteins 
are recognised by the 19S regulatory particle subunit Rpn10 and Rpn 13 and are 
unfolded by the AAA-ATPase prior to their catalytic degradation by the 20S core 
particle. Several DUBs mediate recycling of ubiquitin from proteasomal substrates 
(described in section 1.4). 
(B) The β-rings consist of seven subunits. β1, β2 and β5 have catalytic activities for 
the proteolytic degradation of polypeptide chains.  
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1.3 Discovery of ubiquitylation as a signal for lysosomal and 
autophagic degradation 
After the discovery of ubiquitin as a tag for selective protein degradation and 
the identification of the proteasome as an executor of proteolysis, the general 
consensus was that non-specific bulk turnover of proteins was mediated by 
the lysosome whereas specific protein turnover was mediated by the 
proteasome. It was nearly a decade after the discovery of the ubiquitin 
proteasome system (UPS) that it became apparent that the regulated 
lysosomal degradation of endocytosed membrane proteins, as well as the 
selective removal of organelles from the cytosol by autophagy also involves 
ubiquitin (Hurley and Stenmark 2011, Korolchuk et al. 2010, Clague and 
Urbé 2010). The ability of one small molecule to dictate the different fate of 
cellular proteins is derived from the ability of ubiquitin to modify its substrate’s 
surface topology via different ubiquitin ‘chains’, which will be further 
discussed in the following section.  
 
1.3.1 Ubiquitin structure 
Ubiquitin is a 76-amino acid protein encoded by four different genes, namely 
UBB, UBC, UBA52 and RB27A. UBB and UBC express tandem repeats of 
three and nine ubiquitin moieties, respectively, whereas the UBA52 and 
RPPS27A genes encode for a single ubiquitin fused to the N-terminus of the 
ribosomal proteins, L40 and S27a, respectively (Wiborg et al. 1985, Baker 
and Board 1991). These pro-ubiquitin molecules are constitutively cleaved to 
generate an intracellular pool of free ubiquitin.  
 
Structurally, ubiquitin consists of four antiparallel β-sheets on one side and 
an α-helix on the other side, forming a barrel-like structure with a flexible C-
terminal tail (Figure 1.2) (Vijay-Kumar et al. 1987). Among the 76 amino 
acids that comprise ubiquitin, there are seven highly conserved lysine (K) 
residues, K6, K11, K27, K29, K33, K48 and K63. All seven lysine residues, 
together with the α-amino group of the N-terminus of ubiquitin, can be 
conjugated via an isopeptide or peptide bond, respectively, to the C-terminal 
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glycine of another ubiquitin molecule, forming 8 different types of ubiquitin 
chains.  
 
 
Figure 1.2 Crystal structure of ubiquitin.  
Ubiquitin is composed of 76 amino acids. It consists of four antiparallel β-sheets on 
one side and a α-helix on the other side, forming a barrel-like structure with a 
flexible C-terminal tail. Ubiquitin has seven lysine residues (orange), which allows 
for additional ubiquitylation (This figure was kindly generated by Igor Barsukov). 
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1.3.2 The ubiquitylation cascade  
Following the discovery of ubiquitin, Hershko, Ciechanover and colleagues 
used immobilized ubiquitin as a ‘covalent’ affinity bait and further identified 
the three key enzymes that act in concert to catalyse ubiquitin conjugation, 
namely the E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating 
enzyme) and E3 (ubiquitin ligase) (Hershko et al. 1983, Ciechanover et al. 
1982).  
 
E1, the ubiquitin-activating enzyme, first binds to ATPMg2+ and ubiquitin to 
catalyse acyl-adenylation of the C-terminal glycine of ubiquitin (Figure 1.3A). 
This allows the formation of a thioester linkage between the E1 and the 
ubiquitin intermediate. Next, the ubiquitin is transferred to the catalytic 
cysteine of an E2 via transthioesterification, forming an E2~Ub intermediate 
(Wenzel et al. 2011b). Finally, an E3 ligase binds to both the E2~Ub thioester 
and the substrate to mediate the transfer of ubiquitin from the catalytic 
cysteine of the E2 to the substrate (Berndsen and Wolberger 2014).  
 
The ubiquitin-modifying components have a hierarchical structure, with only 2 
E1s, 40 E2s and more than 600 E3 ligases (Figure 1.3B) (Li et al. 2008, 
Berndsen and Wolberger 2014, Deshaies and Joazeiro 2009). Different E2 
enzymes have been shown to dictate the length and linkage-type of ubiquitin 
chains. For example, Baboshina and Haas demonstrated that the E2 enzyme 
UBE2S only catalyses the formation of K11-linked ubiquitin chains 
(Baboshina and Haas 1996). Other E2s, such as UBE2G2 and UBC13 have 
been shown to specifically form K48 and K63-linkages (Liu et al. 2014, Lim et 
al. 2013).  
 
On the other hand, the high number of E3 ligases provides specificity 
towards a broad array of substrates. There are three types of E3 ligases, 
namely the HECT, RING and RING-between-RING (RBR) E3 ligases (Figure 
1.3A).  
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Figure 1.3 Mechanism of the ubiquitylation.  
(A) Ubiquitylation is accomplished by the coordinated action of three enzymes, an 
E1 ubiquitin-activating enzyme; an E2 ubiquitin-conjugating enzyme; and an E3 
ubiquitin ligase. The E1 hydrolyses an ATP to activate the C-terminus of ubiquitin by 
adenylation. The adenylated ubiquitin forms a thioester bond with the E1 active-site 
cysteine. Ubiquitin is then transferred to the active-site cysteine of an E2 via 
transthioesterification. The ubiquitin-charged E2 binds to an E3, which transfer the 
ubiquitin to a substrate protein. HECT-type E3 ligases form an intermediate 
ubiquitin-thioester bond via an E3 active-site cysteine prior to the formation of an 
isopeptide bond between the C-terminal of ubiquitin with either the N-terminus of a 
substrate protein or the ɛ-amino group of a lysine residue. RING type E3 ligases 
directly transfer ubiquitin from the E2 to the substrate. The RING-between-RING E3 
ligases contain RING domains but also form an intermediate ubiquitin-thioester 
bond with ubiquitin prior to ubiquitin transfer to the substrate.  
(B) There are only two E1s, and approximately 40 E2s in the human genome. The 
large number of E3s in combination with different E2s provide substrate and linkage 
specificities during ubiquitylation. cascade (Modified from (Winklhofer 2014, Heride 
et al. 2014)).  
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The HECT (homologous to E6AP carboxy terminus) family of E3 ligases 
catalyses ubiquitylation in a two-step reaction. Ubiquitin is first transferred 
from the E2 to a catalytic cysteine in the E3 and then subsequently 
transferred to the substrate. The HECT domain consists of two lobes situated 
at each of the N- and C-terminus. The N-lobe associates with the E2 while 
the C-lobe containing the catalytic cysteine forms a thioester bond with 
ubiquitin (Metzger et al. 2012). Some HECT E3s demonstrate specificity in 
ubiquitin linkage synthesis. KIAA10 preferentially catalyses K29 and K48-
linked chains while E6AP only synthesises K48-linked chains (Mastrandrea 
et al. 1999, You and Pickart 2001). Nedd4 (Neural precursor cell expressed, 
developmentally down-regulated 4) and Itch have both been shown to 
specifically synthesise K63-linked chains, but Itch can also form K29-linked 
chains to target Deltex (DTX) for lysosomal degradation (Kim and Huibregtse 
2009, Maspero et al. 2011, Scialpi et al. 2008, H. T. Kim et al. 2007, 
Chastagner et al. 2006).  
 
In the case of the RING (really interesting new gene) family of E3 ligases, 
these enzymes lack a catalytic cysteine and largely serve as scaffolds to 
recruit the E2 in close proximity to the substrate to facilitate direct transfer of 
ubiquitin. The RING domain, which is a sequence containing conserved Cys 
and His residues (typically Cys3HisCys4) allows binding of two zinc cations, 
forming a cross-brace zinc-finger structure (Freemont et al. 1991). Unlike 
HECT E3s, a RING E3 does not form a thioester intermediate with ubiquitin 
and the ubiquitin-linkage specificity is largely conferred by the interacting E2. 
Therefore, a RING E3 that can bind to different sets of E2s will be able to 
produce several distinct types of ubiquitin chains.  
 
The RING E3s can be further categorized into single unit RING E3s and 
multi-subunit Cullin RING ligases (CRLs) (Li et al. 2008). One of the most 
well-known RING E3s is MDM2. MDM2 ubiquitylates p53, a key protein that 
regulates the cell cycle, cell proliferation, cell invasion, cell survival and 
apoptosis (Kubbutat et al. 1997). Loss of p53 and/or overexpression of 
MDM2 are commonly associated with cancer, including sarcomas, gliomas, 
melanomas and breast cancers. (Landers et al. 1997, Pykett et al. 1997). An 
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example of the multimeric RING E3s are the Cullin-RING ligases (CRLs) of 
which the Skp, Cullin, F-box (SCF) complexes are a subgroup. In the SCF 
complex, the Cullin-RBX1 RING module binds an E2 while Skp1 binds the 
opposite end of the Cullin and recruits the F-box protein that confers 
specificity for substrate recognition (Petroski and Deshaies 2005, Zheng et 
al. 2002). Interestingly, the activation of the E3 activity of CRLs requires the 
conjugation of another ubiquitin-like protein, Nedd8, which alters the 
orientations of the different subunits of the SCF complex, thereby preventing 
the binding of the CRL inhibitor, CAND1 and improving E2 binding (Saha and 
Deshaies 2008, Duda et al. 2008).   
 
The RBR family of E3 ligases has only recently been classified as a 
mechanistically distinct family of E3s that share overlapping features with 
both HECT and RING E3s. RBR E3s have at least two RING domains, 
separated by a conserved sequence known as the in-between-ring (IBR) 
domain (Aguilera et al. 2000). However, unlike the RING E3s, RBR E3s 
contain catalytically active Cys and can mediate ubiquitylation in a HECT-like 
mechanism (Wenzel et al. 2011a). The best-studied RBR E3 ligase is Parkin, 
named after its association with Parkinson’s Disease (Wang et al. 2000). 
Parkin plays a cytoprotective role in the cell via its ability to clear misfolded or 
aggregated proteins such as α-synuclein, Pael-R, and CDCrel-1, all of which 
accumulate in patients with Parkinson’s Disease (Shimura et al. 2001, Imai et 
al. 2001, Zhang et al. 2000). In addition, Parkin also regulates the selective 
removal of mitochondria via autophagy (Jin and Youle 2013). Recently, 
Müller-Rischart and colleagues reported that Parkin also increases the linear 
ubiquitination of NEMO formed by linear ubiquitin chain assembly complex 
(LUBAC), thereby activating the canonical NF-κB pathway (Henn et al. 2007, 
Muller-Rischart et al. 2013).  
1.3.3 Different ubiquitin linkages and their physiological roles 
Ubiquitin conjugation occurs between the lysine residues of a protein and the 
C-terminus of ubiquitin. The conjugation of a single ubiquitin moiety is called 
monoubiquitylation (Figure 1.4A). The conjugation of multiple ubiquitin 
moieties to different lysine residues within the same substrate is referred to 
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as multi-monoubiquitylation. Both monoubiquitylation and multi-
monoubiquitylation have been implicated in the internalization of cell surface 
receptors, including G-protein coupled receptors, epidermal growth factor 
receptors and platelet-derived growth factor receptors (Terrell et al. 1998, 
Haglund et al. 2003, Mosesson et al. 2003). In addition, histones (most 
notably H2A and H2B), are also regulated by monoubiquitylation, extending 
the roles of monoubiquitylation to chromosome condensation and gene 
expression (Goldknopf et al. 1975, Robzyk et al. 2000)(reviewed in (Cao and 
Yan 2012, Fuchs and Oren 2014). Monoubiquitylation of Fanconi anemia 
group D2 protein (FANCD2) and Proliferating cell nuclear antigen (PCNA) 
are implicated in interstrand cross-linking (ICL) DNA repair pathway 
(Smogorzewska et al. 2007, Knipscheer et al. 2009). Monoubiquitylation of 
p53 by MDM2 has been shown to induce nuclear to cytoplasmic export of 
p53 for subsequent polyubiquitylation and degradation (Li et al. 2003). 
 
As mentioned before, there are seven lysine residues in ubiquitin, all of which 
can serve as substrates for the attachment of another ubiquitin, forming 
different ubiquitin chains. This modification is termed polyubiquitylation 
(Figure 1.4B). Chain linkages are homogenous if the same lysine residue is 
modified during elongation and are named according to the lysine residue 
within ubiquitin that is used for chain formation, namely K6, K11, K27, K29, 
K33, K48 and K63 linkages. Conversely, “mixed ubiquitin chain” or 
“heterogenous chain” describes different linkages that are found at 
succeeding positions of the same ubiquitin chain. Alternatively, multiple 
modifications on a single ubiquitin can also take place, forming branched 
ubiquitin chains of unknown function. A linear ubiquitin chain is formed if the 
C-terminal glycine of an ubiquitin is linked with the N-terminal methionine of 
another ubiquitin. These different ubiquitin chains adopt different 
conformations and topologies, allowing for recognition by different ubiquitin-
binding proteins (Ikeda and Dikic 2008, French et al. 2005, Hicke et al. 2005, 
Raasi et al. 2005, Clague et al. 2013). Therefore, different ubiquitin chains 
can influence the downstream effect of the ubiquitylated protein and 
constitute another layer of control in the regulation of cellular function (Wong 
and Cuervo 2010, Komander and Rape 2012, Komander 2009).  
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Figure 1.4 The different topologies of ubiquitylation. 
(A) Conjugation of a single ubiquitin onto a substrate is called monoubiquitylation. 
Multiple conjugation of individual ubiquitylation onto different lysine residues of the 
same substrate is termed multi-monoubiquitylation.  
(B) The internal lysine residues of ubiquitin allow the formation of polyubiquitin 
chains. The different types of ubiquitin chains are described in the figure. 
 
All linkages have been detected in yeast, with K48 and K11-linked chains 
being the most abundant forms, followed by K63, K6, K27, K29 and K33-
linked chains (Xu et al. 2009, Peng et al. 2003). In HEK293 cells, Kaiser and 
colleagues reported that the majority of the total ubiquitin pool are 
monoubiquitylated-conjugates (~63%), whereas free ubiquitin and 
polyubiquitin chains constitute approximately 26% and 11% of the total 
ubiquitin pool, respectively (Kaiser et al. 2011). Dammmer et al. further 
demonstrated in the same cell line that Lys48 (52%) and Lys-63 (38%)-linked 
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chains made up the majority of the polyubiquitin chains, followed by K29-
linked chains (8%) (Dammer et al. 2011). 
 
The best-characterised forms of ubiquitylation are K48 and K63 linkages and 
K48-linked chains are referred to as the ‘canonical’ ubiquitin chains. A chain 
of four or more ubiquitin moieties extended through K48 can target proteins 
for proteasomal degradation (Chau et al. 1989). On the other hand, K63-
linked ubiquitin chains are implicated in various cellular processes, for 
example, in the internalization and degradation of cell surface receptors via 
endocytosis and lysosomal degradation (Conze et al. 2008, Galan and 
Haguenauer-Tsapis 1997, Geetha and Wooten 2008). Other roles of K63 
ubiquitylation include DNA repair, autophagy, NF-κB and Wnt signaling 
pathway (Tauriello et al. 2010, Tran et al. 2008, Conze et al. 2008, Lim et al. 
2013, B. Wang et al. 2007, Sobhian et al. 2007, H. Kim et al. 2007).  
 
The remaining ubiquitin linkages are relatively less well characterised 
compared to K48 and K63-linked chains and are often referred to as the 
‘atypical’ ubiquitin linkages. It is worth noting that all linkages, with the 
exception of K63-linked chain, may be able to target substrates for 
proteasomal degradation. Indeed, quantitative mass spectrometry analysis of 
unique signature peptides of each ubiquitin linkage revealed that all linkages, 
apart from K63-linked chain, accumulated both in yeast and in mouse 
neurons upon the inhibition of the 26S proteasome (Bedford et al. 2011, Xu 
et al. 2009). The reported cellular functions of the different ubiquitin 
modifications are summarised in Table 1.1.   
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Type Cellular function Reference 
Single 
ubiquitin 
modification 
Mono Histone regulation (Robzyk et al. 2000) 
Nuclear-cytoplasmic 
shuttling of p53 
(Li et al. 2003) 
Endocytosis (Terrell et al. 1998) 
DNA repair (Huang and D'Andrea 
2010) 
Multi Endocytosis (Mosesson et al. 2003, 
Haglund et al. 2003) 
Polyubiquitin 
modification 
Linear NF-κB signaling (Tokunaga and Iwai 2009, 
Tokunaga et al. 2009) 
K6 Parkin-mediated 
mitophagy 
(Durcan et al. 2014) 
α-tubulin polymerization 
during embryogenesis 
(Srivastava and 
Chakrabarti 2014) 
DNA repair (Morris and Solomon 
2004) 
Ascorbic acid 
conversion 
(L. Wang et al. 2009) 
K11 Proteasomal 
degradation for cell 
cycle regulation  
(Matsumoto et al. 2010, 
Budhavarapu et al. 2012, 
Jin et al. 2008) 
K27 Proteasomal 
degradation during 
Parkin-mediated 
mitophagy  
(Geisler et al. 2010) 
K29 Proteasomal targeting (Johnson et al. 1995) 
Lysosomal targeting (Chastagner et al. 2006) 
K33 Negative regulation of 
T-cell Receptor 
signaling 
(Huang et al. 2010) 
K29/K33 AMP-kinase inhibition (Al-Hakim et al. 2008) 
K48 Proteasomal targeting (Chau et al. 1989) 
K63 Lysosomal targeting (Geetha and Wooten 
2008) 
Autophagy (Chin et al. 2010, Paul and 
Kumar 2011) 
Endocytosis (Galan and Haguenauer-
Tsapis 1997, Duncan et 
al. 2006) 
DNA Damage (Bailly et al. 1997) 
NF-κB signaling (Conze et al. 2008) 
Wnt signaling (Tauriello et al. 2010) 
Heterologous 
linkage 
E3 ligase activation 
(mixed K6, K27 and 
K48) 
(Ben-Saadon et al. 2006, 
Tran et al. 2008) 
 Internalisation of MHC1 
(K63 and K11) 
(Boname et al. 2010) 
Table 1.1 Types of ubiquitin modification and and proposed cellular functions.  
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1.3.4 Linkage specific effects and recognition by ubiquitin binding 
domains  
Some proteins have evolved to encode different ubiquitin-binding domains 
(UBDs) that recognise ubiquitin-conjugated substrates, in a manner similar to 
SH2 domain that allow for the recognition of phosphorylated proteins. In 
addition, the different polyubiquitin linkages provide diversity to substrate 
recognition and interaction with downstream ubiquitin-binding proteins or 
ubiquitin receptors with different UBDs (Hicke et al. 2005).  
 
The first ubiquitin-binding protein identified was a proteasome subunit 
S5A/Rpn10, which contains a ubiquitin interacting motif (UIM) (Young et al. 
1998, Hofmann and Falquet 2001). This discovery offers an explanation for 
the ability of the 26S proteasome to recognise and interact with ubiquitylated 
substrates. Since then, more than 20 UBD families have been reported and 
they all differ in terms of structure and binding modes (Kirkin and Dikic 2007). 
The α-helices (e.g. UIM and ubiquitin-associated domain,UBA) and zinc-
finger (e.g. Nuclear pore localization 4 zinc finger, NZF and ubiquitin-binding 
zinc finger, UBZ) UBDs comprise the largest class of UBDs. The α-helices 
interact with the hydrophobic patch (Ile44) on ubiquitin whereas the zinc-
finger domain offers more diversity than the α-helices and can recognise 
three different regions (Ile44, Asp58 and Gly76) on the surface of ubiquitin 
(Kirkin and Dikic 2007, Hurley et al. 2006). It is worth noting that UBDs have 
a low affinity for free ubiquitin to prevent the high levels of free ubiquitin 
(estimated at 10µM) in the cell from constitutively occupying the UBDs, which 
would render these unavailable for dynamic binding to ubiquitylated proteins 
(Hicke et al. 2005). Instead, multiple UBDs are often found in a ubiquitin-
binding protein, which work cooperatively to bind to two or more ubiquitin 
moieties with high avidity. For example, the tandem UIM peptides on Rap80 
demonstrate preference for K63 over K48 and monoubiquitin conjugation 
(Sims and Cohen 2009). Structural analysis of Rap80 revealed that the α-
helices of two tandem UIMs and the weakly α-helical linker region between 
the two allow for the formation of one continuous α-helical structure that 
binds the two K63-linked ubiquitins simultaneously (Sims and Cohen 2009). 
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1.4 The deubiquitylases 
Similar to most post-translational modification, the conjugation of ubiquitin to 
its substrate is reversible and the deconjugation of ubiquitin is mediated by 
the deubiquitylating enzymes (DUBs, also referred to as deubiquitylases). 
There are more than 90 DUBs that have so far been identified in the human 
genome. These DUBs can be categorized into five distinct families: ubiquitin-
specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian 
tumour proteases (OTUs), Josephins or Machado-Joseph Disease proteins 
(MJDs), Jab1/MPN/MOV34 metalloproteases (JAMM/MPN+s) (Komander et 
al. 2009a, D. Komander 2010, Clague et al. 2013). The number of enzymes 
identified in each family is summarized in Figure 1.5.   
 
Figure 1.5 The different families of DUBs and the number of DUBs in each family. 
 
The general roles of DUBs can be categorised into three functional groups. 
Firstly, ubiquitin can be transcribed from several genes, either as a linear 
fusion of ubiquitin molecules with each other or with ribosomal proteins, 
which need to be cleaved to generate a cellular pool of free ubiquitin (Figure 
1.6A). Secondly, DUBs can remove conjugated ubiquitin chains from 
proteins, thereby reversing proteasomal or lysosomal degradation or other 
downstream signalling activities (Figure 1.6B and C). By removing ubiquitin 
from substrates that are committed to degradation, some DUBs can recycle 
ubiquitin to maintain cellular ubiquitin homeostasis. Specifically, three DUBs, 
USP14, UCHL5 and POH1 are found to associate with the human 26S 
proteasome and their proteolytic activities are required to hydrolyze ubiquitin 
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chains prior to substrate degradation (Figure 1.6D) (Finley 2009). DUBs can 
also be used to edit ubiquitin linkages, thereby leading to alterations in the 
ubiquitin signal and its downstream effects (Figure 1.6E) (Komander et al. 
2009a, Clague et al. 2012). In addition, cytosolic ubiquitin chains generated 
from en bloc cleavage of ubiquitin chains from proteins (i.e. directly between 
the substrate and the proximal ubiquitin) need to be disassembled by DUBs 
to regenerate the pool of free ubiquitin in the cell (Figure 1.6F). An example 
of a DUB, which could act in this fashion is Ubp14 (the yeast homolog of 
USP5/IsoT), which has been shown to bind via its UBD to the free C-
terminus of unconjugated ubiquitin to process cytosolic, unanchored ubiquitin 
chains into single ubiquitin molecules (Amerik et al. 1997, D. Komander 
2010). 
ubiquitinsubstrate DUB
A. Precursor
processing 
UBC
UBB
UBA52
UBA80
B. Rescue from
degradation
D. Recycling of
ubiquitin
E. Editing
F.
Disassembly
C. reversal of
non-degradative
ubiquitin signal
Degradation
Free ubiquitin pool 
Degradative
signal
Non-degradative
signal
Figure 1.6 General functions of deubiquitylases. 
The large number of DUBs in the human genome serves different functions: (A) 
processing of newly translated tandem ubiquitin repeats or ubiquitin fused to riboso-
mal proteins; (B) rescuing proteins targeted for proteasomal or lysosomal degrada-
tion; (C) reversal of non-degradative signals; (D) recycling of ubiquitin prior to 
substrate degradation to maintain ubiquitin homeostasis; (E) editing ubiquitin chains 
and altering ubiquitin signal; (F) disassembling ubiquitin chains generated by en bloc 
removal from substrates to form individual ubiquitin molecules. (Adapted from 
Komander et al. 2009).
19
 20 
1.4.1 Structure and catalytic activity of the cysteine-dependent DUBs 
The USPs, OTUs, UCHs and Josephins are all cysteine proteases that 
catalyse the proteolytic reaction between a Lys ε-amino group and a carboxyl 
group that corresponds to the C-terminus of ubiquitin. Current understanding 
of the mechanism of cysteine proteases comes from studies of the plant 
protease, papain (Storer and Menard 1994). Cysteine proteases usually rely 
on a catalytic triad or diad for their functions. The two crucial amino acid 
residues for the proteolytic action are a histidine (His) and cysteine (Cys). 
The side chain of the His residue lowers the pKa of the Cys residue, enabling 
its nucleophilic attack on the isopeptide bond between the C-terminal of 
ubiquitin with the lysine residue of the conjugated substrate. Usually, a third 
residue of either asparagine or aspartic acid aligns and polarizes the catalytic 
His.  However, this is not always essential as some enzymes (e.g. A20) lack 
the third residue and can still polarize the His by other means. The 
nucleophilic attack forms a catalytic acyl intermediate between the C-
terminus of ubiquitin and the thiol group of the catalytic Cys. Next, a water 
molecule hydrolyses the acyl-Cys intermediate, thereby releasing the 
ubiquitin and completing the catalytic cycle (reviewed in (Clague et al. 
2013)). 
1.4.2 Structure and catalytic activity of the Zinc-metalloprotease DUBs 
The JAMM family of DUBs are zinc-dependent metalloproteases. They 
contain highly conserved His, Asp and Ser residues that coordinate the 
catalytic zinc (Maytal-Kivity et al. 2002). During catalysis, the zinc ion is 
coordinated by two His residues, an Asp residue and water molecule. A 
nearby invariant Glu residue accepts a proton from the water molecule, 
leaving a hydroxyl ion, which then attacks the carboxyl carbon of the 
isopeptide bond. The ε-amino group from the proximal ubiquitin that is linked 
to the carboxyl carbon of the distal ubiquitin is then replaced with the 
hydroxyl group from the activated water molecule (Komander et al. 2009a, D. 
Komander 2010, Clague et al. 2013). 
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1.4.3 Substrate specificity of DUBs 
The 98 human DUBs exhibit specificity for their substrates at multiple levels, 
including the ability to distinguish between ubiquitin and ubiquitin-like 
modifiers, different ubiquitin linkages and substrates at different subcellular 
localisations. 
 
Ubiquitin belongs to one of the 17 small ubiquitin-like modifiers (UBLs) 
encoded by the human genome. While the sequence of the UBLs varies, 
they all take on a characteristic ubiquitin fold. In addition, several UBLs, 
including small ubiquitin-like modifier (SUMO), neural precursor cell 
expressed, developmentally down-regulated 8 (Nedd8), Interferon-stimulated 
gene 15 (ISG15), ubiquitin D (FAT10) and autophagy related protein 12 
(ATG12) use a similar conjugation mechanism to ubiquitin for protein 
modification, resulting in a similar topological change in the targeted 
substrate (Hochstrasser 2009). However, DUBs are able to distinguish 
between ubiquitin and some of these UBLs, partly due to the fact that the C-
terminal four residues of ubiquitin preceding the Gly-Gly-motif of are 
dissimilar to those of SUMO, Atg12 and FAT10. Even though Nedd8 has a 
similar sequence to Ubiquitin, the fact that arginine at position 72 is replaced 
by alanine means that this UBL cannot be processed by USPs (Ye et al. 
2011). The identical sequence of ISG15 at the four residues with ubiquitin, 
allows some DUBs, including USP2, USP5, USP13, USP14, USP18 and 
USP21 to recognise and hydrolyse ISG15 (Gong et al. 2000, Catic et al. 
2007, Ye et al. 2011, Clague et al. 2013).  
 
The specificity of DUBs also extends to their ability to recognise different 
ubiquitin linkages and also different positions within the ubiquitin chain. For 
example, the JAMM/MPN+ family of DUBs including AMSH, AMSH-LP and 
BRCC36 display intrinsic specificity for Lys63-linked chains only (Cooper et 
al. 2009, McCullough et al. 2004, Sato et al. 2008, Komander et al. 2009b). 
Other examples of DUBs that demonstrates linkage specificity include CYLD 
(K63-linked) and Cezanne (K11-linked) (Komander et al. 2008, Bremm et al. 
2010). Recently, a newly identified DUB, OTULIN that is involved in NF-κB 
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signaling has been shown to specifically recognise linear ubiquitin chains and 
several other enzymes of the OTU-family have also been shown to exhibit 
ubiquitin chain specificity (Keusekotten et al. 2013, Mevissen et al. 2013).  
 
The subcellular localisation of DUBs also provides another level of regulation 
towards their substrate specificity. For example, USP19 and USP30 both 
have a transmembrane domain that localises these DUBs to the endoplasmic 
reticulum and mitochondria, respectively (Hassink et al. 2009, Nakamura and 
Hirose 2008). USP19 is involved in the ER-associated degradation (ERAD) 
pathway during unfolded protein response and has been shown to rescue 
cystic fibrosis transmembrane conductance regulator (CFTR) from 
proteasomal degradation (Hassink et al. 2009). USP30 has been implicated 
in the regulation of mitochondrial morphology (Nakamura and Hirose 2008).   
 
1.4.4 USP domain DUBs 
The USPs are the largest and most diverse family of DUBs, consisting of 67 
distinct members (Clague et al. 2013, David Komander 2010). The USP 
domain comprises three sub-domains resembling the Palm, Thumb and 
Fingers of a right hand (Hu et al. 2002). The Fingers bind to a distal ubiquitin, 
bringing it in close proximity to the catalytic site located at the interface 
between the Palm and the Thumb. 
 
 Most of the USP family enzymes also contain different accessory domains 
that provide substrate specificity and localization. As mentioned before, 
USP19 and USP30 both contain transmembrane domains that localize these 
DUBs to the ER and mitochondria respectively (Lee et al. 2014, Nakamura 
and Hirose 2008, Hassink et al. 2009). In addition, most DUBs contain one or 
more UBDs. The most common UBD found in the USPs is the Zinc-finger 
domain (ZnF-UBP), which has been demonstrated or predicted in at least a 
subset of USPs (USP3, USP5, USP14, USP16, USP44, USP45 and USP49) 
to specifically bind to the free C-terminus Gly-Gly motif of ubiquitin (Bonnet et 
al. 2008, Nicassio et al. 2007, Pai et al. 2007, Reyes-Turcu et al. 2006). The 
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other UBDs, UBA and UIM are also observed not only in USPs but also in 
other DUB families (reviewed in (Clague et al. 2013)).  
 
Another domain that is commonly observed in ubiquitin-interacting/modifying 
proteins, the UBL is also observed in many USPs (Faesen et al. 2012, Xiao 
Zhu et al. 2007). UBL domains serve variable functions in different proteins. 
In the context of USP14, the UBL domain is required for its recruitment to the 
proteasome. The binding of USP14 with the proteasome promotes the 
catalytic activity of USP14, presumably via conformational change that 
unblocks the catalytic site (Hu et al. 2005). The five C-terminal UBL domains 
of USP7 function to promote the catalytic activity of USP7 (Faesen et al. 
2011a). In addition USP15 contains a DUSP-UBL double domain, which 
serves as a binding module for the E3 ligase BRAP, further demonstrating 
the functional diversity of UBL domains in the USPs (Hayes et al. 2012, 
Elliott et al. 2011).  
 
Generally, USPs are less selective between polyubiquitin chains. Faesen 
and colleagues demonstrated that USP1, USP4, USP7, USP8, USP11, 
USP15 USP21 and USP25 hydrolyse all forms of di-ubiquitin linkages at 
similar rates, with the exception of linear di-ubiquitin chains, which were only 
cleaved by in USP4, USP16 and USP21 (Faesen et al. 2011b).  
 
1.4.5 Ubiquitin C-terminus Hydrolases (UCHs) 
The UCH family of DUBs consists of only 4 members, namely UCHL1, 
UCHL3, UCHL5 and BAP1. The UCH domain consists of approximately 210 
a.a., which either span the entire protein (UCHL1 and UCHL3) or the N-
terminus (UCHL5 and BAP1) (Clague et al. 2013, Komander et al. 2009a). 
The two smaller UCHs, UCHL1 and UCHL3 demonstrate negligible in vitro 
activity towards K48, K63 and linear ubiquitin chains (Komander et al. 
2009b).  
 
One feature that is unique to the UCH family is a large surface loop that 
forms right over the active site upon ubiquitin binding and ubiquitin needs to 
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pass through this loop to reach the active site. This restricts the size of 
ubiquitylated substrates that are allowed assess to the catalytic site and only 
ubiquitin conjugated to small peptides or molecules is allowed to access the 
catalytic site. This also explains the inability of UCHL1 and UCHL3 to 
deubiquitylate ubiquitin chains (Das et al. 2006, Johnston et al. 1997, 
Johnston et al. 1999, Misaghi et al. 2005). As mentioned before, ubiquitin is 
synthesised as pro-ubiquitin chains consisting of head-to-tail ubiquitin 
repeats capped with a short peptide at the C-terminus. UCHL1 and UCHL3 
might be involved in the processing of pro-ubiquitin chains to generate free 
ubiquitin by removing these short peptides. An alternative hypothesis 
suggests that the unstable ubiquitin thioester intermediates generated during 
ubiquitin activation may escape the ubiquitylation cascade and undergo thiol 
or amine modification in the cytosol. UCHL1 and UCHL3 may serve to 
reverse this process and restore the free ubiquitin levels in the cell. Indeed, 
the high copy numbers of these DUBs as observed from proteomic studies 
and the lack of other domains for protein-protein interaction support this 
hypothesis (Geiger et al. 2012, Schwanhausser et al. 2011). However, a 
recent paper reported that UCHL1 deubuiquitylates and rescues NOXA (a 
BH3-only protein that promotes apoptosis), from proteasomal degradation in 
both human cells and Caenorhabditis elegans (Brinkmann et al. 2013). It is 
also worth mentioning that a point mutation (I93M) in UCHL1 has been 
associated with Parkinson’s Disease, causing a partial decrease in its 
catalytic activity (Leroy et al. 1998) 
 
The other two larger UCH enzymes, UCHL5 and BAP1, have a more 
extended crossover loop, which provides more flexibility for larger ubiquitin 
conjugates (Zhou et al. 2012). Intriguingly, the catalytic activity of both 
UCHL5 and BAP1 is only activated upon binding to their appropriate 
physiological partners (Zhou et al. 2012). In the case of UCHL5, the C-
terminal extension after the UCH domain is required for its association with 
the proteaosome subunit Rpn13 (Hamazaki et al. 2006, Qiu et al. 2006, Yao 
et al. 2006). In Drosophila, dBAP1 (Calypso) forms a complex with the 
Polycomb group (PcG) protein ASX to oppose the monoubiquitylation of H2A 
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by the E3 ligase complex, PRC1-dRAF (Polycomb repressive complex I – 
dRing-associated factor) (Scheuermann et al. 2010). 
 
1.4.6 Ovarian tumour proteases (OTUs) 
The OTU domain structure does not resemble that of the USP domain. 
However, the catalytic residues superimpose well with those of the USP and 
UCH domains (Komander and Barford 2008). Members of the OTU family 
display variable specificity towards different linkages (Mevissen et al. 2013). 
OTUD1 and OTUB5/DUBA preferentially act on K63-linked chains whereas 
OTUB1 are reported to be K48 specific (Kayagaki et al. 2007, Edelmann et 
al. 2009, T. Wang et al. 2009, Virdee et al. 2010). TRABID was first identified 
to be a K63-specific DUB, but was later shown to display greater preference 
for K29 and to a lesser extend K33 and K63-linked chains (Virdee et al. 
2010, Tran et al. 2008). OTULIN, a recently discovered OTU family member, 
has been reported to hydrolyse linear ubiquitin chains only (Keusekotten et 
al. 2013, Mevissen et al. 2013).  
 
Several OTU enzymes have been implicated in different signaling processes. 
For example, A20, OTULIN and Cezanne (together with CYLD from the USP 
family) are involved in NF-κB signaling, TRABID regulates WNT signaling, 
and OTUD5 modulates IRF3 signaling (Wertz et al. 2004, Enesa et al. 2008, 
Tran et al. 2008, Kayagaki et al. 2007, Trompouki et al. 2003, Keusekotten et 
al. 2013). Several other members of the OTU-family have also been shown 
to exhibit specificity for particular ubiquitin chains (Mevissen et al. 2013). In 
particular, A20/TNFAIP3 is a unique protein, which comprises both intrinsic 
DUB and E3 activities at the N- and C-terminus, respectively (Wertz et al. 
2004, Heyninck and Beyaert 2005). A20 is transcriptionally upregulated by 
NF-κB but it operates in a negative feedback loop to suppress the signaling 
pathway. A20 demonstrates high deubiquitylating activity towards K63-linked 
chains on receptor-interacting protein 1 (RIP1; an essential mediator of the 
proximal TNF receptor 1 signaling complex) yet conjugates K48-linked 
chains onto the same substrate. Formation of K63-linked chains on RIP1 
provides platform for the recruitment of an adaptor protein, Mitogen-activated 
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protein kinase kinase kinase 7 interacting protein 1 (TAB), which in turn 
recruits Mitogen-activated protein kinase kinase kinase 7 (TAK1) for 
autophosphorylation and subsequently activates NF-κB. The replacement of 
K63-linked chain to K48-linked chain by A20 targets RIP1 for proteasomal 
degradation, thereby suppresing NF-κB signaling. In addition, A20 also 
disrupts the interaction between various E3s (e.g. TRAF6, an E3 that is 
involved in NF-κB activation) with the E2s, Ubc13 and UbcH5c, by targeting 
the E2s for proteasomal degradation, further suppressing NF-κB signaling 
(Shembade et al. 2010).  
 
1.4.7 Machado-Joseph disease proteins (MJDs) 
Ataxin-3 (ATXN3) is the most prominent member of the MJD family. In fact, 
the name of this DUB family arises from the disease caused by ATXN3 
mutation. Machado-Joseph Disease is the major form of spinocerebellar 
ataxia (Riess et al. 2008). This disease is caused by the C-terminal 
amplification of an unstable CAG triplet repeat that results in the extension of 
poly-glutamine (polyQ) in Ataxin 3. The resulting polyQ stretch fails to fold 
properly, leading to protein aggregation in cells (Williams and Paulson 2008).  
 
The MJD domain is found at the N-terminus of all the MJD family members. 
All four members of this family, ATXN3, ATXN3L, JOSD1 and JOSD2, have 
been shown to be catalytically active (Burnett et al. 2003). Nuclear magnetic 
resonance studies on the MJD domain of ATXN3 revealed that the structure 
is in a non-productive conformation at steady state, due to the presence of a 
large helical lever that occludes the active site (Mao et al. 2005, Nicastro et 
al. 2005, Nicastro et al. 2006). Intriguingly, the Josephin domains of both 
ATXN3 and JOSD1 have been shown to be mono-ubiquitylated and such 
ubiquitylation increases the catalytic activity of both DUBs (Winborn et al. 
2008, Seki et al. 2013). ATXN3 demonstrates preference for K63-linkages 
and together with JOSD1, and the closely related family member, ATXN3L, 
have been implicated in the transcriptional repression of phosphatase and 
tensin homolog (PTEN) in lung cancer cells (Winborn et al. 2008, Sacco et 
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al. 2014). In addition, JOSD1 has been implicated in the regulation of 
membrane dynamics, cell motility and endocytosis (Seki et al. 2013).  
 
1.4.8 JAB1/MPN/Mov4 metalloenymes (JAMM) 
The JAMM metalloenzyme family consists of 8 members. These DUBs often 
operate as part of a multimeric protein complex (David Komander 2010, 
Clague et al. 2013). For example, POH1/PSMD14 is constitutively 
incorporated in the 19S regulatory particle of the proteasome and recycles 
ubiquitin chains from substrates destined for proteasomal degradation (Finley 
2009). AMSH and AMSH-LP are both associated with the ESCRT machinery 
for membrane trafficking (Williams and Urbe 2007, Clague and Urbe 2006). 
CSN5 is a subunit of the COP9 signalosome that deneddylates the Cullin E3 
ligases for inactivation (Cope et al. 2002). BRCC36 is implicated in DNA 
repair pathway via association with two complexes, the BRISC and BRCA1-
RAP180 complexes (Cooper et al. 2009, Shao et al. 2009). MYSM1 
associates with the histone acetyltransferase, p300/CBP-associated factor 
(p/CAF) to coordinate histone acetylation and deubiquitylation (P. Zhu et al. 
2007). 
 
Several members of the JAMM family display high specificity for K63-linked 
ubiquitin chains, including AMSH, AMSH-LP, BRCC36 and POH1/PSMD14 
(Cooper et al. 2009, McCullough et al. 2006, McCullough et al. 2004, Sato et 
al. 2008). POH1 can also cleave ubiquitin chains en bloc, a feature important 
for the rapid removal of ubiquitin chains from proteasome-targeting 
substrates (Yao and Cohen 2002). MYSM1 on the other hand, has been 
shown to remove monoubiquitin from H2A (P. Zhu et al. 2007).  
 
1.5 Autophagy 
The term ‘autophagy’ arises from the Greek word ‘auto’ for self and ‘phagein’ 
for eating. The first observation of autophagy by Christian de Duve stems 
from his early discovery of the lysosome (Duve et al. 1953, De Duve and 
Wattiaux 1966). He coined the term autophagy, to describe the lysosomal 
degradation of cellular organelles, distinct from that of the degradation of 
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mediated autophagy (CMA) is different from both macroautophagy and 
microautophagy as the autophagic cargo is usually a cytosolic protein rather 
than on organelle or bulk cytoplasmic contents (Kaushik and Cuervo 2012, 
Massey et al. 2004). The targeted protein usually contains a pentapeptide 
motif (KFERQ) for the recognition by a cytosolic chaperone, heat shock 
cognate protein of 70kDa (HSC70) (Dice 1990, Chiang et al. 1989). This 
substrate-HSC70 complex then interacts with lysosome-associated 
membrane protein type 2A (LAMP-2A) for lysosomal translocation of the 
substrate (Cuervo and Dice 1996). In this thesis, I will focus on 
macroautophagy, hereafter referred to as autophagy. 
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Figure 1.7 Different forms of autophagy. 
Autophagic degradation can occur by at least three mechanisms. During 
macroautophagy, an isolation membrane expands and engulfs autophagic cargo, 
forming an autophagosome. The autophagosome then fuses with lysosomes to 
degrade the autophagic content. Microautophagy occurs via the invagination of the 
lysosomal membrane to engulf cytosolic material, which is then internalized and 
degraded in the lysosome. During chaperone-mediated autophagy, soluble cytosolic 
proteins are recognised by heat shock cognate 70 (HSC70) chaperone and its co-
chaperones for translocation and import into the lysosome. 
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other intracellular proteins or endocytosed proteins (Klionsky 2008, Essner 
and Novikoff 1961). 
 
1.5.1 Different forms of autophagy 
For many years, it was thought that autophagy is a non-specific catabolic 
process to provide new energy sources during cell starvation. However, 
autophagy is now known to have crucial roles in development, immune 
defense, programmed cell death, tumor suppression and prevention of 
neuronal degeneration (Levine and Klionsky 2004, Munz 2006, Shintani and 
Klionsky 2004). In addition, recent advancement in the field revealed sub-
classes of selective autophagic pathways that could specifically remove 
unwanted or dysfunctional organelles and protein aggregates in response to 
different stimuli or insults.  
 
Depending on the mechanisms by which cargos are being sequestered into 
the autophagic pathway, autophagy can be classified into macroautophagy, 
microautophagy and chaperon-mediated autophagy (CMA) (Klionsky 2005, 
Wang and Klionsky 2003). Macroautophagy is the most studied form of 
autophagy. During the initiation of macroautophagy, a double-membraned 
structure, known as the isolation membrane engulfs the autophagic cargo, 
forming the autophagosome (Figure 1.7). The autophagosome then fuses 
with the lysosome, leading to the formation of autolysosomes for the 
degradation of the autophagic material.  The sequestration and engulfment of 
cargo can either be non-specific (bulk-engulfment) or selectively targeted. 
Selective macroautophagy can further be specified based on the autophagic 
cargo, including mitophagy (mitochondria), reticulophagy (endoplasmic 
reticulum), ribophagy (ribosomes), pexophagy (peroxisomes), lipophagy (lipid 
droplets), xenophagy (invading pathogens) and aggrephagy (protein 
aggregates).  
 
In contrast to macroautophagy, microautophagy is the engulfment of 
cytoplasmic material directly into the lysosome via lysosomal membrane 
invagination and without the prior formation of autophagosome. Chaperone-
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1.5.2 Formation of autophagosome  
Although autophagy was discovered at the same time as the lysosome, our 
current understanding of the molecular mechanism of autophagy truly 
expanded dramatically upon the discovery of over 30 autophagy-related 
(ATG) genes through yeast genetic studies in the last few decades (Harding 
et al. 1995, Klionsky et al. 2003, Thumm et al. 1994, Tsukada and Ohsumi 
1993). Most of the ATG genes are conserved in higher eukaryotes, including 
ATG1 to ATG10 and ATG12 to ATG18 (Table 1.2). These autophagy 
components can be functionally categorized into three groups following the 
progression of autophagy: (1) Atg1/unc-51-like kinase (ULK) and its 
regulators, (2) the VPS34class III PI3K complex I, (3) the Atg9 cycling 
complex and (4) the ubiquitin-like Atg8/LC3 and Atg12 conjugation pathways 
(Table 1.2).  
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 Yeast Mammal Functions/ 
Characteristics 
Atg1/ULK 
kinase 
complex 
Atg1 ULK1/2 Serine/threonine protein 
kinase 
Atg13 ATG13 Regulator of Atg1 
complex through 
phosphorylation 
Atg17 FIP200/RB1CC1 Component of the Atg1 
complex Atg29 - 
Atg31 - 
- ATG101/C12orf44 Component of the ULK 
complex in mammals  
Atg9 and 
its cycling 
system 
Atg9 ATG9 Transmembrane protein 
Atg18 WIPI1/2 Peripheral membrane 
protein 
Class III 
PI3K 
complex 
Vps15 PIK3R4/VPS15/p150 Serine/threonine protein 
kinase 
Vps34 PIK3C3/VPS34 PI3K 
Vps30/Atg6 Beclin-1 Component of class III 
PI3K complex  
Atg14 ATG14 Class III PI3K complex I 
Vps38 UVRAG Class III PI3K complex II 
Ubiquitin-
like 
conjugation 
systems 
Atg3 ATG3 E2-like enzyme for Atg8 
conjugation 
Atg4 ATG4A to ATG4D LC3/Atg8 C-terminal 
hydrolase; deconjugating 
enzyme  
Atg5 ATG5 Conjugates with Atg12 
Atg7 ATG7 E1-like enzyme for Atg12 
and Atg8 
Atg8 LC3A, B, B2, C, 
GAPARAP, L1, L2 
Ubiquitin-like molecule 
(Ubl), conjugates to 
phosphatidylethanolamide 
(PE) 
Atg10 ATG10 E2-like enzyme for Atg12 
conjugation 
Atg12 ATG12 Ubl 
Atg16 ATG16L1, L2 Forms Atg12-Atg5-Atg-16 
complex  
Table 1.2 Atg and Atg-related proteins that form the core molecular machinery of 
autophagosome formation. 
(Mizushima et al. 2011, Jin and Klionsky 2013). 
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1.5.2.1 The mTOR complexes 
Autophagy is a stress-induced catabolic process. Various stimuli have been 
shown to trigger autophagy in cells, including nutrient starvation, energy 
depletion and lack of growth factors (Reviewed in (Yang and Klionsky 2010)). 
A key player in autophagy is the mammalian target of rapamycin (mTOR).  
 
mTOR is a nutrient and energy sensing kinase that can be activated by 
various upstream signaling events, for example insulin receptor activation 
(Klionsky and Emr 2000, Zoncu et al. 2011b). mTOR forms two functionally 
distinct protein complexes, mTORC1 and mTORC2, both of which share two 
subunits: the positive regulator, mammalian lethal with SEC13 protein 8 
(mLST8/GβL) and the negative regulator, REP domain-containing mTOR-
interacting protein (DEPTOR) (Figure 1.8) (Loewith et al. 2002). Accessory 
subunits that are unique to mTORC1 include the scaffolding protein, 
RAPTOR (regulatory-associated protein of mTOR) and a negative regulator, 
PRAS40/AKT1S1 (40kDa Pro-rich Akt substrate). On the other hand, 
subunits that are unique to mTORC2 include RICTOR (rapamycin-insensitive 
companion of mTOR; a scaffolding protein), PROTOR1/2 (protein observed 
with RICTOR1/2; for complex assembly) and mSIN1/MAPKAP1 (mammalian 
stress-activated map kinase-interacting protein 1; for membrane targeting) 
(reviewed in (Zoncu et al. 2011b)). The name mammalian target of 
rapamycin is perhaps slightly misleading as rapamycin does not directly 
target mTOR itself. Instead, rapamycin forms a complex with FKBP12 
(FK506-binding protein of 12kDa), which in turn binds and inhibits RAPTOR-
bound mTOR. Since MTORC2 is RICTOR, rather than RAPTOR bound, only 
mTORC1 is sensitive to rapamycin (Loewith et al. 2002). However, it has 
been reported that prolonged treatment with rapamycin can also indirectly 
inhibit mTORC2 as rapamycin-FKBP12 depletes the cellular pool of mTOR, 
thereby inhibiting the mTORC2 complex formation (Sarbassov et al. 2006).  
 
Both of the mTOR complexes are involved in the suppression of autophagy. 
However, MTORC2 acts upstream of mTORC1. Their involvement in 
autophagy regulation will be described in the next section.  
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Figure 1.8 Schematic illustration of the organisations of mTOR complex I (mTORC1) 
and complex II (mTORC2).  
Both mTORC1 and mTORC2 contain the core components, mTOR, DEPTOR and 
mLST8. The accessory subunits unique to mTORC1 are RAPTOR and PRAS40 
whereas RICTOR, mSIN1 and PROTOR are only found in mTORC2 (Adapted from 
(Zoncu et al. 2011b)).  
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1.5.2.2 ULK1/2 complex activation upon mTORC1 inactivation 
In fed cells, activation of growth factor/insulin receptors phosphorylates the 
insulin receptor substrate (IRS), which then activates class I PI3K to 
generate PtdIns3,4,5-P3 (White 1998, Yu et al. 1998). PtdIns3,4,5-P3. binds 
and activates PDK1 (Phosphoinositide-dependent kinase-1), which in turn 
phosphorylates AKT/PKB, among many other kinases (Datta et al. 1999, 
Liao and Hung 2010). In addition, mTORC2 also phosphorylates AKT/PKB, 
leading to its activation (Moore et al. 2011). Activated AKT/PKB then 
phosphorylates and inhibits the function of a GTPase activating protein 
(GAP) complex, TSC1-TSC2 complex, on RHEB (Ras homolog enriched in 
brain) (Q. Yang et al. 2006, Frias et al. 2006, Zoncu et al. 2011a).  
 
In parallel, another family of small GTPases, Ras-related GTPases (RAGs) is 
also involved. RAGs exist in heterodimers, which consist of either RAGA or 
RAGB paired with RAGC or RAGD. In the presence of high amino acid 
concentration, the heterodimer is in an active conformation state, 
characterised by a GTP-bound RAGA/B and a GDP-bound RABC/D (Sancak 
and Sabatini 2009). This conformation allows the heterodimer to interact with 
RAPTOR and recruit mTORC1 to the lysosomes or the late endosomes, 
where both RAG and RHEB reside (Sancak et al. 2008, Sancak et al. 2010). 
RHEB in turn is an activator of mTOR (Huang and Manning 2008, Zoncu et 
al. 2011b). Active mTORC1 binds and hyperphosphorylates ULK1/2 and 
ATG13 disrupting the interaction between the two (Kim et al. 2011, Kamada 
et al. 2010).  
 
During nutrient starvation, the inactivation of PKB and simultaneous 
phosphorylation of AMPK (AMP-activated protein kinase) by LKB1 (liver 
kinase B1) leads to an activating phosphorylation of the TSC complex and 
subsequently inactivates RHEB (Shackelford and Shaw 2009, Sancak et al. 
2008). In addition, low amino acid levels also cause the RAG heterodimer to 
assume an inactive conformation, such that RAGA/B is now GDP-bound 
whereas RABC/D is GTP-bound (Kim et al. 2008, Sancak and Sabatini 
2009). Subsequently, mTORC1 is inactivated, allowing ATG13, FIP100 and 
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ATG101 to form a complex with ULK1/2 and promote nucleation of 
autophagic membranes (Figure 1.9) (Ganley et al. 2009, Chan and Tooze 
2009). 
 
 
Figure 1.9 ULK1/2 complex activation during autophagy. 
(A) Under steady state conditions, constitutive growth factor and/or insulin 
stimulation activates PKB/Akt, which phosphorylates and inhibits the GAP activity of 
TSC1/2 complex on RHEB, resulting in the activation the mTORC1 by RHEB. In 
parallel, high amino acid level in the cell promote GTP-bound and GDP-bound 
states of RAGA/B and RABC/D, respectively, resulting in an active conformation 
that recruits mTORC1 to the lysosome or late endosome for activation by RHEB. 
Activated mTORC1 hyperphosphorylates both ULK1/2 and Atg13, causing 
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dissociation of the UL1/2 complex and inhibiting downstream activation of 
autophagy.  
(B) During nutrient starvation, the loss of insulin stimulation and decrease in ATP 
energy results in the phosphorylation of AMPK by LKB1. AMPK1 in turn 
phosphorylates and activates the GAP activity of TSC1-TSC2 complex on RHEB, 
leading to the inactivation of mTORC1. In parallel, the absence of amino acid 
switches the GTP and GDP bound states of RAGA/B and RABC/D, resulting in the 
release of mTORC1 from the lysosome. The inactivation of mTORC1 removes its 
suppression on ULK1/2, which can then phosphorylate ATG13, FIP200 and itself for 
activation of autophagy. A red circle indicates inhibitory phosphorylation, whereas 
blue circle indicates activating phosphorylation. 
 
1.5.2.3 The VPS34 complex I /II  
The activated ULK1/2 complex has been reported to phosphorylate Beclin-1, 
a core component of the mammalian class III phosphoinositide 3 kinase 
(PtdIns3K; also referred to as VPS34 complex), thereby promoting 
autophagy progression (Russell et al. 2013). The VPS34 complex is 
implicated in the nucleation of the autophagosomal membrane.  
 
The core complex of the Class III PI3K consists of VPS34, VPS15, and 
Beclin-1. These core components can bind either ATG14L or ultraviolet 
irradiation resistance-associated gene (UVRAG), forming two distinct 
complexes, complex I and II, respectively (Figure 1.10A and B) (Kihara et al. 
2001, Itakura et al. 2008). ATG14L is found at the ER at steady state and 
localises to autophagosomal membranes upon starvation. Importantly, 
depletion of ATG14L impedes the phosphorylation of phosphatidylinositol 
(PtdIns) to phosphatidylinositol 3-phosphate (PtdIns-3P) and its downstream 
autophagosomal membrane formation and autophagy induction (Figure 
1.10A) (Sun et al. 2008, Itakura et al. 2008, Matsunaga et al. 2009, Zhong et 
al. 2009). Therefore, the VPS34 complex I has been proposed to be involved 
in the early stages of autophagosome formation. On the other hand, the 
UVRAG-containing VPS34 complex II acts at the later stages of autophagy 
maturation (Figure 1.10B). The BAR-domain protein Bif-1 interacts with 
Beclin-1 via UVRAG and promotes ATG9 trafficking from the Golgi to the 
autophagosomal membrane (Takahashi et al. 2007, Takahashi et al. 2011). 
UVRAG also interacts with the homotypic fusion and protein sorting (HOPS)-
tethering complex, which promotes the fusion of autophagosomes with late 
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endosomes and lysosomes (Chong et al. 2008). At steady state, Beclin-1, 
the subunit of the core complex that is present in both the VPS34 complex I 
and II binds AMBRA1, which in turn interacts with dynein, tethering the 
VPS34 complex to the cytoskeleton (Di Bartolomeo et al. 2010). During 
autophagy induction, ULK1 phosphorylates AMBRA1, resulting in the release 
of VPS34 complex I and II from dynein and relocalisation to the ER to 
promote autophagosome formation. The other subunit of the VPS34 core 
complex, p150, is reported to be required for VPS34 membrane association 
and activity (Stack et al. 1995).  
 
Recruitment of VPS34 to the isolation membrane promotes the 
phosphorylation of PtdIns to PtdIns-3P (Foster et al. 2003, Vanhaesebroeck 
and Waterfield 1999). PtdIns-3P has been proposed to recruit double FYVE 
domain-containing protein 1 (DFCP1) via its FYVE (conserved in Fab1, 
YOTB, Vac1 and EEA1) domain (Axe et al. 2008). Other PtdIns-3P effectors, 
WD repeat domain phosphoinositide-Interacting protein 1 and 2 (WIPI1 and 
2) are also recruited to the autophagosomal membrane during autophagy 
induction (Figure 1.10A) (Proikas-Cezanne and Pfisterer 2009, Su et al. 
2011, Polson et al. 2010). WIPI1 and WIPI2 recruitment to the 
preautophagosomal membrane has been reported to promote LC3 lipidation 
during autophagy (Mauthe et al. 2011, Dooley et al. 2014, Polson et al. 
2010). On the other hand, DFCP1 has been suggested to act as a platform 
for the recruitment of other ATG proteins to the isolation membrane, such as 
LC3 and ATG5. However, this remains to be fully investigated.  
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Figure 1.10 The VPS34 complex I /II and the ATG9 cycling system. 
(A) Apart from the core components (VPS34, p150 and Beclin1), VPS34 complex I 
contains an accessory subunit, ATG14L. VPS34 complex I is responsible for the 
formation of isolation membrane (IM). VPS34 complex I phosphorylates PI to 
PtdIns-3P, which promotes the recruitment of WIPI1/2 and DFCP1 to the IM to 
promote LC3 lipidation and insertion into the autophagosomal membrane.  
(B) VPS34 complex II (with UVRAG instead of ATG14L) is associated with the later 
stages of autophagy and has been shown to recruit BIF-1, a protein that binds and 
promote membrane curvature and has been implicated in ATG9 recruitment to the 
autophagosomal membrane. 
(C) ATG9 localises to the Golgi and endocytic vesicles at steady state. Upon 
autophagy induction, it shuttles between the autophagosome and Golgi or endocytic 
vesicles. It is proposed to deliver lipid membranes for the formation and expansion 
of the isolation membrane. 
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1.5.2.4 The ATG9 cycling system 
Another key player in autophagosome formation is ATG9. ATG9 is the only 
reported multipass transmembrane ATG protein to date. ATG9 is also 
thought to act at the early stages of autophagosome formation and is 
proposed to deliver lipid bilayers to the preautophagosome structures as the 
depletion of ATG9 results in the formation of significantly fewer 
autophagosome (Figure 1.10C) (Orsi et al. 2012). Interestingly, yeast Atg9 is 
observed to shuttle between the mitochondria and the preautophagosomal 
structure (the isolation membrane structure equivalent in yeast) whereas 
mammalian ATG9 shuttles between either the trans-Golgi network or 
endocytic vesicles and the isolation membrane (Reggiori et al. 2005, Young 
et al. 2006, Reggiori and Tooze 2012, Longatti and Tooze 2012). This 
observation suggests that the autophagosomal membrane could originate 
from several organellar membranes. 
 
Indeed, the origin of the isolation membrane (IM) has been a constant 
debate. Longatti and Tooze proposed four models for the origin of 
autophagosome formation: (1) de novo synthesis of lipid bilayers via delivery 
of lipids, (2) gradual expansion of the IM via heterotypic fusion of vesicles 
from other organelles, (3) homotypic fusion of a constitutive pool of 
autophagic vesicles, and (4) membrane remodeling/extension of a pre-
existing membrane sheet derived from other organelles, for example, the ER 
(Longatti and Tooze 2009).  
 
In both the second and fourth models, various organelles have been shown 
to contribute towards membrane expansion. Several studies demonstrated 
that ER is a main source of lipid bilayer, as evidenced by the PtdIns-3P 
positive membrane structures that stem from the ER membrane upon 
autophagy induction. These membranes were termed omegasomes as they 
are frequently observed to form a Ω-shape. Omegasomes have been shown 
to mature into autophagosomes, which bud off from the ER and stain positive 
for ATG8 and ATG5 (Axe et al. 2008). Apart from the ER, the mitochondria 
have also been reported to participate in autophagosome biogenesis (Hailey 
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et al. 2010). In addition, ER-mitochondria contact sites are known to regulate 
various processes, including lipid exchange, mitochondria fusion/fission and 
Ca2+ exchange has also been shown to give rise to autophagosomes 
(Hamasaki et al. 2013). Ravikumar and colleagues also provided evidence 
that the plasma membrane contributes to the formation of pre-
autophagosomal membranes and also the expansion of existing 
autophagosomal membranes (Ravikumar et al. 2010b, Ravikumar et al. 
2010a). Recently, Longatti and Tooze reported that the overexpression of a 
RAB11 GTPase effector, TBC1D14 inhibited autophagy. Since RAB11 is 
involved in the regulation of endocytic recycling, this observation suggests 
that the recycling endosomes are also necessary for autophagosome 
formation (Longatti and Tooze 2012). It is likely that multiple sources could 
contribute to the nucleation and expansion of the autophagosomal 
membrane in either a cell type and/or stimulus-dependent manner.  
 
1.5.2.5 Autophagosome expansion 
Two ubiquitin-like (UBL) conjugation systems are involved in the expansion 
of the isolation membrane (Figure 1.11). In the first ubiquitin-related system, 
Atg12 is conjugated to Atg5, via the sequential action of Atg7 and Atg10, 
which act as E1 and E2-like enzymes, respectively (Figure 1.11C). The 
Atg12-Atg5 complex then interacts with Atg16L, forming a trimeric structure 
that further homodimerises to form a multimeric complex called the Atg16L 
complex (Mizushima et al. 2003). 
LC3 (ATG8) is synthesized as pro-LC3. Prior to its conjugation to 
phosphatidylethanolamide (PE), the C-terminal residues of pro-LC3 are 
cleaved off by a cysteine protease, Atg4B, to expose its glycine residue for 
covalent conjugation to PE (Ichimura et al. 2000, Kirisako et al. 2000). A 
second ubiquitin-related system involving Atg7 (E1-like enzyme), Atg 3 (E2-
like enzyme) and the Atg5-Atg12-Atg16L complex (E3-like enzyme) 
conjugates LC3 to PE in the isolation membrane, thereby determining the 
site of LC3 lipidation (Figure 1.11) (Hanada et al. 2007, Fujita et al. 2008). 
The cleaved, soluble form of LC3 is termed LC3-I and the PE-conjugated, 
membrane-bound form of LC3 is referred to as LC3-II (Klionsky et al. 2008).  
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LC3-II is inserted into both sides of the lipid bilayer. However, LC3-II on the 
cytoplasmic surface can be extracted by Atg4 whereas LC3-II in the 
autophagosomal lumen remains bound to the autophagic membranes and is 
degraded together with the autophagic cargo (Kirisako et al. 2000). 
Therefore, LC3-II also serves as an important biomarker to monitor 
autophagy progression.   
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Figure 1.11 The two UBL conjugation systems. 
In the first ubiquitin-lke conjugation system, Atg12 acts as a UBL that is conjugated 
to Atg5 and Atg16L, via sequential conjugations with Atg 7 (E1-like enzyme) and 
Atg10 (E2-like enzyme). In this case, there is no E3-like enzyme involved. The Atg5-
Atg12-Atg16L complex is involved in another UBL conjugation system for the 
lipidation of LC3. LC3 is synthesized as a precursor (pro-LC3). It is constitutively 
cleaved by Atg4B into LC3-I. LC3-I acts as a UBL that is sequentially conjugated to 
Atg7 (E1-like enzyme), Atg3 (E2-like enzyme), and the previously described Atg5-
Atg12-Atg16L complex (E3-like enzyme). LC3-I is finally lipidated with 
phosphatidylethanolamide (PE), forming LC3-II for its insertion into autophagosomal 
membranes. LC3-II can bind to LIR-containing adaptor proteins such as p62, which 
recognise ubiquitylated proteins on the surface of damaged organelles during 
selective autophagy.  
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1.5.3 Selectivity of autophagy 
Similar to proteasomal and lysosomal degradation, the selectivity of 
autophagic cargo is tightly regulated by post-translational modifications, most 
notably phosphorylation and ubiquitylation. Proteins on the surface of 
damaged or malfunctioning organelles, for example, the ER and 
mitochondria, are ubiquitylated by specific E3 ligases, such as GP78 and 
Parkin (Fang et al. 2001, Narendra et al. 2009). The ubiquitylated proteins 
can then be recognized by molecular adaptors such as p62, NBR1 and 
optineurin (Lamark et al. 2009, Birgisdottir et al. 2013). These adaptors 
contain two domains: a LIR (LC3-interacting region) for interaction with ATG8 
family proteins, and a C-terminal UBA domain for interaction with ubiquitin, 
thereby recruiting the autophagosomal membrane to the ubiquitin-tagged 
organelles (Figure 1.11) (Lamark et al. 2009, Birgisdottir et al. 2013). In the 
next section, I will discuss in detail the selective autophagy of mitochondria 
via PINK1 and Parkin-mediated mitophagy as this pathway is explored in this 
project.  
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1.6 Selective removal of mitochondria by autophagy 
1.6.1 Mitochondria 
Mitochondria, often referred to as the ‘powerhouse of the cell’, are primarily 
responsible for the generation of ATP via aerobic respiration. Mitochondria 
are also involved in various housekeeping functions, including the 
biosynthesis of amino acids and steroids, fatty acid oxidation, cytosolic 
calcium homeostasis and mitochondrial antiviral signaling (MAVS) (reviewed 
in (Johri and Beal 2012)). Last but not least, mitochondria also play a pivotal 
role in the orchestration of apoptosis.  
 
Considering the multiple roles of mitochondria in the cell, it is not surprising 
that defects in mitochondrial function have significant impacts on the 
physiology of the cell and the health of an individual. In particular, 
mitochondrial dysfunction has been linked to neurodegenerative disease, 
most notably to Parkinson’s Disease (PD). The etiology of PD is diverse, with 
both environmental and genetic factors contributing to the loss of 
dopaminergic neurons and the accumulation of α-synuclein positive 
inclusions, termed Lewy bodies (LB), in the substantia nigra. PD patients are 
clinically diagnosed based on several characteristic features, including 
tremor, rigidity, slowness of movement and postural instability (reviewed in 
(Sherer et al. 2002, Saito et al. 2000, Nuytemans et al. 2010, Morrison 
2003)).  
 
The environmental and genetic risks of PD converge at least partially on 
mitochondrial dysfunction. Exposure to rotenone, paraquat and MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine), three chemical compounds that 
disrupt the mitochondrial electron transport chain (ETC) and result in the 
accumulation of reactive oxygen species (ROS), have all been linked to 
increase risk of Parkinson Disease (Tanner et al. 2011, Bove et al. 2005).  
 
At least three genes for which mutation has been associated with PD are 
functionally related to the mitochondria: Parkin (PARK2), PINK1 (PARK6) 
and DJ1 (PARK7) (Nuytemans et al. 2010). All three genes are associated 
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with early onset familial PD. In particular, extensive studies in Drosophila 
revealed that the PINK1 and Parkin loss-of-function mutants result in 
strikingly similar phenotypes, including locomotor defects (apoptosis of 
indirect flight muscle), male sterility (defect in spermatogenesis) and reduced 
lifespan (Greene et al. 2003, Park et al. 2006). Strikingly, the phenotype 
observed with the PINK1 mutant can be rescued by Parkin overexpression 
but not vice versa, suggesting that Parkin acts downstream of PINK1 in a 
common pathway (Clark et al. 2006, Y. Yang et al. 2006). Indeed, it was later 
discovered that PINK1 and Parkin act sequentially to mediate the selective 
elimination of impaired mitochondria by mitophagy (Narendra et al. 2008, D. 
P. Narendra et al. 2010, Vives-Bauza et al. 2010).  
 
1.6.2 Parkin structure 
Parkin belongs to the RBR family of E3 ubiquitin ligases, which combines the 
features of both the RING and HECT E3 ligases (Nuytemans et al. 2010, 
Riley et al. 2013, Wenzel et al. 2011a). Structurally, Parkin contains a N-
terminal UBL domain, followed by an atypical RING domain (RING0) and a 
RBR domain at the C-terminus. The RBR domain at the C-terminus 
comprises two different RING domains, RING1 and RING2, separated by an 
in-between RING (IBR) domain (Figure 1.12A). Under steady state 
conditions, Parkin is auto-inhibited because the multi-domain protein folds 
into a compact structure, resembling a coiled snake (Figure 1.12B). The 
RING0 domain blocks the catalytic cysteine found in the RING2 domain 
(C431). On the other hand, a short sequence named the repressor element 
of Parkin (REP) sequence located between the IBR and RING2 domains 
binds to RING1, thereby preventing the interaction between RING1 and the 
ubiquitin-charged E2 (Hristova et al. 2009, Trempe et al. 2013, Riley et al. 
2013, Wauer and Komander 2013). 
 
Understanding the structure of Parkin provides clues that help interpret the 
effects of the different Parkin mutations associated with PD (Figure 1.12A). In 
general, the mutations can be classified into three groups. The first group of 
mutations lead to a change in protein domain folding such as R42P, K211N, 
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C212R, C289G, T351P, C441R (Figure 1.12A; colour-coded in blue). In 
particular, the cysteine mutations in the RING domains abolish their zinc 
binding ability, thereby altering the domain folding. The C431F mutation 
affects the catalytic sites at the RING2 domain (C431F; colour-coded in 
green). The last group of mutations affects interactions between domains 
(colour-coded in orange). For example, the G328E mutation between RING1 
and IBR alters its ‘hinge’ property and thereby affecting the conformational 
flexibility. On the other hand, the R33Q mutation may promote interaction 
between the UBL domain and the IBR domain that is structurally in close 
proximity (Trempe et al. 2013).  
 
While the auto-inhibited structure of Parkin at steady state has been 
revealed, the conformational changes occurring upon ubiquitin and substrate 
binding remain unsolved. Three different groups have recently reported that 
PINK1 activates Parkin in a ‘feed-forward’ mechanism: mitochondrial 
depolarisation stabilizes PINK1 on the mitochondrial surface. PINK1 then 
phosphorylates the UBL domain of Parkin and, surprisingly, ubiquitin at a 
positionally equivalent serine (S65) (Kane et al. 2014, Kazlauskaite et al. 
2014, Koyano et al. 2014). The phosphorylated ubiquitin in turn can activate 
and recruit Parkin to the mitochondria. To date, it remains to be seen 
whether the phosphorylated ubiquitin is in fact incorporated into Parkin 
substrates.  
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Figure 1.12 Parkin domain architecture and structure.  
(A) Domain architecture illustrating the linear arrangement of the five Parkin 
domains and the REP sequence. The RBR domain is subdivided into RING1, IBR 
and RING2. RING1 is responsible for Parkin interaction with ubiquitin-charged E2 
whereas the RING2 contains the catalytic cysteine (C431). The reported PD 
mutations are annotated as shown and colour coded according to proposed effects 
of mutations based on the crystal structure of Parkin (Spratt et al. 2013, Trempe et 
al. 2013, Wauer and Komander 2013).   
(B) Parkin folds into a compact structure, loosely resembling a coiled snake. Each 
coloured segment corresponds to the domains indicated in (A). The red dots 
represent the occlusion of the interaction between RING1 with E2 by the REP 
sequence and the blockage of the catalytic cysteine of RING2 by the hydrophobic 
region of RING0. (Adapted and modified from (Dove and Klevit 2013, Trempe et al. 
2013). 
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1.6.3 The protective roles of Parkin 
Studies in Drosophila and human cell lines indicate that Parkin serves 
cytoprotective roles in response to different stress paradigms, including 
mitochondrial and ER stress, misfolded protein aggregation, excitotoxicity 
and proapoptotic stimulation (reviewed in (Winklhofer 2014)). To date, more 
than 30 bona fide Parkin substrates have been discovered (Dawson and 
Dawson 2010). Parkin-dependent ubiquitylation of these substrates can lead 
to different cellular fates: proteasomal degradation is most common but there 
are a few instances where ubiquitylation by Parkin results in activation of 
different cell signaling pathways. Based on the identified substrates, the 
cytoprotective activity of Parkin can be attributed to three distinct areas: (1) 
selective removal of damaged mitochondria via mitophagy; (2) promoting 
proteasomal degradation of toxic/aggregated proteins; and (3) modulating 
non-degradative signaling for cell death or survival pathways. These 
functions of Parkin will be discussed in the next sections.  
1.6.3.1 PINK1 and Parkin-mediated Mitophagy 
PTEN-induced putative kinase-1 (PINK1) is a serine/threonine kinase 
(Woodroof et al. 2011). It has a N-terminal mitochondrial targeting signal 
(MTS; a.a.1-94) and a transmembrane region consisting of a series of 
positively charged amino acids (TM; a.a. 94-110) (S. M. Jin et al. 2010).  
Under normal condition, mitochondrial membrane potential drives PINK1 into 
the mitochondria via the translocase of outer mitochondrial membrane (TOM) 
and translocase of inner mitochondrial membrane (TIMM) complex. The 
mitochondria-targeting signal (MTS) is first cleaved by mitochondrial 
processing peptidase (MPP) and the transmembrane domain (TM) is then 
cleaved by both mitochondrial processing peptidase (MPP) and presenillin-
associated rhomboid-like protease (PARL) to produce the shorter 53kDa ΔN-
PINK1 fragment (Figure 1.13) (Deas et al. 2011, Seok M. Jin et al. 2010, Lin 
and Kang 2008, Meissner et al. 2011, Whitworth et al. 2008, Greene et al. 
2012). The cleaved ΔN-PINK1 fragment exposes the bulky and hydrophobic 
phenyalanine (F104), which can then be recognised and ubiquitylated by 
several E3 ligases including UBR1, UBR2 and UBR4 for degradation by the 
proteasome via the N-end rule pathway (Yamano and Youle 2013).  
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When mitochondria are impaired, there is a loss of membrane potential, 
causing an inhibition of PINK1 translocation into the mitochondria (Lin and 
Kang 2008). Instead, PINK1 interacts with the TOM complex, forming a 
700kDa complex on the outer mitochondrial membrane (OMM), with the 
kinase domain facing the cytosol (Lazarou et al. 2012). OMM-localised 
PINK1 autophosphorylates at Ser228 and Ser402, an event that is required 
for the subsequent phosphorylation of Parkin (Okatsu et al. 2012). The 
activated Parkin can ubiquitylate many OMM proteins including MFN1/2, 
MIRO1/2, voltage-dependent anion channels VDAC1/2/3, subunits of the 
TOM complex (TOMM20, TOMM70A and TOMM22) and the BCL-2 family 
members including MCL1, BAK and BAX (Sarraf et al. 2013, Lazarou et al. 
2012, Gegg et al. 2010, Wang et al. 2011, Kane and Youle 2011, Sun et al. 
2012). In fact, quantitative proteomic study of CCCP-treated HeLa, SH-SY5Y 
and HCT116 cells overexpressing Parkin revealed widespread Parkin-
dependent ubiquitylation, suggesting that Parkin activation induces major 
OMM remodeling, at least when ectopically expressed (Sarraf et al. 2013). 
 
The influence of PINK1 extends beyond the activation of Parkin. At least two 
OMM Parkin substrates, the two GTPases, MIRO and MFN2, are 
phosphorylated by PINK1 for their recognition by Parkin (Wang et al. 2011, 
Kane and Youle 2011, Chen and Dorn 2013, Ziviani et al. 2010). The 
ubiquitylation of OMM proteins may either lead to their extraction by p97 and 
subsequent proteasomal degradation (for example, MCL1 and MFN) or act 
as docking signal for the recruitment of p62 (Tanaka et al. 2010, Xu et al. 
2011, Yoshii et al. 2011). The selective degradation of MFN inhibits 
mitochondrial fusion, thereby segregating depolarised mitochondria from the 
healthy population of mitochondria. In addition, the degradation of MIRO 
dissociates mitochondria from the microtubules and arrests mitochondrial 
movement to allow efficient mitophagy (Wang et al. 2011). The role of p62 in 
the context of PINK1/Parkin-mediated mitophagy remains controversial. 
Geisler and colleagues reported that p62 is required for mitophagy while two 
other groups (Narendra et al. and Okatsu et al.) reported that depletion of 
 51 
p62 resulted in a loss of perinuclear clustering of mitochondria but did not 
inhibit mitophagy (Derek Narendra et al. 2010, Okatsu et al. 2010).  
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Figure 1.13 Mechanism of PINK1 stabilisation, Parkin recruitment and mitophagy 
progression during mitochondrial depolarisation.  
(A) At steady state, (1) PINK1 is driven by the membrane potential to (2) partially 
translocate into the intermitochondrial membrane space (IMS) and is inserted into 
the inner mitochondrial membrane (IMM). (3) The mitochondrial-targeting signal 
(MTS) and the transmembrane domain (TM) are sequentially cleaved by 
mitochondrial processing peptidase (MPP) and presenillin-associated rhomboid-like 
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protease (PARL), respectively. (4) Cleaved PINK1 is proposed to be released into 
the cytosol and degraded constitutively via the proteasomal degradation pathway.  
(B) When the mitochondrial membrane potential is disrupted, (1) PINK1 is not 
translocated into the mitochondria. Instead it interacts with the TOM complex and 
physically recruits Parkin. (2) PINK1 phosporylates itself and Parkin for its 
activation. In addition, PINK1 also phosphorylates MIRO and MFN for their 
recognition by Parkin. (3) Ubiquitinated outer mitochondrial membrane (OMM) 
proteins can either be extracted by p97 AAA-ATPase for proteasomal degradation, 
or, (4) recruit autophagy machinery including p62 and LC3 to promote the formation 
of autophagosomal membrane around the mitochondria.  
 
 
 
1.6.3.2 Parkin-mediated degradation of toxic substrates 
The ubiquitylating activity of Parkin extends beyond mitophagy. Several 
proteins that are mutated and/or accumulated in neuronal cells during familial 
autosomal recessive PD, particularly in the intracytoplasmic inclusions, 
known as Lewy bodies (LB), have also been reported to be substrates of 
Parkin. These proteins include O-linked glycosylated α-synuclein (α-sp22), 
CDCrel-1, synphilin-1 and PAEL-R (Shimura et al. 2001, Imai et al. 2001, 
Zhang et al. 2000, Chung et al. 2001).  
 
The discoveries of CDCrel-1 and α-synuclein as substrates of Parkin were 
made around the same time. Zhang et al. reported that Parkin ubiquitylates 
and degrades CDCrel-1 in an UbcH2 (E2)-dependent process (Zhang et al. 
2000). CDCrel-1 is a member of the Septin family, with intrinsic GTPase 
activity and is predominantly expressed in the nervous system (Beites et al. 
1999). In addition, CDCrel-1 co-precipitates with synaptic vesicles via its 
interaction with syntaxin and has been speculated to modulate dopamine 
release, thereby contributing towards neurodegeneration (Zhang et al. 2000, 
Beites et al. 1999).  
 
Shimura and colleagues demonstrated by immunohistochemistry and affinity 
purification that Parkin colocalises with α-synuclein in Lewy bodies. Further 
co-immunoprecipitation experiments showed that Parkin binds to two E2 
conjugating enzymes, UbH7 and, to a weaker extend, UbcH8. E2 binding 
allows Parkin to ubiquitylate α-synuclein (Shimura et al. 2001). In addition, 
Chung and colleagues also reported that an α-synuclein-interacting protein, 
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synphilin-1 is also ubiquitylated by Parkin. Synphilin-1 co-localises with α-
synuclein in the Lewy bodies observed in PD (Chung et al. 2001). 
 
Another Lewy body-component, Pael-R is also a substrate of Parkin 
(Murakami et al. 2004). Imai and colleagues showed that CHIP (carboxyl 
terminus of the Hsc70-interacting protein), Hsp70, Parkin and Pael-R form a 
dynamic complex both in vitro and in vivo. Upon ER stress, CHIP plays dual 
roles in the ubiquitylation and subsequent degradation of Pael-R. Firstly, 
CHIP association with the complex is enhanced during ER stress, removing 
the association and inhibitory action of Hsp70 on Parkin and Pael-R. 
Secondly, CHIP acts as an E4-like, ubiquitin-elongation enzyme to promote 
Parkin-mediated ubiquitylation of Pael-R. Importantly, overexpression of 
Pael-R correlates with increased cell death and this can be rescued by the 
expression of Parkin, suggesting a cytotoxicity effect of Pael-R accumulation 
in cells (Imai et al. 2001).  
 
It is worth noting that, unlike sporadic cases of PD, the majority cases of 
autosomal-recessive juvenile Parkinsonism (AR-JP) with loss-of-function 
Parkin mutations do not accumulate Lewy bodies (Saito et al. 2000, Morrison 
2003). This supports the idea that the formation of Lewy bodies requires the 
E3 activity of Parkin. Indeed, the co-expression of Parkin, α-synuclein and 
synphilin-1 (an interacting protein of α-synuclein) resulted in the formation of 
Lewy-body-like ubiquitin-positive cytosolic inclusions (Chung et al. 2001). It is 
most likely that the pathophysiological effect of Parkin loss-of-function is 
mediated through other mechanisms, such as the accumulation of damaged 
mitochondria due to mitophagy defects. Hardy et al. proposed that the loss of 
function of Parkin might result in direct cell death without Lewy body 
formation in contrast to incomplete loss of function of Parkin or mutation of 
other PD associated genes (Hardy et al. 2003). Further pathological studies 
of patients with different forms of Parkin mutations need to be carried out to 
support this hypothesis.  
 
Another protein that is degraded via Parkin-mediated ubiquitylation is 
FBXW7/FBXO7/FBX7. FBXW7 is a cytosolic substrate-binding adaptor 
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protein of the SCF multi-subunit E3 ligase complex. FBXW7 was first 
reported to form a complex with Parkin to mediate the degradation of cyclin 
E1. High levels of cyclin E1 have been associated with neuronal apoptosis 
(Padmanabhan et al. 1999). Consistent with this, Burchell et al. reported that 
depletion of FBWX7 affects Parkin recruitment during mitophagy (Burchell et 
al. 2013). Parkin was also shown to directly ubiquitylate FBXW7 for 
proteasomal degradation during mitophagy (Ekholm-Reed et al. 2013). Since 
SCFFBWX7 ubiquitylates and promotes the degradation of MCL1, a pro-
survival BCL2 family member, this Parkin-dependent loss of FBXW7 was 
proposed to promote MCL1 accumulation and cell survival.  
 
1.6.3.3 Parkin-mediated cell viability and apoptotic pathways 
Apart from the proteasomal and lysosomal degradation of mitochondrial 
proteins and mitochondria, Parkin can also transcriptionally promote 
mitochondrial biogenesis. This is achieved via the ubiquitylation of PARIS 
(Parkin Interacting Substrate, ZNF746), a Kruppel-associated box (KRAB) 
domain-containing transcriptional repressor that regulates the transcription of 
many genes involved in cellular metabolism. Of relevance here, PCG-1α 
(peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a 
gene involved in mitochondrial biogenesis, respiration and ROS metabolism, 
is one of the genes that is also suppressed by PARIS. Consistent with this, 
accumulation of PARIS following the expression of a loss-of-function mutant 
of Parkin affects mitochondrial biogenesis and leads to neurodegeneration in 
a mouse model (Shin et al. 2011, St-Pierre et al. 2006).  
 
Parkin has also been shown to upregulate NF-κB pathway in response to 
different cellular stresses including ROS accumulation (CCCP), ER stress 
(thapsigargin) and wide spectrum kinase inhibition (staurosporine) (Henn et 
al. 2007, Muller-Rischart et al. 2013, Sha et al. 2010). Using mouse 
embryonic fibroblasts deficient in NEMO, it was demonstrated that the 
cytoprotective role of Parkin, at least in the face of these stimuli, depend on 
the linear ubiquitylation of NEMO and was independent of Parkin-mediated 
mitophagy as selective knockdown of PINK1, ATG5, or p62 did not affect the 
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stress protective phenotype. NEMO has been previously shown to be 
ubiquitylated by LUBAC (linear ubiquitin chain assembly complex), which 
consists of two RBR E3 ligases, HOIL-1L and HOIP (Muller-Rischart et al. 
2013, Kirisako et al. 2006, Tokunaga et al. 2009). Under cellular stress, 
Parkin is recruited to HOIP and significantly enhances the linear 
ubiquitylating activity of LUBAC on NEMO (Figure 1.14). It remains to be 
determined whether Parkin enhances linear ubiquitylation of NEMO directly 
or indirectly by promoting the activity of LUBAC. One of the downstream 
transcriptional genes of NF‐κB is the mitochondrial GTPase, OPA1 (optic 
atrophy 1). OPA1 is an inner mitochondrial membrane protein that is involved 
in the regulation of mitochondrial cristae arrangement. Inhibition of the 
electron transport chain complex I has been reported to cause cristae 
disintegration and increase cell death (Ramonet et al. 2013). While it might 
not be the only protein upregulated via this pathway, it certainly is an 
essential protein involved in Parkin-mediated NF-κB activation during cell 
stress as OPA1 knockdown in SH-SY5Y cells or knockout in mouse 
embryonic fibroblasts abrogated the pro-survival effects of Parkin expression 
(Muller-Rischart et al. 2013).  
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Figure 1.14 Parkin-mediated NF-κB pathway activation to promote mitochondrial 
integrity and cell survival. 
During cell stress, Parkin is recruited to the LUBAC complex (consisting of HOIL-1L, 
HOIP and SHARPIN) and increases linear ubiquitylation of NEMO, an essential 
regulatory component of the IκB kinase complex. Once activated, this 
phosphorylates IκBα for subsequent proteasomal degradation, releasing the NF-κB 
dimers (p50/p65) for translocation into the nucleus to regulate transcription of target 
genes, which include OPA1. OPA1 is localised in the inner mitochondrial membrane 
and helps to maintain mitochondrial integrity, hence is indirectly involved in the 
promotion of cell survival (adapted from (Winklhofer 2014)). 
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In addition to its crosstalk with the NF-κB pathway, ectopic expression of 
Parkin in Drosophila suppressed the constitutively active form of 
Hempipterous (Hep(CA)), a JNK kinase that normally induces apoptosis in 
the eye imaginal disc and causes an with eye degeneration phenotype. 
Parkin overexpression also suppresses the Drosophila JNK, Basket (Bsk), 
preventing the formation of extra vein (Hwang et al. 2010). In line with this, 
Parkin expression in monkey kidney fibroblasts (COS1 cells) significantly 
suppresses JNK activity (Cha et al. 2005, Hwang et al. 2010). 
 
In conclusion, Parkin is involved in a wide spectrum of pathways that 
converge to oppose cell death and promote cell survival. As a consequence, 
the loss of Parkin or its loss-of-function mutation during cell stress, either 
mediated by the degradative substrates of Parkin (both mitochondrial 
proteins and aggregate-prone cytosolic proteins) or its non-degradative 
substrates (activation of different cellular pathways) may cause cells to 
undergo apoptosis.  
 
1.7 Apoptosis 
The word ‘apoptosis’ originates from the Greek word meaning ‘falling off’, 
such as leaves from a tree. This term was coined in 1972 by Kerr and 
colleagues, who described a specific morphological pattern of scattered 
single cell death, with pyknotic nuclei (condensed chromatin), and formation 
of small spherical cytoplasmic fragments (membrane blebbing) (Kerr et al. 
1972). Cytoplasmic fragments known as apoptotic bodies are often formed, 
with altered chemical composition (externalization of phosphatidylserine, PS) 
that signal neighbouring cells or macrophages to engulf them, causing 
minimal disruption to the overall tissue integrity with no inflammation.  
 
In fact, apoptosis was first referred to as ‘shrinkage necrosis’, due to the 
observation of cell shrinkage, which baffled Kerr and colleagues (Kerr 1971). 
In necrotic cells, ionic pumps stop functioning, leading to the accumulation of 
intracellular lactate, which promotes the osmotic entry of water. As a result, 
necrotic cells swell and eventually rupture. The idea that apoptosis is a form 
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of programmed cell death that plays a complementary but opposing role to 
mitosis and cytokinesis arises from the observation that the growth and 
development of Caenorhabditis elegans involves the invariant apoptosis of 
131 somatic cells (out of the 1090 cells that are present) (Sulston et al. 1983, 
Sulston and Horvitz 1977). Trump and Berezesky later demonstrated that in 
contrast to the passive progression of necrosis, cells execute apoptosis via a 
calcium and ATP energy-dependent mechanism (Trump and Berezesky 
1995, Lockshin and Zakeri 2001).  
 
1.7.1 Activation of the caspase cascade 
Apoptosis is mediated by a family of cysteine proteases known as caspases, 
(c for cysteine and asp for aspartic acid). As the name suggests, these 
proteases cleave their target proteins at specific aspartic acids. The caspase 
family can be divided into two groups based on their position in the apoptotic 
signaling cascade: (1) the initiator caspases (Casp-2, 8, 9 and 10) and (2) 
the effector/executioner caspases (Casp-3, 6 and 7). There is another subset 
of caspases that are not involved in apoptosis. Instead, these groups of 
caspases (Casp1, 4 and 5) are involved in the inflammatory response.  
 
To avoid aberrant, non-specific proteolytic cleavage in the cell, caspases are 
synthesized as inactive precursors, known as pro-caspases (Parrish et al. 
2013, Boatright and Salvesen 2003). Upon stimulation, two initiator caspases 
are brought together by an adaptor protein, which promotes their 
dimerization and ‘close-proximity’ activation (Figure 1.15A) (Baliga et al. 
2004, Wachmann et al. 2010). Following dimerization, the initiator caspases 
are weakly activated, allowing them to undergo autocatalytic cleavage to 
remove their prodomains, further improving their catalytic activity and 
complex stability for downstream cleavage of effector caspases (Baliga et al. 
2004, Wachmann et al. 2010).  
 
For their activation, effector procaspases need to be cleaved at two specific 
aspartic acid sites (by the activated initiator caspases) to remove the 
prodomain and to generate one large and one small fragment. These two 
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fragments dimerise and assemble with another heterodimer to form the final 
active tetramer (Figure 1.15B) (Boatright and Salvesen 2003). The activated 
effector caspases can then further cleave other caspases, thereby amplifying 
the apoptotic signal (Figure 1.15C). In addition, effector caspases also cleave 
a wide array of cellular proteins, ranging from Bid (BH3-only protein) to actin, 
γ-catenin, vimentin, lamin A, PARP (poly-ADP-ribose polymerase), 
topoisomerase I, XIAP (X-linked inhibitor of apoptosis protein) and ICAD 
(inhibitor of caspase-activated DNAse, CAD). This results in cytoskeletal and 
plasma membrane remodeling, breakdown of nuclear lamina, DNA 
fragmentation, cell cycle arrest and further amplification of apoptotic signal 
(reviewed in (Slee et al. 2001, Jin and El-Deiry 2005)).  
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Figure 1.15 Activation of procaspases during apoptosis . 
(A) Caspases are synthesized as inactive procaspases. During activation of 
apoptosis, initiator caspases are recruited to adaptor proteins, leading to ‘close-
proximity’ activation of their catalytic activity. The initiator caspases then undergo 
autocatalytic cleavage at two specific aspartic acid residues, removing the 
prodomains and generating the long and short caspase fragments. Two caspases 
(with two fragments each) associate to form a tetramer. (B) Effector procaspases 
are activated via the proteolytic cleavage by (already activated) initiator caspases. 
The activated caspases cleave the effector procaspases at two similar aspartic acid 
residues, and generate similar fragments, which also form tetramer similar to that of 
the initiator caspases. (C) The upstream initiator caspase can cleave and activate 
many executioner procaspases, who in turn, can cleave other caspases, producing 
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an amplifying proteolytic cascade. In addition, the executioner caspases can also 
cleave a range of key proteins in the cell, causing the phenotypic changes observed 
during apoptosis.  
 
1.7.2 The BCL2 family proteins  
The B-cell lymphoma 2 (BCL2) family proteins are involved in the regulation 
of mitochondria-mediated apoptosis (Cory and Adams 2002, Ola et al. 2011, 
Burlacu 2003). The BCL2 family members are characterised by the presence 
of at least one BH domain (block homology) (Figure 1.16). The pro-apoptotic 
and anti-apoptotic family members have four BH domains (BH1-4) whereas 
the BH3-only proteins, as the name suggests, only has the BH3 domain. In 
addition, most of the pro-apoptotic and anti-apoptotic family members (with 
only a few exceptions) and some of the BH3-only proteins have a 
transmembrane domain, which allows the protein to be inserted into the outer 
mitochondrial membrane. Some of the members are constitutively localized 
to the outer mitochondrial membrane (e.g. BAK, MCL1 and BCL-xL), while 
some (for e.g. BAX) adopt a conformation that tucks away the 
transmembrane domain until activation by cytotoxic signals (Griffiths et al. 
1999, Suzuki et al. 2000).  
 
A main characteristic of the BCL2 family members is their ability to form 
homo and heterodimers among each other. At steady state, the relative 
amounts of the pro- and anti-apoptotic proteins are in equilibrium and the 
anti-apoptotic BCL2 members bind and inhibit the oligomerisation of the pro-
apoptotic members, which can induce mitochondrial outer membrane 
permeabilization (MOMP), causing the release of cytochrome C (Kluck et al. 
1997). The BH3-only proteins are responsible for the initiation of apoptotic 
signals. Upon a trigger, the BH3-only proteins can either sequester the anti-
apoptotic proteins away from the pro-apoptotic members, or they can directly 
activate the pro-apoptotic members (Figure 1.16B) (reviewed in (Czabotar et 
al. 2014)). The functions of the BCL2 family members are further discussed 
in the next section.  
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Figure 1.16 The domain architecture of BCL2 family proteins and the mode of 
action.  
(A) The BH3-only proteins contain one BH (block homology) domain. Some of the 
BH3-only proteins also contain a transmembrane (TM) domain. Both the pro- and 
anti-apoptotic family members have four BH domains and most of the proteins 
within these two categories also have a TM domain.  
(B) The anti- and pro-apoptotic proteins exist in equilibrium at basal state. Upon 
cytotoxic trigger, the BH3-only proteins bind with the anti-apoptotic proteins, thereby 
releasing the pro-apoptotic proteins to oligomerise on the outer mitochondrial 
membrane, releasing cytochrome C and inducing apoptosis.  
 
1.7.3 Extrinsic and intrinsic apoptotic pathways 
A wide array of stimuli may trigger apoptosis in mammalian cells via two 
major apoptotic pathways, the extrinsic and intrinsic pathways, both of which 
converge on the activation of the effector caspases. 
 
Upon activation of the intrinsic apoptotic pathway, for example, due to DNA 
damage or ER stress, p53 accumulates in the cell (Figure 1.17). p53 
transcriptionally upregulates BCL2 homology 3 (BH3)-only proteins, PUMA 
and NOXA (P. Wang et al. 2007, Akhtar et al. 2006, Chipuk et al. 2005). 
PUMA and NOXA bind and inhibit the BCL2 anti-apoptotic family members, 
BCL2, BCL-xL and MCL1, alleviating their inhibition of the pro-apoptotic 
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BCL2 family members, BAX and BAK (Yee and Vousden 2008). BAK and 
BAX can then oligomerise on the mitochondrial outer membrane, inducing 
mitochondrial outer membrane permeabilisation (MOMP). Alternatively, p53 
has also been shown to directly translocate to the mitochondria and bind 
competitively with BCL2 and BCL-xL, resulting in the release of BAK and 
BAX for MOMP induction (Mihara et al. 2003, Mikhailov et al. 2003, Basanez 
et al. 2002, Kuwana et al. 2002).  
 
MOMP results in the release of several pro-apoptotic proteins from the 
mitochondrial intermembrane space (IMS), including cytochrome C, 
Omi/htrA2 (high-temperature requirement) and Smac/DIABLO (second 
mitochondrial activator of caspases) to initiate or regulate caspase activation 
(Riedl and Salvesen 2007, Li et al. 1997, Yang et al. 1997, Kluck et al. 1997). 
Upon release from the mitochondria, these proteins promote apoptosis in 
various ways. Cytochrome C release induces the formation of an intracellular 
multicomplex structure, termed ‘apoptosome’ that contains APAF1 (apoptotic 
protease-activating factor 1) and procaspase 9 (Riedl and Salvesen 2007, Li 
et al. 1997). Procaspase 9 is activated in the apoptosome, which in turn 
cleaves and activates the downstream effector caspases, most notably, 
caspase 3 (Li et al. 1997, Jiang and Wang 2000). Both Smac/DIABLO and 
Omi/htrA2 bind and neutralize the inhibitory activity of the IAP family 
members (inhibitors of apoptosis) against caspases (Martins 2002, Martins et 
al. 2002, Verhagen et al. 2000, Du et al. 2000). In addition, Omi/htrA2 has 
also been reported to cleave ped/pea-15, an anti-apoptotic protein (Trencia 
et al. 2004). 
 
On the other hand, the extrinsic apoptotic pathway is activated by cell 
surface death receptors, including Fas, TNF (tumour necrosis factor), and 
TRAIL (TNF-related apoptosis-inducing ligand) receptors (Figure 1.17) 
(reviewed in (Jin and El-Deiry 2005). Binding of the respective ligands 
triggers homotrimerisation of the receptors and recruits an adaptor protein, 
FADD (Fas-associated death domain). FADD in turn recruits caspase-8 (the 
initiator caspase) to form a death-inducing signaling complex (DISC) (Figure 
1.17). Caspase-8 is autoactivated at the DISC, allowing it to proteolytically 
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cleave and activate downstream effector caspases, including caspase-3, 
caspase-6 and caspase-7 (Jin and El-Deiry 2005, Ashkenazi and Dixit 1998). 
Alternatively, caspase-8 can also amplify the apoptosis cascade by cleaving 
Bid. The truncated form of Bid (tBid) then oligomerises with BAK and BAX, 
leading to the release of cytochrome C and subsequent activation of 
caspase-9 follows the same downstream events as in the intrinsic apoptotic 
pathway (Wei et al. 2000). 
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Figure 1.17 Key events in extrinsic and intrinsic apoptotic signaling pathways. 
Intrinsic apoptotic signal triggers the accumulation of p53. p53 transcriptionally 
upregulates the BH3-only proteins, PUMA and NOXA.  PUMA, NOXA and p53 can 
bind and neutralize the inhibition of the BCL2 anti-apoptotic family members (BCL2, 
BCL-xL and MCL1) towards the BCL2 pro-apoptotic family members (BAK and 
BAX), causing them to oligomerise on the OMM and form pores that lead to 
mitochondrial outer membrane permeabilisation (MOMP). Several apoptosis 
regulators, including cytochrome C, Omi/htrA2 and Smac/DIABLO are release into 
the cytosol. Cytochrome C binds with APAF-1 and procaspase 9, forming the 
multicomplex ‘apoptosome’. The activation of caspase 9 by the apoptosome results 
in the downstream activation of effector caspases (caspase 3, 6, 7) and apoptosis. 
Both htrA2 and Smac bind and inhibit the IAPs, further amplifying the apoptotic 
signal.  
The extrinsic pathway is activated by the binding of ‘death’ ligands to the death 
receptors (including FAS, TNF and TRAIL receptors). The activated receptors then 
oligomerise and recruit both FADD and caspase-8, forming the DISC complex, 
which activates caspase 8. Caspase 8 can either directly activate caspase 3, 6 and 
 67 
7, or, it can cleave Bid, forming tBid. tBID can then bind to BAX and BAK to promote 
their oligomerisation on the OMM, converging with the intrinsic apoptotic pathway. 
 
1.8 Autophagic cell death 
Autophagy plays dual roles in cells. While moderate autophagy confers 
cytoprotective roles in response to nutrient starvation or growth factor 
deprivation, autophagy has also been observed in apoptotic cell death during 
excessive stress (He and Klionsky 2009, Eisenberg-Lerner et al. 2009). 
Indeed, the interplay between autophagy and apoptosis is highly complex 
and can be generalised into two different types as described below.  
 
1.8.1.1 The antagonist 
Autophagy acts as an alternative pathway to apoptosis (Figure 1.18A). For 
example, ER stress activates autophagy to selectively remove protein 
aggregates and misfolded proteins, thereby dampening the unfolded protein 
response (UPR) that could lead to apoptosis (Ogata et al. 2006, Castino et 
al. 2005). In addition, the selective removal of depolarised mitochondria via 
autophagy prevents the accumulation of ROS, which otherwise can cause 
DNA damage and activation of apoptosis (I. Kim et al. 2007). This 
antagonistic relationship between autophagy and apoptosis is often 
employed by cancer cells to evade cell death under unfavorable conditions, 
such as hypoxia and DNA damage. Ito and colleagues demonstrated that 
inhibition of autophagy using 3-methyladenine and bafilomycin A1 sensitises 
human malignant glioma cells to radiation-induced cell death, although these 
inhibitors would also interfere with the lysosomal pathway itself (Ito et al. 
2005). 
 
1.8.1.2 The partner / the enabler 
Apoptosis and autophagy may occur simultaneously, either in parallel, or 
cooperatively (often with one predominating the other) to cause cell death 
(Figure 1.18B). The idea is that if one pathway is inhibited or defective, the 
other serves as a back-up to ensure efficient cell death. (Eisenberg-Lerner et 
al. 2009). Alternatively, autophagy can assist apoptosis without directly 
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causing cell death (Figure 1.18C). This is best represented by the generation 
of cellular ATP via autophagy for the energy-dependent processes during the 
activation of apoptosis (Eguchi et al. 1999, Zamaraeva et al. 2005). For 
example, membrane blebbing during apoptosis requires ATP to drive acto-
myosin contraction (Inbal et al. 2002). Indeed, several known activators of 
apoptosis can also activate autophagy, including etoposide (in mouse 
embryonic fibrolasts), ceramide (breast and colon cancer cells) and the 
activation of the TRAIL receptors (various human cancer cell lines, including 
MCG-7, HCT116 and U87MG) (Park et al. 2007, Pattingre et al. 2009, Feng 
et al. 2005). In these cases, it is unclear whether autophagy occurs together 
with apoptosis to trigger cell death, or to generate ATP energy for 
subsequent apoptosis.  
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Figure 1.18 Schematic representation of the interplay between autophagy and 
apoptosis during cell stress. 
(A) Autophagy and apoptosis act as alternative mechanisms to induce cell death.  
(B) Autophagy and apoptosis can occur together during cell stress but in mutually 
exclusive pathways.  In this case, autophagy may or may not contribute to cell 
death.  
(C) Autophagy assists the progression of apoptosis via ATP production, leading to 
apoptotic cell death. 
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1.9 Aims of this study 
In this chapter, I have introduced the ubiquitin system, from the ubiquitin 
structure to the ubiquitin-modifying family of E1, E2, E3 and DUBs that are 
involved in reversible ubiquitylation. I also discussed our currently knowledge 
on the autophagy pathway, focusing especially on the involvement of 
ubiquitylation in selective autophagy of specific organelles. Mitophagy, the 
selective autophagy of mitochondria by PINK1 and Parkin was introduced in 
detail as the loss-of-function mutations of this kinase and E3 ligase, 
respectively, have been reported to cause neuronal cell death in AR-JP 
(autosomal recessive-juvenile Parkinsonism). The mechanism and key 
players involved in apoptosis as well as the interplay between autophagy and 
cell death were also introduced in this chapter.  
 
Our laboratory has a long-standing interest in the involvement of DUBs in 
various ubiquitin-mediated cellular processes. At the start of this project, the 
identity of DUBs that are involved in Parkin-mediated mitophagy, either 
opposing or assisting the E3 activity of Parkin was unknown. Therefore, the 
aims of my research project are:  
• To characterise Parkin-mediated mitophagy in cell lines expressing either 
endogenous or exogenous Parkin levels 
• To characterise the effects of different mitochondrial depolarizing drugs 
on mitophagy  
• To biochemically dissect the different stages of mitophagy by western 
blotting 
• To develop robust assays for both visual inspection and western blot 
analysis of Parkin-mediated mitophagy  
• To utilize these assays as readouts for DUB siRNA screens  
• To identify and deconvolute DUBs involved in Parkin-mediate mitophagy 
• To understand the mechanisms by which the identified DUBs regulate 
Parkin-mediated mitophagy. 
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Chapter 2: Materials and 
Methods 
2.1 Molecular biology 
2.1.1 Reagents  
Taq DNA Polymerase (BIO-21040) was purchased from Bioline (London, 
UK). Deoxynucleotide mix (100mM, #200415) and PfuUltra HF DNA 
Polymerase (#600390) were from Agilent (La Jolla, CA, USA). DH5α 
subcloning efficiency cells (#18265-017), S.O.C medium (#1554-034) and 
electrophoresis grade agarose powder were from Invitrogen (Paisley, UK). 
TAE buffer was obtained from National Diagnostics (Hull, UK). XL1-Blue 
supercompetent cells (#200236) were purchased from Agilent Technologies 
(Santa Clara, CA, USA). Miniprep (#27106), HiSpeed Maxiprep (@12633), 
RNeasy Mini (#74106), gel extraction (#28604) and PCR purification 
(#28704) kits were all from QIAGEN (Crawley, UK). Quick Ligation Kit 
(#M2200S), 1kDa DNA ladder (#N3232) and 100bp DNA ladder (#N3231) 
were purchased from New England Biolab (Herts, UK). PCR nucleotide Mix 
(#C1441), RNasin® plus RNAse inhibitor (#N2611) and nuclease free water 
(#P1193) were obtained from Promega (Madison, WI, USA). All primers were 
ordered from Eurofins MWG Operon (Ebersberg, Germany). All other 
chemicals were obtained from Sigma Aldrich (Poole, UK) unless otherwise 
stated. 
2.1.2 Polymerase Chain Reaction (PCR) 
DNA amplification by PCR was performed to clone RFP from pRFP-c1 vector 
to be used later to replace a GFP-tag from USP30-siRNARes1-GFP plasmid 
(Mullis et al. 1992). PfuUltra HF DNA polymerase was used to amplify RFP 
from pRFP-c1 vector and to insert BamHI and NotI restriction sites at each 
end of the RFP, forming BamHI-RFP-NotI. The primer sequences are shown 
in Table 2.1. PCR mixture was set up as shown in Table 2.2 and run using 
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according to the thermal cycle programmes as shown in Table 2.3 using a 
Techne TC-3000 Thermal Cycler (Scientific Laboratory Supplies Ltd., Hessle, 
UK). 
Target Primer No. 5'-3' Tm 
RFP 1837 F gaGGATCCatggcctcctccgaggacgtc 69 
1838 R gaGCGGCCGCttaggcgccggtggagtgg 72 
Table 2.1 PCR primer sequences for amplification of RFP from pRFP-c1.  
Capital letters in the primer sequence represents the insertion of sequence for 
recognition by BamHI (forward) and Not1 (reverse) restriction enzymes. 
 
Plasmid (100ng/µl) 1µl 
10x PCR buffer 5µl 
dNTP (25mM each) 0.4µl 
5’ primer (100ng/µl) 1.0µl 
3’ primer (100ng/µl) 1.0µl 
PfuUltra HF  1µl 
Sterile water y µl 
Total volume 50 µl 
Table 2.2 PCR reaction mixture. 
Segment Step No. of 
cycles  
Temperature  Duration 
1 Initial 
Denaturation 
1 95˚C 5 min 
2 Denaturation 34 95˚C 1 min 
Annealing  Tm-5˚C* 1 min 
Extension 68˚C 1 min /kb 
3 Final 
Extension 
1 68˚C 5 min 
Table 2.3 Thermal cycler programme for PfuUltra Hotstart DNA polymerase. 
Asterisk: annealing temperature is set 5˚C below the melting temperature. 
2.1.3 TOPO blunt-end cloning  
TOPO blunt-end cloning was catalyzed by topoisomerase I that was 
covalently bound to the phosphate group of thymidine residue at each end of 
the linearized pCR4®Blunt-TOPO vector. The open reading frame (ORF) of 
interest was first amplified by PCR and resolved on a DNA agarose gel 
(Section 2.1.7). The amplified construct was then cut out from the gel and 
eluted using the gel extraction kit from Qiagen according to manufacturer’s 
instructions. The eluted PCR product was then ligated with pCR4®Blunt-
TOPO vector with the cloning reaction described in Table 2.4 at room 
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temperature for 5min. The ligated plasmids were transformed into TOP10 
Escherichia coli as described in the next section. 
Reagent Volume 
pCR4®Blunt-TOPO vector 1µl 
Salt solution 1µl 
PCR product 1µl 
Sterile water 3µl 
Total volume 6 µl 
Table 2.4 TOPO cloning reaction mixture. 
2.1.4 Bacteria transformation 
Bacteria transformation was carried out using either TOP10 or DH5α 
Escherichia coli cells. Prior to transformation, 50µl of bacteria (per 
transformation reaction) was thawed on ice. 2µl of PCR product (from 50µl of 
PCR mixture) or approximately 100ng of DNA was added to the competent 
cells and left to incubate on ice for 20min. The cells were then heat-shocked 
at 42°C in water bath for 30sec and placed back on ice for 2min. 250µl of 
S.O.C. (super optimal broth with catabolite repression) medium was added to 
the bacteria suspension. The bacteria were shaken at 250rpm for 1hr and 
then inoculated on selective lysogeny broth (LB) agar plates with the 
appropriate antibiotic selection (Kanamycin: 10mg/ml, Ampicillin: 100mg/ml) 
and incubated at 37°C overnight. 
3-5 bacteria colonies per condition were selected for overnight culture in 5ml 
of LB medium with the appropriate antibiotic selection. DNA was purified 
from the bacteria culture using Qiagen MiniPrep Kit. Purified DNA samples 
were test-digested and positive constructs were sent for sequencing. All DNA 
constructs generated were sequenced at the DNA Sequencing Service 
(University of Dundee, UK). Bacteria with sequence-verified constructs were 
further expanded in 250ml of LB medium for DNA extraction using the 
Qiagen MaxiPrep Kit and glycerol stock was made as described in the next 
section. 
2.1.5 Glycerol stock 
5ml of overnight-growth bacteria cultured in LB medium was centrifuged at 
2,700xg to collect the bacteria pellet. The pellet was then resuspended in 
40% glycerol in LB medium and kept at -80°C. 
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2.1.6 Restriction digest 
Restriction digest mixture was set up as shown in Table 2.5. In general, 
500ng of DNA sample was used for test digest and 5µg of DNA sample was 
used for restriction cloning. The reaction mixture was incubated for 1hr and 
optimal incubation temperature varies according the restriction 
endonuclease(s) used (mostly 37°C). 
 
DNA sample x µl 
Restriction endonuclease 0.4 µl 
10x Reaction buffer 1.0 µl 
BSA (optional depending on restriction endonuclease) 1.0 µl 
Sterile water y µl 
Total volume 10 µl 
Table 2.5 Reaction mixture for restriction digest. 
2.1.7 Agarose gel electrophoresis 
Agarose gels were prepared by mixing electrophoresis grade agarose 
(Invitrogen) with TAE buffer (40mM Tris-acetate, 1mM Na2-EDTA) and 
heated in a microwave for approximately 4min (until the agarose had 
completely dissolved in the buffer). A final concentration of 0.5µg/ml of 
ethidium bromide was added to allow visualization of DNA using an 
ultraviolet (UV) light source. The gel was then poured and left to set at room 
temperature. Prior to loading, 10x sample buffer (5% w/v glycerol, 0.1mM 
EDTA, 0.04% bromophenol w/v blue) was added to DNA samples at 1:10 
dilution. DNA samples were resolved using TAE buffer in a horizontal midi 
electrophoresis tank (Fisher Scientific, Loughborough, UK) at 120V for 30 to 
60min. 10µl of Quickload 1kb DNA ladder standard was loaded alongside the 
samples. DNA bands were checked using the UVIDoc (UVITECH, 
Cambridge, UK) . 
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2.1.8 RNA extraction and quality control 
RNA from monolayer of cells was harvested using Qiagen RNeasy Kit as per 
manufacturer guidelines. The RNA concentration was determined using a 
NanoDrop Spectrophotometer ND1000 at 260nm. The quality of the nucleic 
acids was assessed by the ratios between 260nm to 230nm and 260nm to 
280nm. A high 260/280 ratio (>2.0) indicates low level of protein 
contamination whereas a high 260/230 ratio (>2.0) indicates low level of 
other contaminants such as salts, ethanol, guanidinium, or phenol. 5µl of 
RNA was also resolved on a 1.2% agarose gel with ethidium bromide 
(0.5µg/ml) by electrophoresis to visualize the 28S and 18S RNA bands which 
indicate the absence of RNAse and RNA degradation.  
2.1.9 Reverse Transcription 
A 10µl solution of 1µg of RNA in sterile water was prepared. The solution 
was then incubated with 1µl of oligo dT primers at 70°C for 5min to prime the 
poly(A) tails of mRNA. Afterwards, 8µl of reaction buffer was added to the 
diluted mRNA and oligo dT primers (see Table 2.6 for buffer composition). 
The tube was incubated at 37°C for another 5min before 1µl of MuLV reverse 
transcriptase was added to the tube. The reaction was carried out at 42°C for 
1hr, followed by 70°C for 10min. The final reaction mixture was made up to 
100µl with sterile water. 
 
5X reverse transcription buffer 4 µl 
PCR nucleotide mix 2 µl 
RNasin 0.5 µl 
Nuclease free deionised water 1.5 µl 
Total volume 8 µl 
Table 2.6 Reaction buffer mixture for reverse transcription. 
2.1.10 Quantitative real-time polymerase chain reaction (qRT-PCR) 
The primer pairs used for qRT-PCR were summarized in Figure 2.8. All qRT-
PCR primers were designed to contain 50-55% GC content, a melting 
temperature of approximately 58-60˚C and with a final amplicon of 
approximately 100-200bps. In addition, the primers also span an intron to 
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avoid amplification of genomic DNA. Designed primers were ordered from 
Eurofins MWG Operon (Ebersberg, Germany). Prior to use by qRT-PCR, the 
primers were tested by PCR with reverse-transcribed cDNA samples and 
resolved by gel electrophoresis to visualize the amplified DNA band (as 
described in section 2.1.9). As a negative control, RNA samples that were 
reverse-transcribed without dT-primers were used to ensure that no genomic 
DNA was amplified.  
cDNA generated from reverse transcription was used for qRT-PCR (Higuchi 
et al. 1992). A negative control was also included by replacing cDNA sample 
with nuclease free deionised water to ensure no amplification of 
contaminants. The reaction buffer was prepared using iTaqTM Universal 
SYBR® Green Supermix (Bio-Rad) according to manufacturer’s instruction 
(see Table 2.7). The cDNA sample was diluted 3-fold and 3µl of the diluted 
cDNA sample was added to the reaction mixture to reduce pipetting error. 
qRT-PCR was performed in triplicates using the CFX ConnectTM Real-Time 
PCR Detection System (Bio-Rad). cDNA samples were first denatured at 
95°C for 3min, followed by a two-step amplification protocol of 95°C (10sec) 
and 60°C (30sec) for 40 cycles. Melt curve was analysed after 40 cycles. The 
Ct values for test genes were normalized to actin and relative expression 
was represented as 2-[ΔΔCt] . 
 
At the early stage of my project, qRT-PCR was routinely used to monitor the 
knockdown efficiency of USP30 due to the lack of specific antibody for 
USP30. qRT-PCR was also used to assess the knockdown efficiency of 
USP31, USP42 and USP43 knockdown efficiency. 
 
 X1 Rxn 
2x SYBR Mastermix 5µl 
H2O 1.66µl 
Forward Primer 
(20µM) 0.17µl 
Reverse Primer 0.17µl 
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Total 7µl 
Vol Per well 7µl 
Vol. cDNA per well 3µl 
Table 2.7 iTaq Universal SYBR Green reaction buffer. 
Gene 5'-3' 
Tm 
(˚C) 
Location in 
Transcript 
(bp) 
Actin 
F CACCTTCTACAATGAGCTGCGTGTG 58 1068-1155 
R ATAGCACAGCCTGGATAGCAACGTAC 59 
MIRO1 
F ATCCAGAGAGGGAGACACGA 58 1167-1351 
R GCTCATCAGGTGACAAAGCA 58 
MIRO2 
F AGTGGGCAACAAGTCAGACC 59 462-655 
R GCTTGGCCTCAGGGTCATAG 60 
USP30 
F GCACCTTCTGAAAGCCTTGT 59 467-575 
R CGTGAGCATCCTGTTCTTCA 58 
USP31 
F CCTCCTCTGAAGCCACCATC 58 760-964 
R CATAGAGAGGCCTTGTGTGGG 58 
USP42 
F TCACCAGCTTGGAGACTGTCG 60 4018-4134 
R CAATCACCCTGGCCATACTCA 60 
USP43 
F AGAAGCTTCCGCCTGAAGC 60 728-905 
R TGGCGCAAGGGGATAGGTA 60 
Table 2.8 List of primers used for qRT-PCR. 
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2.2 Cell biology 
2.2.1 Materials and Reagents  
GeneJuice® transfection reagent was obtained from EMD Millipore 
(Darmstadt, Germany). Carbonyl cyanide m-chlorophenylhydrazone (CCCP; 
#C2759), DBeQ (SML0031), oligomycin A (#75351) and antimycin A 
(#A8674) were purchased from Sigma-Aldrich (poole, UK). Epoxomicin 
(#324800) and folimycin (#344085) were from Merck Milipore (Darmstadt, 
Germany). ABT-263 (#S1001) and ABT-737 (#S1002) were purchased from 
Stratech (Suffolk, UK). OligofectamineTM (#12252-011), LipofectamineTM 
RNAiMAX (#13778150) trypsin-EDTA (#15400), and Opti-MEM (#409864) 
transfection reagents and most cell culture reagents were purchased from 
Invitrogen (Paisley, UK) unless otherwise indicated. All plastic wares for cell 
culture were obtained from Corning Inc. (NY, USA). 
2.2.2 Cell culture 
Parental human telomerase reverse transcriptase-immortalized retional 
pigment epithelial (hTERT-RPE1) and HeLa S3 cells were provided by 
Francis Barr (University of Oxford, Oxford, UK). hTERT-RPE1 cells stably 
expressing YFP-Parkin were a gift from Dr. Jon Lane (University of Bristol, 
Bristol, UK). SH-SY5Y neuroblastoma, U2-OS osteosarcoma and A549 non-
small cell lung cancer cells were purchased from ECACC (Salisbury, UK). 
Parental hTERT-RPE1, hTERT-RPE1-YFP-Parkin and SH-SY5Y cells were 
maintained in Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 
Ham (DMEM/F12). U2-OS, A549 and HeLa S3 cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM). Both types of media were 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 0.1mM 
MEM non-essential amino acids (NEAA) and 100units/ml each of Penicillin 
and Streptomycin. All cells were cultured in a humidified 5% CO2 atmosphere 
at 37°C. For maintenance, confluent cells were split every 2-3 days at 1:4 – 
1:6 dilutions as appropriate using trypsin-EDTA. Briefly, cells were rinsed 
once in pre-warmed PBS and 1ml of trypsin was added to the cells and 
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incubated for 3-5mins in the incubator. Cells were then resuspended in 
complete medium and split accordingly.  
2.2.3 siRNA transfection in 6-well plates and 15cm2 dishes  
siRNA transfection of HeLa S3 cells was performed using Oligofectamine. 
For a 6-well plate setting, HeLa S3 cells were seeded overnight. On the next 
day, the cells were washed with PBS and replaced with 800µl of no addition 
DMEM (DMEM without FBS, NEAA and penicillin/streptomycin). 2µl of 20µM 
siRNA oligos was first incubated with 180µl of OptiMEM (Invitrogen). In 
parallel, 2µl of Oligofectamine was added to 18µl of OptiMEM. Both solutions 
were left to incubate at room temperature for 5min.  The two solutions were 
then mixed and left at room temperature for 20min. The transfection mixture 
was then added dropwise to each well. The final siRNA oligo concentration in 
each well is 40nM. The cells were then incubated for 4hr and FBS was 
added to the medium to a final of 10% concentration. The next day, the 
medium and siRNA transfection mixture were replaced with 2ml of fresh 
complete DMEM (supplemented with FBS, NEAA, and 
penicillin/streptomycin). For the SILAC experiments (described in chapter 7), 
cells were cultured and transfected in 15cm dishes. The volume of 
transfection reagents, siRNA oligos, OptiMEM and growth media were scaled 
up by 15 times of that for a transfection in a 6-well plate. 
 
siRNA transfection of SH-SY5Y, HEK293T, U2-OS, parental hTERT-RPE1, 
hTERT-RPE1-YFP-Parkin cells was carried out using Lipofectamine 
RNAiMAX transfection reagent following the ‘Reverse Transfection’ protocol. 
In the ‘Reverse Transfection’ protocol, cells were seeded and transfected at 
the same day. For a 6-well plate setting, 2µl of 20µM siRNA oligos was first 
incubated with 83µl of OptiMEM. In parallel, 2µl of Lipofectamine RNAiMAX 
was incubated with 83µl of OptiMEM. Both solutions were left to incubate at 
room temperature for 5min before being mixed together, vortexed and left at 
room temperature for 20min. Meanwhile, cells were trypsinised, and 
resuspended in complete medium (supplemented with FBS and NEAA but 
without penicillin/streptomycin). The desired number of cells was seeded per 
well to a final volume of 830µl. After 20min, 170µl of siRNA and transfection 
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reagent mixture was added dropwise to each well, giving a final 
concentration of 40nM of siRNA oligos per well. The next day, the medium 
and siRNA transfection mixture were replaced with 2ml of fresh complete 
medium (supplemented with FBS, NEAA, and penicillin/streptomycin). 
Unless stated otherwise, siRNA transfections for qRT-PCR were carried out 
for 24hr whereas siRNA transfections for protein lysate or fixation were 
normally carried out for 72hr. The siRNA oligo sequences used are 
summarized in Table 2.9. 
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Target Type  Oligo No.  Target sequence 
NT1 siOTP NT1 TGGTTTACATGTCGACTAA 
USP30 Custom 
order 
D1* CAAATTACCTGCCGCACAA 
siGenome D3** ACAGGATGCTCACGAATTA 
siGenome D4 GCCAAGAAGTTACTGATGA 
siOTP D6 CCAGAGTCCTGTTCGATTT 
siOTP D7 GGACATAAACCTAGTCAAC 
siOTP D8 CGTCAGATATAAAGTCATG 
siOTP D9 GTCATTACCTCGTCATTGG 
Qiagen  Q2 CACACCAGTATTTATCCTTAA 
Qiagen  Q5* AACAAATTACCTGCCGCACAA 
Qiagen  Q6 CTCCGATGACACTGTCCGCAA 
Qiagen  Q7** CTCACGAATTATTCCATGTCA 
MIRO1 siGenome D9 TGTGGAGTGTTCAGCGAAATT 
siGenome D10 GCAATTAGCAGAGGCGTTATT 
siGenome D11 CCAGAGAGGGAGACACGAATT 
siGenome D12 GCTTAATCGTAGCTGCAAATT 
MIRO2 siGenome D9 GCGTGGAGTGTTCGGCCAATT 
siGenome D10 CCTCAAGTTTGGAGCCGTTTT 
siGenome D11 GAGGTTGGGTTCCCTGATTATT 
siGenome D12 AGGAGATCCACAAGGCAAATT 
PINK1 siOTP D6 GCAAATGTGCTTCATCTAA 
siOTP D7 GCTTTCGGCTGGAGGAGTA 
siOTP D8 GGACGCTGTTCCTCGTTAT 
siOTP D9 GAGACCATCTGCCCGAGTA 
PARKIN siOTP D5 GUAAAGAAGCGTACCATGA 
siOTP D6 GAACATCACRRGCATTACG 
siOTP D7 GATAGTGTTTGTCAGGTTC 
siOTP D8 TTAAAGAGCTCCATCACTT 
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USP7 siOTP D5 AAGCGTCCCTTTAGCATTA 
siOTP D6 GCATAGTGATAACCTGTA 
siOTP D7 TAAGGACCCTGCAAATTAT 
siOTP D8 GTAAAGAAGTAGACTATCG 
 USP28 custom 
order 
A1 CUGCAUUCACCUUAUCAUUTT 
custom 
order 
A2 UUGGUUUAGUGCUGUUAUUTT 
Ambion A9 GUGAUUGCUUUAUACCGA 
Ambion A10 GATTATAGTTTGTTCCGAA 
Caspase 8 Qiagen Q11 GAGTCTGTGCCCAAATCAATT 
Caspase 9 Qiagen Q7 GTGACATCTTTGTGTCCTATT 
USP33 siOTP D6 GGGCATGTCTGGAGAATAGTT 
VPS35 siOTP D5 GAACATATTGCTACCAGTA 
siOTP D6 GAAAGAGCATGAGTTGTTA 
siOTP D7 GTTGTAAACTGTAGGGATG 
siOTP D8 GAACAAATTTGGTGCGCCT 
BAX siOTP D7 AAGTGGAGCTGACATGTTT 
siOTP D8 TGCCGGAACTGATCAGAAC 
siOTP D9 GCAAACTGGTGCTCAAGGC 
siOTP D10 CATCATGGGCTGGACATTG 
BAK siOTP D6 CGACATGAACCGACGCTAT 
siOTP D7 TATGAGTACTTCACCCCGA 
siOTP D8 GACGGCAGCTCGCCATCAT 
siOTP D9 AATCATGACTCCCAAGGGT 
Table 2.9 siRNA oligo sequences used for transfection. 
siRNA oligos are purchased from Dharmacon (siGenome and siONTARGETplus; 
siOTP), Qiagen or Ambion. Note that the Qiagen DUB siRNA oligos that are used 
for initial deconvolution only are described in the Qiagen siRNA oligo library (shown 
in appendix).  
* USP30 siRNA oligo D1 (from Dharmacon) and Q5 (from Qiagen) are the same 
sequence, with two additional nucleotides present in oligo Q5.  
** USP30 siRNA oligo D3 and Q6 have 11 overlapping nucleotides.   
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2.2.4 Transfection protocol for DUB siRNA screen in 96-well plates and 
6-well plates  
For the purpose of DUB siRNA screens (one live-cell imaging screen and two 
western blot screens described in Chapter 5), two custom-made DUB siRNA 
libraries were purchased from Qiagen. The first DUB siRNA library consists 
of siRNA against 92 DUBs, of which, each contains 4 individual siRNA oligos 
targeting the same DUB. At the later stage of my project, a second DUB 
siRNA library was obtained from Qiagen, which was an upgrade of the first 
library, containing two additional DUBs that were discovered later, namely, 
FAM105B/OTULIN and C14orf28. The usage of each of the DUB siRNA 
library and the cell types used are summarized in Table 2.10. The siRNA 
sequences used to target each of the 94 DUBs are listed in Supplementary 
Table 1.  
 
For the first siRNA screen (live-cell imaging), transfection was carried out in a 
96-well plate using RNAiMAX according to the ‘Reverse Transfection’ 
protocol described in the previous section. However, the volumes of 
transfection reagent, OptiMEM and growth media were scaled down by 8.5 
times of that for a standard 6-well plate transfection. The 10µM siRNA oligo 
stocks were also further diluted to 1.2µM prior to transfection so that 2µl of 
1.2µM of siRNA oligos were used per transfection to reduce pipetting error 
(final siRNA concentration 20nM). 
 
The second and third screens for western blot analysis were carried out in 6-
well plates and the siRNA transfection protocol follows exactly of that 
described in the previous section for hTERT-RPE1-YFP-Parkin cells and SH-
SY5Y cells. 
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 siRNA stock 
concentration 
Cell types 
First DUB siRNA 
library 
Live-cell imaging screen 
(96-well plate format) 
10µM à 1.2µM (further 
dilution prior to use) 
hTERT-RPE1-YFP-
Parkin cells (5000 
cells/well) 
Second DUB siRNA 
library  
Western blot screen  
(6-well plate format) 
10µM  hTERT-RPE1-YFP-
Parkin cells (3x10E5 
cells/well)  
SH-SY5Y cells (3x10E5 
cells/well) 
Table 2.10 Usage of different DUB siRNA libraries for different siRNA screens and 
cell lines.  
2.2.5 DNA transfection 
GeneJuice was used for transient DNA transfection in all the cell lines. For a 
6-well plate setting, cells were seeded into each well and incubated overnight 
at 37°C. The next day, the medium in each well was replaced with 1ml of 
fresh full DMEM. For DNA transfection, 1µg of plasmid was added to 100µl of 
OptiMEM and mixed by gently vortexing. Then, 3µl of GeneJuice was added 
in, vortexed and the mixture was left at room temperature for 20min before 
adding the mixture dropwise into each well. In the case of hTERT-RPE1 
(both parental and YFP-Parkin expressing cells), 5µl instead of 3µl of 
Genejuice were used to improve transfection efficiency. Unless stated 
otherwise, cells were harvested or fixed either 24 or 48hr post-transfection. 
For high expression DNA plasmids, the amount of plasmid was reduced and 
made up to 1µg by replacing the plasmid of interest with pBlueScript. In the 
case of expression for immunoprecipitation experiments, 3µg of DNA 
plasmids were used per 6cm dish of cells. 
2.2.6 Drug treatments 
Except during titration and in specified experiment, cells were treated with 
10µM of CCCP in complete medium (supplemented with NEAA and FBS). 
Oligomycin A and antimycin A were both used at 1µM. Epoxomicin and 
Folimycin were both used at 100nM. DBeQ was used at 5, 10 and 20µM. z-
VAD-FMK was used at 20µM. ABT-263 and ABT-737 were both used at 
10µM. 
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2.3 Protein Biochemistry 
2.3.1 Materials  
Mitochondria isolation kit (#130-094-872) was purchased from Miltenyi 
Biotech (Surrey, UK). BCA protein assay kit (#23225) was obtained from 
Pierce Biotechnology (Rockford, IL, USA). Protran nitrocellulose membrane 
(#B3-0042), ProtoGel Resolving Buffer (#B9-0010), ProtoGel Stacking Buffer 
(#B9-0014), SDS PAGE Tank Buffer, 10x (#B9-0032), ProtoGel (#A2-0072) 
were purchased from GeneGlow (Elmhurst, UK). Prestained broad range 
molecular weight marker (#P7708S) and unstained broad range molecular 
weight marker (#P7702S) were from New England Biolabs (NEB; Hitchin, 
UK). Bovine IgG (Immunoglobulin G), 2-mercaptoethanol (#M6250), 
Ponceau S (#P7170), ammonium persulphate (APS) (#A3678), digitonin 
(D141) mammalian protease inhibitors (#P8340), N-ethylmaleimide (NEM; 
#E1271) were from Sigma-Aldrich (Poole, UK). Mammalian phosphatase 
inhibitor cocktail was from Roche (Sussex, UK). Marvel skimmed milk 
powder was from Premier Brands, UK. DRAQ7 ( #7406) and annexin V-
AF350 (#A23202), DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride; 
#D1306), NuPaGE Bis- Tris 4-12% gels (10 well 1mm: #NP0321BOX, 10 
well 1.5mm: #NP0303BOX, 12 well 1.0mm: #NP0322BOX, 15 well 1.5mm: 
#NP0336, 20 well 1mm: #W61402A, 26-well 1mm: #WG1003), NuPAGE 
antioxidant (#NP0005), NuPAGE MES (#NP0002-02) and MOPS (#NP0001-
02) buffers, Colloidal stain kit (#LC6025) were all from Invitrogen (Paisley, 
UK). Mowiol (#475904) was purchased from Merck Millipore (Darmstadt, 
Germany). 
2.3.2 Cell lysis for protein harvest 
A monolayer of adherent cells were washed three times with ice-cold PBS on 
ice and harvested with either Nonidet P-40 (NP-40) lysis buffer (0.5% w/v 
NP-40, 25mM Tris-HCl pH7.5, 100mM NaCl, 50mM NaF), 
Radioimmunoprecipitation assay (RIPA) lysis buffer (1% Nonidet P-40, 
10mM Tris-HCl, pH7.5, 150mM NaCl, 1% sodium deoxycholate, 0.5% SDS), 
or ‘hot lysis buffer’ (1% SDS, 50mM NaF and 1mM EDTA at 110°C). Both 
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NP-40 and RIPA lysis buffers were supplemented with mammalian 
proteinase inhibitor cocktail. In specified experiments, N-ethylmaleimide 
(NEM) and mammalian phosphatase inhibitor cocktail were also added to 
NP-40 and RIPA lysis buffers to a final concentration of 10 mM to inactivate 
cysteine proteinases. Lysates were pre-cleared by centrifugation at 14,000 x 
g for 5min. ‘Hot lysate’ samples were harvested by washing cells three times 
with room temperature PBS. The cells were then scraped with rubber 
policemen in pre-heated ‘hot lysis buffer’ at 110°C on a heat block. The 
harvested ‘hot lysate’ samples were boiled at 110°C for 10min, with vigorous 
vortexing every 2min interval to shear the DNA content in the samples. 
2.3.3 Protein Assay  
BCA protein assay kit was used to measure the protein concentration of cell 
lysates according to manufacturer’s instructions. Bovine IgG was used to 
establish a standard curve. Table 2.11 shows a typical BCA protein assay. 
Samples were measured in triplicates and were read at OD562. 
 
 Water (µl) 1mg/ml 
IgG (µl) 
Lysis 
buffer (µl) 
Cell lysate 
(µl) 
BCA 
Mixture* 
(µl) 
Standard 
curve 
10 - 3 - 200 
8 2 
6 4 
4 6 
2 8 
0 10 
Sample 10 - - 3 
Table 2.11 Typical BCA protein assay. * BCA mixture was made by mixing 50 part 
of BCA Reagent A with 1 part of BCA Reagent B (50:1, Reagent A:B). 
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2.3.4 Mitochondria fractionation by TOMM22 antibody-affinity 
purification 
This mitochondria enrichment protocol was modified from Hornig-Do et al. 
(2009). Cells were rinsed twice with ice-cold phosphate-buffered saline 
(PBS). Cells were scraped using a rubber policeman in 5ml of cold PBS and 
spun down at 1000 x g for 2min at 4°C. The cell pellet was gently 
resuspended in 500µl of HIM buffer (200mM mannitol, 70mM sucrose, 1mM 
EGTA, 10mM HEPES, pH7.5, 1x mammalian protease inhibitor) and spun 
down at the same condition as before. Cell suspension was passed through 
a 23G needle 4-6 times to break the cell membrane. A small amount of the 
cell lysate was checked under the light microscope to assess the efficiency of 
homogenisation. The sample was centrifuged at 600g for 10min at 4°C to 
pellet the nucleus. The post-nuclear supernatant (PNS) was further 
centrifuged at 7000 x g for 15min at 4°C to pellet the mitochondria. The 
mitochondrial pellet was resuspended in 10ml of ice-cold separation buffer 
with 100µl of anti-TOM22 conjugated with iron microbeads from the 
mitochondria isolation kit (MACS Miltenyi Biotec). The suspension was 
incubated for 1hr at 4°C using a tube rotator. The antibody-bound 
mitochondria were then isolated by passing the suspension through a LS 
column attached to a MACS magnetic separator. The column was then 
washed three times with 3ml of separation buffer. The column was detached 
from the MACS separator and 1.5ml of separation buffer was pipetted into 
the column to elute the mitochondria. The mitochondria were spun down at 
13,000 x g for 2min at 4°C and resuspended in 50ul of NP-40 lysis buffer. 
Iron microbeads were pelleted by centrifugation using Beckman TLA100.2 
rotor at 184,000xg for 20min at 4°C. 
2.3.5 Crude mitochondria fractionation by centrifugation 
Before harvesting, cells from a 10cm dish were washed with ice-cold 
phosphate-buffered saline (PBS) and scraped off in PBS using a rubber 
policeman. Cells were centrifuged at 500 x g for 2min and resuspended in 
500µl of HIM buffer (200mM D- mannitol, 70mM sucrose, 1mM EGTA, 10mM 
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HEPES, pH7.5) supplemented with mammalian protease inhibitor. The cells 
were homogenized by passing through a 23G needle 4-6 times and then 
centrifuged at 700 x g for 5min. The PNS was further centrifuged at 7000 x g 
for 15min to pellet the mitochondria. The mitochondrial fraction was 
resuspended in 50µl of RIPA lysis buffer supplemented with mammalian 
protease inhibitor. 
2.3.6 Cytochrome-C release assay with Digitonin permeabilization 
Digitonin was dissolved in water at 1% (w/v) and stored at 4°C. Prior to use, 
digitonin solution was briefly heated at 95°C for 10sec to dissolve 
precipitated digitonin. To measure Cyt-C release from mitochondria, cells 
were scraped from a 10cm dish using a rubber policeman in ice-cold PBS. 
Cells were then spun down at 700 x g for 5min. The cell pellet was then 
resuspended gently (by flicking the tube) in 200µl of HIM buffer 
supplemented with mammalian  protease inhibitor and phosphatase inhibitor 
and 0.025% of digitonin. The cell suspension was incubated on ice for 10min 
followed by 5min centrifugation at 20,000 x g. The supernatant was collected 
in a separate tube and the pellet was resuspended in 200µl of RIPA lysis 
buffer supplemented with mammalian protease and phosphatase inhibitors. 
The pellet and supernatant fractions were resolved on a NU-PAGE at 1:3 
(v/v). 
2.3.7 Immunoprecipitation 
Protein concentration of pre-cleared lysates (as described in section 2.3.2 
and 2.3.3) were determined and adjusted to equal concentration using lysis 
buffer. Typically, 500-800µg of lysates were used per immunoprecipitation. 
The lysates were incubated with 1µg of anti-GFP antibody (provided by Ian 
Prior, University of Liverpool, UK),  and 30µl of 50% slurry protein-G agarose. 
The mixture was incubated on a rotating wheel at 4°C for 1-2hr. Beads were 
precipitated at top speed in a bench top centrifuge and washed three times 
with YP-IP buffer (0.1% Nonidet P- 40, 25mM Tris/HCl, pH7.5, 150mM 
NaCl), followed by a final wash with 10mM Tris/HCl, pH7.5. The pellet was 
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then resuspended in 20-30µl of 1.5 x SDS-PAGE sample buffer and boiled at 
98°C for 5min to retrieve proteins that were bound to the beads. 
 
An alternative immunoprecipitation method was also used in specified 
experiments using nanotrap, a 13-kDa GFP-binding fragment derived from a 
llama single-chain antibody (Rothbauer et al. 2008). Similar to the former 
immunoprecipitation protocol, pre-cleared lysates were incubated with 30µl of 
50% slurry of nanotrap cross-linked with beads for 2hr at 4°C. Beads were 
washed three times with YP-IP buffer (0.1% Nonidet P- 40, 25mM Tris/HCl, 
pH7.5, 150mM NaCl) and once with 10mM Tris/HCl, pH7.5. The pellet was 
then resuspended in 20-30µl of 1.5 x SDS-PAGE sample buffer and boiled at 
98°C for 5min to retrieve proteins that were bound to the beads. 
2.3.8 Sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-
PAGE) 
Protein samples were resolved by SDS-PAGE using the precast NUPAGE® 
4-12% Bis-Tris gels (Invitrogen, Paisley, UK). Protein samples were 
standardized to the same concentration. Samples harvested in NP-40 or 
RIPA lysis buffer were then resuspended in 5x sample buffer (50% w/v 
glycerol, 310mM Tris-HCl, pH6.8, 15% w/v SDS, 16% w/w 2-
Mercaptoethanol, 0.05% w/v Bromophenol Blue) and boiled at 98°C for 5min 
prior to loading onto gel. ‘Hot lysates’ were resuspended in 10x ‘hot lysis’ 
sample buffer (1M DTT and 1% Bromophenol Blue) and boiled at 110°C for 
5min before loading onto gel. Depending on the abundance of the protein of 
interest, 10-20µg of protein lysates were usually loaded. 
 
The Invitrogen NUPAGE system was used for most of the experiments using 
precast NUPAGE Bis-Tris 4-12% gradient gels in either an XCell SureLock 
Mini-Cell System (10,12 or 15 wells) or XCell SureLock Midi-Cell System (20 
or 26 wells). Generally, 3-(N-morpholino)propanesulfonic acid (MOPS) buffer 
was typically used in most experiment. 2-(N-morpholino)ethanesulfonic acid 
(MES) buffer was used to separate low molecular weight proteins. In general, 
gels were run at 180V for 60min (mini gel) or 75min (midi gel). 
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2.3.9 Western blotting 
Western blotting (Burnette 1981) was performed by transferring protein from 
SDS-PAGE onto 0.45µm Protran ® nitrocellulose membrane in transfer 
buffer (20ml methanol, 80ml water, 3.03g Tris and 14.4g glycine) at a 
constant current of 0.9A, 24V for an hour in in a Genie blotter (Research 
Products International Corp., Ill, USA). Following transfer, the nitrocellulose 
membrane was stained with Ponceau-S stain (Sigma Aldrich) to monitor the 
efficacy of transfer and to check for equal protein loading. The Ponseau-S 
stain was washed off with PBS. The membrane was then blocked for at least 
30min in 5% Marvel milk powder in PBS containing 0.1% Tween-20 (w/v) 
(PBS-T) at room temperature. Primary antibody incubation was carried out at 
the indicated time of either 1hr at room temperature or overnight at 4°C 
(Table 2.12). Unbound antibody was washed off with PBS-T (three times for 
5min each), followed by incubation with IRDye conjugated-secondary 
antibody (LICOR Biosciences; Table 2.13) at room temperature for 30min. 
Unbound secondary antibody was washed off with PBS-T (three times for 
5min each) followed by a final wash with PBS for 5min. Image acquisition 
was carried out using LI-COR Odyssey imaging system. Protein band 
intensities were quantified using ImageJ. Note that the blots were routinely 
cut into 2 or 3 parts to maximize the number of probings.  
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Antibody 
name 
Target 
protein 
Spec
-ies 
Source/ Cat. No. Dilution/ 
Duration 
Actin Actin R Sigma, A2206 1:2000, 1hr 
Actin Actin M Abcam, Ab6276 1:10000, 
1hr 
ACTN4 ACTN4 R from Kazufumi Honda, NA 1:1000, 1hr 
AGR2 AGR2 M From Laurent Dumartin, 
NA 
1:500, 1hr 
AHCYL2 AHCYL2 R GeneTex, GTX112212 1:1000, 1hr 
alpha-
Tubulin 
alpha-
Tubulin 
M Sigma, T5168 1:100, o/n 
BAK (G-23) BAK R Santa Cruz, SC-832 1:1000, 1hr 
BAX BAX M BD Transduction, 610982 1:1000, 1hr 
BCL-XL BCL-XL R Cell Signaling, 2764S 1:1000, 1hr 
BCL2 BCL2 M Abcam, AB692 1:1000, 1hr 
Caspase 3 Caspase 3 M Cell Signalling, 9668 1:1000, o/n 
Caspase 8 Caspase 8 R R&D, AF1650 1:1000, 1hr 
Caspase 9 Caspase 9 M Enzo, ADI-AAM-139-E 1:1000, 1hr 
Cytochrom
e C 
Cytochrome 
C 
Sh Sigma, C5723 1:1000, o/n 
DJ-1 DJ-1 R Bethyl, A300-744A 1:1000, o/n 
FKBP38 
(c391505) 
FKBP38/ 
FKBP8 
M R&D systems, MAD3580 1:1000, o/n 
GFP GFP Sh Ian Prior, NA 1:1000, 1hr 
IkB-a IkB R Cell Signaling, 9242 1:1000, o/n 
LC3 (5F10) LC3 M Nanotools, 5F10 1:200, o/n 
MCL1 (S-
19) 
MCL1 R Santa cruz, sc-819 1:1000, 1hr 
MFN2 MFN2 R Sigma, M6444 1:1000, o/n 
MGST1 MGST1 M From Ralf Morgenstern, 
NA 
1:500, 1hr 
MIRO1 MIRO1 R Sigma , HPA010687 1:1000, 1hr 
MUL1 MUL1/ 
MULAN 
R ABCAM, ab84067 1:500, o/n 
Myc (4A6) Myc M Millipore, 05-724 1:1000, 1hr 
OPA1 OPA1 R Abcam, ab54046 1:1000, o/n 
p53-DO1 p53 M Santa Cruz, sc-126 1:1000, o/n 
Parkin Parkin M Santa Cruz, sc32282 1:250, o/n 
PARP p85 
(ASP214) 
PARP-p85 M Cell Signalling, 9546 1:2000, o/n 
PINK1 PINK1 R Novus Biologicals, BC100-
494 
1:500, o/n 
RAB35 RAB35 R GeneTex, GTX112212 1:500, 1hr 
RFP RFP R Ian Prior, NA 1:5000, 1hr 
TIMM44 TIMM44 R Sigma, HPA043052 1:2000, o/n 
TOM20 TOM20 M Sigma , HPA011562 1:1000, 1hr 
TOM20 TOM20 M BD transduction 1:1000, o/n 
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laboratories, 612278 
USP15 
(1C-10) 
USP15 M Abnova, H00009958-MO1 1:1000, o/n 
UCHL5 UCHL5 R Epitomics, 3904-1 1:1000, o/n 
TOM22 
(1C9-2) 
TOM22 M Sigma, sc-58308 1:1000, 1hr 
USP30 USP30 R Gift from Genentech, NA 1:250, o/n 
USP28 USP28 R Bethyl, IHC-00176 1:1000, o/n 
USP21 USP21 R Sigma, HPA028397 1:1000, o/n 
USP33 USP33 R Bethyl, A300-925A 1:1000, 1hr 
USP8 USP8 R Sigma, HPA004869 1:1000, o/n 
USP7 USP7 R Abcam, ab4080 1:1000, 1hr 
VPS35 VPS35 G ABCAM, AB10099 1:1000, o/n 
Table 2.12 Primary antibodies for western blotting. (R: rabbit; M: mouse; Sh: sheep; 
G: goat; NA: Not applicable; o/n: overnight incubation) 
 
Secondary Antibody  Catalogue No.  Dilution 
Donkey anti-mouse IRDye 800CW 926-32212 1:15000 
Donkey anti-mouse IRDye 680CW 926-32222 1:15000 
Donkey anti-rabbit IRDye 800CW 926-32213 1:15000 
Donkey anti-rabbit IRDye 680CW 926-32223 1:15000 
Donkey anti-sheep IRDye 800CW 926-32214 1:15000 
Donkey anti-sheep IRDye 680CW 926-32224 1:15000 
Table 2.13 Secondary antibodies for western blotting. 
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2.3.10 Immunofluorescence staining 
Cells cultured on coverslips were washed three times with room temperature 
PBS. For most of the immunofluorescence staining, cells were fixed with 4% 
paraformaldehyde (PFA) in PBS for 15min. PFA was then quenched with 
50mM of ammonium chloride in PBS for 10min. Cells were then 
permeabilised with 0.2% Triton-X100 in PBS for 5min before blocking with 
10% goat serum in PBS for 20min. 
 
For LC3 staining, cells were first fixed with 4% PFA in PBS for 15min, 
followed by permeabilization with methanol for 5min at room temperature 
before blocking with 10% goat serum in in PBS for 20min. 
 
Next, cells were incubated with primary antibody in 5% goat serum in PBS 
for 1hr (Table 2.14), followed by three washes with PBS. Cells were then 
incubated with secondary antibody in 5% goat serum in PBS for 30min 
(Table 2.15). After that, cells were washed three times with PBS, rinsed with 
water and mounted onto glass slides with Mowiol plus 4’,6-diamidino-2-
phenylindole (DAPI). Immunofluorescence images were taken using either a 
Nikon Ti-Eclipse with a CFI Plan Apo VC 60x oil objective or a Leica confocal 
SP2 AOBS with a HCX PL APO CS, 63×, 1.40 oil objective. 
2.3.11 Live-cell microscopy 
Cells were placed in a humidified chamber with 5% CO2 at 37°C. Images 
were taken using a Nikon Ti-Eclipse microscope. The Perfect Focus System 
(PFS) was used to ensure accurate focusing. In specified experiments, 
DRAQ7 (0.3µM) and annexin V-AF350 (5µl per 1ml) were added to visualize 
dead cells and apoptotic cells, respectively. Images were captured using a 
CFI S Plan Fluor ELWD 20x objective. For comparison of different treatment 
conditions, video collages were made using Nikon NIS-Element software and 
exported as AVI files. Videos were labeled and time-stamped using ImageJ 
before being downsized into JPEG format and saved at 3 frames per second. 
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Antibody name Target 
protein 
Species Source/ 
Cat. No.  
Fixation Dilutio
n 
Caspase-3 
(Active) 
Cleaved 
Casp-3 
R R&D 
systems, 
AF835 
PFA 1:200 
cPARP (Asp214) 
clone D64E10 
Cleaved 
PARP 
R Cell 
Signaling, 
5625 
PFA 1:400 
Cyt-C Cyt-C  R BD 
Pharmigen, 
556432 
PFA 1:200 
FK2 ubiquitin M Enzo, 
PW8810 
PFA 1:2000 
LC3 clone 5F10 LC3 M Nanotools, 
5F10 
PFA & 
methanol 
1:200 
Myc Clone 4A6 Myc M Millipore, 
05-724 
PFA 1:500 
TOM20 TOM20 M Sigma , 
HPA01156
2 
PFA 1:1000 
Table 2.14 Primary antibodies used for immunofluorescence staining. (R: rabbit; M: 
mouse; PFA: paraformaldehyde) 
 
Secondary Antibody Catalogue No. Dilution 
Donkey anti-mouse AF350 A10035 1:200 
Donkey anti-rabbit AF350 A10039 1:200 
Donkey anti-sheep AF488 A11015 1:500 
Donkey anti-sheep AF594 A11016 1:500 
Donkey anti-rabbit AF488 A21206 1:500 
Donkey anti-rabbit AF594 A21207 1:500 
Donkey anti-mouse AF488 A21202 1:500 
Donkey anti-mouse AF594 A21203 1:500 
Table 2.15 Secondary antibodies used for immunofluorescence staining. All 
secondary antibodies were from Invitrogen.  
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2.4 Mass spectrometry 
2.4.1. Materials 
HPLC grade Acetonitrile (#20060320) and Water (#23595328) were from 
VWR (Lutterworth, UK). Trypsin Gold (#V5280) was obtained from Promega 
(Southampton,UK). LoBind Eppendorf tubes (#022431081) were purchased 
from Eppendorf (Hamburg, Germany). Stainess steel blades were sourced 
from Swann-Morton (Sheffield,UK). All other chemicals were obtained from 
Sigma Aldrich (Poole, UK) unless otherwise stated. 
2.4.2 Stable isotope labeling by amino acids in cell culture (SILAC)  
HeLa S3 cells were cultured in DMEM with 10% dialyzed FBS (Dundee Cell 
Products). Different amino acids were supplemented to generate light (L-
lysine, Lys0; L-arginine, Arg0), medium (L-lysine-2H4, Lys4; L-arginine-13C6, 
Arg6) and heavy (L-lysine-2H6-15N2, Lys8; L-arginine-13C6-15N4, Arg10) SILAC 
labeled cells. All L-lysines were supplemented at 146mg/L and all L-arginines 
were supplemented at 28mg/L. 200mg/L of L-proline was also supplemented 
to prevent arginine to proline conversion (Bendall et al. 2008). Cells were 
grown in the SILAC media for at least five passages prior to use for 
experiment to ensure maximal isotopic labeling. 
2.4.3 In-gel Digestion 
Protein samples (40-60µg) were run on a 4-12% NU-PAGE precast gel and 
stained using Colloidal Blue Staining Kit (Invitrogen) according to 
manufacturer’s instruction. Briefly, the gel was incubated in a fixing solution 
while gently shaking for 10min (seeTable 2.16), followed by a further 10min 
incubation in a staining solution (see Table 2.17). 5ml of Stainer B solution 
was then added into the staining solution and the gel was incubated for 3hr. 
After that, the staining solution was decanted and the gel was left in 200ml of 
deionized water and gently shaken overnight at room temperature to remove 
background staining. The visible protein bands were excised and diced into 
small pieces using a stainless steel blade. The gel pieces were transferred 
 96 
into a LoBind eppendorf tube and destained using 20µl of 1:1 volume of 
50mM ammonium bicarbonate and 50% acetonitrile (ACN). De-staining was 
carried out at 37°C for 10min each time. This step was repeated two to three 
times until gel pieces became transparent. The de-stain solution was 
discarded and replaced with 20µl of 1.5mg/ml DTT in 100mM ACN and 
further incubated at 37°C for 30min. The DTT solution was replaced with an 
equal volume of 55mM chloroacetamide (CAA) and further incubated at 37°C 
for 30min in the dark. The gel pieces were then dehydrated using 10µl of 
100% acetonitrile and incubated at 37°C for 10min. This step was repeated 
two to three times until gel pieces shrank and turned white. The solvent was 
removed and the residual solvent was left to evaporate with the lid of the 
LoBind tube open in a fume hood. 20µl of 1ng/µl of trypsin in 50mM of acetic 
acid was added to the gel pieces and incubated at 37°C for 1hr. A further 
10µl (or more, to completely cover the gel pieces) of ammonium bicarbonate 
was added and the samples were incubated at 37°C overnight. 
 
The next day, the solution was collected and an equal volume of 1% formic 
acid was added to the gel pieces and incubated for 20min before combining 
with the previous solution. The gel pieces were dehydrated by incubation 
with 100% ACN for 10min and the supernatant was collected in the same 
tube as the previous step. The collected mixture was dried using SpeedVac 
Concentrator Plus (Eppendorf) at 60°C. The dried samples were 
resuspended in 30µl of 0.05% trifluoroacetic acid (TFA). 
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Reagents Volume (ml) 
Methanol 100ml 
Acetic acid 20ml 
Ultrapure water 80ml 
Table 2.16 Fixing solution for NU-PAGE precast gel. 
Reagents Volume (ml) 
Deionized water 55ml 
Methanol 20ml 
Stainer A 20ml 
Table 2.17 Staining solution for NU-PAGE gel. 
2.4.4 Detection and identification of peptides 
5µl of each sample was loaded on high performance liquid chromatography 
column coupled to an LTQ-Orbitrap XL (Thermo Fisher) fitted with a Proxeon 
nanoelectrospray source. Samples were resolved on a 1-62% linear ACN 
gradient over 21mins. MS spectra were acquired by the Orbitrap at a 
resolution of 30,000 and MS/MS was performed on the TOP 5 ions. All 
spectra were acquired using Xcalibur software (version 2.0.7; Thermo Fisher 
Scientific). Raw MS spectra were searched against human.ipi.library and 
analyzed using MaxQuant (Cox et al. 2009, Cox and Mann 2008). 
2.4.5 Bioinformatic and statistical analysis  
The gene ontology (GO) terms of each protein identified were annotated by 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(Dennis et al. 2003). To maximize the identification of mitochondrial proteins, 
the list of proteins identified was also cross-referenced to the Mitocarta 
Database (Pagliarini et al. 2008). The significance A value for the change in 
SILAC protein ratio of each protein was analysed using Perseus (Cox and 
Mann 2012). 
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Chapter 3: Characterisation of 
Parkin-mediated Mitophagy 
3.1 Introduction 
Mitophagy is the selective removal of mitochondria by autophagy. 
Autophagy, similar to proteasomal and lysosomal degradation, involves the 
ubiquitylation of proteins as a signal for the recruitment of the autophagic 
machinery (Clague and Urbé 2010). In the context of mitophagy, the best-
characterised ubiquitin E3 ligase is Parkin. In this chapter, I describe the 
work that I carried out to characterise the cell lines to investigate Parkin-
mediated mitophagy with the following aims: (1) to assess the level of Parkin 
in different cell lines, (2) to compare different mitophagic stimuli, and (3) to 
characterise the ubiquitylation and turnover of mitochondrial proteins during 
mitophagy.  
3.2 Characterisation of cell lines expressing endogenous Parkin 
3.2.1 HEK293T cells express endogenous Parkin  
I first set out to analyse the levels of endogenous Parkin in a few cell lines 
available in the laboratory. The cell lines include: HeLa, HeLa S3, MCF7, 
HEK293T and A549 cells (Figure 3.1A). In addition, I also included a human 
telomerase reverse transcriptase-immortalised retinal pigment epithelial cell 
line stably expressing yellow fluorescence-tagged Parkin (hTERT-RPE1-
YFP-Parkin) as a positive control (gift from Jon Lane, University of Bristol).  
As shown in Figure 3.1A, hTERT-RPE1-YFP-Parkin cells express YFP-
Parkin at very high levels (indicated by arrow; 77kDa). Of the cells that I have 
analysed, only HEK293T cells showed a band corresponding to the 
molecular weight of endogenous Parkin (indicated by §; 51.6kDa). The ratio 
of protein band intensities (as measured with the Licor ImageStudio software 
associated with the Odyssey) suggests an approximately 87-fold 
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overexpression of Parkin in hTERT-RPE1-YFP-Parkin cells compared to 
HEK293T cells.  
 
Next, I characterised Parkin-mediated mitophagy progression in HEK293T 
cells (Figure 3.1B). For this, I used carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP), a potent small molecule membrane-permeable 
protonophore to disrupt the inner mitochondrial membrane potential. Upon 
CCCP treatment, I observed rapid cleavage of long OPA1 (L-OPA1) to short 
OPA1 (<4hr). This event occurs only in respiration-compromised 
mitochondria and serves as a good readout in my experiments to reflect the 
potency of drugs to induce inner mitochondrial membrane (IMM) 
depolarization (Ishihara et al. 2006). In addition, PINK1 accumulated in the 
cells upon CCCP treatment at 4hr and peaked at 8hr. I also observed a 
gradual increase in a higher molecular weight form of MIRO, indicative of 
ubiquitinated MIRO, whilst the unmodified form of MIRO and other outer 
mitochondrial membrane (OMM) and IMM proteins, including TOM20 and 
TIMM44, remained unchanged over the course of 24hr.  Note that the 
apparent decrease of TIMM44 levels at times 8 and 24hr shown in the 
representative experiment in Figure 3.1B is most likely due to underloading 
of the lanes (compare Actin levels of these timepoints). 
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Figure 3.1 Characterisation of endogenous Parkin level in different cell lines. 
(A) 20µg of NP40 lysates from hTERT-RPE1-YFP-Parkin, HeLa, HeLa S3, MCF7, 
HEK293T and A549 cells (non-stimulated) were immunoblotted with Anti-Parkin 
antibody. Arrow: YFP-Parkin. §: endogenous Parkin. High exp.: Intensity of blots 
was leveled in Adobe Photoshop to show the higher molecular weight species of 
MIRO. A representative blot is shown.   
(B) HEK293T cells were treated with 10µM of CCCP. Cells were harvested with 
NP40 lysis buffer at the indicated time. 20µg of lysates were immunoblotted as 
indicated. Asterisk: non-specific band. Bracket: high molecular weight, ubiquitylated 
MIRO (n=1). 
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3.2.2 SH-SY5Y cells express endogenous Parkin 
Since Parkin and PINK1 mutations have been associated with 
neurodegeneration in Parkinson’s disease, I also analysed the level of 
endogenous Parkin and investigated mitophagy in SH-SY5Y cells, a 
dopaminergic neuroblastoma cell line that is commonly used as an in vitro 
cell model for Parkinson’s disease (Xie et al. 2010). Similar to HEK293T 
cells, CCCP treatment induced accumulation of PINK1 starting at 4hr and 
peaked at 8hr in SH-SY5Y upon CCCP treatment (Figure 3.2A). I also 
observed the appearance of high molecular weight forms of MIRO in these 
cells, indicative of ubiquitylated MIRO. Note that the seemingly gradual loss 
of TIMM44 over time parallels the decrease in Actin and therefore is most 
likely due unequal SDS-PAGE to nitrocellulose membrane transfer.  
 
Since the Parkin antibody that I used detected multiple weak bands at high 
exposures in SH-SY5Y cells, I depleted Parkin by siRNA to visualize the 
band specific to Parkin (51.6kDa; Figure 3.2B). I found that a fuzzy band 
above the 43kDa marker was lost upon treatment with Parkin-specific siRNA, 
indicating that this is the endogenous Parkin. Further characterization work 
carried out by a colleague in the laboratory (Aitor Martinez) revealed that SH-
SY5Y cells weakly express endogenous Parkin compared with hTERT-
RPE1-YFP-Parkin cells and at a level similar to endogenous Parkin in 
HEK293T cells.  
 
I also used oligomycin A and antimycin A (O+A), which are inhibitors of the 
electron transport chain complex V and complex III, respectively as an 
alternative, more specific option to depolarise the mitochondria. Upon 24hr of 
O+A treatment, L-OPA1 is fully converted to S-OPA1. Interestingly the 
endogenous Parkin is depleted in the non-targeting control siRNA-
transfected cells (NT1, Ctrl IX). The low level of endogenous Parkin and its 
subsequent rapid depletion during mitophagy could potentially explain the 
general lack of mitophagy in these cells as indicated by the stable levels of 
TIMM44 over the course of O+A treatment. Surprisingly, PINK1 depletion by 
siRNA interference did not fully rescue the protein level of endogenous 
Parkin during O+A treatment.   
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Figure 3.2 Characterisation of Parkin-mediated mitophagy in SH-SY5Y cells.  
(A) SH-SY5Y cells were treated with 10µM of CCCP for the depicted time. The cells 
were then harvested in NP40 lysis buffer and immunoblotted for the respective 
proteins. Asterisk: non-specific band. Bracket: high molecular weight, ubiquitylated 
MIRO. A representative blot is shown.  
(B) SH-SY5Y cells were transfected with 40nM of either non-targeting controls (NT1 
and control IX) or siRNA oligos against PINK1 and Parkin for 72hr. Cells were then 
treated with 1µM of oligomycin A and 1µM of antimycin A (O+A) for 24hr. Cells were 
lysed with RIPA lysis buffer and immunoblotted as indicated. Asterisk: non-specific 
band; arrow: endogenous Parkin (n=1). 
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3.3 Mitophagy in Parkin-overexpressing cells 
Since cell lines with endogenous Parkin expression do not undergo robust 
mitophagy, I proceeded to induce mitophagy in hTERT-RPE1 cells stably 
expressing YFP-Parkin (hTERT-RPE1-YFP-Parkin).  
 3.3.1 Characterisation by immunofluorescence microscopy 
I first characterised mitophagy in these cells by immunofluorescence 
microscopy (Figure 3.3A). I counterstained fixed cells with anti-TOM20 
antibody to visualize the mitochondria. Under basal conditions, YFP-Parkin is 
expressed and localised to the cytosol. YFP-Parkin is recruited to the 
mitochondria as shown by TOM20 colocalisation as early as 1hr after CCCP 
treatment. At 4hr, the Parkin punctae gradually form larger perinuclear 
aggregates. These Parkin-decorated mitochondrial aggregates will 
henceforth be referred to as Parkin aggregates. At 8hr, approximately 40% of 
the Parkin aggregates are lost. By 12hr, up to 80% of the cells have 
undergone complete mitophagy and newly synthesised Parkin is cytosolic 
again. Cells that do not express Parkin still retain their mitochondria, 
although these are fragmented.  
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Figure 3.3 Timecourse of CCCP treatment in hTERT-RPE1-YFP-Parkin cells.  
(A) hTERT-RPE1-YFP-Parkin cells were treated with CCCP for the indicated times. The cells were fixed and stained with anti-TOM20 (mouse). 
Single confocal sections were taken using a Leica confocal microscope at 63x magnification. Scale bar: 10µm. 
(B) The number of cells that showed Parkin recruitment (colocalisation with TOM20) and the number of cells that are positive for TOM20 
staining were counted and expressed as a percentage of total cells. ~200 cells per condition were quantified. Error bar represents standard 
deviation of 3 or 5 (*) independent experiments.  
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3.3.2 Western blot analysis of mitophagy  
I also assessed the progression of mitophagy biochemically using western 
blotting. To this end, I compared lysates from hTERT-RPE1-YFP-Parkin cells 
in parallel with those from SH-SY5Y and also hTERT-RPE1 cells (Figure 
3.4).  In all three cell lines, PINK1 gradually accumulates over time. The 
accumulation of PINK1 is slower and weaker in SH-SY5Y cells. The OMM 
protein, MIRO, is ubiquitinated upon CCCP treatment in SH-SY5Y and 
hTERT-RPE1-YFP-Parkin cells but not in the parental hTERT-RPE1 cells. 
Nonetheless, the ubiquitylation pattern of MIRO is different in SH-SY5Y cells 
and hTERT-RPE1-YFP-Parkin cells. The data also show that both OMM and 
IMM proteins, as represented by MIRO and TIMM44 respectively, are only 
visibly degraded when there is an excessive amount of Parkin. I also 
observed an intriguing increase in the accumulation of PARP-p85, a cleaved 
fragment of PARP (Poly ADP-ribose polymerase) that is cleaved by caspase 
3 during apoptosis (Tewari et al. 1995). This observation will be further 
discussed in detail in chapter 4. 
3.3.3 Spatial and temporal analysis of PINK1 accumulation and Parkin 
activation 
To further characterise the accumulation of PINK1 at the OMM and Parkin 
recruitment to the mitochondria in hTERT-RPE1-YFP-Parkin cells, I carried 
out a crude mitochondria enrichment (Figure 3.5). As controls for the 
mitochondria enrichment, I probed for different mitochondrial proteins, 
including MIRO (OMM protein), TIMM44 (IMM protein) and Cyt-C 
(mitochondria intermembrane space protein). These proteins were only 
present in the mitochondria-enriched fraction (MF). CCCP treatment also led 
to ubiquitylation of MIRO, as shown by the characteristic ubiquitin laddering 
that appeared at 2-4hr after CCCP treatment. MIRO, TIMM44 and Cyt-C 
levels decreased at 6hr of CCCP treatment. Interestingly, PINK1 and Parkin 
were present both in the post-mitochondrial supernatant (PMS) and the MF.  
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Figure 3.4 Comparative biochemical dissection of the progression of mitophagy in 
SH-SY5Y, hTERT-RPE1 and hTERT-RPE1-YFP-Parkin cells. 
The three different cell lines were treated with 10µM of CCCP for the indicated 
times. The cells were lysed in NP40 lysis buffer and probed for the depicted 
proteins. For the PINK1 and Parkin western blot, the RPE1-YFP-Parkin lysate 
samples were resolved and exposed separately to that for SH-SY5Y and RPE1. A 
representative blot is shown. Arrow: Endogenous Parkin. 
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Figure 3.5 Spatial and temporal analysis of PINK1 and Parkin localisation during 
CCCP treatment. 
hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM) and harvested in 
PBS by gently scraping the cells using a rubber policeman at the indicated times. 
Mitochondria fractions (MF) were enriched using the crude mitochondria 
fractionation method (described in chapter 2, section 2.3.5) and resuspended in 
RIPA lysis buffer. 10µg of lysates from each fraction were resolved to probe for the 
indicated proteins. Shown is a representative blot. PMS: post-mitochondrial 
supernatant; MF: mitochondrial fraction. Bracket: Ubiquitin laddering of MIRO.  
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3.4 Optimisation of mitophagy-stimuli 
3.4.1 Selection of drugs to induce mitophagy in hTERT-RPE1 cells 
Mitophagy is generally triggered by the loss of mitochondrial membrane 
potential, whereupon, PINK1 fails to be imported into the mitochondria, 
interacts with the TOM complex and recruits Parkin to the mitochondrial outer 
membrane (Jin et al. 2010). The experiments I described prior to this section 
were mostly carried out using CCCP treatment. Although CCCP has been 
widely used in the study of mitophagy, its non-selective ability to increase 
proton conductance in any organellar membrane also extends to the 
lyososomal membrane, raising concern on its effect on the lysosome during 
autophagy (Padman et al. 2013). Therefore, I compared CCCP-induced 
mitophagy with a selection of other chemical compounds (see Table 3.1).  
 
Chemicals Description and mechanism of action 
CCCP 
Small membrane permeable ionophore; depolarizes 
mitochondrial membrane potential (and dissipates proton 
gradients in other membranes) 
Rotenone Inhibitor for electron transport chain (ETC) complex I (NADH-coenzyme Q reductase) 
Oligomycin A Inhibitor of the ETC complex V (F0/F1-ATP synthase)  
Antimycin A Inhibitor of the ETC complex III (Cytochrome C oxidoreductase) 
Table 3.1 Selection of chemical compounds tested to induce mitophagy 
3.4.2 Carbonyl cyanide C-chlorophenyl hydrazine (CCCP)  
CCCP was the first choice to induce mitophagy as it has been extensively 
used in the field to induce mitochondrial membrane depolarization. In earlier 
experiments, I took reference from published literature and used 10µM of 
CCCP to induce mitophagy (general working concentration of CCCP ranges 
from 5-20µM) (W. X. Ding et al. 2010, MacVicar and Lane 2014, Tanaka et 
al. 2010, Narendra et al. 2010, Narendra et al. 2008, Sarraf et al. 2013). 
Since I can observe robust translocation of Parkin to the mitochondria and 
also the loss of mitochondrial proteins, I decided not to increase the 
concentration of CCCP to avoid non-specific effects. Instead, I tested lower 
concentrations of CCCP. 0.1 or 1µM of CCCP were not sufficient to induce 
Parkin recruitment to the mitochondria in these cells (Figure 3.6).  
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Figure 3.6 Titration of CCCP concentration in hTERT-RPE1-YFP-Parkin cells. 
hTERT-RPE1-YFP-Parkin cells were treated with 0.1, 1 and 10µM of CCCP up to 
24hr. The cells were fixed in 4% PFA and mounted onto glass slides using Mowiol 
with DAPI. 200 cells per condition were counted. Error bar represents standard 
deviation of 3 independent experiments.  
  
A.
B.
0%  
20%  
40%  
60%  
80%  
100%  
0   4   8   12   16   20   24  
C
el
ls
  w
ith
  T
O
M
20
  s
ta
in
in
g  
(%
)  
CCCP  (hr)  
0.1 M  
1 M  
10 M  
0%  
20%  
40%  
60%  
80%  
100%  
0   4   8   12   16   20   24  
C
el
ls
  w
ith
  P
ar
ki
n  
R
ec
ur
itm
en
t  (
%
)    
CCCP  (hr)  
0.1 M  
1 M  
10 M  
 110 
3.4.3 Rotenone does not induce mitophagy  
We asked if a more specific inhibitor of the mitochondrial ETC could induce 
mitophagy. I first tested rotenone, a compound that selectively inhibits NADH 
oxidation via the NADH-ubiquinone oxide reductase complex (complex I) 
(Hartley et al. 1994). As shown in Figure 3.7, 10µM of CCCP efficiently 
induced mitophagy in hTERT-RPE1-YFP-Parkin cells. In contrast, 100nM of 
rotenone did not induce mitophagy, as evidenced by the lack of TOM20 and 
TIMM44 degradation. Moreover, rotenone treatment did not induce L-OPA1 
cleavage, a process that depends on mitochondria depolarisation in either 
parental or Parkin-overexpressing hTERT-RPE1 cells. This suggests that 
rotenone treatment alone is insufficient to trigger mitochondrial damage. 
 
I further titrated the concentration of rotenone ranging from 0.1µM to 100µM 
for 8hr (Figure 3.7B). No OPA1 cleavage or PINK1 recruitment was 
observed. In addition, both MIRO and TIMM44 levels remained unchanged at 
all concentrations of rotenone. At higher concentrations (10µM and 100µM), I 
observed slightly higher levels of both LC3-1 and LC3-II. I concluded that 
rotenone does not induce mitophagy, although it may induce some general 
autophagy in these cells.  
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Figure 3.7 Comparison of CCCP and rotenone treatment for mitophagy induction. 
(A) hTERT-RPE1 (parental and YFP-Parkin expressing) cells were treated with 
10µM of CCCP or 100nM of rotenone for 8hr. Cells were lysed in RIPA lysis buffer. 
10µg of lysates were immunoblotted as indicated.  
(B) hTERT-RPE1-YFP-Parkin cells were treated with varying concentration of 
rotenone (0.1µM to 100µM) for 8hr. Cells were lysed in RIPA lysis buffer. 10µg of 
lysates were immunoblotted as indicated.  
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3.4.4 Oligomycin A and antimycin A synergistically induce mitophagy 
Oligomycin A and antimycin A are inhibitors of the ETC complex V and III, 
respectively. To test if these two drugs induce mitophagy in hTERT-RPE1-
YFP-Parkin cells, I followed their effects using live-cell imaging of YFP-
Parkin. Treatment with either of these two drugs individually at 0.1 and 10µM 
did not induce any Parkin recruitment, up to 12hr of exposure. At a higher 
concentration (100µM), 90% of the antimycin A treated cells show Parkin 
recruitment (Figure 3.8). Oligomycin A treatment at 100µM did not induce 
any Parkin recruitment. However, approximately 90% of the cells 
simultaneously treated with just 100nM of oligomycin A and antimycin A 
underwent Parkin recruitment. Moreover, the kinetics of Parkin recruitment, 
increased with the concentration of the drugs.  
 
The induction of mitophagy by oligomycin A and antimycin A can also be 
seen with western blotting, as Parkin was autoubiquitylated 1hr after 
application (Figure 3.2). It is also apparent that 10µM of CCCP and 1.0µM of 
oligomycin A and Antimycin A (O+A) treated cells had faster OPA1 cleavage 
(1hr instead of 4hr) compared to 0.1µM of O+A. In addition, MIRO 
degradation is also enhanced (seen first at 1hr instead of 4hr). Similar to 
CCCP treatment, I observed PARP cleavage with O+A treatment, reflecting 
the presence of cell death during the treatment. The level of PARP-p85 
directly correlates with the concentration of O+A used.  
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Figure 3.8 Simultaneous treatment of oligomycin A and antimycin A induced Parkin 
recruitment. 
hTERT-RPE1-YFP-Parkin cells were treated with DMSO, CCCP (10µM) and 
different concentrations of oligomycin A and antimycin A as indicated. YFP-Parkin 
recruitment was monitored by live-cell imaging. Images show representative still 
frames at 4hr of treatment. Scale bar: 20µm.   
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Figure 3.9 Comparison of CCCP, Oligomycin A and Antimycin A treatment. 
hTERT-RPE1-YFP-Parkin cells were treated with either 10µM of CCCP or 
oligomycin A and antimycin A (O+A; 0.1µM each or 1µM each) for the indicated 
times. The cells were harvested with NP40 lysis buffer supplemented with 
mammalian protease inhibitor. 10µg of lysates were immunoblotted as indicated. 
Shown is a representative blot.  
3.5 Discussion 
In this chapter, I summarized the work I carried out to characterise the 
expression of Parkin in several cell lines and the link between Parkin 
expression level and the ability of cells to undergo mitophagy. Of the cell 
lines that I have tested, I observed no endogenous Parkin expression in 
HeLa or A549 cells. Consistent with the literature, SH-SY5Y and HEK293 
cells, from which HEK293T cells are derived from, express endogenous 
Parkin and are commonly used in the field to study Parkin biology (Van 
Humbeeck et al. 2011a, Narendra et al. 2008, Van Humbeeck et al. 2011b, 
Zhao et al. 2003, Ren et al. 2003, Finney et al. 2003). Endogenous Parkin 
levels in HEK293T and SH-SY5Y cells were expressed at very low levels and 
high intensity imaging was required during western blotting to visualize the 
band. Upon mitochondrial depolarization in HEK293T and SH-SY5Y cells 
using CCCP and O+A, respectively, I found that MIRO is ubiquitylated. 
However, the unmodified form of MIRO and other mitochondrial markers, 
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including TOM20 (OMM protein) and TIMM44 (IMM protein) were not 
degraded. 
 
Importantly, I found that 24hr of O+A treatment in SH-SY5Y cells depleted 
endogenous Parkin. This observation is consistent with the notion that 
mitochondrial depolarization induced PINK1-dependent activation of the E3 
ligase activity of Parkin, leading to its self-ubiquitylation and proteasomal 
degradation (A. Rakovic et al. 2013, Shiba-Fukushima et al. 2012). It has 
previously been demonstrated that in the presence of two E2 conjugating 
enzymes, UbcH7 and UbcH8, Parkin has the ability to self-ubiquitylate and 
target itself for proteasomal degradation both in vivo and in vitro (Zhang et al. 
2000). Finney and colleagues further demonstrated using truncated Parkin 
constructs that the self-ubiquitylation and degradation of Parkin is dependent 
on the N-terminal UBL, without which, the level of the truncated Parkin is 
markedly stabilised (Finney et al. 2003).  
 
While translocation of endogenous Parkin to depolarized mitochondria has 
been demonstrated in HEK293 and SH-SY5Y, endogenous Parkin in general 
does not induce robust mitophagy. In most studies in the literature, stable cell 
lines overexpressing Parkin are employed to amplify the effect of Parkin-
mediated mitophagy (Aleksandar Rakovic et al. 2013, Narendra et al. 2008). 
Most notably, Grenier and colleagues reviewed and compared 
comprehensively the differences in the response of immortalized cell lines 
and primary neurons to CCCP (Grenier et al. 2013). They hypothesized that 
primary neurons, unlike immortalized cells, are heavily dependent on 
mitochondria for ATP generation via oxidative phosphorylation (OXPHOS) 
and are incapable of utilizing glycolysis to generate energy (Almeida et al. 
2001). Subsequently, complete degradation of mitochondria is unlikely a 
default mechanism of these cells upon mitochondrial depolarisation. This 
hypothesis is further supported by Kanki and Klionsky (2008) who 
demonstrated that amino acid starvation of yeast cultured in non-fermentable 
carbon source (lactate) induced low level of mitophagy while amino acid 
starvation of yeast cultured in fermentable carbon source (glucose) induced 
high levels of mitophagy (Kanki and Klionsky 2008). In mammalian cells, 
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MacVicar and colleagues have also made similar observations. Conditioned 
in galactose-based medium, hTERT-RPE1 cells become resistant to CCCP-
induced OPA1 cleavage by OMA1 and therefore are more resistant to 
mitophagy (MacVicar and Lane 2014). These reports suggest that global 
mitophagy is unlikely to be the ‘default’ mechanism for neuronal and 
OXPHOS-dependent cells in the face of complete mitochondrial 
depolarization by CCCP as this could severely affect the bioenergetics in 
neuronal cells. Instead, it is likely that the low and ‘self-limiting’ endogenous 
level of Parkin exists in neuronal cells to selectively remove small pools of 
dysfunctional mitochondria from the healthy population of mitochondria.  
 
I next characterised mitophagy induction in Parkin-overexpressing hTERT-
RPE1 cells. This cell line was kindly provided to us by Jon Lane and has 
previously been shown to undergo bulk mitophagy upon CCCP treatment 
(MacVicar and Lane 2014). CCCP induced rapid recruitment of Parkin to the 
surface of mitochondria within the first 4hr of treatment. At 12hr, most of the 
cells have cleared their Parkin aggregates. Titration on the concentration of 
CCCP showed that that 10µM of CCCP is the minimal concentration that is 
required to induce mitophagy in these cells. Intriguingly, CCCP treatment at 
8hr also induced cell death in these cells. The cell death was observable 
under the light microscope and was further confirmed by western blotting 
with anti-PARP-p85 antibody. Since Parkin-mediated mitophagy has been 
reported to confer cytoprotection, this observation is unexpected and is 
further characterised in Chapter 4 (Ekholm-Reed et al. 2013, Johnson et al. 
2012).  
 
Another important question in Parkin-mediated mitophagy concerns the type 
of stimuli that should be used to induce mitochondrial damage. Carbonyl 
cyanide m-chlorophenylhydrazone (CCCP) is the most commonly used 
chemical compound to depolarize the mitochondria. CCCP is a lipid-soluble 
weak acid that acts as a protonophore, capable of increasing the 
conductance of lipid bilayers by several order of magnitude (Kasianowicz et 
al. 1984). This property of CCCP has been applied to dissipate the proton 
gradient that is actively generated by the electron transport chain, thereby 
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collapsing the inner mitochondrial membrane potential and inhibiting ATP 
generation by OXPHOS. However, CCCP does not specifically target the 
inner mitochondrial membrane only. Instead, CCCP depolarizes any 
organellar membranes with proton gradient, including the lysosomes and 
peroxisomes (Jankowski et al. 2001, Padman et al. 2013). Since 
autophagosomes fuse with lysosomes at the later stage of autophagy, the 
use of CCCP raises concern whether lysosome acidification could be 
inhibited with CCCP treatment. Currently, the jury is still out as opposing 
observations were made on the effect of CCCP on the lysosome. Padman 
and colleagues demonstrated using electron microscopy that remnants of 
mitochondria remains in cells after 24hr of CCCP treatment (20µM) in HeLa 
cells expressing Parkin (Padman et al. 2013). On the other hand, Ding et al. 
reported the release of GFP from GFP-LC3 during CCCP treatment (30µM) 
as evidence for functional lysosomes in the same cell line as the former 
(Wen-Xing X. Ding et al. 2010). In my case, CCCP treatment (10µM) on 
hTERT-RPE1-YFP-Parkin cells induced Parkin activation and also loss of the 
IMM protein, TIMM44. Since IMM proteins are inaccessible to the 
proteasome, the loss of IMM proteins during mitophagy is generally 
considered to take place via the autolysosomal pathway. Therefore, it is most 
likely that CCCP does not affect the lysosomal activity in these cells. 
However, to unequivocally address this issue, one should measure the pH of 
the lysosome (for example, using lysotracker or acridine orange) or the 
degradation of a known lysosomal substrate such as the epidermal growth 
factor receptor (EGFR) (Pierzynska-Mach et al. 2014, Opresko et al. 1995).  
 
Epidemiological studies showed correlation between the exposure of 
pesticides and increased risk of Parkinson’s Disease (PD) (Gorell et al. 1998, 
Menegon et al. 1998). Interestingly, exposure to rotenone, a high affinity 
inhibitor of the ETC complex I that is commonly used as a broad-spectrum 
insecticide and pesticide, has also been associated with an increased risk of 
Parkinson’s Disease. Rotenone-treated rats exhibited many characteristics of 
PD, including nigrostriatal dopaminergic degeneration caused by caspase 3 
activation and Lewy body-like cytoplasmic inclusions with alpha-sycnuclein 
accumulation ((Betarbet et al. 2000, Betarbet et al. 2002, Sherer et al. 2002, 
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Alam and Schmidt 2002, Sherer et al. 2003a, Sherer et al. 2003b). In 
addition, exposure of rats to another ETC complex I inhibitor, 1-methyl-4-
phenyl-2,3-dihydropyridinium (MPP+), the active metabolite of N-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), also induced similar Parkinson-
like symptoms.  
 
Therefore, I sought to determine if inhibition of ETC complex I by rotenone 
treatment could induce mitophagy in hTERT-RPE1-YFP-Parkin cells. Using 
rotenone concentrations ranging from 100nM to 100µM, I did not observe 
any loss of MIRO or TIMM44 up to 8hr of treatment. This observation is 
consistent with most studies, which showed that inhibition of the ETC 
complex I with rotenone does not induce mitophagy (Tanaka et al. 2010, 
Chan et al. 2011). Chan et al. (2011) suggested that localized mitochondrial 
dysfunction per se might not be sufficient to induce activation of Parkin. 
Instead, a severe mitochondrial depolarisation is required for the recruitment 
and activation of Parkin at the mitochondria (Chan et al. 2011). Indeed, it has 
been shown that rotenone treatment has a modest effect on overall ATP 
production in cells (30% decrease at 1µM of rotenone treatment) and even 
less effect on mitochondria depolarization (10%) (Chu et al. 2013, Li et al. 
2003). Nonetheless, long duration of rotenone treatment induces a chronic 
accumulation of ROS and has been shown to trigger cell death after 36hr of 
treatment in HL-60 (human promyelocytic leukemia cells) and HT-1080 
(human fibroscarcoma cells) (Li et al. 2003). Since I only treated my cells 
with rotenone for 8hr, this might explain the lack of visible changes in the 
cells. It is worth noting that rotenone (1µM) has recently been shown to 
induce mitophagy independent of Parkin and p62 recruitment in rat cortical 
neurons (Chu et al. 2014, Chu et al. 2013). This rotenone-induced mitophagy 
is mediated by the externalisation of cardiolipid, a diphosphatiylglycerol lipid 
that normally exists in the IMM, which subsequently recruits LC3 directly to 
the mitochondria (Chu et al. 2014, Chu et al. 2013).  
 
I also investigated the effect of chemical inhibition of complex III and complex 
V of the ETC by antimycin A and oligomycin A, respectively on Parkin 
recruitment to the mitochondria. At 10µM or lower concentrations, oligomycin 
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A and antimycin A did not induce Parkin recruitment to the mitochondria. At 
100µM, antimycin A induced Parkin recruitment. Simultaneous treatment of 
antimycin A and oligomycin A (O+A) effectively induced mitophagy at a 
concentration as low as 100nM each. 1µM each of O+A treatment induced 
similar Parkin activation and mitophagy kinetics as CCCP treatment. This 
finding corroborates with most of the studies on Parkin-mediated mitophagy, 
which reported that O+A treatment effectively induces mitophagy, in a similar 
fashion to CCCP treatment (Vives-Bauza et al. 2010, Allen et al. 2013, 
Hollville et al. 2014). Intriguingly, I observed PARP cleavage during O+A and 
CCCP treatment. This observation is further characterised in the next 
chapter.  
3.6 Conclusion 
In conclusion, through the work presented in this chapter, I showed that 
endogenous levels of Parkin are insufficient to induce bulk mitophagy. 
Overexpression of Parkin at high levels is required for global clearance of 
mitochondria. I also investigated the ability of different chemical compounds 
to induce mitophagy. CCCP, as a non-selective membrane depolarizer, 
effectively induced mitophagy. Simultaneous inhibition of the ETC complex III 
and complex V by antimycin A and oligomycin A, respectively, also induced 
mitophagy whereas the ETC complex I inhibitor, rotenone, did not. These 
characterization studies lay the foundation for my subsequent work to 
develop an assay to screen for deubiquitylase(s) that are involved in Parkin-
mediated mitophagy. 
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Chapter 4: PINK1/Parkin-
mediated Mitophagic Cell Death 
4.1 Introduction 
PINK1 and Parkin mutations associated with Parkinson’s Disease are 
recessive, and the loss of their kinase and E3 ligase functions, respectively, 
are detrimental for cell survival. Consistent with their cytoprotective roles, 
PINK1 and Parkin expression have been reported to reduce protein 
aggregations and increase longevity in flies (Anil Rana et al. 2013). In this 
chapter, I describe a contradicting observation: induction of mitophagy in 
Parkin-overexpressing hTERT-RPE1 cells induces cell death in a small 
population of cells. Intriguingly, proteasome inhibitor halts this type of 
mitophagic cell death.  
4.2 PINK1 depletion protects hTERT-RPE1 cells against cell death 
Since PINK1 acts upstream of Parkin in the induction and progression of 
mitophagy, depletion of PINK1 by siRNA transfection provides a good control 
to assess the siRNA transfection efficiency. It also serves as a positive 
control for mitophagy induction (See Video 1). Upon CCCP treatment, the 
control cells (NT1) accumulate PINK1 and lose MIRO and TIMM44 (Figure 
4.1A). On the contrary, depletion of PINK1 prevents the loss of MIRO and 
TIMM44. LC3 conversion from LC3-I (top band) to LC3-II (bottom band) 
occurs in both conditions, indicating that the activation of general autophagy 
is not dependent on PINK1, but rather, is triggered by the accumulation of 
intracellular ROS levels in response to CCCP treatment. Intriguingly, I 
consistently observed cell death at the late stages of CCCP treatments (6-
8hr), as reflected by the appearance of PARP-p85, a cleaved PARP 
fragment that is generated by activated caspase 3 during apoptosis (Tewari 
et al. 1995). This observation is also confirmed by live-cell imaging of the 
progression of mitophagy upon CCCP treatment (Video 1 and Figure 4.1B). 
A membrane impermeable dye (DRAQ7) that is only taken up by membrane-
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Figure 4.1 siRNA depletion of PINK1 in hTERT-RPE1-YFP-Parkin cells protects 
against cell death. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either a non-
targeting control siRNA oligo (NT1) or siRNA oligo targeting. Cells were then treated 
with CCCP (10µM) and lysed with NP40 lysis buffer at the indicated times. 15µg of 
lysates were probed with the indicated antibodies. 
(B) hTERT-RPE1-YFP-Parkin cells were transfected as described in (A). Cells were 
then treated with CCCP (10µM) in the presence of a membrane impermeable dye, 
DRAQ7 (0.3µM). Images were taken at 15min interval with Nikon Ti-Eclipse and CFI 
S Plan Fluor ELWD 20x objective. Shown are frames before and after CCCP treat-
ment  (T=12hr). Scale bar: 40µm.
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compromised (dead) cells was added to the medium during CCCP treatment 
to visualize dead cells. A striking accumulation of DRAQ7-positive cells (pink
spot) was observed over time only in control but not PINK1-depleted cells.
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 4.3 Mitophagic cell death is dependent on Parkin 
Since PINK1 and Parkin act in concert to promote mitophagy, the role of 
Parkin in the observed cell death was also investigated. To this end, I 
compared parental hTERT-RPE1 cells and hTERT-RPE1-YFP-Parkin cells 
(Figure 4.2A). While PINK1 accumulates in both cell lines during CCCP 
treatment, PARP cleavage (PARP-p85) is only observed in hTERT-RPE1-
YFP-Parkin cells. It is worth noting that the full length PARP (FL) was not 
observed consistently across different experiments. This may not be 
surprising as the antibody used was raised to detect cleaved PARP fragment 
(PARP-p85; Cell Signaling, 9546). YFP-Parkin is auto-ubiquitylated during 
CCCP treatment, indicating that Parkin is activated and mitophagy is taking 
place.  
 
In addition, siRNA-mediated depletion of Parkin in hTERT-RPE1-YFP-Parkin 
cells also partially reduced the levels of PARP-p85 (Figure 4.2B). The very 
high Parkin expression level in these cells makes it difficult to fully deplete 
Parkin. Nevertheless, reduction of Parkin levels clearly protected the cells 
from apoptosis whilst mitochondrial protein degradation (MIRO and TIMM44 
loss) was not affected. This suggests that the residual Parkin levels are 
sufficient for mitophagy and it is the excessive levels of Parkin that cause cell 
death.  
  
 123 
 
Figure 4.2 Parkin expression is required for mitophagic cell death. 
(A) Parental hTERT-RPE1 cells and hTERT-RPE1-YFP-Parkin cells were treated 
with CCCP (10µM). Cells were lysed in NP40 lysis buffer at the indicated times. and 
15µg of lysates were probed with the indicated antibodies. FL: full length PARP; 
p85: p85 fragment of PARP. Note that this is the same blot as shown in Fig 3.4. 
(B) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-
targeting siRNA control (NT1), siRNA targeting PINK1 or siRNA targeting Parkin. 
Cells were then treated with CCCP (10µM) for 8hr and lysed with RIPA lysis buffer. 
15µg of lysates were probed with the indicated antibodies.  
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4.4 Dissection of the Parkin-dependent mitophagy pathway and cell 
death using inhibitors of protein degradation 
Next, I wanted to know if the cell death observed is a consequence of 
proteasomal degradation of OMM proteins or the end result of autolysosomal 
degradation. To understand this, I inhibited the proteasome and the 
lysosome using epoxomicin and folimycin, respectively. In addition, I also 
inhibit p97, an AAA-ATPase that has been described to extract OMM 
proteins for proteasomal degradation, using DBeQ (Chou et al. 2011, Xu et 
al. 2011).  
 
4.4.1 Different cell fates with selective inhibition of the proteasomal and 
lysosomal degradation pathways 
Co-treatment of cells with CCCP and epoxomicin, the proteasome inhibitor, 
accumulated MIRO in both unmodified and higher molecular weight, 
ubiquitylated forms. On the other hand, co-treatment of cells with CCCP and 
folimycin, a vacuolar ATPase inhibitor, inhibited the degradation of TIMM44 
and promoted the accumulation of LC3-II. Unexpectedly, folimycin treatment 
partially affects the turnover of MIRO. This suggests that MIRO turnover (and 
possibly other OMM proteins) during mitophagy is not strictly dependent on 
the proteasome. On the other hand, epoxomicin treatment also partially 
prevented CCCP-induced loss of TIMM44, suggesting that proteasomal 
degradation of OMM proteins is required for the progression of mitophagy. 
Strikingly, co-treatment of hTERT-RPE1-YFP-Parkin cells with CCCP and 
proteasomal inhibitor (Epoxomicin) but not lysosomal inhibitor (Folimycin) 
protects the cells from cell death (Figure 4.3).  
 
One possible interpretation for the inhibition of cell death by epoxomicin is 
that the physical extraction of OMM proteins could damage the outer 
mitochondrial membrane. Therefore, proteasomal inhibition protects the 
integrity of the OMM, thereby preventing the release of Cyt-C into the 
cytosol.  
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Figure 4.3 Proteasomal but not lysosomal inhibition protects cells from CCCP-
induced, Parkin-dependent apoptosis. 
hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM), epoxomicin (Epox; 
100nM) or/and folimycin (Foli; 100nM) for 8hr. The cells were then harvested in 
NP40 lysis buffer and 15µg of samples were probed with the indicated antibodies.  
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4.4.2 DBeQ, a p97 inhibitor does not prevent mitophagic cell death 
The extraction of two OMM proteins, MCL1 and MFN1 for degradation has 
been shown to be mediated by p97, a AAA+ family member, prior to 
proteasomal degradation (Xu et al. 2011). Therefore, I wondered if DBeQ, a 
p97 inhibitor, could phenocopy the effect of proteasome inhibitor. I first 
titrated the concentration of DBeQ (Figure 4.4A). Since DBeQ has been 
reported to block the maturation of autophagosomes, I probed for LC3 as a 
readout for the efficacy of the inhibitor (Chou et al. 2011). Indeed, at 10 and 
20µM, DBeQ treatment alone promotes accumulation of LC3-II, suggesting 
inhibition of the autophagy pathway. At 20µM, DBeQ also induces OPA1 
cleavage, and a partial loss of MIRO, suggesting that high concentration of 
DBeQ alone can trigger mitophagy or general autophagy. Epoxomicin 
treatment alone induced the accumulation of a 52kDa fragment of PINK1. 
Intriguingly, I also observed mild accumulation of the 52kDa fragment of 
PINK1 with 20µM of DBeQ treatment. At steady state, this 52kDa fragment is 
normally constitutively degraded by the proteasome (Jin et al. 2010). The 
observation of this cleaved fragment at high DBeQ concentration suggests 
that the proteasomal degradation process might be affected by DBeQ. Upon 
co-treatment with CCCP, DBeQ induced higher levels of cell death as shown 
by the increase in cleaved PARP, contrary to the protective effect seen with 
epoxomicin. I also assessed the efficacy of DBeQ by blotting for MCL1 
(Figure 4.4B). Consistent with the prior observations in the literature, DBeQ 
alone elevated the level of MCL1 (Xu et al. 2011). 
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Figure 4.4 p97 inhibition exacerbates mitophagic cell death. 
(A) hTERT-RPE1-YFP-Parkin cells were treated with varying concentrations of 
DBeQ or epoxomicin (Epox: 100nM) in the absence or presence of CCCP (10µM) 
for 5hr. Epoxomicin (Epox) treatment (100nM) was used as a negative control for 
PARP cleavage. Cells were lysed in RIPA lysis buffer and samples were probed 
with the indicated antibodies.  
(B) hTERT-RPE1-YFP-Parkin cells were treated with DBeQ (10µM), epoxomicin 
(Epox; 100nM) and folimycin (Foli; 100nM) for 5hr in the presence or absence of  
CCCP (10µM). Cells were lysed in ‘hot lysis’ SDS buffer and samples were probed 
with the indicated antibodies.  
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4.5 Immunofluorescence characterization of the effect of epoxomicin, 
folimycin and DBeQ on mitophagy 
Following a series of interesting observations from the proteasome, 
lysosome and p97 inhibition experiments, we decided to visualize the effects 
of these inhibitors on mitophagy by immunofluorescence microscopy. For the 
visualization of mitochondria, I stained the cells with anti-TIMM44 antibody.  
After 8hr of treatment with DBeQ alone, I observed perinuclear-aggregation 
of Parkin-positive mitochondria in ~20% of the cells. This is consistent with 
the biochemical data in Figure 4.4A whereby high concentration of DBeQ 
promotes OPA1 cleavage, an early event that precedes Parkin-mediated 
mitophagy. In addition, I observed that ~40% of the cells had short and 
swollen mitochondria. When cells were co-treated with DBeQ and CCCP, 
there was a dramatic delay or inhibition of Parkin clearance at 8hr compared 
with the control cells. Both epoxomicin and folimycin co-treatment with CCCP 
also delayed or inhibited clearance of Parkin aggregates. However, 
epoxomicin treated cells had 2-3 enlarged Parkin aggregates per cells 
whereas folimycin treated cells had numerous small Parkin aggregates.  
4.5.1 Proteasomal inhibition affects clearance of mitophagic vesicles 
Since proteasomal inhibition delays or possibly inhibits the clearance of 
mitophagic vesicles, one hypothesis would be that the clearance of some 
OMM proteins by the proteasome is required for the subsequent recruitment 
of autophagy components including p62 and LC3 to the mitochondria. To 
investigate this, I stained cells treated with CCCP with or without epoxomicin 
with p62 and LC3 antibodies (Figure 4.6A and B). After 8hr of CCCP 
treatment, Parkin aggregates co-localized with p62 staining and by 12hr, 
most of the Parkin aggregates were cleared (Figure 4.6A). However, when 
cells were treated with both CCCP and epoxomicin, the Parkin aggregates 
were present even after 12hr, consistent with previous observations in Figure 
4.5. These Parkin aggregates also stained positive for p62, suggesting that 
the recruitment of p62 is not impeded during proteasomal inhibition.  
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Figure 4.5 Differential effects of p97-targeted, proteasomal and lysosomal inhibitors 
on Parkin recruitment and mitophagy. 
hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM), DBeQ (10µM), 
epoxomicin (Epox; 100nM), and folimycin (Foli; 100nM) for 8hr. The cells were then 
fixed with PFA and stained with anti-TIMM44 antibody. The coverslips were 
mounted using mowiol with DAPI to stain the nuclei (blue in merged image). Scale 
bar: 10µm. 
 
Similar observations are also made with the LC3 staining. After 8hr of CCCP 
treatment, smaller Parkin aggregates were enveloped by LC3, which forms a 
circle around the aggregates (see 8hr CCCP + DMSO treatment; left inset) 
while bigger Parkin aggregates were decorated with spots of LC3 (see the 
same condition as previous; right inset). CCCP and epoxomicin treated cells 
contained only large Parkin aggregates (both 8 and 12hr) that were 
decorated by spots of LC3, which do not complete surround the aggregates.  
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Figure 4.6 Epoxomicin treatment delays mitophagic vesicle clearance. 
(A) hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM) and epoxomicin 
(Epox; 100nM) for the indicated times. The cells were then fixed with PFA and 
stained with anti-p62 antibody. The coverslips were mounted using mowiol. Scale 
bar: 10µm.  
(B) hTERT-RPE1-YFP-Parkin cells were treated as described in (A). The cells were 
then fixed with PFA followed by methanol. Cells were stained with anti-LC3 antibody 
The coverslips were mounted using mowiol with DAPI (blue in merged image). 
Scale bar: 10µm.  
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4.6 Cytochrome-C is released from the mitochondria during mitophagic 
cell death  
If the ubiquitylation and degradation of OMM proteins induce rupture of 
OMM, Cytochrome-C (Cyt-C) should be released, leading to the activation of 
apoptosis. To test this hypothesis, I fixed and stained CCCP treated hTERT-
RPE1-YFP-Parkin cells with anti-Cyt-C antibody to check for Cyt-C release 
from the mitochondria using immunofluorescence microscopy (Figure 4.7A). 
After 6hr of CCCP treatment, I observed a mixture of cytosolic and 
mitochondrial Cyt-C in approximately 20% of the cells, whereas in DMSO 
treated cells, the Cyt-C staining was restricted to the mitochondria.  
 
Cyt-C release from the mitochondria was also confirmed using digitonin-
permeabilised cells. For this, I incubated CCCP-treated cells in HIM buffer 
with varying digitonin concentrations for 10min on ice. I then harvested and 
centrifuged the cells at 14,000xg for 3min to separate the permeabilised cells 
from the released cytosolic fraction (Figure 4.7A, detailed protocol described 
in Chapter 2, section 2.3.6). At lower digitonin concentrations (0.01 and 
0.25%), Cyt-C is only released in the CCCP treated cells. At higher (0.075%), 
Cyt-C is released in both DMSO and CCCP-treated cells. As a control to 
show that inner mitochondrial membrane proteins were not released into the 
cytosol during digitonin treatment, I also probed the blot for TIMM44 (inner 
mitochondrial transmembrane protein).  
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Figure 4.7 Cyt-C is released during Parkin-mediated mitophagy.  
(A) hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM) for 6hr. The 
cells were then fixed with PFA and stained with anti-Cyt-C antibody. Coverslips 
were mounted onto glass slides with mowiol and DAPI (blue in merged image). 
Scale bar: 10µm. Graph represents quantitation of cells with exclusively 
mitochondrial Cyt-C or a mixture of cytosolic and mitochondrial Cyt-C staining. Error 
bar represents standard deviation from 3 independent experiments.  
(B) hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM) for 6hr. Cells 
were then treated with different concentration of digitonin for 10min in HIM buffer. 
The treated samples were then centrifuged at 14,000rpm for 3min. The pellet and 
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supernatant fractions were loaded at 1:3 (volume:volume) on a NU-PAGE to probe 
for the depicted proteins.  
(C) hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM) for 6hr. Cells 
were then treated with 0.025% of digitonin for 10min in HIM buffer. The treated 
samples were then centrifuged at 14,000rpm for 3min. The pellet and supernatant 
fractions were loaded in duplicates at 1:3 (volume:volume) on a NU-PAGE to probe 
for the depicted proteins.  
 
4.7 Mitophagic cell death occurs via apoptosis 
4.7.1 Phosphatidylserine and phosphatidylethanolamide externalization 
precedes mitophagic cell death 
The observation of PARP cleavage and Cyt-C release during CCCP 
treatment suggests that the cell death is apoptosis. Another hallmark of 
apoptotic cell death is the externalisation of phosphatidylserine (PS) and 
phosphatidylethanolamide (PE) from the cytosolic side of the cell membrane 
(Fadok et al. 1992, Martin et al. 1995, Emoto et al. 1997). I treated hTERT-
RPE1-YFP-Parkin cells with CCCP in the presence of annexin V (a Ca2+-
dependent phospholipid-binding protein that has high affinity for PS and PE) 
and the membrane impermeable dye, DRAQ7. I monitored the progression of 
mitophagy and cell death by live-cell imaging. As shown in Figure 4.8, 
annexin V stained the plasma membrane after 8hr of CCCP treatment. In 
contrast, cells were only DRAQ7-positive after 12hr. This strongly supports 
the notion that the mitophagic cell death is apoptotic.  
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Figure 4.8 Phosphatidylserine and phosphatidylethanolamide externalization 
precedes cell death. 
hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM) and imaged in the 
presence of DRAQ7 (0.3µM) and annexin V-AF350 (Invitrogen; 5µl annexin V/ml of 
medium, supplemented with 2.5mM of CaCl2). Mitophagy progression was imaged 
every 30min up to 16hr. YFP-Parkin was pseudo-coloured grey, annexin V was in 
blue and DRAQ7 was in yellow. Scale bar: 40µm. 
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4.7.2 Mitophagic cell death is prevented by Z-VAD-FMK 
Next, I treated the hTERT-RPE1-YFP-Parkin cells with CCCP and a broad-
spectrum caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp (OMe) 
fluoromethyl ketone (Z-VAD-FMK) (Slee et al. 1996, Sun et al. 1999). Live-
cell imaging of mitophagy progression with DRAQ7 staining to monitor for 
dead cells demonstrated that Z-VAD-FMK effectively inhibited cell death 
without affecting the progression of mitophagy (Video 2 and Figure 4.9). This 
was also confirmed by western blotting (Figure 4.9B). Activation and 
progression of mitophagy, indicated by the loss of MIRO, TOM20 and 
TIMM44, occurred normally in both CCCP and CCCP with Z-VAD.FMK 
treatment. However, PARP cleavage (PARP-p85) is inhibited when cells are 
treated with Z-VAD.FMK.  
 
Figure 4.9 The broad-spectrum caspase inhibitor, Z-VAD-FMK prevents mitophagic 
cell death. 
(A) hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM) or CCCP with 
Z-VAD-FMK (ZVAD; 20µM). The progression of mitophagy and cell death were 
recorded by live-cell imaging at 15min intervals in the presence of the membrane 
impermeable dye, DRAQ7 (0.5µM). Shown are single frames (T=12hrs) from a 
representative video, with YFP-Parkin shown in grey and DRAQ7 shown in pink. 
Scale bar:40µm.  
(B) hTERT-RPE1-YFP-Parkin cells were treated the same as in (A). The cells were 
lysed in RIPA lysis buffer. 10µg of lysates were immunoprobed as indicated.  
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4.7.3 Mitophagic cell death is dependent on both caspase 8 and 
caspase 9  
Next I wanted to investigate whether the cell death is triggered via the 
intrinsic or extrinsic apoptotic pathway. I induced mitophagy in cells depleted 
of caspase 8 (Casp-8) and caspase 9 (Casp-9) by RNA interference. The 
current understanding is that Casp-8 cleavage and activation is generally 
required for the activation of the extrinsic apoptotic pathway while Casp-9 
activation is required mostly for the intrinsic pathway. However, Casp-9 can 
also be activated in the extrinsic pathway to amplify the apoptotic cascade. 
Interestingly, both Casp-8 and Casp-9 were required for mitophagic cell 
death (Figure 4.10). Consistent with the data from the Z-VAD-FMK treatment, 
inhibition of apoptosis by knocking down Casp-8 and Casp-9 did not block 
mitophagy, as indicated by the loss of TOM20 in all three conditions. It is 
worth pointing out that while I could observe the efficient depletion of both 
Casp-8 and Casp-9 in their respective knockdown conditions, I only observed 
the p43/p41 cleaved Casp-8 fragments that are commonly observed in the 
literature (Sohn et al. 2005, Sawai 2013, Ferreira et al. 2012). I did not detect 
any Casp-9-derived fragment (either p37 or p35) in these cells (Del Bello et 
al. 2003, Zou et al. 2003).  
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Figure 4.10 Mitophagic cell death occurs via Casp-8 and Casp-9 dependent 
apoptosis 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
siRNA control (NT1), siRNA targeting caspase 8 (Casp-8) or siRNA targeting 
caspase 9 (Casp-9). The cells were then treated with CCCP (10µM) for 8hr and 
harvested in ‘hot lysis’ SDS buffer. 25µg of lysates were probed with the indicated 
antibodies. 
Asterisk: non-specific band. Arrow: cleaved caspase 8 fragment. 
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4.8 Discussion 
For many years, PINK1 and Parkin have been assigned cytoprotective roles 
in various organisms. Rana and colleagues demonstrated that the 
overexpression of Parkin in neurons promoted the lifespan of Drosphila. This 
was attributed to the efficient turnover of drosophila Mitofusin and the 
maintenance of normal mitochondrial morphology and respiratory activity by 
Parkin (A. Rana et al. 2013). Johnson and colleagues demonstrated in 
Parkin-expressing mouse embryonic stem cells that BAX is targeted for 
ubiquitylation and proteasomal degradation during activation of mitophagy, 
and subsequently prevents Cytochrome-C release (Johnson et al. 2012). 
Furthermore, Parkin has been shown to promote cell survival by stabilising 
MCL1 indirectly, via the degradation of FBXW7, an E3 ligase that 
ubiquitylates and promotes the degradation of MCL1 (Inuzuka et al. 2011, 
Ekholm-Reed et al. 2013).  
 
While the concept of PINK1 and Parkin-induced cell death is contradicting 
our current understanding of the cytoprotective roles of PINK1 and Parkin, 
our observation is supported by Yoshii et al. (2011) who demonstrated that 
Parkin overexpression leads to disruption of mitochondrial membrane 
integrity (Yoshii et al. 2011). Yoshii and colleagues discovered that 
overexpression of Parkin in mouse embryonic fibroblasts (MEFs) promotes 
widespread ubiquitylation and proteasomal degradation of OMM proteins 
during mitophagy (e.g. TOM20, TOM40, TOM70a and OMP25). Using 
electron microscopy, they observed mitochondrial swelling, rupture of the 
OMM, and loss of cristae structure and suggested that the proteasomal 
degradation of these proteins may damage the integrity of the OMM and lead 
to the rupture to the OMM. They further showed that proteasomal inhibition 
could protect the integrity of the mitochondrial double membranes. 
Consistent with their observation, the cell death that I observed can also be 
inhibited by proteasomal inhibition whereas inhibition of the lysosome by 
vacuolar ATPase by folimycin did not rescue the cell death.  While the 
authors did not detect cell death based on caspase 3 activation or nuclear 
fragmentation in their setting, it is possible that the cell death that I observed 
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in our system is also caused by the rupture of OMM, causing cytochrome C 
release into the cytosol.  
 
Immunofluorescence microscopy revealed that both proteasomal and 
lysosomal inhibition blocked the clearance of Parkin aggregates. However, 
proteasomal inhibition promoted the accumulation of large Parkin aggregates 
(2-3 aggregates per cell) while lysosomal inhibition accumulated numerous 
small Parkin aggregates. Further investigation of the effect of proteasomal 
inhibition on Parkin-mediated mitophagy revealed that p62, the adaptor for 
the recruitment of LC3, as well as LC3 itself were recruited to the 
mitochondria during both CCCP and CCCP plus epoxomicin treatments, 
suggesting that the initiation of autophagic process, including the 
ubiquitylation of mitochondrial proteins and the lipidation of LC3 were not 
affected by proteasomal inhibition. However, I observed that the Parkin 
aggregates were larger in epoxomicin co-treated cells, with LC3 punctae 
decorating the edges of the aggregates. In contrast, in the absence of 
epoxomicin, cells had smaller Parkin aggregates that were completely 
enveloped by LC3 (in a ring morphology). This suggests that smaller Parkin 
aggregates might be turned over more efficiently compared to larger Parkin 
aggregates. It is likely that the degradation of certain OMM proteins by the 
proteasome is required for the dissociation of large Parkin aggregate into 
smaller aggregates prior to lysosomal degradation. For example, the 
degradation of mitochondrial proteins that are involved in the fusion and 
fission machinery (e.g. MFN1/2) and the movement of mitochondria (e.g. 
MIRO1/2) might be impeded, affecting the dissociation of the Parkin-
decorated mitochondrial aggregates (Fransson et al. 2006, Fransson et al. 
2003, Chen et al. 2003). Both MFN1/2 and MIRO1/2 are known substrates of 
Parkin during mitophagy and the degradation of the two have been shown to 
promote mitophagy (Ziviani and Whitworth 2010, Gegg et al. 2010, Wang et 
al. 2011).   
 
P97, an AAA-ATPase, has been shown to retrotranslocate MCL1 and MFN1 
from the mitochondria OMM to the cytosol prior to proteasomal degradation 
(Xu et al. 2011, Tanaka et al. 2010). To further test if the physical action of 
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protein extraction from the mitochondria by p97 is responsible for the 
damage of the OMM, I used DBeQ, a p97 inhibitor. I observed that high 
concentrations of DBeQ treatment alone could induce OPA1 cleavage and 
Parkin recruitment, suggesting that mitophagy was induced upon p97 
inhibition. Unlike proteasomal inhibition, p97 inhibition did not rescue the 
cells from cell death. Instead, simultaneous treatment of cells with CCCP and 
DBeQ exacerbated cell death. Since p97 is involved in a wide array of 
functions, ranging from chromatin remodelling, endocytic vesicle maturation, 
autophagosomal maturation to ER-associated degradation (ERAD), it is 
possible that the cell death observed is not a direct result of mitophagic cell 
death but a combined effect from multiple cellular stresses (Meyer et al. 
2012, Chou et al. 2011). Indeed, Chou and colleagues reported that DBeQ is 
highly potent in activating caspase 3 and caspase 7 via a mechanism that is 
not yet understood (Chou et al. 2011). Therefore, no strong conclusion can 
be drawn from the effect of p97 on mitophagic cell death.  
 
Cyt-C release is generally associated with apoptotic cell death (Jiang and 
Wang 2000). Indeed, I observed Cyt-C release during CCCP treatment using 
digitonin permeabilisation of the cell membrane. This was further supported 
by the observation of a small population of cells (20%) with partial cytosolic 
localization of Cyt-C.  
 
In healthy cells, phospholipids are assymetrically-distributed between the 
outer and inner membranes. The outer membrane is composed mostly of 
cholinephospholipids, such as phosphatidylcholine and sphingomyelin 
whereas the inner membrane is composed mostly of aminophospholipids, 
including phosphatidylserine (PS) and phosphatidylethanolamide (PE). The 
distribution of PS and PE is actively maintained by the enzyme 
aminophospholipid translocase (‘flippase’) (Diaz and Schroit 1996). During 
apoptosis, an enzyme known as the phospholipid scramblase is cleaved and 
activated by effector caspases, which promotes bidirectional movement of 
phospholipids, thereby exposing PS and PE to the cell surface (Zhou et al. 
1997, Martin et al. 1995). The externalized PS and PE can be recognized 
and bound by annexin V in a Ca2+-dependent manner. Therefore, annexin V 
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affinity to the plasma membrane serves as an alternative read out for 
apoptosis. I treated the cells with CCCP in the presence of annexin V 
conjugated with a fluorescent dye and a membrane impermeable dye, 
DRAQ7. During CCCP treatment, annexin V was seen to localize to the 
plasma membrane (at 8hr) and this event precedes the incorporation of 
DRAQ7 (at 12hr). 
 
The apoptotic nature of this cell death is also confirmed by its sensitivity of Z-
VAD-FMK, a broad spectrum caspase inhibitor (Slee et al. 1996). However, 
Z-VAD-FMK does not differentiate between the intrinsic and extrinsic 
pathway. The current view is that caspase 8 is cleaved and activated during 
extrinsic apoptotic activation, which could either cleave caspase 3 to directly 
trigger apoptosis, or cleave Bid into tBid to activate Bak and Bax 
oligomerisation on the OMM, resulting in Cyt-C release into the cytosol. Cyt-
C then triggers the assembly of the apoptosome that subsequently activates 
Caspase 9. Caspase 9 cleaves Caspase 3 to promote apoptosis. On the 
other hand, intrinsic apoptosis is triggered directly via the mitochondria where 
internal insults trigger the release of Cyt-C from the mitochondria, sharing the 
same downstream mitochondria-mediated pathway as described above for 
extrinsic apoptosis (Mukhopadhyay et al. 2014).  
 
In our setting, it seems that both caspase 8 and caspase 9 are required for 
the activation of apoptosis. We postulate two explanations to the observation 
(Figure 4.11). In the first scenario, cell death might take place via the 
extrinsic pathway but activation of caspase 8 alone is insufficient to activate 
caspase 3. Instead, the activation of caspase 9 via Bid cleavage and Cyt-C 
release might be required to amplify the caspase cascade. This is less likely 
to be the case as the extrinsic triggers are usually Fas, TNF or TRAIL ligands 
that bind to their respective receptors to activate the extrinsic pathway. In the 
alternative, and more likely scenario, cell death might take place via the 
intrinsic pathway. In a situation where a small subset of damaged 
mitochondria is not efficiently engulfed by the lysosomes, only a small 
amount of Cyt-C is released into the cytosol. This low level of Cyt-C might 
not be sufficient to activate apoptosis. Instead, a positive feedback loop via 
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the activation of caspase 3, which has been reported to cleave caspase 8 
might be required to further activate tBid and pemeabilise the OMM to 
amplify the caspase cascade (Figure 4.11)(Sohn et al. 2005, Viswanath et al. 
2001). Viswanath and colleagues demonstrated in rat adrenal medulla cell 
line (PC12 cells) that 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) 
treatment (150µM) induces caspase 9 activation within 2hr of treatment, 
followed by caspase 3 activation (2-4hr). Caspase 8 activation and Bid 
cleavage did not occur until late stages (4-6hr). They further demonstrated 
that inhibition of caspase 9 using LEHD-FMK, a cell-permeable caspase-9 
specific inhibitor, prior to MPTP treatment did not block Cyt-C release but 
inhibited caspase 8 activation and the subsequent cell death (Viswanath et 
al. 2001). Therefore, it is possible that the cell death observed in our cell line 
follows a similar intrinsic apoptotic pathway as PC12 cells. 
 
Very recently, Zhang and colleagues reported that HeLa cells expressing 
Parkin underwent apoptosis after valinomycin and mitophagy after CCCP 
treatment (Zhang et al. 2014). They demonstrated that the differential 
response was due to the selective ubiquitylation and degradation of MCL1 by 
Parkin during valinomycin but not CCCP treatment, which dictate whether 
cells undergo mitophagy or apoptosis. While I have not tested valinomycin in 
hTERT-RPE1-YFP-Parkin cells, I propose that the trigger and mechanism for 
our cell death observation is most likely different from that described by 
Zhang and colleagues. MCL1 degradation induces apoptosis by allowing 
BAK and BAX oligomerisation on the OMM for Cytochrome-C release. In 
chapter 6, I will demonstrate that BAK and BAX knockdown does not affect 
CCCP-induced cell death, which argues against the upstream effect of MCL1 
degradation.  
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Figure 4.11 Proposed model for the involvement of caspase 8 and caspase 9 in 
Parkin-mediated mitophagic cell death. 
Mitochondrial depolarisation triggers PINK1 and Parkin recruitment to the outer 
mitochondrial membrane (OMM). High expression of Parkin causes aberrant 
ubiquitylation of OMM proteins, resulting in their extraction by p97 for proteasomal 
degradation, which affects the integrity of the outer mitochondrial membrane. 
Cytochrome-C is release from the mitochondrial intermembrane space, triggering 
the intrinsic apoptotic pathway. The assembly of the apoptosome activates caspase-
9, which then activates caspase 3. Caspase 3 and caspase 8 can inter-activate 
each other, further amplifying the caspase cascade to trigger apoptosis.  
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Chapter 5: Identification of 
Deubiquitylases Involved in 
Parkin-mediated Mitophagy 
5.1 Introduction 
Parkin is an ubiquitin-E3 ligase that is involved in mitophagy. During 
mitochondrial depolarisation, Parkin is recruited to the OMM via its 
interaction with PINK1 and subsequently phosphorylated by PINK1. This 
activates Parkin to ubiquitylate several OMM proteins, leading to their 
degradation or the recruitment of the autophagic machinery, which efficiently 
removes malfunctioning mitochondria. While the Parkin-mediated 
ubiquitylation event is well characterized during mitophagy, the DUBs that 
oppose or regulate these events remain relatively uncharacterized. This 
chapter reports on work carried out to identify DUBs that are involved in the 
regulation of PINK1/Parkin-mediated mitophagy.  
 
The aims discussed in this chapter are: (1) to develop a live-cell imaging, 
medium-throughput assay to visualise Parkin recruitment and mitophagy 
progression in hTERT-RPE1-YFP-Parkin cells, (2) to perform a focused 
siRNA screen using a targeted DUB siRNA library to identify potential DUBs 
that can regulate PINK1/Parkin-mediated mitophagy, and (3) to validate the 
top-hits from this siRNA screen.  
 
 145 
5.2 Live cell imaging screen for DUBs involved in Parkin-mediated 
mitophagy  
hTERT-RPE1 cells stably expressing YFP-tagged Parkin provide a nice 
visualization tool of (YFP-) Parkin recruitment to the mitochondria during 
mitochondria depolarization. Having characterised the timeline of YFP-Parkin 
recruitment, aggregation and clearance during mitophagy in chapter 3, I 
decided to carry out a DUB siRNA screen by imaging the progression of 
mitophagy in these cells (Figure 5.1).  
 
A custom-made DUB siRNA library supplied by QIAGEN consisting of siRNA 
pools targeting 92 DUBs was used for this screen. The oligo pools were each 
comprised of 4 individual siRNA oligos. hTERT-RPE1-YFP-Parkin cells were 
transfected with the siRNA pools (20nM) using Lipofectamine RNAiMAX 
according to the ‘reverse transfection’ protocol described in Chapter 2. 
Briefly, the siRNA oligos, OptiMEM, and RNAiMAX transfection reagent were 
mixed in a 96-well plate. After incubation, 5,000 cells were seeded into each 
of the wells.  
 
CCCP (10µM) was used to depolarize the mitochondria and trigger Parkin 
recruitment. The progression of mitophagy was recorded by live-cell imaging 
using a Nikon Ti-Eclipse microscope with a CFI S Plan Fluor ELWD 20x 
objective. I first set up the 96-well plate on a motorised microscope stage 
contained within a humidified chamber with 5% CO2 at 37°C. I manually 
selected 1 position per well for imaging using the Perfect Focus System 
(PFS) to ensure the cells remain in focus across all timepoints. Images were 
taken every 10min for up to 12hr.  
 
Candidate DUBs, for which depletion altered the response to CCCP, were 
selected based on Parkin recruitment at 2hr, Parkin aggregation at 4hr and 
Parkin clearance at 12hr. These DUBs were then selected for further 
deconvolution using the individual siRNA oligos to eliminate off-target effects.  
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Figure 5.1 Experimental workflow of the live-cell imaging screen for DUBs involved 
in Parkin-mediated mitophagy. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hrs with siRNA pool oligos 
(20nM) using RNAiMAX transfection reagent. The siRNA oligos were obtained as a 
custom-made library targeting 92 DUBs (20nM). The initial screen was carried out 
with a pool of four individual siRNA oligos targeting each DUB. CCCP (10µM) was 
used to depolarize the mitochondria and activate Parkin recruitment. The 
progression of mitophagy was recorded by live-cell imaging using the Nikon Ti-
Eclipse microscope. Candidate DUBs for which depletion altered mitochondrial 
response to CCCP were identified based on visual inspection of Parkin recruitment, 
aggregation and clearance. DUB candidates that were selected were further 
deconvoluted with individual siRNA oligos to eliminate off target effects.  
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5.2.1 Optimisation of the siRNA transfection protocol and transfection 
efficiency  
Routinely, I carried out all of my siRNA transfections using 40nM of siRNA 
oligos in a 6-well plate. However, all the previous siRNA screens that were 
carried out in our laboratory using the Qiagen DUB siRNA library were based 
on 20nM siRNA oligos. Therefore, I wanted to check whether transfection 
with 20nM siRNA is sufficient to deplete the proteins of interest in hTERT-
RPE1-YFP-Parkin cells. I carried out a test transfection with a previously 
characterised siRNA oligo against USP33 (oligo 6) in a 96-well plate using 
Lipofectamine® RNAiMAX transfection reagent using the exact reverse 
transfection protocol that I would want to use later in my screen. USP33 
siRNA transfection was used for this purpose as this protein has been well 
studied in our laboratory and the USP33 antibody that we routinely use is 
specific and sensitive (Thorne et al. 2011). 72hrs after transfection, I pooled 
the cell lysates from 12 wells of a 96-well plate and assessed the siRNA 
transfection efficiency by western blotting. As shown in Figure 5.2, both 
20nM and 40nM of siRNA oligos knocked down USP33 to comparable levels 
in these cells. Therefore, I decided to use 20nM of siRNA oligos for the DUB 
siRNA screen.  
 
5.2.2 Transfection of NT1 and PINK1 siRNA oligos as controls to assess 
knockdown efficiency and efficacy of CCCP treatment 
Since PINK1 acts directly upstream of Parkin during mitophagy, depletion of 
PINK1 prevents Parkin recruitment to the mitochondria during CCCP 
treatment. This provides a good visual assessment for the knockdown 
efficiency and also serves as a positive control for CCCP-induced mitophagy. 
As shown in Figure 5.2B, siRNA-mediated depletion of PINK1 blocked Parkin 
recruitment upon CCCP treatment in up to 80% of the cells. In addition, I 
chose the non-targeting oligo (NT1), which should not target any mRNA as a 
negative control that should not affect mitophagy. 
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Figure 5.2 Optimisation of the siRNA transfection protocol including positive and 
negative controls for the mitophagy screen. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with 20nM of either 
non-targeting control (NT1) or siRNA oligo targeting UPS33 (D6). Cells were 
harvested in NP40 lysis buffer and 20µg of lysates were probed with anti-USP33 
and anti-Actin antibodies. 
(B) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with NT1 or PINK1 
targeting siRNAs(20nM). Cells were then treated with 10µM of CCCP. Mitophagy 
progression was imaged live with frames captured in 15min intervals. 
Representative frames at the indicated times after CCCP (10µM) addition are shown 
for both NT1 and PINK1 siRNA transfected cells. Scale bar: 40µm. 
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5.2.3 Identification and deconvolution of DUBs of interest 
As demonstrated in Figure 5.3, normal Parkin recruitment to the mitochondria 
occurs within the first two hours, with the formation of first small and 
numerous Parkin punctae. These punctae gradually aggregate and form 
larger spots at 4hr, with most cells clearing the Parkin aggregates between 8-
12hr (Figure 5.3). While I attempted to quantitatively measure the area and 
number of Parkin aggregates based on the YFP-Parkin fluorescence 
intensity, this method falls short for the following reasons: (1) Parkin 
expression levels vary greatly across different cells and different wells, (2) 
some cells undergo mitophagic cell death (as discussed in Chapter 4) and 
these apoptotic cells usually round up and have high fluorescence intensity, 
and (3) early Parkin recruitment to the mitochondria forms smaller Parkin 
punctae that have weaker intensity compared to the larger Parkin aggregates 
formed at the later stages of mitophagy. The difference in fluorescence 
intensity and size of Parkin punctae and aggregates made it difficult to set a 
uniform fluorescence intensity threshold for all the wells for quantitation. In 
the end, I visually assessed the effect of DUB depletion on Parkin 
recruitment at 2hr, Parkin aggregation at 4hr and Parkin clearance at 8hr with 
reference to the non-targeting 1 (NT1) siRNA oligo-transfected cells.  
 
I carried out the DUB siRNA screen twice with pooled siRNA oligos. DUBs, 
which upon depletion showed the same effect on Parkin-mediated mitophagy 
in both of the screens were selected for further deconvolution. While there 
are a few subtle differences in Parkin recruitment and aggregation upon 
knockdown of some of the DUBs, the most striking effect that I observed was 
delayed recruitment of Parkin to the mitochondria during the first 2 to 4hr of 
CCCP treatment. In most cases, the delay in Parkin recruitment did not 
visibly affect Parkin clearance at the later stage (8-12hr). In fact, in some 
cases, the cells with delayed Parkin recruitment seemed to proceed to Parkin 
clearance faster than the control (NT1) cells. At this stage, since I did not 
have a mitochondrial marker in the screen, it is not possible to tell if this 
phenotype represents an enhanced mitophagy or simply a transient 
recruitment of Parkin to the mitochondria that eventually dissociates without 
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activating ubiquitylation. For simplicity, I refer to this observation as a 
‘reduced response (RR)’ as assessed at the 4hr timepoint of CCCP 
treatment, followed with either normal Parkin aggregate clearance (NC) or 
faster Parkin aggregate clearance (FC; see Table 5.1). An example of 
reduced response with faster Parkin aggregate clearance during CCCP 
treatment is shown with the knockdown of USP43 (Figure 5.3). 
 
 
 
Figure 5.3 Comparison of normal response and reduced response towards CCCP 
treatment.  
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr using either non-targeting 
control siRNA oligo (NT1) or USP43 siRNA oligo 3 (20nM). Cells were then treated 
with CCCP (10µM). Mitophagy progression was recorded by live-cell imaging. Scale 
bar:40µm.  
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I shortlisted 10 DUBs, for which depletion showed a reduced response 
towards CCCP treatment. To eliminate off target effects, I further 
deconvoluted these 10 DUBs using 4 individual siRNA oligos, each used at 
20nM (Table 5.1). Based on the deconvolution result, I selected 8 DUBs, 
which showed a consistent phenotype in at least two out of four individual 
oligos. DUBs that deconvoluted with two oligos include: BAP1, ZRANB1, 
USP30 and USP38 whereas USP10, USP42 and USP49 deconvoluted with 
three. USP43 presented the most promising result, with all four oligos 
showing the same phenotype (Figure 5.4 to Figure 5.11). Since only one 
oligo recapitulated the siRNA pool effect for both ATXN3 and OTUD4, these 
two DUBs were not followed up.  
 
I also observed more cell death with USP30 depletion. This effect was seen 
with two individual siRNA oligos (Oligo 2 and Oligo 3) as demonstrated by 
staining with the cell impermeable dye, DRAQ7 during live-cell imaging 
(Figure 5.12). This effect will be further discussed in the next chapter. 
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DUB Family DUB Screen Deconvolution Oligos with the same effects Pool Pool Oli 1 Oli 2 Oli 3 Oli 4 
UCH BAP1 RR RR, FC N RR, FC RR, FC N 2 
USP 
USP10 RR RR, FC RR, FC N N RR, FC 3 
USP30 RR RR, FC, X N RR, FC, X X RR, FC 2 
USP38 RR RR, FC RR, FC X DR, FC N 2 
USP42 RR RR, FC RR, NC RR, FC RR, NC N 3 
USP43 RR RR, FC RR, FC RR, FC RR, FC RR, FC 4 
USP49 RR RR, FC N RR, FC RR, FC RR, FC 3 
OTU 
ZRANB1 RR RR, FC RR, FC *, FC N RR, NC 2 
OTUD4 RR RR, DC RR, DC  Sick** N N 1 
MJD ATXN3 RR N N N RR, NC N 1 
Table 5.1 Overview of shortlisted DUBs from live-cell imaging screen with follow up deconvolution of pool oligos to assess the effect of 
the DUBs upon siRNA depletion on Parkin-mediated mitophagy.  
 
N: Normal response; NR: Normal recruitment; RR: Reduced response; NC: Normal clearance; FC: Faster clearance; DC: Delayed 
clearance; X: Cell death 
* Cells transfected with ZRANB1 oligo 2 have weak Parkin expression at steady state.  
** Cells transfected with OTUD4 oligo 2 looked sick and have very low cell density at steady state. 
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Figure 5.4 BAP1 depletion reduces the mitophagic response during CCCP 
treatment in hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
control siRNA (NT1) or siRNA oligos targeting BAP1 (Qiagen pool oligos and 4 
individual oligos; Oli 1-4). Cells were then treated with CCCP (10µM). Progression 
of mitophagy was recorded by live-cell imaging at 30min interval. Representative 
still frames at 0, 4 and 8 hr after CCCP treatment are shown. Scale bar: 40µm. 
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Figure 5.5 USP10 depletion reduces the mitophagic response during CCCP 
treatment in hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
control siRNA (NT1) or siRNA oligos targeting USP10 (Qiagen pool oligos and 4 
individual oligos; Oli 1-4). Cells were then treated with CCCP (10µM). Progression 
of mitophagy was recorded by live-cell imaging at 30min interval. Representative 
still frames at 0, 4 and 8hr after CCCP treatment are shown. Scale bar: 40µm. 
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Figure 5.6 USP30 depletion reduces the mitophagic response during CCCP 
treatment in hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
control siRNA (NT1) or siRNA oligos targeting USP30 (Qiagen pool oligos and 4 
individual oligos; Oli 1-4). Cells were then treated with CCCP (10µM). Progression 
of mitophagy was recorded by live-cell imaging at 30min interval. Representative 
still frames at 0, 4 and 8hr after CCCP treatment are shown. Scale bar: 40µm. 
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Figure 5.7 USP38 depletion reduces the mitophagic response during CCCP 
treatment in hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
control siRNA (NT1) or siRNA oligos targeting USP38 (Qiagen pool oligos and 4 
individual oligos; Oli 1-4). Cells were then treated with CCCP (10µM). Progression 
of mitophagy was recorded by live-cell imaging at 30min interval. Representative 
still frames at 0, 4 and 8hr after CCCP treatment are shown. Note that transfection 
with USP38 oligo 2 causes cell death during CCCP treatment. Scale bar: 40µm. 
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Figure 5.8 USP42 depletion reduces the mitophagic response during CCCP 
treatment in hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
control siRNA (NT1) or siRNA oligos targeting USP42 (Qiagen pool oligos and 4 
individual oligos; Oli 1-4). Cells were then treated with CCCP (10µM). Progression 
of mitophagy was recorded by live-cell imaging at 30min interval. Still frames at 0, 4 
and 8hr after CCCP treatment are shown. Scale bar: 40µm. 
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Figure 5.9 USP43 depletion reduces the mitophagic response during CCCP 
treatment in hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
control siRNA (NT1) or siRNA oligos targeting USP43 (Qiagen pool oligos and 4 
individual oligos; Oli 1-4). Cells were then treated with CCCP (10µM). Progression 
of mitophagy was recorded by live-cell imaging at 30min interval. Still frames at 0, 4 
and 8hr after CCCP treatment are shown. Scale bar: 40µm. 
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Figure 5.10 USP49 depletion reduces the mitophagic response during CCCP 
treatment in hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
control siRNA (NT1) or siRNA oligos targeting USP49 (Qiagen pool oligos and 4 
individual oligos; Oli 1-4). Cells were then treated with CCCP (10µM). Progression 
of mitophagy was recorded by live-cell imaging at 30min interval. Representative 
still frames at 0, 4 and 8hr after CCCP treatment are shown. Scale bar: 40µm. 
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Figure 5.11 ZRANB1 depletion reduces the mitophagic response during CCCP 
treatment in hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
control siRNA (NT1) or siRNA oligos targeting ZRANB1 (Qiagen pool oligos and 4 
individual oligos; Oli 1-4). Cells were then treated with CCCP (10µM). Progression 
of mitophagy was recorded by live-cell imaging at 30min interval. Representative 
still frames at 0, 4 and 8hr after CCCP treatment are shown. Note that transfection 
with oligo 2 resulted in weak Parkin expression. Scale bar: 40µm.  
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Figure 5.12 USP30 depletion enhanced mitophagic cell death.  
Representative still frames at 12hr of CCCP treatment in USP30 depleted cells from 
the same experiment shown in Figure 5.6. Membrane impermeable DRAQ7 dye 
was used to visualize dead cells (pseudocoloured in pink). Scale bar: 40µm. 
Asterisk: Oligos that showed a reduced mitophagic response at 4hr. 
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5.2.4 Western blot analysis of the effects of selected DUB siRNAs on 
Parkin-mediated mitophagy  
Live-cell imaging of YFP-Parkin translocation to the mitochondria provides 
limited information regarding the ubiquitylation of mitochondrial proteins and 
their subsequent degradation. On the contrary, a biochemical analysis of the 
cell lysates after CCCP treatment by western blotting, allows one to probe for 
multiple proteins of interest and provides more information regarding 
mitophagy activation and progression. Therefore, I followed up on the top hits 
from the live-cell imaging screen with a western blotting approach (Figure 
5.13). Note that USP30 was not included in this analysis, as it will be fully 
characterised in Chapter 6.  
 
I first assessed cleavage of L-OPA1 to S-OPA1 in these cells. OPA1 
cleavage is one of the indicators of mitochondrial fragmentation, which in 
turn, is one of the earliest responses towards mitochondrial depolarization. 
NT1 and PINK1 both showed partial OPA1 cleavage at 4hr and near 
complete OPA1 cleavage after 8hr of CCCP treatment. Intriguingly, all of the 
siRNAs targeting the candidate top hits either partially or completely inhibited 
OPA1 cleavage. This effect is particularly apparent in USP42 and USP43-
depleted cells, which did not exhibit OPA1 cleavage. PINK1 accumulation 
during CCCP treatment in these cells was also reduced compared to the 
other DUB siRNA samples. Consistent with this, USP42 and USP43-
depleted cells showed increased levels of unmodified and less ubiquitylated 
Parkin. USP42 and USP43-depleted cells also displayed higher basal levels 
of MIRO, which remained steady even after 8hr of CCCP treatment. These 
observations strongly indicate that USP42 and USP43-depleted cells have 
an impaired response to CCCP-induced mitochondrial depolarisation.  
 
Knockdown of the remaining DUBs, including USP10, USP49, BAP1 and 
ZRANB1 resulted in partial OPA1 cleavage and also weaker PINK1 
accumulation compared to control NT1. This also translates into weaker 
Parkin autoubiquitylation and less MIRO degradation. These observations 
corroborate the reduced CCCP response I observed by live-cell imaging. 
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Interestingly, USP49 depletion reduced the basal protein levels of MIRO, 
indicating that USP49 might affect its stability. For these reasons, I 
proceeded by deconvoluting the siRNA oligo pools targeting USP42, USP43 
and USP49.  
 
 
 
Figure 5.13 Biochemical analysis of DUBs shortlisted from the visual screen. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either the non-
targeting siRNA control (NT1) oligo or the indicated Qiagen pooled siRNA oligos.  
Cells were then treated with CCCP (10µM) and harvested using NP40 lysis buffer at 
the indicated times. 10µg of lysates were probed for the indicated proteins.	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5.2.5 Deconvolution of USP49 siRNA oligos in hTERT-RPE1-YFP-Parkin 
cells 
I first assessed MIRO protein levels upon transfection with four individual 
siRNA oligos targeting USP49 (Figure 5.14). Only transfection with oligo Q8 
recapitulated the reduced MIRO levels observed with the pool of siRNA 
oligos in Figure 5.13. In addition, TIMM44 and TOM20 levels were also 
reduced. This suggests that USP49 oligo Q8 might cause global reduction in 
mitochondria in cells. While I did not assess the knockdown efficiency, the 
fact that only one oligo recapitulated the effect of the pool suggests that this 
is most likely an off-target effect.  
 
 
Figure 5.14 USP49 siRNA deconvolution.  
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either mock 
(transfection reagent without siRNA oligo), non-targeting siRNA oligo (NT1), or 
siRNA oligos targeting USP49 (Q4, Q7, Q8 and Q9). Cells were harvested in RIPA 
lysis buffer. 10µg of lysates were probed as indicated.  
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5.2.6 Characterisation of the effects of USP42 and USP43 depletion on 
Parkin depending mitophagy 
5.2.6.1 USP42 and USP43 depletion impedes mitophagy 
Deconvolution of USP42 oligos showed that three (Q5, Q6 and Q7) out of the 
four siRNA oligos inhibited or delayed PINK1 accumulation and Parkin 
activation (Figure 5.15). Subsequently, MIRO, MFN2, TOM20 and TIMM44 
were not degraded. This recapitulated the effects seen with the pooled oligos 
in Figure 5.13.  
 
Since USP42 has previously been described as a DUB for p53(Hock et al. 
2011), I also assessed p53 levels in USP42 depleted cells. In the control 
cells, I observed that CCCP treatment induced accumulation of p53. Two out 
of four oligos (Q5 and Q7) targeting USP42 prevented the accumulation of 
p53. In order to assess the knockdown efficiency, I measured the mRNA 
levels of USP42 after 24hr of siRNA transfection using qRT-PCR (Figure 
5.15B). Transfection with all four oligos decreased USP42 mRNA level by 
30-60%. While transfection with oligo Q2 reduced the mRNA levels by 60%, 
it did not inhibit PINK1 accumulation, Parkin activation or degradation of 
MIRO, MFN2, TOM20 and TIMM44. One possibility is that oligo Q2 
transfection has other off-target effects that override the inhibition of 
mitophagy caused by USP42 depletion.  
 
USP43 depletion with oligos Q2, Q5 and Q6 has similar, but weaker effects 
on CCCP-induced mitophagy than USP42 depletion. In NT1-transfected 
cells, PINK1 and Ub-Parkin accumulated by 4hr of CCCP treatment. USP43 
Q5 and Q6 transfected cells only showed low levels of both PINK1 and Ub-
Parkin even after 8hr of CCCP treatment. MIRO, MFN2, TOM20 and 
TIMM44 degradation was also inhibited with Q2 and delayed with oligo Q5 
and Q6. As the cells transfected with USP43 oligo Q7 at 8hr of CCCP 
treatment were infected, that sample was not included in the analysis. Two 
out of four oligos prevented p53 accumulation. As there is no commercially 
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available USP43 antibody, I also assessed the relative knockdown efficiency 
by measuring USP43 mRNA levels 24hr post-transfection. Transfection with 
all four oligos decreased USP43 mRNA levels by 30-50%. 
 
Figure 5.15 siRNA deconvolution for USP42 and USP43. 
 
(A) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-
targeting siRNA control oligo (NT1) or siRNA oligos targeting USP42 (Q2, Q5, Q6 
and Q7) and USP43 (Q2, Q5, Q6 and Q7). Cells were then treated with CCCP 
(10µM) and harvested with RIPA lysis buffer at the indicated times. 15µg of lysates 
were probed as indicated.  
(B) hTERT-RPE1-YFP-Parkin cells were transfected for 24hr in parallel with cells 
shown in (A). Cells were then harvested for reverse transcription and qRT-PCR. 
cDNA levels of USP42 and USP43 were normalized to actin and expressed as 
relative fold change compared to NT1 (n=1).  
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5.2.6.2 USP42 and USP43 depletion partially inhibits OPA1 cleavage 
Since OPA1 cleavage precedes, and is independent of Parkin recruitment, 
this suggests that the inhibitory effect of USP42 and USP43 depletion lies 
most likely upstream of PINK1 and Parkin activation. Indeed, also in parental 
hTERT-RPE cells, USP42 and USP43 depletion followed by 8hr of CCCP 
treatment partially inhibited the cleavage of L-OPA1 and the accumulation of 
S-OPA1 (Figure 5.16A). In addition, PINK1 accumulation was also reduced 
in USP42 and USP43 depleted cells. These results suggest that USP42 and 
USP43 depletion reduces the mitochondrial response to membrane 
depolarisation. However, USP42 and USP43 depletion in HEK293T cells did 
not prevent CCCP-induced OPA1 cleavage, suggesting that this may be a 
cell type-dependent effect (Figure 5.16B). 
 
One hypothesis for the inhibition of OPA1 cleavage could be decreased 
sensitivity of the cells towards CCCP treatment upon USP42 and USP43 
depletion. Therefore, I asked if the partial inhibition of OPA1 cleavage could 
be overcome by increasing the concentration of CCCP. Indeed, by doubling 
the concentration of CCCP used, from 10µM to 20µM, the inhibitory effect on 
OPA1 cleavage was abolished. Subsequently, PINK1 accumulation, Parkin 
activation and mitochondrial protein degradation (MIRO, TOM20 and 
TIMM44) were now also observed in USP42 and USP43 depleted cells 
(Figure 5.16C).  
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Figure 5.16 Delayed OPA1 cleavage observed in USP42 and USP43 depleted cells 
is independent of Parkin but can be overcome by high concentrations of CCCP. 
 
(A) Parental hTERT-RPE1 cells were transfected for 72hr with either non-targeting 
siRNA control (NT1) oligo or siRNA oligos targeting USP42 (Q5 and Q7) and 
USP43 (Q2 and Q5) for 72hr. Cells were then treated with CCCP (10µM) for 8hr and 
harvested with RIPA lysis buffer. 10µg of lysates were probed as indicated. 
(B) HEK293T cells were transfected and treated the same as in (A).  
(C) hTERT-RPE1-YFP-Parkin cells were transfected with 40nM of siRNA against 
USP42 (Qiagen pool oligos) and USP43 (Qiagen pool oligos) for 72hr. Cells were 
then treated with either 0, 10 or 20µM of CCCP for 8hr. Cells were harvested in 
RIPA lysis buffer. 10µg of lysates were immunoprobed as indicated. 
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Next, I chose two siRNA oligos each for USP42 (Q5 and Q7) and USP43 (Q2 
and Q5) to follow up on the effects of USP42 and USP43 depletion on 
mitochondria by fixed-cell immunofluorescence (Figure 5.17). Based on 
staining with TOM20 antibodies, I did not observe obvious changes in 
mitochondrial morphology upon USP42 and USP43 depletion. After 8hr of 
CCCP treatment, TOM20 staining was either lost or co-localised with YFP-
Parkin aggregates in NT1 cells. In contrast, TOM20 staining remained strong 
in PINK1, USP42 and USP43-depleted cells and did not co-localise with 
YFP-Parkin. However, unlike PINK1-depleted cells in which mitochondria 
appeared fragmented, USP42 and USP43-depleted cells still presented with 
elongated mitochondria. This observation is in agreement with the lack of 
OPA1 cleavage first seen in delayed/inhibited degradation of MIRO, TOM20 
and TIMM44 observed in Figure 5.13.  
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Figure 5.17 siUSP42 and USP43 prevent mitochondrial fragmentation and loss of 
mitochondria in CCCP-treated hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-targeting 
siRNA control (NT1) oligo or siRNA oligo targeting PINK1, USP42 (Q5 and Q7) or 
USP43 (Q2 and Q5). Cells were then treated with CCCP (10µM). After 8hr, cells 
were fixed and stained with anti-TOM20. Images were taken using confocal 
microscope. Scale bar: 20µm.   
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5.2.6.3 USP43 depletion does not affect VPS35 protein levels 
One of the reported interactors of USP43 is VPS35, a subunit of the retromer 
complex (Sowa et al. 2009). Interestingly, VPS35 mutations have been 
reported in Parkinson’s Disease (Zimprich et al. 2011, Vilarino-Guell et al. 
2011). I assessed VPS35 protein levels under basal and CCCP-treated 
conditions. USP43 depletion over 72hrs did not affect VPS35 protein levels. 
 
Figure 5.18 USP43 siRNA deconvolution to assess the levels of VPS35.  
hTERT-RPE1-YFP-Parkin cells were transfected for 72hrs with either non-targeting 
siRNA control (NT1) or siRNA targeting USP43 (Q2, Q5, Q6, Q7) for 72hr. Cells 
were then treated with CCCP (10µM) for 4hr. Cells were harvested in RIPA lysis 
buffer and 20µg of lysates were probed as indicated. 
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5.3 Biochemical screen for DUBs involved in Parkin-mediated 
mitophagy in hTERT-RPE1-YFP-Parkin cells  
At a later stage of my project, I decided to carry out a full siRNA DUB screen 
by western blotting assess the different stages during mitophagy:  
(1) Mitochondrial depolarization and fragmentation (L-OPA1 to S-OPA1 
cleavage) 
(2) Activation of Parkin (PINK1 accumulation and Parkin ubiquitylation) 
(3) Proteasomal degradation of OMM proteins (MIRO loss) 
(4) Autophagosomal degradation of mitochondria (TIMM44 and S-OPA1 
loss)  
 
I first carried out a biochemical screen in hTERT-RPE1-YFP-Parkin cells. For 
this screen, I used a new customized DUB siRNA library provided by 
QIAGEN consisting of siRNA pools comprised of four individual siRNA oligos 
targeting 94 DUBs. This DUB siRNA library is identical to the previous 92-
DUB siRNA library described in the previous screen but upgraded with two 
newly identified DUBs, namely FAM105B (OTULIN) and C14orf28. I 
performed the screen using a total of 18x 6-well plates. On top of the 94 
siRNA pools, I also included two non-targeting siRNA oligos (NT1, NT3) as 
negative controls whereas an siRNA pool targeting PINK1 was used as a 
positive control. For internal comparison as well as comparison across 
different blots, I also included mock controls (transfection reagent without 
siRNA) of pre- and post-treatment (named Mock T0 and T8) to be loaded 
onto each gel.   
 
Instead of CCCP, I decided to use a combination of 1µM each of oligomycin 
A and antimycin A (O+A) for 8hr, which I showed in chapter 3 to effectively 
induce Parkin-mediated mitophagy by specifically inhibiting the mitochondrial 
electron transport chain complex V and complex III. I split the 18x 6-well 
plates into four batches, for which I staggered O+A treatment of each batch 
in 30min interval to allow sufficient time for harvesting.  
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Figure 5.19 Biochemical Screen for DUBs regulating Parkin-dependent mitophagy in 
hTERT-RPE1-YFP-Parkin cells. 
 
hTERT-RPE1-YFP-Parkin cells were treated for 72hr with either mock (transfection 
reagent without siRNA oligo), non-targeting siRNA oligos (NT1 and NT3), PINK1, or 
siRNA oligos targeting 94 DUBs (20nM). Cells were treated with oligomycin A and 
antimycin A (1µM each) for 8hr and harvested in RIPA lysis buffer. 10µg of lysates 
were probed as indicated. Asterisk: infected sample. DUBs labeled in red: 
shortlisted hits. 
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Figure 5.20 Biochemical Screen for DUBs regulating Parkin-dependent mitophagy in 
hTERT-RPE1-YFP-Parkin cells (continued from Figure 5.19). 
 
hTERT-RPE1-YFP-Parkin cells were treated for 72hr with either mock (transfection 
reagent without siRNA oligo), non-targeting siRNA oligos (NT1 and NT3), PINK1, or 
siRNA oligos targeting 94 DUBs (20nM). Cells were treated with oligomycin A and 
antimycin A (1µM each) for 8hr and harvested in RIPA lysis buffer. 10µg of lysates 
were probed as indicated.  
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The first striking observation from the screen was the high number of DUBs-
targeting siRNA that either partially or completely inhibited OPA1 cleavage 
after 8hr of O+A treatment (Figure 5.19 and Figure 5.20). This is 
demonstrated by the scatter plot in Figure 5.21. DUB siRNAs positioned on 
the top right-hand quadrant (e.g. USP7 and OTUD4) represents proteins with 
high protein band intensities for both L-OPA1 and S-OPA1, indicating the 
lack of L-OPA1 cleavage and the lack of downstream mitophagic degradation 
of OPA1. DUB-siRNAs that are distributed more towards the bottom left-hand 
quadrant promote cleavage of L-OPA1 and lower levels of S-OPA1 due to 
efficient mitophagy (e.g. ATXN3 and USP47). On the other hand, DUB-
siRNAs that are distributed more towards the top left-hand quadrant (e.g. 
USP25 and USP28) represents proteins with L-OPA1 cleavage but 
accumulated S-OPA1 due to inhibited mitophagy.  
 
Proportionally, DUB depletions that led to partial cleavage of OPA1 showed 
weaker PINK1 accumulation, Parkin ubiquitylation and loss of MIRO and 
TIMM44. Since PINK1 accumulation and Parkin ubiquitylation requires the 
preceding cleavage of OPA1, it is not possible to assess whether these 
DUBs affect the downstream events of mitophagy. 
  
I next assessed the proteasomal and lysosomal degradation of mitochondrial 
proteins in DUBs for which depletion did not affect, or only partially affected 
OPA-1 cleavage. To this end, I assessed MIRO levels (proteasomal 
degradation) and TIMM44 levels (lysosomal degradation). In addition, OPA1 
is also an IMM protein. While L-OPA1 is cleaved and accumulated as S-
OPA1, the latter, is degraded in lysosomes. This is illustrated by a good 
correlation between S-OPA1 and TIMM44 protein levels across the dataset 
(R2=0.595; Figure 5.22A). In contrast, whilst proteasomal degradation of 
MIRO is usually followed by TIMM44 degradation, the correlation between 
TIMM44 and MIRO protein levels is lower compared to that between S-OPA1 
and TIMM44 (R2=0.357; Figure 5.22B), revealing a differential regulation of 
the proteasomal and lysosomal degradation pathways.  
 
 
Figure 5.21 Statistical analysis of OPA1 cleavage upon 8hr of oligomycin A and 
antimycin A-induced mitophagy in hTERT-RPE1-YFP-Parkin cells.
Scatter plot demonstrating the correlation between log2 (L-OPA1) and log2 
(S-OPA1). Band intensities were normalised to actin and expressed as relative to the 
Mock T0 condition. Protein bands were measured using ImageStudio software. Note 
that the Mock T8 intensity of each blot is also included and is annotated according to 
the blot number. For example, B2 T8 represents the Mock T8 sample from blot 2. 
DUBs labelled in blue and red are 2 and 3 standard deviations from the average value 
of the total samples.
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Therefore, MIRO, TIMM44 and S-OPA1 protein levels were all taken into 
consideration to identify DUBs for which depletion differentially affect the 
proteasomal and lysosomal degradation. Based on these criteria, I selected 
UCHL1, USP25, USP28 and USP31 for further investigation. Note that while 
the effect of UCHL1 is milder compared to the other DUB siRNAs, it was still 
selected for deconvolution as mutation of this DUB has been reported in 
Parkinson’s Disease. While the cleavage of OPA1 in cells treated with these 
siRNAs was not affected, these cells accumulated higher levels of S-OPA1, 
TIMM44 but not MIRO levels compared to the mock-transfected cells.  
 
It is also worth mentioning that siRNA depletion of PSMD7 and PSMD14 
resulted in the accumulation of a 52kDa fragment of PINK1 (Figure 5.20). 
This fragment is normally constitutively degraded by the proteasome and is 
typically observed upon treatment of cells with proteasome inhibitor. On the 
other hand, S-OPA1 and TIMM44 degradation via the lysosomal pathway 
was not affected. These observations are consistent with the role of both 
PSMD7 and PSMD14 as subunits of the 19S regulatory particle of the 
proteasome (Yao and Cohen 2002, Wauer and Komander 2014). In fact, 
depletion of these two DUBs is the only condition for which an inhibition of 
the proteasomal but not the lysosomal degradation pathway is observed. 
O+A treatment in PSMD14-depleted cells also accumulated a distinct lower 
molecular weight species of MIRO that is not observed in other samples. 
Based on its approximate molecular weight, this fragment might represents a 
cleaved MIRO lacking its transmembrane domain. 
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Figure 5.22 Statistical analysis of TIMM44, S-OPA1 and MIRO protein levels from 
DUB siRNA screen in hTERT-RPE1-YFP-Parkin cells.  
 
(A) Scatter plot of log2 TIMM44 versus log2 S-OPA1. Protein bands were quantified 
using ImageStudio. Protein bands were normalised to actin and expressed as a 
relative value to the Mock T0 loading control at basal state. Proteins labeled in blue 
and red represent 2 and 3 standard deviations from the average value of the total 
samples. Note that the Mock T8 intensity of each blot is also included and is 
annotated according to the blot number. For example, B2 T8 represents the Mock 
T8 sample from blot 2. DUBs labelled in blue and red are 2 and 3 standard 
deviations from the average value of the total samples. 
 
(B) Scatter plot of log2TIMM44 versus log2 MIRO. Asterisk: Quantitation for MIRO in 
PSMD14 siRNA trasfected cells were based on MIRO doublet that only exists in that 
sample.
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5.3.1 Deconvolution of UCHL1, USP25, USP28 and USP31 
I first deconvoluted the DUBs that I selected from the biochemical screen by 
measuring MIRO, TIMM44, L-OPA1 and S-OPA1 protein levels for each 
individual siRNA oligo after 8hr of O+A treatment.  
 
Of the UCHL1 siRNAs, only oligo Q3 recapitulated the effect observed with 
the siRNA pool, namely normal degradation of MIRO but delayed 
degradation of TIMM44 whereas knockdown with oligo Q1 strongly inhibited 
both MIRO and TIMM44 degradation (Figure 5.23A). The residual two oligos 
did not affect either MIRO or TIMM44 degradation. Note that in the OPA1 
blots for the UCHL1, USP25 and USP28 deconvolution, there is a non-
specific band that is just above the L-OPA1 band. To avoid confusion, I 
marked that band with an asterisk sign.  
 
With regards to USP25 knockdown, only oligo Q1 phenocopied the effects 
seen with the pool, whereas oligo Q3 showed mild inhibition of the induction 
of mitophagy, as evident from the partial cleavage of OPA1 and the higher 
levels of both MIRO and TIMM44 (Figure 5.23B). I did not assess the 
knockdown efficiency for either UCHL1 or USP25 deconvolution.  
 
On the other hand, USP28 deconvolution revealed that knockdown with both 
oligos Q2 and Q3 inhibited TIMM44 degradation but not MIRO degradation, 
recapitulating the results observed with the pool. However, upon assessing 
the knockdown efficiency, it was clear that USP28 was not depleted in the 
cells transfected with oligo Q3, strongly suggesting that the effect seen with 
USP28 is also an off-target effect. Therefore, I did not follow up on these 
DUBs. 
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Figure 5.23 UCHL1, USP25 and USP28 deconvolution in hTERT-RPE1-YFP-Parkin 
cells. 
(A-C) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either mock 
(transfection reagent without siRNA oligo), non-targeting siRNA control (NT1), 
PINK1, or siRNA oligos targeting UCHL1, USP25, and USP28 (four siRNA oligos 
per DUB). Cells were then treated with oligomycin A and antimycin A (O+A, 1µM 
each) for 8hr. Cells were harvested in RIPA lysis buffer. 15µg of lysates were 
probed as indicated. Asterisk: non-specific band. 
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The most promising results were obtained with the USP31 deconvolution, 
with two oligos, Q2 and Q3, partially inhibiting TIMM44 but not MIRO 
degradation in response to O+A treatment. qRT-PCR analysis showed that 
oligos Q2, Q3 and Q5 knocked down USP31 (Figure 5.24B).  I further 
investigated the effect of USP31 with or without O+A treatment. Before 
treatment with O+A, LC3-I levels were lower with USP31 Q2 and Q3 
knockdown, suggesting a defect in the autophagic machinery (Figure 5.24C). 
This might explain the inhibition of TIMM44 and S-OPA1 degradation during 
mitophagy. After 8hr of O+A treatment, MIRO was degraded but residual S-
OPA1 and TIMM44 levels were higher in cells transfected with oligos Q2 and 
Q3 compared to the two non-targeting controls, NT1 and Ctrl IX.  
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Figure 5.24 USP31 deconvolution in hTERT-RPE1-YFP-Parkin cells.  
 
(A) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either mock 
(transfection reagent without siRNA oligo), non-targeting siRNA control (NT1), 
PINK1, or USP31 (Q1, Q2, Q3 and Q5) siRNA oligos. Cells were then treated with 
oligomycin A and antimycin A (O+A, 1µM each) for 8hr. Cells were harvested in 
RIPA lysis buffer. 15µg of lysates were probed as indicated.  
(B) hTERT-RPE1-YFP-Parkin cells were transfected for 24hr with either mock 
(transfection reagent without siRNA oligo), non-targeting siRNA control (NT1), or 
siRNA oligos targeting USP31 (Q1, Q2, Q3 and Q5). Cells were then harvested for 
RNA extraction, reverse transcription and qRT-PCR. cDNA level of USP31 were 
normalized to actin and expressed as relative fold change compared to mock 
control.  
(C) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-
targeting controls, (Ctrl IX, NT1), or USP31 (Q1, Q2, Q3 and Q5) siRNA oligos. 
Cells were then treated with oligomycin A and antimycin A (O+A, 1µM each) for 8hr. 
Cells were harvested in RIPA lysis buffer. 15µg of lysates were probed as indicated.  
 
P
oo
l
Q
1
Q
2
Q
3
Q
5
M
oc
k  
D
M
S
O
M
oc
k  
N
T1
P
IN
K
1
8hr  O+A
USP31
IB:  MIRO
IB:  OPA1
IB:  TIMM44
IB:  Actin
97
77
43
43
N
T1
USP31
Veh
C
trl
  IX
Q
2
Q
3
N
T1
USP31
O+A
C
trl
  IX
Q
2
Q
3
8hr:
siRNA:
siRNA:
IB:  OPA1
IB:  TIMM44
LC3-­I
LC3-­II
IB:  Actin
IB:  MIRO
IB:  LC3
97
77
14
43
43
A B
C
0  
0.2  
0.4  
0.6  
0.8  
1  
U
S
P
31
  m
R
N
A
  fr
ac
tio
n
M
oc
k
N
T1
P
oo
l
Q
1
Q
2
Q
3
Q
5
USP31
 183 
5.4 Western blot screen for DUBs involved in Parkin-mediated 
mitophagy in SH-SY5Y cells  
In neither the live-cell imaging screen, nor the western blot-based screen did 
I find a DUB for which the knockdown would enhance Parkin recruitment. 
This is most likely due to the high levels of Parkin that may mask the 
involvement of DUBs that may oppose Parkin-dependent mitophagy. 
Therefore, I decided to turn to SH-SY5Y cells, which express low 
endogenous Parkin and in which an enhancement of mitophagy might be 
easier to observe. In chapter 3, I showed that SH-SY5Y cells treated with 
either CCCP or O+A show mild ubiquitylation of MIRO. No bulk mitophagy 
was observed in these cells even after 24hr of treatment. I speculated that 
the low expression of endogenous Parkin coupled with the autoubiquitylation 
and degradation of Parkin during activation of mitophagy rapidly exhausts the 
small pool of endogenous Parkin. It is however, possible that this is further 
compounded by the deubiquitylating activity of an opposing DUB, weakening 
the effects of Parkin. I decided to perform a siRNA screen in these cells to 
determine if depletion of any of the DUBs promotes mitophagy in SH-SY5Y 
cells.  
 
Prior to the actual siRNA screen, I compared the knockdown efficiencies of 
forward and reverse transfection using Lipofectamine RNAiMAX in SH-SY5Y 
cells. As shown in Figure 5.25, both methods knocked down USP33 to 
comparable levels. For simplicity, I decided to also use the same reverse 
transfection protocol as in hTERT-RPE1-YFP-Parkin cells. 
 
The same DUB siRNA library from Qiagen was used to transfect SH-SY5Y 
cells. I also included the same non-targeting siRNAs (NT1 and NT3) and 
siRNA targeting PINK1 as negative and positive controls, respectively. Mock-
transfected samples (transfection reagent without oligo) were also included 
for comparison across different blots. SH-SY5Y cells were also treated with 
1µM of O+A but the treatment was extended to 24hrs to maximize the effects 
(see Chapter 3). 
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Figure 5.25 Comparison of Lipofectamine RNAiMAX forward and reverse 
transfection protocols in SH-SY5Y cells.  
 
SH-SY5Y cells were transfected for 72hrs with 40nM of either mock (transfection 
reagent without siRNA oligo), non-targeting siRNA control oligo (NT1) or siRNA 
targeting USP33 (D6). Cells were harvested in RIPA lysis buffer and 10µg of lysates 
were probed with USP33 and actin antibodies. 
 
One of the first issues I observed was the lack of PINK1 accumulation in 
mock-transfected cells as well as in cells transfected with six of the siRNA 
pools (OTUB6B, OTUB6A, OTUD5, OTUD1, BRCC3 and COPS5) after 24hr 
of O+A treatment. I also observed a slight decrease in the levels of MIRO 
and TIMM44 under these conditions compared to the O+A treated mock 
condition (Mock T8). These six transfections (on the same 6-well plate) as 
well as the mock-transfected cells had been very confluent on the day of 
mitophagy induction. Therefore, it is possible that the high cell density alters 
the accumulation of PINK1 and MIRO levels. Since these observations on 
the mock-transfected cells were not consistent with previous characterization 
work, the mock controls were not used as standards for comparison. Instead, 
comparisons were made based on the overall protein levels across all of the 
DUB depletions.  
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Figure 5.26 Biochemical screen for DUBs regulating Parkin-mediated mitophagy in 
SH-SY5Y cells.  
SH-SY5Y cells were treated for 72hr with either mock (transfection reagent without 
siRNA oligo), non-targeting siRNA oligos (NT1 and NT3) or siRNA oligos targeting 
94 DUBs (20nM). Cells were treated with oligomycin A and antimycin A (1µM each) 
for 8hr and harvested in RIPA lysis buffer. 10µg of lysates were probed as indicated. 
DUBs labeled in red: shortlisted DUBs. Asterisk: non-specific band. 
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Figure 5.27 Biochemical screen for DUBs regulating Parkin-mediated mitophagy in 
SH-SY5Y cells (continued). 
SH-SY5Y cells were treated for 72hr with either mock (transfection reagent without 
siRNA oligo), non-targeting siRNA oligos (NT1 and NT3) or siRNA oligos targeting 
94 DUBs (20nM). Cells were treated with oligomycin A and antimycin A (1µM each) 
for 8hr and harvested in RIPA lysis buffer. 10µg of lysates were probed as indicated. 
Asterisk: non-specific band. §: Misloaded lane (Mock T0 sample was added instead 
on PINK1-depleted sample). 
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In contrast to the DUB siRNA screen in hTERT-RPE1-YFP-Parkin cells, SH-
SY5Y cells underwent complete OPA1 cleavage upon O+A treatment. 
However, cells were treated for 24hr as opposed to 8hr in hTERT-RPE1-
YFP-Parkin cells. It is also possible that the partial or inhibited OPA1 
cleavage observed in hTERT-RPE1-YFP-Parkin cells is a cell-type 
dependent effect, as previously discussed.  
 
Overall, most of the siRNA pools did not induce obvious changes in response 
to O+A treatment based on the proteins I assessed, except for an increase in 
PINK1 accumulation and MIRO ubiquitylation upon USP7 and USP28 
depletion (Figure 5.26).  
 
I wondered whether poor knockdown efficiency might be responsible for the 
lack of effects seen in this DUB screen. Therefore, I randomly selected a few 
DUB siRNA lysate samples from the western blot screen to assess the 
general siRNA transfection efficiency (Figure 5.28). While there is a visible 
decrease in the levels of PINK1, USP8 and USP33 upon treatment with their 
respective siRNA pools, depletion was not complete for either of these 
proteins. Knockdown of several other DUBs, including UCHL5, USP15, 
USP21 and USP28 did not significantly decrease the respective protein 
levels, which may be due to a combination of poor transfection efficiency and 
long half-lives of these DUBs.  
 
Subsequent deconvolution of USP28, using the four Qiagen siRNA oligos 
and also additional Dharmacon and Ambion siRNA oligos did not yield any 
consistent effect on PINK1 accumulation and MIRO ubiquitylation (Figure 
5.29). USP7 deconvolution demonstrated that siRNA oligo Q1, Q10, Q2, Q3 
and D6 knocked down USP7 most efficiently compared to oligo D5, D7 and 
D8 (Figure 5.30). These oligos also seemed to induce higher accumulation of 
PINK1. However, subsequent experiments failed to reproduce this result.  
In both USP28 and USP7 deconvolution, both DUBs were also only partially 
depleted, which may explain the lack of consistent changes in both cases, 
rendering these results inconclusive.  
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Figure 5.28 Assessment on the knockdown efficiency of DUB siRNA transfection.  
 
Selected lysates from the same experiment in Figure 5.26 and Figure 5.27 were 
rerun to probe for the respective DUBs.  
 
 
 
Figure 5.29 USP28 siRNA deconvolution in SH-SY5Y cells. 
 
SH-SY5Y cells were transfected for 72hr with either mock (transfection reagent 
without siRNA oligo), non-targeting siRNA oligos (NT1, NT3 and Ctrl IX), siRNA 
oligos targeting PINK1 or USP28. The cells were then treated with oligomycin A and 
and antimycin A (O+A; 1µM each) for 24hr. The cells were harvested in RIPA lysis 
buffer and 15µg of lysates probed as indicated. Asterisk: non-specific band.  
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Figure 5.30 USP7 siRNA deconvolution in SH-SY5Y cells.  
 
SH-SY5Y cells were transfected for 72hr with either mock (transfection reagent 
without siRNA oligo), non-targeting siRNA oligos (NT1, NT3 and Ctrl IX), siRNA 
oligos targeting PINK1 or USP7. The cells were then treated with oligomycin A and 
and antimycin A (O+A; 1µM each) for 24hr. The cells were harvested in RIPA lysis 
buffer and 15µg of lysates probed as indicated.  
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5.5 Discussion 
Having characterised hTERT-RPE1-YFP-Parkin and SH-SY5Y cells in 
chapters 3 and chapter 4, I first carried out a DUB siRNA screen by live-cell 
imaging using the former cell line, followed by two western blotting screens 
with both of the cell lines to identify DUBs that are involved in mitophagy. 
However, the poor siRNA transfection efficiency in SH-5Y cells in the last 
DUB siRNA screen renders the results inconclusive. Therefore, the results 
from that screen will not be further discussed.  
5.5.1 DUB knockdowns that inhibited OPA1 cleavage 
From the live-cell imaging screen, I identified USP10, USP30, USP38, 
USP42, USP43, USP49, BAP1, OTUD4 and ZRANB1, for which depletion 
resulted in delayed Parkin recruitment but without any obvious effect on 
Parkin clearance. Further analysis of the top hits by western blotting revealed 
that the depletion of the DUB candidates induced partial or complete 
inhibition of OPA1 cleavage, and caused similar inhibition of the downstream 
PINK1 accumulation, Parkin autoubiquitylation and mitochondrial protein 
degradation. In addition, the second screen by western blotting revealed 
more DUB siRNAs that also caused either partial or complete inhibition of 
OPA1 cleavage. Shortlisted proteins and their functions are summarised in 
Table 5.2. 
 
Based on the characterisation work performed on USP42 and USP43 
depleted cells, I came to the conclusion that: (1) OPA1 cleavage inhibition is 
most likely a cell type-dependent effect as it was only observed in both 
parental and YFP-Parkin expressing hTERT-RPE1 cells but not in HEK293T 
cells; (2) The inhibition of OPA1 cleavage was not a CCCP-specific effect, 
but rather, is due to the decrease in cellular response towards mitochondrial 
depolarisation. This assumption is made based on the observation that 
OPA1 cleavage was inhibited not just upon CCCP but also upon O+A 
treatments and importantly could be overcome by doubling the concentration 
of CCCP. It still remains to be seen whether these observations can be 
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extrapolated to the other DUB siRNAs that showed a similar lack of OPA1 
cleavage inhibition.  
 
One hypothesis is that the depletion of these DUBs may upregulate the 
multidrug resistance-associated proteins (MRPs), a family of drug 
transporters that pump a wide range of anionic organic drugs out of the cells 
and have been proposed to contribute to unexplained cases of anticancer 
drug resistance (Borst et al. 2000). To assess whether the observed lack of 
OPA1 cleavage is truly due to a reduction in CCCP, oligomycin A and 
antimycin A being taken up and retained in the cells, one pivotal experiment 
that remains to be carried out in the future is to assess the mitochondrial 
membrane potential upon CCCP or O+A treatment. This can be achieved 
using tetramethylrhodamine (TMRE), a positively-charged, red-orange dye 
that accumulates in active mitochondria with a relative negative membrane 
potential. Cells that retain their membrane potential are stained with TMRE 
and can then be quantitatively assessed by fluorescence-activated cell 
sorting (FACS).  
 
MacVicar and Lane (2014) recently reported that hTERT-RPE1-YFP-Parkin 
cells cultured in glucose-based media undergo Parkin-mediated mitophagy 
upon CCCP treatment but the same cells cultured in galactose switched to 
dependence on oxidative phosphorylation (OXPHOS) and were resistant to 
CCCP-induced mitophagy (MacVicar and Lane 2014). This effect is due to 
the suppression of OMA1, an inducible OPA1 protease that cleaves L-OPA1 
to S-OPA1 in OXPHOS-dependent hTERT-RPE1 cells. Since I cultured 
hTERT-RPE1-YFP-Parkin cells in glucose rich medium (17.5mM of D-
glucose), these cells should be more glycolytic and less dependent on 
OXPHOS for cellular energy production. However, it is possible that the 
depletion of a subset of DUBs reprogrammes the cells to be more OXPHOS 
dependent. This could be tested in the future by measuring the oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) of the 
cells. Glycolytic cells have lower OCR and higher ECAR whereas OXPHOS-
dependent cells have higher OCR and lower ECAR (Wu et al. 2007). 
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Interestingly, two of the DUBs, USP10 and USP42 for which depletion 
inhibited OPA1 cleavage were previously implicated in p53 regulation. 
Cytosolic and nuclear p53 pools have been shown to inhibit and promote 
autophagy, respectively (Levine and Abrams 2008, Morselli et al. 2008, 
Tasdemir et al. 2008a, Tasdemir et al. 2008b). Consistent with a role of p53 
during autophagy, cytosolic p53 has also been shown to physically bind to 
and inhibit the activity of Parkin in pancreatic β-cell (Hoshino et al. 2014, 
Hoshino et al. 2013).  
 
USP10 is a DUB that counteracts the nuclear export of ubiquitylated p53 
(Yuan et al. 2010). In addition, Liu and colleagues showed that USP10 and 
USP13 form a complex with Beclin-1 and regulate the stability of each other, 
thereby inhibiting autophagy (Liu et al. 2011). However, USP13 depletion did 
not induce any visible change in either the live-cell imaging or western 
blotting screen.  
 
USP42 has previously been reported to directly interact with and regulate the 
stability of p53 during DNA damage, allowing rapid accumulation of p53 to 
induce cell cycle arrest (Hock et al. 2011). While I did not assess the 
localization of p53, USP42 depletion with two siRNA oligos inhibited the 
accumulation of p53 during CCCP-induced mitophagy, which is observed in 
the control cells. Since the same two USP42 siRNA oligos also inhibited 
OPA1 cleavage and its subsequent mitophagic readouts, it is uncertain 
whether the p53 accumulation is a consequence of a failure to trigger OPA1 
cleavage and mitophagy or more directly due to a proposed failure of CCCP 
to trigger depolarisation in these cells. A systematic proteomic interaction 
screen of DUBs performed by Sowa et al. identified a group of mitochondrial 
ribosomal protein subunits that were immunoprecipitated with HA-tagged 
USP42, suggesting that USP42 may also regulate general mitochondrial 
translation of genes encoded by the mitochondrial DNA (Figure 5.31A) 
(Sowa et al. 2009).  
 
USP43 is a poorly characterized DUB. The same interaction screen 
described above by Sowa et al. identified VPS35 as an interactor of USP43 
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(Figure 5.31B) (Sowa et al. 2009). VPS35 is a core component of the 
retromer complex mediating endosome-to-Golgi transport of membrane 
proteins such as the cation-independent mannose 6-phosphate receptor 
(CIMPR) (Seaman 2012). Importantly, mutation in VPS35 (D620N), which 
causes reduced binding efficiency for the WASH complex to the endosome, 
has been reported in some cases of autosomal-dominant, late-onset 
Parkinsonism (Zimprich et al. 2011, Vilarino-Guell et al. 2011, Harbour et al. 
2010, Jia et al. 2012, Zavodszky et al. 2014a, Zavodszky et al. 2014b). In 
addition, Zavodszky and colleagues reported that cells with a VPS35 
(D620N) mutation or depleted of WASH complex also show defects in the 
trafficking of ATG9A to autophagosomal membrane, causing inhibition of 
autophagy (Zavodszky et al. 2014b). Although a link between VPS35 or 
WASH and mitophagy has not yet been established, I assessed the protein 
levels of VPS35 in USP43-depleted cells. While I did not observe any 
decrease in the levels of VPS35 upon USP43 knockdown, I cannot exclude 
possible changes in the localization of VPS35 upon USP43 depletion.  
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Figure 5.31 Reported interactors of USP42 and USP43.  
 
Interactors of USP42 and USP43 are derived from the systematic proteomic 
interaction screen of DUBs carried out by Sowa et al. 2009. 
 
BAP1 (BRCA1-Associated Protein 1) depletion also resulted in delayed 
Parkin recruitment and partial OPA1 cleavage. BAP1 localises to the nucleus 
and promotes the stability of HCF-1, a scaffolding protein that binds to 
different transcription factors such as Yin Yang 1 (YY1) (Yu et al. 2010, 
Machida et al. 2009). One of the genes that is transcribed by YY1 is cox7c, 
which encodes for a component involved in the mitochondria electron 
transport chain (Yu et al. 2010, Deng et al. 2010). In addition, BAP1 also 
regulates the stability of O-linked N-acetylglucosamine transferase (OGT), an 
interacting partner of HCF-1 (Dey et al. 2012). N-acetylglygosylation of 
peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α; a key 
co-activator involved in gluconeogenesis and mitochondrial biogenesis) by 
the HCF-1/OGT complex confers recognition of PGC-1α by BAP1 to protect it 
from degradation, thereby promoting mitochondrial biogenesis (Ruan et al. 
2012).  
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USP38 depletion also resulted in delayed Parkin recruitment upon CCCP 
treatment. USP38 has been shown in a proteomic interaction screen to 
interact with RPL7 and RPS12 both of which are components of the 60S and 
40S ribosomes, respectively (Seshadri et al. 1993, Herault et al. 1991, Sowa 
et al. 2009). Other interacting partners include LGALS7 (a carbohydrate-
binding protein implicated in cell adhesion and cell matrix interaction), 
HSPB1 (a chaperone protein that is upregulated during stress response) and 
HMX3 (a transcription factor involved in inner ear development and 
reproduction) (Wang et al. 1998, Seshadri et al. 1993, Herault et al. 1991, St-
Pierre et al. 2012, Arrigo et al. 2007). A siRNA screen for DUBs that regulate 
E-cadherin levels performed by an ex-colleague in the laboratory, Jia Lih 
Wong, reported that USP38 depletion reduces the levels of E-cadherin in 
A549 and MCF7 cells (Wong 2012). However, further work so far failed to 
elucidate the mechanistic link between USP38 and E-cadherin.  
 
ZRANB1-depleted cells demonstrated delayed Parkin recruitment followed 
by enhanced Parkin clearance whereas the western blot screen showed 
inhibition of OPA1 cleavage in ZRANB1-depleted cells. ZRANB1 (also known 
as TRABID) was reported to bind and deubiquitylate adenomatous polyposis 
coli (APC), an antagonist of the Wnt-β-catenin signaling pathway (Tran et al. 
2008). Hyperubiquitylation of APC in TRABID-depleted cells leads to its 
hyperactivation and subsequently repression of Wnt target genes.  
5.5.2 USP31, a DUB required for late stages of mitophagy 
From the western blot screen, USP31 was the only DUB for which more than 
one oligo (two in this case) recapitulated the effect of the siRNA pool, namely 
selective inhibition of the lysosomal but not the proteasomal degradation of 
mitochondrial proteins during mitophagy. I also observed less LC3-I in 
untreated, USP31-depleted cells. Under steady state conditions, precursor 
LC3 (pro-LC3) is constitutively cleaved and converted to LC3-I by Atg4B 
(Kabeya et al. 2000). During autophagy, or in this case, mitophagy, LC3-I 
(upper band) is conjugated with phosphatidylethanolamide (PE), forming 
LC3-II (lower band), which then recruits autophagosomal membranes to the 
mitochondria (Mizushima and Yoshimori 2007, Klionsky et al. 2007). The 
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lower LC3-I at steady state suggests that there could be a defect in the 
expression of pro-LC3 or its proteolytic processing to form LC3-I. 
Subsequently, this may affect LC3-II conversion and the recruitment of 
autophagosomal membrane to the mitochondria during mitophagy induction. 
 
To understand the effect of USP31 depletion on LC3-I, the mRNA levels of 
pro-LC3 need to be assessed by qRT-PCR. Immunofluorescence 
microscopy should also be performed to see if there is any difference in the 
abundance and distribution of LC3-punctae both at steady state and upon 
induction of mitophagy. USP31 depletion could also affect the acidification of 
the lysosome, a crucial step to activate lysosomal hydrolases for their optimal 
degradative capacity (Pillay et al. 2002). Immunofluorescence visualization of 
mitochondria and lysosomes using TOM20 antibody staining (for 
mitochondria) and either acridine orange dye or LAMP1 antibody staining (for 
lysosomes) may provide information on the targeting of mitochondria to the 
lysosomes. In addition, a coral-derived acid-stable fluorescent protein that 
displays pH-dependent changes in fluorescence emission (450nm at pH>6; 
543nm at pH<6), conjugated with a mitochondria-targeting signal from the 
mitochondrial matrix protein COXVIII, called ‘mitoKeima’ could been used to 
monitor delivery of mitochondria into an acidic environment upon fusion of 
autophagosomes with lysosomes (Katayama et al. 2011). This has recently 
been used by Bingol and colleagues to show that USP30 overexpression 
antagonizes Parkin-mediated mitophagy in hippocampal neurons (Bingol et 
al. 2014).  
5.5.3 Recent advances in the identification of DUBs regulating Parkin-
mediated mitophagy  
Recently, two papers have been published, identifying USP15 and USP30 
respectively as DUBs that oppose Parkin-mediated mitophagy. Bingol and 
colleagues reported that the overexpression of USP30 opposes Parkin-
mediated mitophagy in HEK293, HeLa and SH-SY5Y cells stably expressing 
Parkin. They further demonstrated that TOM20 and MIRO are bona fide 
substrates for USP30. Importantly, whole fly or dopaminergic neuron 
knockdown of dUSP30 rescued the climbing defect and the dopamine 
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depletion observed in PINK1 mutant and paraquat-treated flies, respectively, 
suggesting that USP30 inhibition may be a therapeutic target for Parkinson’s 
disease by promoting mitochondrial clearance and quality control (Bingol et 
al. 2014). 
 
Using tandem affinity purification coupled to mass spectrometry, Cornelissen 
and colleagues identified USP15 as an interactor of FLAG-Parkin in HEK293 
cells (Cornelissen et al. 2014). They further demonstrated that co-expression 
of USP15 and Parkin in HeLa cells rescues cells from mitophagy. 
Interestingly, they reported that USP30 overexpression did not oppose 
Parkin-mediated mitophagy in their system. In my hTERT-RPE1-YFP-Parkin 
screens, USP30 depletion led to delayed Parkin recruitment and partial 
OPA1 cleavage in hTERT-RPE1-YFP-Parkin cells whereas USP15 depletion 
inhibited OPA1 cleavage.  
 
In both the USP15 and USP30 studies, they used an overexpression system, 
similar to a ‘gain-of-function’ study to identify DUBs that oppose the 
ubiquitylating activity of Parkin. In my case, the use of a siRNA approach to 
study the loss-of-function effect of DUBs makes it difficult to identify such 
DUBs in a cell line that is already overexpressing high levels of Parkin. 
Indeed, Bingol and colleagues could only demonstrate the effect of USP30 
depletion in SH-SY5Y cells expressing a mutant form of Parkin (G430D) that 
only has partial ubiquitylating ability. On the other hand, knockdown of 
USP15 was performed in cells expressing normal Parkin and assessed by 
immunofluorescence quantitation of HSP60 staining (an IMM protein) after 
24hr of CCCP treatment. Considering that only 30% of the cells undergo 
complete mitophagy in the control cells and USP15 depletion only enhanced 
the loss of mitochondria by 15%, this effect may not be easily visible by 
western blotting. 
 
During the course of writing up this thesis, another group reported that USP8 
is also involved in Parkin-mediated mitophagy (Durcan et al. 2014). Durcan 
and colleagues reported that knockdown of USP8 delayed Parkin recruitment 
to mitochondria upon CCCP treatment in U2-OS cells expressing GFP-
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Parkin. USP8 preferentially removes K6-linked ubiquitin chains from Parkin, 
which promotes efficient recruitment of Parkin to depolarised mitochondria, 
thereby serving as a positive regulator of Parkin activity in mitophagy. The 
delayed Parkin recruitment reported with USP8 depletion is reminiscent of 
the delayed Parkin recruitment observed with USP42, USP43 and possibly 
other DUBs reported in my DUB screen. In my initial visual screen, USP8 
depletion affected cell growth and resulted in cell death at steady state. In my 
western blot screen, USP8 depletion affected OPA1 cleavage in hTERT-
RPE1-YFP-Parkin cells. Therefore, its downstream effect on mitophagy was 
masked and USP8 was not further pursued in this study.  
 
The current understanding of the regulation of DUBs on Parkin-mediated 
mitophagy (USP30, USP15, and USP8), together with the deconvoluted 
DUBs identified in my project and their proposed functions are summarised 
in Table 5.2 and Figure 5.32. My results concerning USP30 will be the focus 
of Chapter 6.  
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DUB family  DUB 
Live-cell imaging Screen 
(RPE1-YFP-Parkin) 
Western blot screen 
(RPE1-YFP-Parkin) 
Western blot screen 
(SH-SY5Y) Literature References Observations (no. of 
oligos) 
Observations (no. of 
oligos) 
Observations (no. of 
oligos) 
UCH 
BAP1 Reduced response (2) Partial OPA1 cleavage --- 
Binds to BRCA1, tumour 
suppressor, interacts with 
AHCYL2  
(Sowa et al. 2009) 
UCHL1 - Inhibited lysosomal degradation (1) - 
Mutated in Familial 
Parkinson’s Disease (Maraganore et al. 2004) 
OTU 
OTUD4 Reduced response (2) Normal - - - 
ZRANB1 Reduced response (2) Inhibited OPA1 cleavage - DUB for APC (Wnt pathway) (Tran et al. 2008) 
USP 
USP3 Reduced response (1) Inhibited OPA1 cleavage - 
DUB for H2A and H2B, 
involved in DNA damage 
response   
(Nicassio et al. 2007) 
USP7 Reduced response (1) Inhibited OPA1 cleavage Higher Ub-MIRO levels (0) 
Regulate p53 and Mdm2 
levels 
(Cummins and 
Vogelstein 2004, Li et al. 
2004, Li et al. 2002) 
USP10 Reduced response (3) Normal - 
Regulates p53 localisation & 
stability; regulates NEMO 
stability and suppresses NF‐
κB 
(Yuan et al. 2010, Niu et 
al. 2013, Liu et al. 2011) 
USP25 - 
Inhibited lysosomal 
degradation of TIMM44 
and S-OPA1 (1) 
- Opposes HRD1 E3 ligase activity in ERAD pathway (Blount et al. 2012) 
USP28 - 
Inhibited lysosomal 
degradation of TIMM44 
and S-OPA1 (1) 
Higher Ub-MIRO levels 
(0) 
Opposes FBX7 E3 ligase 
activity, regulates myc, LSD1 
and HIF-1α stability; homolog 
of USP25 
(Popov et al. 2007, Wu 
et al. 2013, Flugel et al. 
2012, Valero et al. 2001) 
USP30 Reduced response, cell death (2) Inhibited OPA1 cleavage - 
Regulates mitochondrial 
morphology 
(Nakamura and Hirose 
2008, Bingol et al. 2014) 
USP31 - 
Inhibited lysosomal 
degradation of TIMM44 
and S-OPA1 (2) 
- - - 
USP38 Reduced response (2) Inhibited OPA1 cleavage - Possible role in regulating with E-cadherin levels (Wong 2012) 
USP42 Reduced response (2) Inhibited OPA1 cleavage - Regulates p53 stability, interacts with AHCYL1 
(Sowa et al. 2009, Hock 
et al. 2011) 
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USP43 Reduced response (4) Inhibited OPA1 cleavage - Interacts with VPS35, PSME3 (Sowa et al. 2009) 
USP49 Reduced response (3) Partial OPA1 cleavage - Interacts with HUWE1  (Sowa et al. 2009) 
MJD ATXN3 Reduced response (1) Normal - Binds and inhibits E3 ligase activity of Parkin  
(Bai et al. 2013, Durcan 
et al. 2012) 
Table 5.2 Overview of candidate DUBs that were selected for deconvolution in all three DUB siRNA screens. 
(number in bracket represents numbers of oligos that recapitulated the effect seen with the siRNA pool).  
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Figure 5.32 Schematic illustration of the current understanding of the role of DUBs 
in Parkin-mediated mitophagy.  
 
USP8 has recently been reported to deubiquitylate K6-linked chains from Parkin, 
which promotes Parkin recruitment to the mitochondria during mitophagy (Durcan et 
al. 2014). Conversely, USP30 and USP15 are both reported to oppose Parkin-
mediated mitophagy (Bingol et al. 2014, Cornelissen et al. 2014). In the case of 
USP30, two substrates have been identified as TOM20 and MIRO. In my screen, I 
found a subset of DUBs, for which depletion desensitized the hTERT-RPE1-YFP-
Parkin cell response towards mitochondrial depolarisation by CCCP and O+A 
treatment. These DUBs include USP42 and USP43. USP30 might have a 
cytoprotective role during mitophagy as depletion of USP30 resulted in enhanced 
cell death during mitophagy (see Chapter 6). USP31 depletion resulted in delayed 
lysosomal degradation without affecting proteasomal degradation of mitochondrial 
proteins, suggesting that USP31 might be involved in the later stages of 
autophagosomal fusion with the lysosomes or the maturation of autolysosomes.  
CCCP
ParkinParkin
USP8
USP31
USP42
USP43
others?
USP30 USP15
K6
Regulation?
lysosome
autophagosome
ubiquitin proposed  roles(from  my  study)
reported  roles
(from  literature)
mitochondria
regulation  of
lysosomal  fusion?
Affects  OPA1  cleavage
apoptosis?
 202 
Chapter 6: Characterisation of 
USP30  
6.1 Introduction 
USP30 is 517 amino acids in length and belongs to the USP family of 
deubiquitylases (Figure 6.1). It is one of the two deubiquitylases that has a 
specific transmembrane domain, the other one being USP19, which localizes 
to the endoplasmic reticulum (Urbe et al. 2012, Hassink et al. 2009, Clague 
et al. 2013). Nakamura and Hirose (2008) showed that a hydrophobic region 
at the N-terminus (35-54 a.a.) confers its transmembrane (TM) domain. A 
series of positively charged amino acids following the TM domain serves as a 
‘signal-anchor’ sequence that allows the translocation of USP30 from the 
endoplasmic reticulum to the mitochondria (Nakamura and Hirose 2008). The 
catalytic domain of USP30 consists of a catalytic triad (C77, H452 and S477) 
and spans most of the rest of the protein (69 to 499 a.a.) (Ye et al. 2009). 
Using mitochondria-enriched fraction, Nakamura and Hirose (2008) 
demonstrated that USP30 is inserted into the OMM such that its catalytic 
domain is facing the cytosol, making it susceptible to Proteinase K treatment. 
USP30 is conserved across multiple organisms, including cow, fish, mouse 
and fly (Figure 6.1B). In yeast, the only DUB that has a similar TM domain 
and localizes to the mitochondria is ubp16 (Kinner and Kolling 2003, 
Nakamura and Hirose 2008). However, there is only 16.4% identity similarity 
between ubp16 and human USP30, suggesting possible convergent 
evolution of two different genes that serve similar function in the 
mitochondria.  
 
In this chapter, I summarize my findings on the role of USP30 at steady 
states as well as during mitophagy and other stimuli.  
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Figure 6.1 Protein domain architecture of USP30.  
(A) USP30 has a transmembrane domain (TM) at the N-terminus. The catalytic triad 
consists of C77, H452 and an unconventional S452 instead of aspartate or 
asparagine.  
(B) Clustalw alignment of human, cow, mouse, zebrafish, fly (CG3016) and yeast 
USP30 (ubp16). Arrows indicate the catalytic cysteine, histidine and serine, which in 
Ubp16 is an aspartic acid.  
TM USPCys
1 69
35 54 H452
H452
S477
S477
C77
C77
499 517
N C
AVRYKVMKNWGVIGGIAAALAAGIYVIWGPITERKKRRKGLV
Transmembrane  domain ‘Signal-­anchor’  region  
Human USP30         KRRKGLVPGLVNLGNTCFMNSLLQGLSACPAFIRWLEEFTSQYSRDQKEPPSHQYLSLTL 120 
Cow USP30           KRRKGLVPGLVNLGNTCFMNSLLQGLSACPTFIKWLEEFTTQYTGGHKEPPQHQYLSLTL 120 
Mouse USP30         KRRKGLVPGLVNLGNTCFMNSLLQGLSACPAFVKWLEEFTTQYSRDQQGPHTHQCLSLTL 120 
Zebrafish USP30     KKRKGMVPGLLNLGNTCFMNSLLQGLAACPSFIRWLEDFTSQNSADRERTERETQLSRSL 116 
Fly CG3016          RQRRGQIAGLHNFGLTCFLNTLLQAMAACPQFIAWLQLYNN------ASPDRKSLITSML 85 
Yeast ubp16         FRPAVVSSPSVPEGTYTVLNNPKQSTVSRKSFS------------APTSPTRNKRSGSSS 76 
                     :     .     *   .:*.  *.  :   *                 .  .        
 
human USP30         HSGHFVTYRRSPPSARNPLSTSNQWLWVSDDTVRKASLQEVLSSSAYLLFYERVLSRMQH 508 
cow USP30           HSGHFVTYRRSPPSAKNPVSASSQWLWVSDDTVRKASLQEVLSSSAYLLFYERVLSKMQP 508 
mouse USP30         HSGHFVTYRRSPPSAKNPLSTSNQWLWISDDTVRKASLQEVLSSSAYLLFYERVLSRVQQ 508 
zebrafish USP30     HSGHFITYRRCPAAPRGTSPFSSQWLWVSDDSVRKASLQEVLSSSAYLLFYER----MQR 484 
fly CG3016          NSGHFVTYRR------GSLRNAHRWYYTSDTIVREVSIDEVLSVPAYLLFYDRGQQRQLN 556 
Yeast ubp16         RSGHYYSFCK---------SSNGVWLKFDDDFVSNSSIDRVLNQQAYILQYKRKSTSSSK 435 
                    .***: :: :              *   .*  * : *::.**.  **:* *.*         
A
B
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6.2 Understanding the role of USP30 in mitophagy 
In the previous chapter, I identified USP30 as one of the DUBs that may 
regulate Parkin-mediated mitophagy in my live-cell imaging screen.  
6.2.1 USP30 depletion exacerbates cell death during mitophagy 
Knockdown of USP30 enhanced CCCP-mediated mitophagic cell death in 
hTERT-RPE1-YFP-Parkin cells as evident by the increase in DRAQ7-
positive cells (see video 3 and Figure 6.2A). This observation is consistent 
with the preceding cleavage of PARP at 4hr (Figure 6.2B). As seen in Figure 
6.3A, double knockdown of PINK1 and USP30 inhibited PARP cleavage, to 
the same extend as PINK1 knockdown. Furthermore, USP30 depletion in 
parental hTERT-RPE1 cells did not induce cell death during CCCP treatment 
(Figure 6.3B). These observations confirm that USP30 acts downstream of 
PINK1 and Parkin during mitophagic cell death. 
 
At a later stage of my project, I obtained an USP30 antibody from Baris 
Bingol (Genentech, San Francisco). This allowed me to assess the 
knockdown efficiency of our array of siRNA oligos against USP30 (Figure 
6.4A) (Bingol et al. 2014). Prior to obtaining that antibody, I had been 
assessing the knockdown efficiency using qRT-PCR. As shown in Figure 
6.4B, all USP30 siRNA oligos depleted USP30 protein levels to less than 
40% of the control (NT1) with the exception of oligo D8, which did not deplete 
USP30, as assessed by both western blotting and qRT-PCR. There is also a 
good correlation between USP30 mRNA and protein levels across the siRNA 
panel (R-squared value= 0.95).  
 
 205 
 
 
 
Figure 6.2 USP30 depletion in hTERT-RPE1-YFP-Parkin cells enhances cell death. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected with siRNA oligos against 
control (NT1) or USP30 (D1, D3) for 72hr. Cells were then treated with CCCP 
(10µM) for up to 24hrs. The progression of mitophagy was recorded by live-cell 
imaging in the presence of the membrane impermeable dye DRAQ7. Frames were 
captured at 15 min intervals. Shown is a cropped single frame from a representative 
video. YFP- Parkin is shown in grey, DRAQ7 in pink. Scale bar: 10 µm. The number 
of DRAQ7 positive cells (dead cells) at 12hr of CCCP treatment is shown as 
percentage of total cells at T=0. Error bars indicate SD; n= 4 imaged positions.  
(B) hTERT-RPE1-YFP-Parkin cells were transfected as in (A) and treated with 
CCCP (10µM) for 4hr. Cells were lysed in NP40 lysis buffer and lysates were 
probed with indicated antibodies. FL: full length PARP. P85: PARP-p85 fragment. 
The band intensity of PARP-p85 (normalised to Actin) is shown as bar graph relative 
to the PARP-p85 level of USP30D1. Error bars indicate SD, n= 5 independent 
experiments.    
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Figure 6.3 USP30 depletion enhances CCCP-induced cell death in a PINK1 and 
Parkin-dependent manner. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected as before with siRNA against 
control (NT1), PINK1 and USP30 (D1) and treated with CCCP (10µM) for 0, 1, 4 and 
8hrs. Cells were lysed in RIPA lysis buffer.  
(B) hTERT-RPE1-YFP-Parkin cells and parental hTERT-RPE1 cells were 
transfected and treated as in (A). Asterisk: non-specific band. Arrow: high molecular 
weight MIRO band. 
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Figure 6.4 USP30 siRNA deconvolution. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected with siRNA oligos against 
USP30 (dharmacon oligos D1, D3, D6, D7, D8, D9; Qiagen oligos Q6, Q7) or 
control (NT1) and mock (transfected with RNAiMAX transfection reagent without 
siRNA oligo) for 72hr. Cells were then harvested in NP40 lysis buffer. Asterisk: non-
specific band.  
(B) Bar chart represents a comparison of USP30 protein levels and USP30 mRNA 
levels (24hr post-transfection) normalized to actin and expressed relative to NT1 
control.  
(C) Scatter plot illustrates correlation between relative USP30 protein and relative 
mRNA levels after siRNA oligo transfection.  
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6.2.2 USP30 localises to the mitochondria  
A previous member of our laboratory, Richard Buus, had generated several 
different USP30 constructs. The constructs were: (1) full length USP30, (2) 
catalytically inactive (cysteine to serine modification at position 77) and (3) a 
truncated USP30 construct lacking the TM region (Δ1-53). Green fluorescent 
protein (GFP) tag was added to these constructs at the C-terminus instead of 
the N-terminus to avoid interference with the transmembrane signal at the N-
terminus. As shown in Figure 6.5, both USP30-GFP and USP30-C77S-GFP 
localized to mitochondria, as evident by their co-localisation with TOM20. On 
the contrary, the N-terminal truncated USP30-Δ1-53 was distributed in the 
cytosol and nucleus, confirming the mitochondria-targeting function of the TM 
domain and ‘signal-anchor’ region.  
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Figure 6.5 Localisation of USP30 in U2-OS cells.  
U2-OS cells were transfected with 1µg of different USP30 plasmids for 24hr. Cells 
were then fixed in 4% PFA and permeabilised with 0.2% Triton-X100. Anti-TOM20 
was used to visualize the mitochondria. Insets show 3-fold enlargement of the 
boxed area. Scale bar: 10µm. 
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6.2.3 Predicting the substrates and function of USP30  
In Drosophila melanogaster, a large-scale yeast two-hybrid proteomic screen 
identified six interacting partners for CG3016 (fly USP30) (Giot et al. 2003). 
One of the proteins, Miro, was of particular interest as both Miro and USP30 
are OMM proteins, with transmembrane domains that insert into the OMM 
and catalytic domains that face the cytosol (Frederick and Shaw 2007, 
Aspenstrom et al. 2004, Nakamura and Hirose 2008).  
Table 6.1 Interacting partners of CG3016 (fly USP30) and their known functions. 
 Data were obtained from yeast-two hybrid screen by Giot et al. (2003). Protein 
function annotation is based on FlyBase annotation (http://flybase.org/) and 
literature report. 
 
Symbol Name Function Reference 
CG3430 - Uncharacterised - 
Miro Mitochondrial Rho 
Mitochondrion transport 
along microtubule 
(Fransson et 
al. 2006) 
Opa Odd Paired 
Transcription factor; 
essential for 
parasegmental subdivision 
of Drosophila embryo 
(Benedyk et 
al. 1994) 
CG12428 - 
Carnitine O-
octanoyltransferase activity 
(based on domain 
structure) 
FlyBase 
tna tonalli 
Interacts with Osa, a 
subunit of BHRAMA, a 
chromatin-remodeling 
complex, and UBC9, a 
SUMO E2 conjugating 
enzyme 
(Gutierrez et 
al. 2003, 
Monribot-
Villanueva et 
al. 2013) 
Fd68A Forkhead domain 68A 
Transcription factor 
(prediction from domain) FlyBase 
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6.2.4 USP30 depletion affects the levels of MIRO at steady state and 
during mitophagy 
I first investigated the effect of USP30 depletion on MIRO protein stability at 
steady state. Upon USP30 depletion with two different oligos, USP30 D1 and 
D3 (Dharmacon siGenome oligos), MIRO protein levels decreased 
marginally but reproducibly (Figure 6.6A and B). I then questioned if the 
decrease in protein levels is due to transcriptional down-regulation of MIRO. 
qRT-PCR analysis of mRNA samples revealed no consistent effect of USP0 
depletion on the levels of either MIRO1 or MIRO2; except USP30 oligo D1 
decreased the mRNA levels of MIRO1 (Figure 6.1C).  
 
Since MIRO1 and MIRO2 have high protein sequence similarity, we 
suspected the MIRO1 antibody that we used (Sigma, HPA010687) could 
bind to MIRO2 as well. ClustalW alignment revealed 60% protein sequence 
similarity across MIRO1 and MIRO2. The immunogen that was used to 
generate the antibody recognizes a region close to the N-terminus of MIRO1 
that is highly similar in MIRO2 (Figure 6.6E). To verify the specificity of the 
MIRO1 antibody, I knocked down MIRO1 and MIRO2 individually or 
simultaneously (Figure 6.6D). Upon MIRO1 knockdown, there is still a 
considerable MIRO band observed on the western blot. On the contrary, 
MIRO2 knockdown dramatically reduced the intensity of the MIRO band, with 
a further reduction seen with a double knockdown of MIRO1 and MIRO2. 
This confirms that the antibody recognizes both forms of MIRO. In addition, it 
suggests that MIRO2 is the dominant form in hTERT-RPE1-YFP-Parkin cells.   
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Figure 6.6 USP30 depletion only marginally reduces the protein level of MIRO. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected with siRNA oligos against 
either control (NT1) or USP30 (oligo D1 and D3) for 72hr. Cells were harvested in 
RIPA lysis buffer. 
(B) Bar graph represents MIRO protein levels normalised to actin and expressed as 
relative to NT1. Error bar represents standard deviation of 5 experimental repeats.  
(C) hTERT-RPE1-YFP-Parkin cells were transfected with siRNA oligos against 
control (NT1), MIRO1 or MIRO2. Cells were harvested 24hr post-transfection for 
qRT-PCR analysis. mRNA level of USP30, MIRO1, and MIRO2 were normalized to 
B-actin and fold change is expressed in relative to NT1 level. Error bar represents 
standard deviation of 3 experimental repeats.  
(D) hTERT-RPE1-YFP-Parkin cells were transfected with siRNA oligos against 
control (NT1), MIRO1 or/ and MIRO2 for 72hr. Cells were harvested in NP40 lysis 
buffer.   
(E) ClustalW protein sequence alignment of MIRO1, MIRO2 and the immunogen 
sequence of MIRO1 antibody from Sigma (HPA010687).  
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6.2.5 USP30 physically interacts with MIRO  
Next, I investigated the interaction of USP30 and MIRO at the protein level. 
Immunoprecipitation of either USP30-GFP or its catalytically inactive mutant, 
USP30-C77S-GFP in HEK293T cells demonstrated interaction with 
endogenous MIRO (Figure 6.7). This interaction is specific and is not 
observed with GFP alone. Intriguingly, the immunoprecipitated MIRO bands 
are higher molecular weight than that those observed in the total lysates. 
These higher molecular weight forms of MIRO may be due to post-
translational modifications and suggest that MIRO recognition by USP30 may 
be regulated post-translationally. Equally interesting is the weaker interaction 
between USP30-C77S-GFP with endogenous MIRO compared to USP30-
GFP. As negative controls, I reprobed for TIMM44 and actin, neither of which 
was pulled down in either of the immunoprecipitations. It is important to note 
that I have only performed this experiment once and more repeats are 
required to confirm these observations.  
 
Figure 6.7 USP30 physically interacts with MIRO. 
 HEK293T cells were transfected with 3µg of plasmids for 24hr and 800µl of lysate 
(2µg/µl) of NP40 lysate were incubated with 30µl of 1:1 nanotrap slurry in the cold 
room for 2hr. Bound proteins were analysed alongside 1.8% of input sample. U30, 
USP30-GFP; CS, catalytically inactive mutant USP30-C77S-GFP; no lysate input: 
NP40 lysis buffer with nanotrap. 
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6.2.6 USP30 depletion alters the ubiquitylation of MIRO during 
mitophagy 
During the early stages of mitophagy, activated Parkin ubiquitylates MIRO on 
the OMM surface for proteasomal degradation. Loss of MIRO dissociates 
mitochondria from the microtubules and impedes their movement, thereby 
segregating malfunctioning mitochondria from the healthy population.  Upon 
CCCP treatment, USP30 knockdown induced the appearance of a higher 
molecular weight banding indicative of an ubiquitylated species (Figure 6.8). 
In control NT1-treated cells, the ubiquitylated MIRO bands (Ub-MIRO) 
peaked at 4hr after CCCP treatment. On the other hand, USP30 depletion 
promoted earlier ubiquitylation of MIRO (around 1hr). This observation 
suggests that MIRO is a substrate for USP30 and the loss of USP30 
promotes the ubiquitylation and subsequent proteasomal degradation of 
MIRO.  
 
 
Figure 6.8 USP30 depletion alters the ubiquitylation of MIRO during mitophagy. 
hTERT-RPE1-YFP-Parkin and parental hTERT-RPE1 cells were transfected with 
siRNA against control (NT1) or USP30 (oligo D1) for 72hr. Cells were then treated 
with CCCP (10µM). Cells were harvested in RIPA lysis buffer. The same figure as 
Figure 6.3B is shown again to show the MIRO blot.  
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6.2.7 siUSP30-mediated loss of MIRO is not restored with proteasomal 
inhibitors 
I then proceeded to inhibit proteasomal degradation and lysosomal 
degradation in USP30-depleted cells with epoxomicin and folimycin, 
respectively. In theory, if USP30 depletion promotes MIRO ubiquitylation and 
proteasomal degradation, proteasome inhibition should be able to rescue 
MIRO from degradation.  
 
Epoxomicin or folimycin treatment alone for 8hr did not accumulate more 
MIRO in either control NT1 or USP30-transfected cells. Simultaneous 
treatment of CCCP with epoxomicin for 8hr only marginally rescued the 
levels of MIRO and Ub-MIRO in the control NT1-transfected cells. There was 
also a slight accumulation of MIRO and Ub-MIRO in the NT1-transfected 
cells upon CCCP and folimycin treatment, suggesting that a small population 
of Ub-MIRO may be degraded via the lysosomal pathway. We observed little 
rescue of MIRO levels in USP30 knockdown cells in with either epoxomicin 
or folimycin treatment.  
 
 
Figure 6.9 USP30 depletion-induced MIRO protein decrease is not rescued by 
proteasomal inhibition. 
hTERT-RPE1-YFP-Parkin cells were transfected with siRNA against USP30 (oligo 
D1) and NT1 control for 72hr. Cells were then treated with CCCP (10µM), 
epoxomicin (100nM), and folimycin (100nM) for 8hr. Cells were lysed in NP40 lysis 
buffer. 20µg of lysates were probed as indicated.  
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6.2.8 MIRO2 depletion does not lead to enhanced cell death  
Whilst the decrease in MIRO levels upon USP30 depletion was not dramatic, 
I wondered whether this might cause the enhanced cell death we observed 
during mitophagy. To investigate this, I knocked down MIRO2 in hTERT-
RPE1-YFP-Parkin cells and treated the cells with CCCP for 8hr. As shown in 
Figure 6.10A, transfection with three out of four MIRO2 siRNA oligos (D9, 
D10 and D12) reduced the level of PARP-p85, suggesting that MIRO2 
depletion is cytoprotective during mitophagy as opposed to the enhanced cell 
death observed in USP30 depleted cells. Double knockdown of both MIRO2 
and USP30 did not rescue the apoptotic effect of USP30 depletion (Figure 
6.10B). This suggests that the decrease in MIRO2 level in USP30 depleted 
cells is not the cause of enhanced cell death. It is worth noting that I did not 
get good depletion of MIRO2 with any of the MIRO2 siRNA oligos in these 
experiments. It is possible that MIRO2 has a long half-life and might require 
more than 72hr of siRNA transfection for complete depletion of protein level. 
Nevertheless, since USP30 depletion only marginally decreased MIRO 
protein levels (less than that observed with MIRO2 siRNA, see Figure 6.10B) 
but still enhanced mitophagic cell death, it is unlikely that MIRO2 depletion is 
responsible for the enhanced mitophagic cell death observed.  
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Figure 6.10 MIRO2 depletion does not enhance cell death during CCCP treatment. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected with siRNA oligos against 
either control (NT1), or MIRO2 (pool, D9, D10, D11 and D12) for 72hr. Cells were 
then treated with CCCP (10µM) for 8hr. Cells were lysed in RIPA lysis buffer and 
lysates (8µg) were immunoblotted as indicated.  
(B) hTERT-RPE1-YFP-Parkin cells were transfected with siRNA oligos targeting 
Miro2 (M2, D9 and D10), or USP30 (D1 and D3), or with siRNAs targeting both 
Miro2 (D9 and D10) and USP30 (D1and D3), treated with CCCP and harvested in 
RIPA lysis buffer at indicated times. 10µg of lysates were immunoblotted as 
indicated.  
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6.3 TOM20 and TOM22 are substrates of USP30  
6.3.1 USP30 depletion enhanced TOM20 and TOM22 turnover during 
mitophagy 
During the investigation of the effect of USP30 on MIRO, I also probed the 
lysates for TOM20 as a marker for mitochondria and I followed TOM20 
degradation as a readout for mitophagy. I discovered that TOM20 was 
degraded faster in USP30 depleted cells (Figure 6.11). In addition, more 
TOM20 appeared as higher molecular weight species, suggesting that it was 
di-ubiquitinated on one, or monoubiquitinated at two different lysine residues, 
when USP30 was depleted. Similar observations were seen with TOM22 as 
the protein was accumulated as a higher molecular weight species and was 
degraded faster when USP30 was depleted. All the above observations were 
reproducible with two USP30 siRNA oligos, D1 and D3. This strongly 
suggests that TOM20 and TOM22 are direct deubiquitylating substrates of 
USP30. This effect is not due to faster overall mitophagy as other OMM and 
IMM proteins, including MFN, TIMM44 and S-OPA1, were not affected with 
USP30 depletion. LC3 conversion from LC3-I to LC3-II was also not affected.  
 
It is also noteworthy that USP30 itself seems to be ubiquitylated as well 
during CCCP treatment, suggesting that it may be a direct substrate of 
Parkin. The enhanced degradation of TOM20 was further validated with 
additional siRNA oligos and was found to correspond to the knockdown level 
of USP30 (Figure 6.11B). USP30 siRNA oligos D1, D3, D6, D7, D9 and Q6, 
which all depleted USP30, also enhanced TOM20 degradation during CCCP 
treatment whereas USP30 D8, and two controls (NT1, mock) did not affect 
USP30 or TOM20 degradation. Apart from USP30 oligo D1 and D3, I also 
observed higher levels of PARP-p85 accumulation during CCCP treatment 
with USP30 oligo Q6. Interestingly, the higher levels of PARP cleavage 
correlate with the strongest depletion of TOM20.   
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Figure 6.11 USP30 depletion enhanced TOM20 and TOM22 degradation. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with siRNA targeting 
USP30 (D1 and D3) or siRNA control oligo (NT1). Cells were then treated with 
CCCP (10µM) and harvested with RIPA lysis buffer at indicated times.  
(B) The blots presented in Figure 6.4A were shown again to allow for direct 
comparison of degree of USP30 knockdown and TOM20 level. Cells treated with 
siRNA as indicated for 72hr. The cells were either harvested directly or further 
treated with CCCP (10µM) for 4hr.  Cells were harvested in NP40 lysis buffer. 
Asterisk: non-specific band.   
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6.3.2 USP30 physically interacts with TOM20 and TOM22 
I next investigated the physical interaction of USP30 with TOM20 and 
TOM22 by immunoprecipitation. Using GFP-tagged USP30 (USP30-GFP) 
and its catalytically inactive mutant (USP30-C77S-GFP) expressed in 
HEK293T cells, I could show that both TOM20 and TOM22 were 
immunoprecipitated together with both active and inactive USP30 (Figure 
6.12B). On the other hand, TIMM44, the IMM protein and Actin were not 
immunoprecipitated.  
 
 
Figure 6.12 TOM20 is a substrate and interactor of USP30. 
HEK293T cells expressing GFP-tagged USP30 were lysed in NP40 lysis buffer and 
subjected to immunoprecipitation (IP) with GFP-nanotrap and probed as indicated. 
Bound proteins were analysed alongside 1.8% of input sample. U30, USP30-GFP; 
CS, catalytically inactive mutant USP30-C77S-GFP; no lysate input: NP40 lysis 
buffer with nanotrap. Note that these samples were probed in parallel for MIRO 
shown in Figure 6.7. 
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6.3.3 Proteasomal inhibition rescues TOM20 levels in USP30 depleted 
cells 
To further demonstrate that TOM20 is deubiquitylated and rescued from from 
proteasomal degradation by USP30 during CCCP treatment, I treated USP30 
depleted hTERT-RPE1-YFP-Parkin cells with CCCP in the presence of 
epoxomicin and/or folimycin. As can be seen in Figure 6.13, CCCP treatment 
alone induced faster degradation of TOM20 in USP30 depleted cells. 
Simultaneous treatment of CCCP with epoxomicin delayed TOM20 
degradation in NT1 and also USP30 D1 and D3 transfected cells. 
Interestingly, the ubiquitylated forms of TOM20 (Ub-TOM20) accumulated 
only in USP30 D1 and D3 transfected cells whereas Ub-TOM20 is not 
observed in NT1-transfected cells. Strikingly, this effect is only observed with 
epoxomicin but not with folimycin treatment. However, compared to CCCP 
treatment only, simultaneous treatment of CCCP with folimycin slightly 
delayed TOM20 degradation in both control and USP30-depleted cells, 
suggesting partial involvement of the lysosomal degradation in the 
degradation of TOM20. Simultaneous inhibition of both proteasomal and 
lysosomal pathways during CCCP treatment confers additive inhibitory effect 
on the degradation of TOM20. The accumulation of Ub-TOM20 in USP30-
depleted cells is also more striking. 
 
Since the background signal is very high in the TOM22 blot, no conclusive 
statement can be made. It seems like similar but less striking observations to 
that of TOM20 could be observed with TOM22 protein degradation during 
CCCP treatment in the presence of either epoxomicin or folimycin.  
 
Consistent with observations from Figure 6.3 and Figure 6.11, USP30 
depletion did not affect OPA1 cleavage or PINK1 accumulation but enhanced 
PARP cleavage. Proteasomal and lysosomal inhibitors did not affect OPA1 
cleavage or PINK1 accumulation but especially when combined caused a 
slight accumulation. As described in chapter 4, inhibition of proteasomal but 
not lysosomal degradation inhibits PARP cleavage. This inhibitory effect 
overrides the enhanced cell death effect of USP30.  
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Figure 6.13 Proteasomal inhibition rescues TOM20 levels. 
hTERT-RPE1-YFP-Parkin cells were transfected with either non-targeting siRNA 
(NT1) or siRNA against USP30 (D1, D3), then treated with CCCP (10 µM) together 
with either Epoxomicin (100 nM) or Folimycin (100 nM) for 5hrs. Lysates were 
probed with antibodies as indicated. Asterisk: non-specific band. Ub: ubiquitylated 
bands. FL: full length PARP. P85: PARP-p85 fragment. 
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6.3.4 Mouse USP30 (mUSP30) rescued TOM20 and mitophagic cell 
death in USP30 depleted cells  
To further confirm that USP30 depletion causes enhanced cell death during 
mitophagy, I depleted it for 72hr and expressed mouse USP30 during the last 
48hr of siRNA transfection. Subsequent treatment with CCCP showed that 
mouse USP30 expression partially protects the cells from PARP cleavage. 
This is most apparent in NT1 treated cells (Figure 6.14A; compare lane 1 and 
2). In addition, the expression of mouse USP30 in USP30 depleted cells 
partially delayed the degradation of TOM20. Simultaneous treatment of 
CCCP with epoxomicin also showed a slight decrease in the ubiquitylated 
bands of TOM20 when mouse USP30 was expressed. However, these 
experiments will require further validation. Overall, these data support the 
hypothesis that USP30 deubiquitylates TOM20 and promotes cell death 
during mitophagy.     
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Figure 6.14 PARP cleavage can be rescued by overexpression of mouse USP30. 
(A) hTERT-RPE1-YFP-Parkin cells were transfected with 40nM of either NT1 
(control) or USP30 D3 oligo for 72hr. 24hr post-transfection, cells were transfected 
with 1µg of pCMV-myc or pCMV6-myc-ddk-mUSP30 plasmids for 48hr. Cells were 
then treated with 10µM of CCCP or 10µM of CCCP with 100nM of epoxomicin. 15µg 
of NP40 lysates were immunoblotted as indicated. 
(B) Bar chart represents quantitation of PARP-p85 protein band intensities 
normalized to actin and expressed as relative to NT1-myc control samples from 
three independent experimental repeats. Data from Exp1 was obtained from the 
blots of Figure 6.14A. 
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6.4 Investigation of a cytoprotective role of USP30 in the face of other 
apoptotic stimuli 
Given that mitochondria play a pivotal role during apoptosis and USP30 
localises to the mitochondria, it is possible that USP30 has a more general 
role in regulating cell responses to other cell death stimuli. I first tested a list 
of apoptosis-triggering drugs including taxol, thapsigargin, TNF-α, 
tunicamycin, etoposide, ABT-737 and ABT-263. All of these drugs induce 
apoptosis by different mechanisms (summarized in Table 6.2). Due to the 
different timecourse of apoptotic response to different drugs, I carried out the 
initial analysis by live-cell imaging and judged cell death responses by the 
incorporation of the membrane-impermeable dye, DRAQ7 over 24hr. Most of 
the drugs did not induce apoptosis in hTERT-RPE1-YFP-Parkin cells. Taxol 
treatment caused the cells to round up but no DRAQ7 incorporation to the 
cells was observed. Only two drugs, ABT-737 and its orally bioavailable 
analog, ABT-263 induced apoptosis within 8-12hr of treatment.  
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Drug (working 
Concentration) 
DRAQ7 
staining 
Observations Description of 
Mechanism 
References 
TNF-alpha 
(10ng/ml) 
Negative - Binds to TNF receptor 
1/2, recruits TRADD 
and FADD, 
subsequently activates 
caspase 8 
(Wallach et al. 
1996) 
Taxol (100nM) Negative Cells round up 
but are not 
DRAQ7 
positive 
Stabilizes 
microtubules, inhibits 
cell division 
(Das et al. 2001) 
Thapsigargin 
(10µM) 
Negative - SERCA Ca2+ ATPase 
inhibitor (induce Ca2+ 
overload) 
(Brayden et al. 
1989, Foder et al. 
1989) 
Tunicamycin 
(10µM) 
Negative - inhibits N-linked 
gylcosylation (ER 
stress, triggers UPR)  
(Leavitt et al. 1977) 
Etoposide 
(10µM) 
Negative - topoisomerase 
inhibitor (promote 
DNA double strand 
breakage) 
 
(Onishi et al. 1993) 
ABT-737(10µM) 
 
Positive Cell death at 8-
12hr 
BH3 mimetic small 
molecule inhibitor, 
binds and removes 
inhibitory function of 
anti-apoptotic BCL2 
family members (Bcl2, 
BCL-xL, Bcl-w)  
(M. F. van Delft et 
al. 2006, Vogler et 
al. 2008) 
ABT-263 (10µM) Positive Cell death at 8-
12hr 
Orally bioavailable 
analog of ABT-737 
(Tse et al. 2008) 
Table 6.2 Different apoptotic stimuli tested on hTERT-RPE1-YFP-Parkin cells. Cell 
death was recorded by live-cell imaging at every 30min intervals up to 24hr. The 
membrane-impermeable dye, DRAQ7 (0.3µM) was used to assess cell death 
response.  
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6.4.1 USP30 depletion exacerbates cell death induced by ABT-263 and 
ABT-737  
ABT-737 and its orally bioavailable analog, ABT-263 belong to the group of 
Bad-like BH3 mimetics (Oltersdorf et al. 2005). ABT-737 and ABT-263 
induced some cell death in hTERT-RPE1-YFP-Parkin cells within 8-12hr of 
treatment, as demonstrated by the incorporation of DRAQ7 into the cells (see 
video 4 and 5; Figure 6.15). USP30 depletion (siRNA by U30D1 and D3) 
induced more cell death compared to the control (NT1). In addition, I also 
observed that ABT-737 was more potent than ABT-263 in inducing cell death 
in hTERT-RPE1-YFP-Parkin cells.  
 
Figure 6.15 USP30 depletion sensitizes hTERT-RPE1-YFP-Parkin cells to ABT-737 
and ABT263 induced cell death. 
hTERT-RPE1-YFP- Parkin cells were transfected for 72 hrs with either non-targeting 
siRNA (NT1) or siRNA targeting USP30 (D1 and D3). Cells were then treated either 
with CCCP, ABT-263 or ABT-737 (all 10 µM). Cells were imaged at 30 min intervals 
in the presence of the membrane impermeable dye DRAQ7 and a single frame 
corresponding to the 12hr time point is shown (see also video 4 and 5). Top rows 
show the isolated DRAQ7 staining (dead cells, white on black). Bottom rows show 
YFP-Parkin in grey and DRAQ7 in pink. Scale bar 40 µm.  
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I further characterized the cell death triggered by ABT-737 and ABT-263 
using western blotting (Figure 6.16). USP30-depleted cells showed more 
PARP and caspase 3 cleavage compared to NT1. It is noteworthy that there 
is a slight difference in the cleaved caspase 3 fragments between USP30 D1 
and USP30 D3 siRNA-transfected cells. ABT-263 and ABT-737 treatment in 
USP30 D1-transfected cells seemed to accumulate more of the p15 fragment 
compared to USP30 D3-transfected cells. In contrast to CCCP-induced cell 
death, ABT-737 and ABT-263-induced cell death occurs independently of 
mitophagy as evidenced by the lack of PINK1 accumulation and Parkin 
autoubiquitylation. TOM20, MIRO, MFN and TIMM44 were also not degraded 
during ABT-737 and ABT263 treatments. This indicates that ABT-737 and 
ABT-263 trigger cell death via a different mechanism than CCCP. 
 
 
Figure 6.16 USP30 depletion sensitises cells to ABT-737 and ABT-263 induced cell 
death in a Parkin-independent manner.  
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either 40nM of non-
targeting control siRNA (NT1) or siRNA targeting USP30 (D1 and D3). Cells were 
treated either with CCCP, ABT-263 or ABT- 737 (all 10 µM). CCCP-treated cells 
were harvested after 6hr and ABT-263 and ABT-737-treated cells after 4hr of 
treatment, using “hot lysis” buffer, and samples were probed with antibodies as 
indicated. Basal: untreated. 
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6.4.2 USP30 depletion increases the levels of BAK and BCL2 
ABT-737 and ABT263 are BH3 only-mimetics (BAD-like) that show high 
affinity to the pro-survival BCL2 family members, BCL2, BCL-xL and Bcl-W 
(Ki <1nM) but not MCL1 (Ki>1µM).  (Mark F. van Delft et al. 2006, Vogler et 
al. 2009a, Vogler et al. 2009b, Vogler et al. 2008). Binding of ABT-737 and 
ABT-263 sequesters these proteins away from the pro-apoptotic BAK and 
BAX. This allows BAK and BAX to either homo-oligomerise or hetero-
oligomerise on the OMM to induce mitochondrial outer membrane 
permeabilization (MOMP) and cytochrome C release.  
 
Therefore, I decided to measure the levels of both pro-survival and pro-
apoptotic BCL2 family members, including BCL2, BCL-xL, MCL1, BAK and 
BAX. Under basal condition, USP30 depletion induced an increase in BAK 
and BCL2 but not BAX and BCL-xL (Figure 6.17A and B). The effect of 
USP30 on MCL1 is less clear as transfection with USP30 D3 but not USP30 
D1 siRNA oligo decreased MCL1, suggesting a potential off-target effect of 
either of the siRNA oligos on MCL1 expression. Intriguingly, CCCP treatment 
increased MCL1 levels independent of transfection conditions. It is known 
that MCL1 levels are tightly regulated by several E3 ligases, including 
HUWE1, FBXW7 and TRIM17 (Ren et al. 2013, Inuzuka et al. 2011, Pandya 
et al. 2010, Magiera et al. 2013). We speculate that the elevated MCL1 levels 
observed during mitophagy might account for newly synthesized protein that 
cannot be translocated to depolarised mitochondria and are therefore 
protected from degradation.  
 
On the other hand, CCCP treatment promoted the accumulation of higher 
molecular weight forms of BAK that is indicative of ubiquitylated BAK, which 
is consistent with the observation by Chan et al. (2011) that it can be 
ubiquitylated by Parkin during mitophagy (Chan et al. 2011). ABT-263 and 
ABT-737 treatment did not induce ubiquitylation of BAK.  
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Figure 6.17 USP30 depletion increases BAK and BCL2 protein levels 
(A) hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with either non-
targeting control siRNA oligo (NT1) or USP30 (D1 and D3). Cells were treated with 
CCCP (10µM) for 5hr and harvested in RIPA lysis buffer. 15µg of lysates were 
immunoblotted as indicated.  
(B) Samples described in Figure 6.16 were re-run and re-probed for the indicated 
proteins.  
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6.4.3 BAK and BAX are required for ABT-737-induced cell death but not 
mitophagy-induced cell death  
Since there is an upregulation of BAK upon USP30 depletion, I wanted to 
investigate the involvement of BAK and BAX in CCCP and ABT-737-induced 
cell death. I co-depleted either BAK or BAX together with USP30. 
Independently of BAX levels, USP30-depletion increased the levels of BAK 
(Figure 6.18A). In the context of CCCP induced cell death, BAK and BAX 
depletion did not affect the enhanced accumulation of PARP-p85 seen upon 
USP30 knockdown. In ABT-737-treated cells, in contrast, BAX-depletion, 
fully and BAK depletion partially, rescued cell death mediated by USP30 
depletion (Figure 6.18A and B). In Figure 6.18B, I also observed the 
appearance of a lower molecular weight species in both BAX and BAK that 
are indicative of cleaved BAK and BAX by activated caspases and calpains 
during apoptosis induction (Meng et al. 2003, Cao et al. 2003, Choi et al. 
2001, Yanase et al. 2000, Itoh et al. 2000, Wood and Newcomb 2000, Wood 
et al. 1998). These observations suggest that USP30-depletion induced cell 
death via two different mechanisms in response to CCCP and ABT-737. 
6.4.4 USP30 depletion also enhances ABT-737 induced cell death in 
MCF7 and U2-OS cells  
Since the USP30-depletion mediated, ABT-737-induced cell death is 
independent of mitophagy, I decided to test the effect of USP30 depletion on 
other cell lines. Both U2-OS and MCF7 cells responded rapidly to ABT-737 
treatment and I observed some cell death within 1-2hr of ABT-737 treatment 
as evident by annexin V and DRAQ7 staining during live-cell imaging (Figure 
6.19A). The cell death was compounded by USP30 depletion with both 
USP30 D1 and D3 siRNA oligos. In agreement with this, I observed 
enhanced PARP-p85 accumulation upon USP30 depletion in both cell lines. I 
also observed an increase in BAK expression levels upon USP30 depletion 
as well as lower levels of MCL1 in USP30 D3 transfected cells but not in 
USP30 D1 transfected cells, in both cell lines.  
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Figure 6.18 BAK and BAX are required for ABT-737-induced cell death but not 
mitophagy-induced cell death. 
hTERT-RPE1-YFP-Parkin cells were transfected for 72hr with non-targeting siRNA 
oligo (NT1), USP30 (D3), BAK and BAX. Cells were then treated with ABT-737 or 
CCCP (all 10µM) for 6hr (A) and 4hr (B). Cells were harvested in NP40 lysis buffer. 
15µg of lysates were probed as indicated. Asterisk: possible cleaved forms of BAX 
and BAK. 
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Figure 6.19 USP30 depletion enhances apoptosis tirggered by BH3-mimetics in U2-
OS and MCF7 cells.  
(A) U2-OS and MCF7 cells were transfected for 72hr with either non-targeting 
siRNA oligo (NT1) or siRNA targeting USP30 (D1 and D3). Cells were treated with 
ABT-737 (10µM) for 2hr. Progression of apoptosis was recorded using live-cell 
video microscopy imaged at 15min interval. Cells were visualised by phase contrast 
(pseudocoloured in grey), apoptotic cells were visualised with annexin V-AF350 
(pseudocoloured in green), and dead cells were visualised with DRAQ7 
(pseudocoloured in pink). Representative still frames after 2hr of ABT-737 treatment 
from the live-cell imaging are shown. Scale bar: 40µm. Bar chart shows the average 
percentage of DRAQ7 positive cells at T=2hr of ABT-737 treatment from 4 different 
positions of the same well. Error bars represent standard deviation.  
(B) U2-OS and MCF7 cells were transfected and treated as in (A). Cells were 
harvested in NP40 lysis buffer after 2hr of ABT-737 treatment. 10µg of lysates were 
immunoblotted as indicated.  
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6.5 Discussion 
6.5.1 USP30 depletion enhances cell death during Parkin-mediated 
mitophagy 
USP30 is the only DUB with a signal-anchor sequence and a transmembrane 
domain that is targeted to the mitochondrial outer membrane. It was 
previously reported that depletion of USP30 induces mitochondrial elongation 
in HeLa and COS7 cells (Nakamura and Hirose 2008). While the exact 
mechanism and substrate of USP30 have not been identified, it was 
proposed that it might regulate the stability of proteins involved in the 
mitochondrial fusion and fission machineries. Nonetheless, previous 
characterization work carried out in our laboratory by another colleague, 
Richard Buus reported only a mild collapse of the mitochondrial network 
around the perinuclear region but no elongated mitochondria in USP30 
depleted cells (Buus 2008).  
 
In Chapter 4, I characterised a novel observation of PINK1 and Parkin-
mediated mitophagic cell death. In an effort to identify DUBs that oppose 
Parkin, USP30 turned up as one of the top hits in my Parkin-mediated 
mitophagy screen. Upon USP30 depletion, I observed that more cells die 
during CCCP treatment. Since mitochondria play a pivotal role in the 
activation of apoptosis, this observation is particularly interesting and 
suggests that USP30 might play an anti-apoptotic role during mitophagy. 
 
Considering that USP30 is a DUB, it is likely that USP30 regulates the 
stability of a mitochondrial protein that normally serves an anti-apoptotic role. 
I first focused on investigating the effect of USP30 depletion on MIRO, a 
mitochondrial Rho-like GTPase that was previously reported by Giot et al. 
(2003) to be one of the interactors of Drosophila USP30 (CG3016) in a large-
scale yeast two hybrid screen (Giot et al. 2003). MIRO has a C-terminal 
transmembrane domain, which confers localization to the outer mitochondria 
membrane (Fransson et al. 2006). Under normal conditions, Milton, an 
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adaptor protein, links MIRO to the heavy chain of kinesin (KHC) to facilitate 
anterograde mitochondrial transport along the microtubule. MIRO contains 
two EF-hand Ca2+-binding domains. In the presence of high intracellular Ca2+ 
concentration, Ca2+ binds to the EF-hands and causes conformational 
change of MIRO. MIRO then pulls and disengages Milton from KHC, thereby 
arresting mitochondria movement (Cai and Sheng 2009). The ability of MIRO 
to respond to Ca2+ flux has been reported to be crucial in the delivery and re-
localization of mitochondria to regions of high energy demand within 
neurons, for example, at the synapse region where high calcium arrests and 
accumulates mitochondria to provide ATP energy for the exocytosis of 
synaptic vesicles (MacAskill and Kittler 2010). Intriguingly, loss of Drosophila 
MIRO (dMIRO) affects both anterograde and retrograde mitochondrial 
transport (Russo et al. 2009). Exactly how MIRO regulates the bi-directional 
movement of mitochondria is unclear but it is likely that this could be due to 
the interdependency of kinesin and dynein along the microtubule. 
Alternatively, MIRO might have a more direct interaction with dynein, thereby 
facilitating retrograde mitochondrial transport as well. Consistent with this, 
Morlino et al. recently demonstrated MIRO1 plays a role in lymphocyte 
migration and polarity. In response to the presence of integrin, MIRO1 
directly interacts with dynein and redistributes mitochondria to the 
microtubule-organizing center (MTOC) at the adhesion zone to promote 
lymphocyte migration (Morlino et al. 2014). 
 
During mitophagy, MIRO is one of the OMM proteins that is phosphorylated 
by PINK1 for Parkin ubiquitylation and subsequently degraded by the 
proteasome (Wang et al. 2011). There are two MIROs in human, MIRO1 and 
MIRO2. Selective depletion of MIRO1 and MIRO2 revealed that MIRO2 is 
the dominant form in hTERT-RPE1-YFP-Parkin cells. Fransson et al. (2006) 
previously showed that while overexpression of constitutively active forms of 
both MIRO1 and MIRO2 caused aggregation of mitochondria, only 
constitutively active form of MIRO1 induced elongation of mitochondria, 
suggesting overlapping but not redundant functions of the two MIROs 
(Fransson et al. 2006).  
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Under basal condition, I found that USP30 depletion marginally but 
consistently reduces MIRO protein levels with two individual siRNA oligos but 
did not affect its mRNA levels, suggesting that USP30 post-translationally 
regulates MIRO. During CCCP treatment, MIRO was ubiquitylated earlier 
(1hr after CCCP treatment compared to 4hrs in the control cells) and 
degraded faster in USP30-depleted cells, suggesting that USP30 
deubiquitylates and rescues MIRO from proteasomal degradation. However, 
inhibition of the proteasome using epoxomicin (8hr) did not rescue MIRO 
levels in USP30 depleted cells. I speculate that MIRO might have a long half-
life and/ or a low expression rate. Therefore, the marginal decrease in MIRO 
levels observed with USP30 depletion might be a cumulative effect observed 
over the 72hr of transfection. Consistent with this speculation, MIRO2 siRNA 
transfection for 72hr did not deplete MIRO2 completely. 
 
Immunoprecipitation of USP30-GFP showed interaction with endogenous 
MIRO in HEK293T cells under basal condition. This interaction seemed to be 
dependent on the catalytic activity of USP30 as the use of catalytically 
inactive USP30 weakened the interaction with MIRO. It is possible that the 
interaction between USP30 and MIRO may be enhanced with CCCP 
treatment, as Parkin-ubiquitylated MIRO is more likely to be recognised by 
USP30. 
 
Direct depletion of MIRO2 by siRNA interference did not exacerbate CCCP-
induced cell death. Instead, three, out of four MIRO2 siRNA oligos tested, 
reduced PARP cleavage. Furthermore, simultaneous depletion of MIRO2 
and USP30 did not induce additional cell death. Considering that MIRO2 
siRNA transfection reduces MIRO2 level more than that by USP30 depletion, 
it is unlikely that the depletion of MIRO2 is responsible for the enhanced cell 
death observed. Instead, I speculate that the decrease of MIRO levels in 
MIRO2 siRNA-treated cells translates into an overall decrease in the OMM 
proteins that can be ubiquitylated by Parkin, thereby protecting the integrity 
of the outer mitochondrial membrane. 
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I found that during CCCP treatment, USP30 depletion induced higher 
accumulation of ubiquitylated TOM20 and TOM22, which were degraded 
faster than in control cells. TOM20 and TOM22 are subunits of the TOM 
complex, which provides a platform for PINK1 and Parkin recruitment to the 
mitochondria during mitochondrial depolarization (Jin et al. 2010). TOM20 
and TOM22 are likely substrates for USP30 as they have also been 
previously shown to be ubiquitylated by Parkin (Yoshii et al. 2011, Chan et al. 
2011, S. A. Sarraf et al. 2013). USP30 depletion resulted in the accumulation 
of possible diubiquitylated or doubly-monoubiquitylated species whereas NT1 
transfected cells preferentially accumulated monoubiquitylated TOM20. It is 
possible that the differential ubiquitylation status of TOM20 determines the 
stability of the protein. IMM proteins such as TIMM44 and OPA1 were not 
differentially turned over upon USP30 degradation, suggesting that USP30 
specifically regulates the stability of TOM20 and TOM22 but does not 
regulate the degradation of IMM proteins by mitophagy. Strikingly, 
simultaneous treatment of CCCP and epoxomicin (proteasome inhibitor) 
accumulated the ubiquitylated form of TOM20 (Ub-TOM20) in USP30 
depleted cells but not in control cells. In the control cells, it appears that the 
TOM20 is deubiquitylated by USP30 and accumulates as an unmodified form 
of TOM20, whereas in USP30-depleted cells, Ub-TOM20 cannot be 
deubiquitylated and accumulates in the ubiquitylated form. This strongly 
suggests that TOM20 is a bona fide substrate of USP30. Consistent with my 
finding, Bingol et al. (2014) demonstrated by immunoprecipitation of HA-
tagged ubiquitin that ubiquitylated MIRO and TOM20 can be deubiquitylated 
by USP30 (Bingol et al. 2014).  
 
It is not possible to knockdown TOM20 to assess its link with cell death as 
TOM20 depletion would disrupt the TOM complex and affect the import and 
insertion of proteins into the mitochondria, thereby severely affecting their 
normal physiology. I showed that the effect of USP30 depletion on TOM20 
and PARP cleavage could be partially rescued by transfecting the USP30-
depleted cells with mouse USP30. The partial rescue effect might be due to 
the fact that only approximately 40% of the cells were transfected.  
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While I only observed the degradation of MIRO2, TOM20 and TOM22 to be 
differentially regulated with USP30 depletion, it is possible that the Parkin-
mediated ubiquitylation and degradation of other OMM proteins is also 
affected. Using affinity enrichment of ubiquitinated peptides with ubiquitin 
branch-specific (K-GG) antibodies followed by mass spectrometry, Bingol et 
al. recently identified a list of other mitochondrial proteins, including 
VDAC1/2/3, MUL1, FKBP8, TOM70, PRDX3, MAT2B, PTH2 and IDE that 
show increased ubiquitylation upon USP30 depletion in HEK293 cells.  
 
While my observation that USP30 opposes Parkin-mediated mitophagy is 
consistent with Bingol et al. (2014), they reported that USP30 depletion 
rescues the defect in mitophagy by pathogenic mutants of Parkin (G430D 
and K161D) in SH-SY5Y. They further demonstrated in PINK1 and Parkin 
mutant (loss-of-function) flies that depletion of USP30 helped to restore 
normal mitochondrial morphology. Importantly, depletion of USP30 also 
conferred protection against paraquat-induced dopamine depletion and 
promotes fly survival.  
 
The key reason between the opposing cell survival roles of USP30 reported 
by Bingol et al. (2014) and our group is most likely due to the different type 
and the levels of Parkin expressed and the levels of Parkin expression. In 
Bingol’s case. the use of a Parkin mutant with partial defect in ubiquitylating 
ability provides a preceding scenario where defective mitochondria are 
unable to be efficiently turned over by mitophagy. In that case, further 
deubiquitylation of mitochondrial proteins by USP30 promotes the 
accumulation of damaged mitochondria in the cells. Therefore, it is 
unsurprising that the depletion of USP30 plays a cytoprotective role in that 
setting.  
 
In our study, we used fully functional Parkin that is highly efficient at 
ubiquitylating OMM proteins. As discussed in chapter 4, acute ubiquitylation 
of OMM proteins by Parkin induces their extraction and degradation by the 
proteasome (Yoshii et al. 2011). The extraction of OMM proteins during that 
process can damage the outer mitochondrial membrane, which can lead to 
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the activation of apoptosis. We speculate that during Parkin-mediated 
mitophagy, USP30 opposes Parkin-mediated ubiquitylation of OMM proteins, 
serving as a ‘brake’ to keep proteasomal and lysosomal degradations in 
balance. Upon USP30 depletion, the balance is tipped, leading to increased 
rates of hazardous proteasomal degradation at the expense of ‘safe’ 
lysosomal degradation, allowing release of cytochrome c from damaged 
mitochondria (refer to Figure 6.20). 
 
Therefore, we suggest a direct protective effect of USP30 on the 
maintenance of outer mitochondrial membrane integrity whereas Bingol and 
colleagues described USP30 function on the overall quality control of the 
mitochondria population and the subsequent effect on the well being of cells 
and organism as a whole.  
 
Consistent with our observation, in a systemic knockdown of DUBs in 
Drosophila, Tsou and colleagues reported that CG3016 (drosophila USP30; 
dUSP30) knockdown throughout the fly resulted in early death whereas pan-
neuronal knockdown of dUSP30 resulted in slower growth of adult flies (Tsou 
et al. 2012). On the other hand, Bingol and colleagues reported that dUSP30 
depletion in Parkin-mutant flies protects against mitochondrial oxidative 
stress and restores mitochondria morphology as well as improves climbing 
index (Bingol et al. 2014). While the knockdown of dUSP30 in flies 
expressing mutant Parkin might rescue the mitochondria morphology as 
reported by Bingol and colleagues, the knockdown of dUSP30 in normal flies 
may be detrimental to neuronal development and/or regulation. 
6.5.2 USP30 depletion enhances cell death induced by BH3-mimetics 
Given the pivotal role of mitochondria in the activation of apoptosis, we asked 
whether USP30 plays a general moderating role in other forms of cell death. I 
discovered that hTERT-RPE1-YFP-Parkin cells were resistant to apoptosis 
induced by a series of commonly used apoptosis-inducing compounds, 
including DNA topoisomerase inhibitor (etoposide), microtubule 
depolymerisation inhibitor (taxol), sarco/endoplasmic reticulum Ca2+-ATPase 
inhibitor (thapsigargin), N-gylcosylation inhibitor (tunicamycin) and activation 
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of the TNF receptor-mediated extrinsic apoptotic pathway via TNF-α.  
Eventually, I found that hTERT-RPE1-YFP-Parkin cells responded to ABT-
737 and its orally bioavailable analog, ABT263 (Navitoclax)-induced 
apoptosis (Vogler et al. 2009b). In addition, USP30 depletion compounded 
the apoptotic response. This effect is not dependent on mitophagy and was 
observed not only in hTERT-RPE1-YFP-Parkin cells but also in U2-OS and 
MCF7 cells.  
 
It is worth noting that PARP cleavage occurs around 8-12hr of ABT-737 
treatment in hTERT-RPE1-YFP-Parkin cells whereas the similar observation 
takes 1-2hr in U2-OS and MCF7 cells. Whilst the levels of BCL2 family 
members have not been compared across the different cell types, the relative 
abundance and dependency towards different BCL2 pro-survival members 
have been reported to affect the apoptotic response towards ABT-737 and 
ABT-263 in different cell types. This is because ABT-737 and ABT-263 have 
higher affinity to BCL2 and BCL-xL than other BCL2 prosurvival family 
members, especially MCL1. For instance, depletion of another DUB, USP9X, 
has previously been shown to promote polyubiquitylation and degradation of 
MCL1 and enhance ABT-737-mediated cell death in human follicular 
lymphomas and diffuse large B-cell lymphomas (Schwickart et al. 2010). 
Several different groups have also shown that down-regulation of MCL1 
sensitizes different cancer cell types including leukemia, melanoma and 
neuroblastoma cells to ABT-737-mediated apoptosis (Keuling et al. 2009, 
Lestini et al. 2009, Chen et al. 2007). Furthermore, in acute myeloid leukemia 
cells that have elevated expression of MCL1, simultaneous treatment with 
ABT-737 and Maritoclax, a small molecule inhibitor MCL1, has a synergistic 
effect in inducing cell death (Doi et al. 2014). 
 
Intriguingly, USP30 D3 transfection consistently decreased MCL1 protein 
level in all three cell-lines tested. While it is currently uncertain whether this 
effect is truly due to USP30 depletion, it is likely that the depletion of MCL1 
confers additional toxicity to the cells in response to BH3-mimetics. A USP30 
rescue experiment will need to be performed to investigate if USP30 truly 
regulates MCL1 levels.   
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Further investigation into the level of the pro-survival and pro-apoptotic BCL2 
family members suggest that there is a trend of elevated BAK but not BAX in 
all three cell lines upon USP30 depletion while there is a mild elevation of 
BCL2 in hTERT-RPE1-YFP-Parkin cells. Since BCL2 is inhibited during ABT-
737 and ABT-263 treatment, the elevated levels of BCL2 are less likely to be 
a contributing factor to the cell death observed. Normally, the pro-survival 
and pro-apoptotic BCL2 family members exist in equilibrium to counteract the 
effect of each other. Elevation of BAK levels could explain the sensitisation of 
USP30 depletion cells towards ABT-737 treatment. The elevated BAK levels 
can either be transcriptionally or post-translationally regulated by USP30. 
One of the hypotheses is that USP30 might regulate an E3 ubiquitin ligase 
that ubiquitylates BAK for degradation. Considering the localization of both 
USP30 and BAK, it is most likely that USP30 regulates the stability or activity 
of a mitochondrial E3 ubiquitin ligase, for example, MARCH5/MITOL, 
MAPL/GIDE/MULAN, IBRDC2 or RNF185 (Benard et al. 2010, Karbowski et 
al. 2007, Tang et al. 2011, Zemirli et al. 2014). Among these, IBRDC2 is 
particularly interesting as it has been demonstrated to ubiquitylate BAX for 
degradation and suppress spontaneous apoptosis (Benard et al. 2010). It is 
possible that BAK could be regulated in a similar manner by IBRDC2 or an 
alternative E3 ligase.  
 
6.5.3 USP30 depletion sensitises cells to mitophagic cell death and 
BH3-mimetics-induced cell death via different mechanisms  
During CCCP treatment, both BAK and BAX have been reported to be 
ubiquitylated by Parkin (Chan et al. 2011, Shireen A. Sarraf et al. 2013). 
Consistent with this, I observed ubiquitylation of BAK in hTERT-RPE1-YFP-
Parkin cells during CCCP treatment.  
 
However, BAX was not apparently ubiquitylated. USP30-depletion mediated 
BAK upregulation is unlikely to be the cause of enhanced mitophagic cell 
death as ubiquitylated BAK will be degraded together with other OMM 
proteins such as MIRO and TOM20. Indeed, depletion of BAK and BAX did 
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not visibly affect CCCP induced cell death enhanced by USP30 depletion. As 
discussed before, it is more likely that the loss of USP30 promoted aberrant 
ubiquitylation and extraction of OMM proteins by Parkin, which affect the 
integrity of the outer mitochondrial membrane and cause cell death (Figure 
6.20). 
 
On the other hand, elevated levels of BAK may explain the sensitized cell 
death of USP30-depleted cells towards ABT-737 treatment, as more BAK is 
able to either homo-oligomerise or hetero-oligomerise with BAX readily in 
response to the inhibition of BCL2 and BCL-xL (Chandra et al. 2005, Upreti 
et al. 2008). Consistent with this, BAK knockdown partially and BAX 
knockdown fully inhibited the enhanced PARP cleavage caused by USP30 
depletion during ABT-737 treatment. It is possible that BAK and BAX could 
compensate each other to induce apoptosis during ABT-737 treatment and 
this hypothesis could be tested in the future with a double knockdown of BAK 
and BAX (Figure 6.20).  
 
It is also worth mentioning that ABT-737 treatment induced accumulation of 
lower molecular weight species for both BAK and BAX that are indicative of 
cleaved products and that correlate with PARP cleavage. This is consistent 
with previous report of BAK and BAX cleavage by both caspases and 
calpains during apoptosis (Wood et al. 1998, Meng et al. 2003). Whilst the 
effect of cleaved BAK is relatively understudied, cleaved BAX has been 
demonstrated to be more potent than full length BAX in inducing apoptosis 
(Toyota et al. 2003, Cao et al. 2003).   
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Figure 6.20 Illustration of CCCP-induced mitophagic cell death and ABT-737-
induced cell death under normal and USP30-depleted conditions. 
During CCCP treatment, high Parkin expression resulted in acute ubiquitylation and 
extraction of OMM proteins for proteasomal degradation. This can affect the OMM 
integrity and cause Cytochrome-C to be released into the cytosol, causing caspase 
activation and apoptosis. USP30 acts as a ‘brake’ to oppose the ubiquitylation of 
OMM proteins, thereby promoting cell survival.  
During BH3-mimetic treatment, BCL2 pro-survival proteins are inactivated, leading 
to the activation and oligomerisation of BAK and BAX on the outer mitochondrial 
membrane and promote cytochrome C release. We showed that USP30 depletion 
induces higher protein levels of BAK, which might exacerbate BH3-mimetic induced 
cell death. 
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Chapter 7: Identification of 
USP30 Substrates by Mass 
Spectrometry  
7.1 Introduction 
One important role of deubiquitylation is to rescue ubiquitylated proteins from 
proteasomal degradation. Therefore, the loss of a DUB with such a function 
will promote the ubiquitylation and degradation of its substrate(s). 
Quantitative proteomics with the use of mass spectrometry (MS) provides an 
unbiased approach to analyse various changes in the property of a protein 
(e.g. protein abundance, ubiquitylation and phosphorylation) in response to a 
specific stimulus, be it drug/inhibitor treatment, growth factor administration 
or mutation/depletion of a protein of interest. Such a discovery-based study 
allows the identification of proteins that are involved in a common pathway 
and could open up new biology.  
 
Quantitative MS analysis can be achieved using Stable Isotope Labelling by 
Amino acids in Cell culture (SILAC). Stable ‘heavy’ and ‘light’ isotopes 
(introduced in the form of lysine and arginine) are metabolically incorporated 
into separate sets of cells for different treatment conditions. The two 
isotopically labeled samples can then be combined at equal amounts for MS 
analysis. ‘Heavy’ and ‘light’ peptides can be distinguished based on the 
relative shift in mass of the ‘heavy’ peptide compared to the ‘light’ peptide. A 
heavy-to-light ratio can then be quantified for each peptide based on the 
relative MS signal intensities (Ong et al. 2002, Ong and Mann 2006). This 
ratio informs on the relative abundance of the parent protein in each sample.  
 
Alongside the work described in chapter 6 to characterise the effect of 
USP30 depletion on mitophagic and BH3-mimetics-induced cell death, a 
separate strand of my project focused on investigating the effects of USP30 
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depletion at steady state. While depletion of USP30 has been reported to 
induce elongated and interconnected mitochondrial networks in HeLa and 
COS7 cells, the underlying mechanism and the substrate of USP30 that 
regulates this process were not identified (Nakamura and Hirose 2008).  
 
Therefore, I decided to use the SILAC-MS approach to identify proteins with 
altered abundance upon siRNA-mediated USP30 depletion. 
 
In this chapter, the following work will be presented: 
(1) Quality control and optimization of SILAC labeling for HeLa S3 cells, 
mitochondria enrichment protocol and siRNA transfection. 
(2) Analysis of four biological replicates of SILAC MS experiments to 
identify proteins with altered abundance upon USP30 depletion. 
(3) Deconvolution and functional characterisation of the shortlisted 
proteins. 
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7.2 Quality control and optimization of SILAC MS experiment 
7.2.1 Workflow of SILAC MS Analysis  
HeLa S3 cells were selected for this study as this cell line is routinely used in 
the laboratory to perform SILAC-based experiments and isotope labeling 
efficiency is assessed regularly. The SILAC workflow for the identification of 
USP30 substrates is described in Figure 7.1A. Briefly, HeLa S3 cells were 
cultured in ‘light’ (Arg0, Lys0- ‘L’) or ‘heavy’ (Arg10, Lys8- ‘H’) media. ‘Light’-
cells were transfected using Oligofectamine with non-targeting siRNA control 
oligo (NT1; 40nM) whereas ‘heavy’-cells were transfected with a siRNA pool 
targeting USP30 (oligo D1, D3 and D4, total 40nM). Light and heavy cells 
were then harvested and combined at a 1:1 ratio (w/w) for mitochondria 
enrichment using the mitochondria isolation kit (Details described in the next 
section and in Chapter 2 Section 2.3.4.1). The lysate was then resolved on a 
NU-PAGE and protein bands were processed for in-gel digestion followed by 
liquid chromatography and tandem mass spectrometry analysis (LC-MS/MS). 
The H/L protein intensity ratio reflects the change in protein abundance upon 
USP30 depletion.  
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Figure 7.1 Workflow of SILAC experiment and quality control for SILAC labeling of 
cells and siRNA transfection efficiency.  
Illustration of the SILAC workflow with mitochondria enrichment. HeLa S3 cells were 
cultured in ‘light’ (Arg0, Lys0- ‘L’) or ‘heavy’ (Arg10, Lys8- ‘H’) media. L-cells were 
transfected for 72hr with non-targeting siRNA control oligo (NT1; 40nM) whereas H-
cells were transfected with siRNA pool oligo targeting USP30 (oligo D1, D3 and D4, 
total 40nM). L and H cells were then harvested and combined at 1:1 (weight: weight) 
for mitochondria enrichment using the mitochondria isolation kit. The lysate was 
then resolved on a NU-PAGE and protein bands were processed for in-gel digestion 
with trypsin and LC-MS/MS analysis. The H/L protein intensity ratio reflects the 
change in protein abundance upon USP30 depletion.  
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7.2.2 Quality control of SILAC incorporation and siRNA transfection 
HeLa S3 cells were cultured in SILAC media containing either ‘light’ amino 
acids (Arg0 and Lys0- ‘L’) or ‘heavy’ amino acids (Arg10, Lys8- ‘H’) for at 
least 5 passages to ensure maximal labeling efficiency. H and L cells were 
then harvested and resolved on a NU-PAGE. Three protein bands from each 
condition were excised for in-gel digestion and liquid chromatography and 
tandem mass spectrometry analysis (LC-MS/MS). As shown in Figure 7.2A, 
HeLa S3 cells cultured in heavy medium (right graph) incorporated 98.6% 
each of Arg10 and Lys8.  
 
Next, I assessed the siRNA transfection efficiency in HeLa S3 cells. 
Transfection using Oligofectamine with siRNA oligo targeting USP33 (oligo 6, 
40nM) efficiently depleted USP33 in these cells as evident from the western 
blot probed with anti-USP33 antibody (Figure 7.2B). As described in previous 
chapters, USP33 knockdown is used to assess the knockdown efficiency as 
this protein has been extensively studied in our laboratory and the antibody 
we routinely use is specific and sensitive (Thorne et al. 2011). In addition, I 
also tested the knockdown efficiency of USP30 siRNA oligos (D1, D3 and 
D4) that were used later for the actual experiment. Since a working USP30 
antibody was not available at that time, I assessed the knockdown efficiency 
by qRT-PCR (Figure 7.2C; Chapter 2, section 2.1.9). siRNA transfection for 
24hrs reduced the mRNA level of USP30 by more than 80% compared to the 
mock control (Figure 7.2C). 
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Figure 7.2 Quality control for SILAC labeling and transfection efficiency  in HeLa S3 
cells. 
(A) HeLa S3 cells cultured in ‘light’ (Arg0, Lys0) or ‘heavy’ (Arg10, Lys8) media for 5 
passages were lysed in NP40 lysis buffer. Cells were resolved on a NU-PAGE and 
protein identification and isotope incorporation efficiencies were analysed by LC-
MS/MS and MaxQuant.  
(B) HeLa S3 cells were transfected for 72hr with either non-targeting siRNA control 
oligo (NT1) or siRNA targeting USP33 (oligo D6). Cells were then harvested in 
NP40 lysis buffer and probed for USP33 and Tubulin.  
(C) HeLA S3 cells were either transfected with mock (transfection reagent without 
siRNA), non-targeting siRNA control oligo (NT1), or siRNA pool oligo targeting 
USP30 (D1, D3 and D4). RNA extraction was performed 24hr post-transfection for 
qRT-PCR analysis. USP30 mRNA levels were normalized to β-actin mRNA levels.  
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7.2.3 Quality control of mitochondria enrichment protocol 
USP30 is a DUB with an N-terminal transmembrane domain which localizes 
it to the OMM, with the catalytic domain facing the cytosol (Nakamura and 
Hirose 2008). Therefore, it is likely that USP30 deubiquitylates mitochondrial 
substrates. To increase the probability of identifying mitochondrial substrates, 
I decided to enrich mitochondria from the cell lysate prior to LC-MS/MS 
analysis. Mitochondria enrichment was carried out using the mitochondria 
isolation kit (MACS Miltenyi Biotech) according to the manufacturer’s 
instruction but with slight modifications as described in Chapter 2, section 
2.3.4.1). The mitochondria isolation kit relies on the use of anti-TOM22 
antibody conjugated to microbeads (Hornig-Do et al. 2009). The antibody 
recognises a cytoplasmic region of the OMM protein, TOM22, while the 
microbeads consist of a colloidal suspension of extremely small (50nm) 
superparamagnetic particles that can be magnetically isolated upon passing 
through an iron-bead filled column attached to a MACS magnetic separator 
(Figure 7.3). These mitochondria-enriched fractions were subjected to gel 
electrophoresis and gel slices were processed for LC-MS/MS analysis.  
 
I first performed a test experiment to assess the mitochondria-enrichment 
efficiency of the kit. I annotated the subcellular localisation of the list of 
proteins identified from the LC-MS/MS analysis using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID; 
http://david.abcc.ncifcrf.gov/) and MitoCarta (Figure 7.4A). DAVID is an 
integrated database that collates available literature to annotate Gene 
Ontology (GO) based on different classifications, such as metabolic 
processes, biochemical pathways, subcellular localization and protein 
domains (Dennis et al. 2003). On the other hand, MitoCarta is an inventory of 
over 1000 mouse proteins and their human homologs. These genes were 
originally identified from MS analysis of mouse mitochondria enriched 
fractions using Percoll density gradient separation from fourteen different 
tissues. Human homologs of those genes that had previously not been 
reported as associated with mitochondria were GFP-tagged at the C- 
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Figure 7.3 Schematic illustration of the mitochondria enrichment protocol.  
HeLa S3 cells were homogenised using a 23G syringe and nuclei were removed by 
centrifugation. The post-nuclear supernatant was further centrifuged to enrich for 
mitochondria. The mitochondria fraction was then incubated with anti-TOM22 
antibody conjugated with microbeads for 1hr. The antibody-bound mitochondria 
were enriched according to the mitochondria isolation protocol (Hornig-Do et al. 
2009). 
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terminus to visualise their subcellular localization in HeLa cells using 
fluorescence microscopy (Pagliarini et al. 2008). 
 
Analysis of the list of proteins identified in my MS experiment using these two 
databases revealed that 37% of the total proteins identified were known 
mitochondrial proteins, among which, 26% were exclusively mitochondrial 
proteins whereas 5% were annotated as mitochondrial and nuclear, and 6% 
as mitochondrial and cytoplasmic proteins. The next largest group of proteins 
from the mitochondria-enriched sample was endoplasmic reticulum (ER) 
proteins. This is unsurprising and expected as the mitochondrial network is 
tightly tethering with the ER network (Rowland and Voeltz 2012).  
 
I next compared the mitochondria-enriched samples from my four actual 
experiments with the lists of proteins identified from total lysate samples 
reported by the groups of Angus Lamond and Mattias Mann in their 
comprehensive proteomic studies (Cambridge et al. 2011, Boisvert et al. 
2012). While the total number of proteins that I identified using the 
mitochondria isolation kit was approximately 6 to 8-fold lower than that by the 
two studies, I found that mitochondrial proteins made up approximately 15% 
of the total proteins in both of the studies (Figure 7.4B). In my case, the use 
of the mitochondria isolation kit increased the percentage of mitochondrial 
proteins for about two-fold.   
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Figure 7.4 Analysis of the mitochondria-enriched samples. 
(A) Pie diagram illustrates the different subcellular localisation of proteins identified 
in the test mitochondria-enrichment experiment.   
(B) Bar chart shows the percentage of mitochondrial proteins in total lysates 
identified by the groups of Mattias Mann and Angus Lamond compared with the 
relative enrichment of mitochondria proteins in the mitochondria-enriched fractions 
from the four independent experiments that I performed (Cambridge et al. 2011, 
Boisvert et al. 2012).  
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7.3 Analysis of the LC-MS/MS datasets 
I carried out four independent SILAC experiments according to the workflow 
described in Figure 7.1. In experiments 1 to 3, ‘light’-cells were transfected 
with non-targeting siRNA control oligo (NT1) whereas ‘heavy’-cells were 
transfected with siRNA pool targeting USP30. In experiment 4, the 
transfection conditions were inversed, therefore, ‘heavy’-cells were 
transfected with the non-targeting siRNA control oligo (NT1) whereas ‘light’-
cells were transfected with siRNA oligo targeting USP30. 
 
Overall, I managed to identify 810 unique proteins across all four 
experiments, out of which, 309 of the proteins were annotated as 
mitochondrial proteins based on Mitocarta and DAVID analysis. The 
distribution and overlap in number of total proteins and mitochondrial proteins 
is shown in Figure 7.5A. In general, there is a good overlap of proteins 
identified across the four experiments. 29% of the total proteins were 
identified in all four experiments, whereas and additional 22% and 26% of the 
total proteins were only identified in 3 and 2 sets of experiments, respectively 
(Figure 7.5B and C). Only proteins that were found in at least two 
experiments were selected for further analysis.  
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Figure 7.5 Analysis of the proteins identified by LC-MS/MS in each experimental 
repeats.  
(A) Diagrams represent the number of total proteins (left) and mitochondrial proteins 
(right) identified in each category and overlap between each experiment.  
(B) Bar chart shows non-mitochondrial and mitochondrial proteins identified in 4, 3, 
2 or 1 of the experiments.  
(C) Pie diagram illustrates the overlap of proteins (both mitochondrial and non-
mitochondrial proteins) identified in HeLa S3 cells in 4, 3, 2 or 1 of the experiments. 
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7.3.1 Scatter plot analysis of changes in protein abundance upon 
USP30 knockdown  
For experiments 1 to 3, the data were expressed as Heavy-to-light protein 
abundance ratio (H/L ratio or USP30/NT1 knockdown ratio). Since I 
purposely inversed the transfection protocol for experiment 4, such that L-
cells were now transfected with USP30 siRNA oligos and H-cells were 
transfected with control NT1 siRNA oligos, the protein ratios from experiment 
4 were expressed as an L/H.  
 
I then log2-transformed the USP30/NT1 knockdown ratios and expressed 
them as a scatter plot relative to the log10(Intensity) of the proteins, which is 
proportional to the abundance of the protein (Figure 7.6). A positive log2-ratio 
(right side of the plot) reflects relative enrichment whereas a negative log2-
ratio (left side of the plot) reflects relative loss upon USP30 depletion 
compared to the NT1 control. Proteins with unchanged abundance between 
control and USP30-depleted samples have a log-ratio value of zero. To aid 
with visualization, mitochondrial proteins were labeled in blue and non-
mitochondrial proteins in grey. Proteins with significantly altered abundance 
upon USP30 depletion were determined by their significance A score as 
analysed using Perseus software (a data analysis and presentation software 
that is part of MaxQuant). Proteins with significance A score of p<0.05 were 
labeled with solid circle and protein names annotated whereas proteins with 
a significance A score of p>0.05 were labeled with hollow circles (Cox and 
Mann 2012). I further plotted the protein ratios in pairs to compare the ratios 
that were altered in the same trend across the four experiments (Figure 7.7).  
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Figure 7.6 Scatter plots showing the logarithmic ratio of protein intensities versus 
the logarithmic ratio of USP30/NT1 knockdown for all four experiments. 
Proteins labeled in blue are mitochondrial proteins where as proteins labeled in grey 
are non-mitochondrial proteins. Proteins with solid circles have a significance A 
score of p<0.05 whereas proteins with hollow circles have a significance A score of 
p>0.05.  
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Figure 7.7 Comparison of (USP30/NT1 ratio) across all four experiments. 
Proteins labeled in blue are mitochondrial proteins where as proteins labeled in grey 
are non-mitochondrial proteins 
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7.3.2 Shortlisting and functional annotation of top hits   
I further filtered the list of proteins using Perseus, based on the significance 
A score of each protein in each experiment. Proteins with significance A 
scores of less than 0.05 in at least two experiments were shortlisted. The list 
of top hits was presented as a heat map to help visualize the trend of each 
protein across all four experiments (Figure 7.8). Proteins labeled with shades 
of green represent low USP30/NT1 ratios (i.e. are de-enriched upon USP30 
depletion) whereas proteins labeled with shades of red represent high 
USP30/NT1 ratios (i.e. are enriched upon USP30 depletion). In experiments 
where a particular protein is not identified, a grey box was assigned. A total 
of 21 proteins were selected, of which, 5 of the proteins were mitochondrial 
proteins (labeled in bold), including GST12, AGR2, NDUFA4, RAB1C and 
HRSP12. Note that RAB1C is also known as RAB35 and GST12 is also 
known as MGST1. 
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Figure 7.8 Statistical analysis and functional annotation of the shortlisted proteins.  
Heatmap illustrates relative change in protein level upon USP30 knockdown. Top 
hits were selected based on identification in at least two experiments with 
significance A scores of p<0.05. Proteins in bold represents mitochondrial proteins 
compared with DAVID and Mitocarta databases. Boxes in shades of green 
represent protein de-enrichment upon USP30 knockdown. Boxes in shades of red 
represent protein enrichment upon USP30 knockdown. Boxes in grey represents 
protein not identified in that particular experiment. 
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7.3.3 Verification and deconvolution of top hits in post-nuclear 
supernatant and mitochondrial fraction 
To confirm the mass spectrometry data, I assessed the protein levels of the 
shortlisted proteins by western blotting. Based on the availability of 
antibodies, I checked the protein levels of RAB1C (RAB35), AHCYL2, 
ACTN4, AGR2 and GST12 (MGST1) (Figure 7.9A). USP30 depletion 
marginally reduced the levels of RAB35, ACNT4 and MGST1. On the other 
hand, the levels of AGR2 increased upon USP30 depletion. AHCYL2 levels 
were not visibly changed upon USP30 depletion. While the changes were 
mild between USP30 depleted and the control samples, the preliminary work 
revealed that the results were largely consistent with the trend observed from 
the mass spectrometry data. Since MS analysis provides a highly sensitive 
quantitative analysis whereas western blot only provides semi-quantitative 
analysis, it is not surprising that some of the changes reported by MS might 
not be as easily observed by western blotting.  
 
In the end, I decided to follow up on RAB35, AGR2 and ACTN4. To eliminate 
the possibility of off-target effects, I first assessed the levels of these proteins 
with individual USP30 siRNA transfections (USP30 D1, D3 and D4 siRNA 
oligos). As shown in Figure 7.10, all three siRNA oligos efficiently reduced 
the mRNA level of USP30 as assessed by qRT-PCR. However, there was no 
consistent change in the protein levels of RAB35, AGR2 and ACTN4 that 
correspond to the degree of USP30 depletion. Instead, I found that the 
elevated AGR2 levels observed with the pool USP30 siRNA transfection was 
only recapitulated by USP30 D1 oligo. The changes in protein levels of 
RAB35 and ACTN4 were variable and inconsistent across the different 
USP30 siRNA transfections.  
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Figure 7.9 Verification of protein change by western blotting.  
(A) HeLa S3 cells were transfected for 72hr with either non-targeting siRNA control 
oligo (NT1) or a siRNA oligo pool targeting USP30 (D1, D3 and D4). Cells were then 
harvested in HIM buffer. Post-nuclear supernatant (PNS) was obtained by 
homogenization using a 26G needle and centrifugation at 700 x g. Colour codes 
correspond to trends observed by mass spectrometry. RAB35= RAB1C.   
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Figure 7.10 USP30 siRNA deconvolution.  
HeLa S3 cells were transfected for 72hr with either mock (transfection reagent 
without siRNA oligo), non-targeting siRNA controls (NT1 or AllStar), or siRNA oligos 
targeting USP30 (pool, D1, D3 and D4). Cells were then harvested in NP40 lysis 
buffer and probed as indicated. Error bars represent standard deviations of the three 
independent experiments. For the assessment of USP30 knockdown efficiency, 
RNA (from experiment 2) was harvested 24hr post-transfection for qRT-PCR 
analysis. USP30 mRNA levels were normalized to the β-actin mRNA levels. 
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7.4 Discussion 
7.4.1 Functional characterisations of proteins with altered abundance 
upon USP30 depletion 
In this chapter, I summarized the work carried out to identify substrates of 
USP30 under steady state conditions using a SILAC-based mass 
spectrometry approach. Since USP30 is a mitochondrial DUB, it is most likely 
that it regulates the stability of mitochondrial proteins as well. Therefore, I 
enriched for mitochondrial proteins using the mitochondria isolation kit prior 
to mass spectrometry analysis to increase the probability of identifying 
mitochondrial proteins. Overall, I performed four independent experiments 
and shortlisted 21 proteins that were significantly altered in protein 
abundance upon USP30 depletion based on Significance A analysis using 
Perseus software (Cox and Mann 2012).  
 
Out of these 21 proteins, 5 were known mitochondrial proteins based on the 
MitoCarta and DAVID database (Pagliarini et al. 2008, Dennis et al. 2003). 
One of the mitochondrial proteins that was de-enriched upon USP30 
knockdown is GST12. GST12 belongs to the MAPEG (Membrane Associated 
Proteins in Eicosanoid and Glutathione metabolism) family of glutathione 
transferases that conjugate gluthathione to electrophiles and confer 
protection against accumulation of ROS (Morgenstern et al. 2011, 
Morgenstern et al. 1985). Interestingly, GST12 is also found on the outer 
mitochondrial membrane, making it a likely substrate of USP30 (Morgenstern 
et al. 1985, Morgenstern 2005). If depletion of USP30 indeed decreases the 
levels of GST12, then this could lead to increased oxidative stress. However, 
Bingol et al. recently reported that depletion of USP30 in hippocampal 
neurons reduces the relative oxidative index in the cells as assessed using 
mito-roGFP, a mitochondrial redox potential sensor, suggesting that USP30 
depletion may reduce oxidative stress in the cells. However, this remains to 
be validated.  
 
Another mitochondrial protein that is de-enriched upon USP30 knockdown is 
NDUFA4, a core component of the electron transport chain complex IV 
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(cytochrome C oxidase) found in the inner mitochondrial membrane (Balsa et 
al. 2012). siRNA depletion of NDUFA4 affects the assembly and function of 
complex IV, which significantly impairs cell proliferation in OXPHOS-
dependent cells (Balsa et al. 2012). USP30 and NDUFA4 are not localized 
within the same compartment. However, since NDUFA4 is a nuclear 
encoded protein, one hypothesis is that nascent NDUFA4 may be regulated 
by USP30 prior to import into the mitochondria to ensure proper folding and 
insertion of the protein or appropriate protein abundance.  
 
HRSP12/UK114/L-PSP is a heat responsive endoribonuclease that is 
upregulated upon heat shock in mouse tissues (Drabek et al. 2014, Samuel 
et al. 1997). It has been shown to form a homodimer and inhibit the 
translation of mRNA by dissociating the polysome in an in vitro rabbit 
reticulocyte lysate system (Samuel et al. 1997, Morishita et al. 1999, Oka et 
al. 1995). Based on the MitoCarta database, HRSP12 is annotated as a 
mitochondrial protein (Mootha et al. 2003). However, the exact sub-
mitochondrial localisation of HRSP12 is unknown. In my proteomic study, 
USP30 depletion elevated HRSP12 protein levels. Based on the literature on 
HRSP12, the upregulation of HRSP12 seen in my study is most likely a 
secondary effect of cell stress upon USP30 depletion.  
 
The MitoCarta database reported that GFP-tagged AGR2 and RAB35 
colocalise with Mitotracker (Mootha et al. 2003). However, both of these 
proteins have not been functionally related to the mitochondria. AGR2 
(anterior gradient protein 2 homolog) is upregulated in multiple cancers, 
including breast, pancreatic, lung, ovarian, oesophageal, and prostate 
cancers, and is generally associated with the metastatic phenotype and poor 
prognosis (Patel et al. 2013, Barraclough et al. 2009, Zhang et al. 2007, 
Pohler et al. 2004, Armes et al. 2013, Park et al. 2011, Fritzsche et al. 2007). 
A functional study of AGR2 linked it to the post-translational modification of 
MUC2 in the ER for secretion into the gastrointestinal mucus (Park et al. 
2009). Dunmartin and colleagues reported that while AGR2 is mostly found 
in the ER, it has also been detected on the plasma membrane surface and is 
secreted into the media. Loss of its KTEL motif (a variant of the ER-targeting 
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KDEL motif) or mutation of a cysteine residue (C81S) further promotes 
extracellular secretion of AGR2 (Bergstrom et al. 2014, Gupta et al. 2012). In 
my proteomic study, AGR2 levels were consistently upregulated upon 
USP30 depletion. However, only oligo D1 recapitulated the AGR2 effect 
observed with the siRNA pool and this effect did not correlate with the 
knockdown efficiency of each of the siRNA oligo. Therefore, this is most 
likely an off target effect.  
 
RAB35 is involved in the endocytic recycling pathway and is required for the 
transport of cadherin to adherens junctions. (Charrasse et al. 2013). 
Knockdown of RAB35 relocalises N-, M- and E-cadherin to transferrin- and 
clathrin-positive vesicles, suggesting a defect in the recycling pathway. 
(Charrasse et al. 2013). RAB35 knockdown also promoted cell migration and 
proliferation via the hyperactivation of Arf6-mediated recycling of β1-integrin 
and EGF receptors, a mechanism that is consistent with epithelial-to-
mesenchymal transition observed in invasive cancer cells (Allaire et al. 
2013). Based on the reported effects of RAB35 knockdown on cell migration 
and proliferation, the decrease in RAB35 protein levels upon USP30 
knockdown may also cause similar phenotypes. 
 
While shortlisted proteins that are localized to the outer mitochondrial 
membrane are more likely to be regulated by USP30, proteins of other 
localisations such as cytoplasmic or cytoskeletal proteins could also be 
regulated by USP30, either via direct transient interaction or as an indirect 
result of an upstream substrate regulated by USP30. In fact, USP30 
depletion also altered the protein abundance of a subset of ER proteins 
including AHCYL2, ETEA, FACE1, G2AN, GLT25D1 and HMOX1. 
Membrane contact sites between ER and mitochondria, known as ER-
mitochondria junctions have been extensively described in the past (Rowland 
and Voeltz 2012). These contact sites have been proposed to be important 
for lipid and Ca2+ exchange as well as maintenance of mitochondrial 
dynamics (Schlattner et al. 2014, Tatsuta et al. 2014, Friedman et al. 2011). 
Therefore, it is possible that USP30 can also regulate ER proteins.  
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Based on preexisting data in the literature, I further categorized the proteins 
of interest into several functional groups including vesicular transport, actin 
assembly and arrangement, cell adhesion and motility and oxidative stress 
response (Figure 7.11). These functional groups are not mutually exclusive 
since actin assembly and remodeling also play important roles in both the 
trafficking of vesicles and also cell motility. The detailed function and 
subcellular localisation of all the shortlisted proteins are summarized in Table 
7.1.  
 
Figure 7.11 Functional annotations of shortlisted proteins.  
Categorisation of the top-hits based on functional annotations from literature search. 
Color-coding reflects either protein enrichment (red) or de-enrichment (green). 
Proteins in bold represents mitochondrial proteins. 
 
Gene 
Symbol  
Full Name  Localisation Function Reference 
AGR2 é Anterior 
gradient 
protein 2 
homolog 
mitochondria, 
endoplasmic 
reticulum 
Involved in MUC2 post-
translational synthesis and 
secretion; promotes cell 
survival, motility and 
invasion 
(Bergstrom et 
al. 2014, Di 
Maro et al. 
2014) 
GST12 
(MGST1
) ê 
Microsom
al 
glutathion
e S-
transferas
e 1 
mitochondria, 
endoplasmic 
reticulum 
Conjugates reduced 
glutathione to hydrophobic 
electrophiles; cellular 
detoxification and 
protection against ROS 
(Morgenstern et 
al. 2011, 
Morgenstern et 
al. 1985) 
HRSP12 Heat mitochondria, Potentially Inhibits (Lambrecht et 
Actin  
assembly  
&  arrangement
Vesicular  transport
Cell  adhesion  
&  motility Oxidative  stress
response
ANPRC
RAB35VAMP3
SH3BP1
ACTN4 FLN
FLNB
MACS
MCAM
AGR2 HMOX1
CRYZ
NDUFA4
GLT25D1
GST12
FACE1
Enriched  by
USP30  siRNA
De-­enriched  by  
USP30  siRNAProtein Protein
Other  proteins
GNAI2 HRSP12
G2AN
AHCYL2
ETEA
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(UK114) 
ê 
responsiv
e protein 
12 
cytoplasm, 
nucleus 
phosphoribosylamine 
synthesis  
al. 2010) 
NDUFA4 
ê 
NADH 
dehydroge
nase 1α 
subunit 4 
mitochondria Subunit of ETC complex 
IV 
(Balsa et al. 
2012) 
RAB1C 
(RAB35) 
ê 
Ras-
related 
protein 
Rab-35 
mitochondria, 
cytoplasm 
Involved in recycling 
endosome trafficking and 
neurite outgrowth 
(Kobayashi et 
al. 2014b, 
Kobayashi et al. 
2014a) 
ACTN4 
ê 
α-actinin-4 cytoskeleton Binds to actin, regulates 
cell motility; transcriptional 
co-activator of RelA/p65 
sub-unit of NF-kB 
(Aksenova et al. 
2013, Hamill et 
al. 2013) 
AHCYL2 
ê 
Adenosylh
omocystei
nase 3 
endoplasmic 
reticulum 
Potential regulator of 
sodium bicarbonate 
cotransporter NBCe1-B 
(Yamaguchi and 
Ishikawa 2014) 
ANPRC 
(NPR3) 
ê 
Atrial 
natriuretic 
peptide 
receptor 3 
plasma 
membrane 
Indirectly involved in 
TORC1 inactivation and 
autophagy activation via 
GTP hydrolysis of the 
RAG family proteins, Gtr1 
and Gtr2 
(Kira et al. 
2014) 
CRYZ é zeta-
Crystallin 
cytoplasm Binds to AU rich region of 
Bcl2 mRNA and promote 
overexpression of Bcl2 
(Lapucci et al. 
2010) 
ETEA 
(UBXD8) 
é 
FAS-
associated 
factor 2 
endoplasmic 
reticulum 
Contains UBA and UBX 
domains, binds to mis-
folded proteins and 
recruits p97 to ER for 
protein degradation; also 
shown to negatively 
regulates Ira2 and 
neurofibromin 
(Ernst et al. 
2009, Phan et 
al. 2010) 
FACE1 
(ZMPST
E24) ê 
CAAX 
prenyl 
protease 1 
homolog 
endoplasmic 
reticulum, 
Golgi 
Recognizes and cleaves 
C-terminal CAAX-
farnesylated prelamin A to 
form mature lamin A  
(Young et al. 
2005) 
FLN 
(FLNA) 
é 
Filamin A plasma 
membrane, 
cytoskeleton 
FLN and FLNB forms 
homo- and heterodimers, 
bind to actin and promotes 
orthogonal branching of 
actin filaments and links 
actin filaments to 
membrane glycoproteins  
 
(Sheen et al. 
2002, van der 
Flier and 
Sonnenberg 
2001) 
FLNB é Filamin B plasma 
membrane, 
cytoskeleton 
G2AN 
(GANAB
) é 
Neutral α-
glucosidas
e AB 
endoplasmic 
reticulum, 
Golgi 
Cleaves N-linked glucose 
residues from precursor of 
immature glycoproteins  
(Trombetta et 
al. 1996) 
GLT25D
1 
(COLGA
LT1) é 
Procollage
n 
galactosylt
ransferase 
endoplasmic 
reticulum 
Transfers beta-galactose 
to hydroxylysine residues 
of collagen 
(Perrin-Tricaud 
et al. 2011) 
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1 
GNAI2 
ê 
Guanine 
nucleotide
-binding 
protein 
G(i) 
subunit α2 
cytoplasm, 
nucleus 
Binds and inhibits the 
activity of adenylate 
cyclase, leading to 
decrease in cAMP level  
(Dhanasekaran 
et al. 1998, 
Gudermann 
2001) 
HMOX1 
ê 
Heme 
oxygenas
e 1 
cytoplasm, 
endoplasmic 
reticulum 
Cleaves heme ring at α-
methene bridge, forms 
biliverdin, iron and carbon 
monoxide; involves in iron 
efflux, confers 
cytoprotection 
(Chen 2014) 
MACS 
(MARCK
S) é 
Myristoylat
ed 
alanine-
rich C-
kinase 
substrate 
cytoskeleton, 
cytoplasm 
Actin cross-linking protein; 
substrate of protein kinase 
C, involved in cell motility, 
mitosis and exocytosis 
(Blackshear 
1993, Tsaadon 
et al. 2008, Li et 
al. 2008) 
MCAM 
ê 
Melanoma 
cell 
adhesion 
molecule 
plasma 
membrane  
Surface receptor 
expressed on 70% of 
metastatic melanoma 
cells; inducibly 
upregulated by endothelin-
1, proposed to play a role 
in metastasis 
(Mangahas et 
al. 2004) 
SH3BP1 
é 
SH3 
domain-
binding 
protein 1 
cytoplasm, 
nucleus 
Rac1 GAP, inactivates 
Rac1 to promote cell 
motility  
(Parrini et al. 
2011) 
SYB3 
(VAMP3
) é 
Vesicle-
associated 
membrane 
protein 3 
cytoplasm A small R-SNARE protein 
involved in recycling and 
retrograde transport of 
vesicles; regulates 
recycling of integrins, 
transferrin and the 
transferrin receptor to the 
plasma membrane 
(McMahon et al. 
1993, Galli et al. 
1994) 
Table 7.1 GO terms and functional annotations of shortlisted proteins.  
Arrow represents the change in protein abundance upon USP30 depletion. An 
upward pointing arrow represents an increase in protein abundance and a 
downward pointing arrow represents a decrease in protein abundance.  
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Interestingly, I found that several proteins that promote cell motility, including 
FLN, FLNB, SH3BP1 and MACS were enriched whereas RAB35, a protein 
that promotes cell-cell adhesion and inhibits cell migration, was de-enriched 
upon USP30 depletion (Di Maro et al. 2014, Wang et al. 2008, Zhang et al. 
2005, Allaire et al. 2013). However proteins such as ACTN4, which regulate 
vesicular trafficking as well as cell motility and MCAM, its upregulation of 
which correlates with metastatic melanoma, were downregulated upon 
USP30 knockdown (Aksenova et al. 2013, Hamill et al. 2013, Mangahas et 
al. 2004).  
 
Interestingly, a previous PhD student in our laboratory reported that USP30 
knockdown hepatocyte growth factor (HGF)-induced cell scattering in A549 
cells (Buus et al. 2009). The HGF-induced cell scattering response involves a 
complex orchestration of the loss of cell-cell contact, change in cell 
morphology followed by increase cell motility, all of which recapitulates the 
epithelial-to-mesenchymal phenotype of metastatic cancer cells. While the 
exact interplay and the downstream effects of the shortlisted proteins in my 
proteomic study remained to be elucidated, the general trend indicates that 
USP30 depletion affects actin assembly, vesicular trafficking and 
subsequently cell motility, all of which, are key processes that are involved in 
the metastatic behaviors of cancer cells. 
 
7.4.2 Deconvolution of shortlisted proteins by western blotting 
The western blot verification of the shortlisted proteins revealed a marginal 
decrease in the protein levels of RAB35, GST12 and ACTN4, and elevated 
AGR2 protein levels upon USP30 knockdown. Whilst the effects were mild, 
they were consistent with the change in ratio reported from the MS analysis. 
However, further deconvolution of USP30 also revealed marginal changes 
and inconsistency between the knockdown efficiency and the change in 
levels of RAB35, AGR2 and ACTN4. In the case of AGR2, the increase in 
protein levels observed with USP30 pool knockdown was only recapitulated 
with one oligo, strongly indication that the effect observed with AGR2 is an 
off-target effect. On the other hand, the mild effect of USP30 knockdown on 
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RAB35 and ACTN4 might be due to incomplete depletion of USP30. 
Importantly, it should also be taken into consideration that the mass 
spectrometry experiments were performed using mitochondrial-enriched 
samples whereas the subsequent western blotting analyses were performed 
using NP-40 lysates. If UPS30 depletion affects the recruitment of a protein 
to the mitochondria rather than its degradation, this effect will not be visible 
using the NP-40 lysates.  
 
Proteomic analysis of immunoaffinity-purified K-GG peptides performed by 
Bingol and colleagues reported a list of proteins in which the ubiquitylation 
statuses were changed upon CCCP treatment with either USP30 depletion or 
Parkin overexpression (Bingol et al. 2014). Among them, TOM20 and MIRO1 
were highlighted and further verified to be bona fide substrates of USP30. 
Other mitochondrial proteins that were reported include FKBP8, MUL1, 
TOM70, VDAC1/2/3, MAT2B, PRDX3, PTH2 and IDE. These proteins were 
not shortlisted in my experiment but this is unsurprising as the aims and 
experimental settings of our proteomic studies were different (summarised in 
Table 7.2). Firstly, they set out to identify mitochondrial proteins that can be 
deubiquitylated by USP30 during mitophagy. Therefore, they used HEK293 
cells, which express low endogenous levels of Parkin and depolarise the 
cells using CCCP to activate Parkin-mediated ubiquitylation of OMM 
proteins. Since my aim was to characterise the role of USP30 at steady 
state, HeLa S3 cells were used (which do not express endogenous Parkin; 
see Chapter 3, Figure 3.1) and I did not induce mitochondrial depolarisation 
in the cells. Sample-wise, I enriched for mitochondria proteins whereas 
Bingol et al. immunoprecipitated ubiquitylated peptides to compare the 
change in abundance of ubiquitylated proteins between control and USP30 
depleted cells. 
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 My Proteomic Study Bingol et al. (2014) 
Cell types HeLa S3 HEK293 
Parkin expressions No Parkin expression Low endogenous Parkin  
Treatments Steady state CCCP treatment 
Sample types Mitochondria-enriched 
sample 
Immunoprecipitation 
using K-GG antibody for 
ubiquitylated peptides 
Table 7.2 Comparison of the experimental settings of my proteomic study with 
Bingol et al. (2014). 
 
7.5 Future work 
Due to time constraints, I was unable to allocate more time to investigate the 
other proteins of interest from this SILAC-MS study as the other part of my 
project on the role of USP30 in Parkin-mediated mitophagy (described in 
Chapter 6) was showing promising results. The MS data are therefore 
deposited for future use in the laboratory.  
 
If given more time, it will be worthwhile to use other methods to either further 
deplete USP30 or inhibit its activity. For example, the use of new technology 
such as the CRISPR-Cas9 gene editing method allows one to fully deplete a 
targeted protein as it directly alters the DNA rather than the mRNA (reviewed 
in (Zhang et al. 2014)). Alternatively, Yue et al. recently identified a small 
molecule inhibitor of USP30, 15-oxospiramilactone (S3), which inhibits the 
deubiquitylating activity of USP30 on Mitofusin 1 and 2 (MFN1/2). This 
promotes the accumulation of MFN1/2 that are ubiquitylated in a non-
degradative manner, resulting in mitochondria hyperfusion (Yue et al. 2014). 
However, the authors did no demonstrate whether the inhibitor could also 
affect other DUBs, thus casting doubt on the specificity of the inhibitor (Yue 
et al. 2014). If proven specific, this inhibitor could be used in my SILAC MS 
study to understand the function of USP30. In addition, it would be worth 
performing pulse chase dynamic SILAC to compare the synthesis and 
turnover rates of proteins between control and USP30 depleted cells.  
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Chapter 8: Conclusion 
The past decade witnessed the exponential growth in our understanding of 
Parkinson’s Disease (PD) and its complex etiology involving the interplay 
between environmental and genetic factors. In particular, the identification of 
two mutated genes, PINK1 and Parkin, which are functionally linked to the 
quality control of mitochondria, has opened up an entirely new biology on 
mitophagy. While it is known that Parkin ubiquitylates outer mitochondrial 
membrane proteins to target mitochondria for mitophagy, the deubiquitylases 
that oppose this process remained relatively unexplored at the start of my 
PhD. My study was focused on the identification of deubiquitylases that are 
involved in this pathway.  
8.1 Different Parkin expression levels promote mitophagy or cell death  
From the characterisation work that I performed, I found that cells expressing 
low endogenous Parkin levels do not undergo global mitophagy. On the other 
hand, while cells that overexpress high levels of Parkin can undergo global 
mitophagy, a small population of the cells also undergoes apoptosis. This 
observation is in contrast to the general understanding of a cytoprotective 
role of Parkin. I speculate that high levels of Parkin may cause acute 
ubiquitylation of OMM proteins, targeting them for proteasomal degradation 
and thereby disrupting the outer mitochondrial membrane integrity. However, 
it remains to be seen whether this effect can also be observed in other cell 
lines that overexpress Parkin or whether this is specific to non-transformed 
hTERT-RPE1 cells. It may be useful perform a titration of Parkin expression 
levels using inducible promoter to assess whether there is a specific 
threshold beyond which high levels of Parkin induce cell death. Electron 
microscopy studies of the structure of the outer mitochondrial membrane 
may also help to provide further clues for the mechanism of cell death.  
 
Other forms of Parkin-independent mitophagic pathways, namely GP78 and 
cardiolipin-mediated mitophagy, have been recently described (Fu et al. 
2013). GP78 is an E3 ligase previously implicated in endoplasmic reticulum-
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associated degradation (ERAD), mitochondrial antiviral signaling (MAVS) and 
mitophagy (Jacobs et al. 2014, Chen et al. 2014, Liu et al. 2014, Fu et al. 
2013). Chu et al. recently reported that rotenone induces cardiolipid 
redistribution from the inner to outer mitochondrial membrane surface, which 
directly recruits LC3 to promote mitophagy in rat cortical neurons (Chu et al. 
2014, Chu et al. 2013).  It will be interesting to investigate the involvement of 
ubiquitylation, in particular, the roles of DUBs in these mitophagic pathways 
as well. For example, USP13 has been reported to oppose GP78-mediated 
ERAD but it is unclear whether it also antagonizes GP78-mediated 
mitophagy (Liu et al. 2014).  
8.2 USP30 depletion enhances cell death in two scenarios 
I originally discovered that USP30 depletion enhances Parkin-mediated 
mitophagic cell death in hTERT-RPE1-YFP-Parkin cells. I further 
demonstrated that TOM20 is a bona fide substrate of USP30. At a later stage 
of my project, I found that USP30 depletion also enhances cell death induced 
by the BH3-memetics, ABT-737 and ABT-263. Importantly, CCCP-induced, 
Parkin-mediated cell death occurs via a BAK and BAX independent fashion 
whereas the latter depends on both of the BCL2 pro-apoptotic members, 
suggesting that USP30 may regulate more than just TOM20. 
 
While I shortlisted several proteins that might be regulated by USP30 in my 
SILAC MS study, I was unable to fully validate and characterise these 
proteins due to time constraint. Other alternatives to identify DUB substrates 
have previously been reported. For example, Bingol et al. compared the 
ubiquitome of USP30 depleted cells with Parkin overexpressing cells after 
CCCP treatment (Bingol et al. 2014). Sowa and colleagues also previously 
characterised the interactome of 75 HA-tagged DUBs, including USP30, 
using affinity purification coupled with mass spectrometry analysis (Sowa et 
al. 2009). However, the HA-tag was attached to the N-terminus of USP30, 
which disrupted the N-terminal mitochondrial targeting signal and 
transmembrane domain crucial for its mitochondrial localisation, rendering 
the interactome inconclusive. Alternatively, a yeast-two hybrid screen may 
also reveal interacting partners and potential substrates of USP30.  
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8.3 USP31 depletion affects the later stages of mitophagy  
From the western blot screen, I identified USP31 as a DUB for which 
depletion results in the partial inhibition of the lysosomal degradation of 
mitochondrial proteins during mitophagy. Further investigation revealed that 
LC3-I levels were lower at steady state upon USP31 depletion, suggesting 
that it might regulate autophagy. However, this result requires further 
validation. For example, it remains to be answered whether USP31 regulates 
LC3-I at a post-transcriptional or post-translational level. Fluorescence 
microscopy study will also be required to assess the abundance and 
distribution of LC3-I and LC3-II at steady state and during mitophagy. In 
addition, the effect of USP31 depletion on the acidification of the lysosome 
and general lysosomal degradation pathways should also be assessed.  
 
8.4 Other DUBs that influence Parkin-mediated mitophagy  
Recently, USP30, USP15 and USP8 have been implicated in Parkin-
mediated mitophagy. While my results on USP30 agree with Bingol and 
colleagues, and I have obtained convincing results that USP30 opposes 
Parkin dependent ubiquitylation and proteasomal degradation of its substrate 
TOM20, I have not obtained any data suggesting that USP15 or USP8 may 
be involved.  
 
It is worth mentioning that the major function of USP8 lies in the 
deubiquitylation of endosomal cargos, including growth factor receptors and 
the stabilization of the endosomal ESCRT-0 machinery (Clague and Urbe 
2006, Clague et al. 2012). Depletion of USP8 has been shown to affect 
multiple trafficking pathways (Row et al. 2006, Row et al. 2007, Bowers et al. 
2006, MacDonald et al. 2014). In particular, Macdonald and colleagues 
recently showed that lysosomal enzymes are mis-sorted in USP8 depleted 
cells, leading to their secretion instead of deposition in the lysosomes. 
Therefore, it is possible that USP8 depletion may affect autophagic 
degradation by affecting the biogenesis and functionality of lysosomes 
(MacDonald et al. 2014).  
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Overall, my data suggest that high levels of Parkin may be just as bad as not 
having enough Parkin. This should be taken into consideration in future 
therapeutic approaches to treat PD. The identification of USP30 as a DUB 
that opposes the degradation of Parkin-mediated substrates as well as its 
anti-apoptotic role suggest that USP30 may be a potential drug target not 
only for PD, but also for combinatorial anti-cancer therapies. 
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Appendices  
Supplementary table 1 DUB siRNA oligo sequences used for DUB screen. 
Gene  Plate Id Product Id siRNA Target Sequence 
Ro
w Col 
ATXN3 oligo 1 SI00071113 TACGATGGGATCATTATTTCA H 5 
ATXN3 oligo 2 SI00071134 TGCGTCGGTTGTAGGACTAAA H 5 
ATXN3 oligo 3 SI05185068 CTGCTGCAGGTAAACTCTATA H 5 
ATXN3 oligo 4 SI05185075 ATGGATATATATGTGACCCTA H 5 
ATXN3L oligo 1 SI05002795 CAAGGAGACATTCAGCAATTA H 6 
ATXN3L oligo 2 SI05002802 CTGTGTGATTATACTGTAGGA H 6 
ATXN3L oligo 3 SI03027290 AACAAGTTCGAGAGCAATTGA H 6 
ATXN3L oligo 4 SI03052833 CAACACTGGTTTACTATTAGA H 6 
BAP1 oligo 1 SI00066696 CAGCAGCTGATAAGAGTAACA A 4 
BAP1 oligo 2 SI00066703 CTCAATTCCTCTGTCCATCAA A 4 
BAP1 oligo 3 SI00066710 CCCGCTGGTGCTGGAAGCAAA A 4 
BAP1 oligo 4 SI03036390 AAGGTGAACCGTCAGACAGTA A 4 
BRCC3 oligo 1 SI03109456 TACGACGTTCTGATAAGAGGA G 5 
BRCC3 oligo 2 SI00136136 TACGATGTTGATTATAACATT G 5 
BRCC3 oligo 3 SI00136143 CAGATTGAGATGAATTTGCAA G 5 
BRCC3 oligo 4 SI00136150 CAGCATTTGCAGGAATTACAA G 5 
C14orf28 oligo 1 SI00319739 AAGAGATCAAAGCATCAATTA H 10 
C14orf28 oligo 2 SI04230786 CACCTGATTGCATGAACTGAA H 10 
C14orf28 oligo 3 SI04305301 AGCAGCGCACAATTAATATAA H 10 
C14orf28 oligo 4 SI04333497 CCCTACCTCACTATAATCCAA H 10 
COPS5 oligo 1 SI05031488 AAGGTGCTCTGAAGTGTCCTA G 6 
COPS5 oligo 2 SI05031495 CTGAGAAGTACTTTACCTGAA G 6 
COPS5 oligo 3 SI00092274 TAGGACATACCCAAAGGGCTA G 6 
COPS5 oligo 4 SI03030832 AAGAACAATATCCGCAGGGAA G 6 
COPS6 oligo 1 SI00092204 CCCAACCTTATAAACATGATA G 7 
COPS6 oligo 2 SI05079354 AAACATGATAATTGACTACTT G 7 
COPS6 oligo 3 SI00092225 CCCGGTGCTCAGCACAGACAA G 7 
COPS6 oligo 4 SI03081169 CCGCGTCAAGCTCATCTTGGA G 7 
CYLD oligo 1 SI00110082 AAGGGTAGAACCTTTGCTAAA F 1 
CYLD oligo 2 SI00110089 AAAGAACGATGTAGAATATTA F 1 
CYLD oligo 3 SI00110096 AAGGTTCATCCAGTCATAATA F 1 
CYLD oligo 4 SI03056949 CACCAAGATGCCCAATACCAA F 1 
EIF3F oligo 1 SI05017635 CAGTTGTGTGTGACTCTAATA G 9 
EIF3F oligo 2 SI05017642 CACACTGAGATAGTCAGTTGT G 9 
EIF3F oligo 3 SI00055482 TACGCGTACTACGACACTGAA G 9 
EIF3F oligo 4 SI02631811 CACAATGAGTCAGAAGATGAA G 9 
EIF3H oligo 1 SI00300111 GCGGAGCCTTCGCCATGTAAA G 8 
EIF3H oligo 2 SI05062911 AACAGTGTCTTTCTAGCCATA G 8 
EIF3H oligo 3 SI05062918 CACAGAGGATTTCTTTAGTGT G 8 
EIF3H oligo 4 SI04341379 ATGCGGAGCCTTCGCCATGTA G 8 
FAM105B oligo 1 SI03130897 AAGCGGAAGCATACGGGAATA H 9 
FAM105B oligo 2 SI04193392 GGGCATCAGAACCGAGATTAA H 9 
FAM105B oligo 3 SI04221196 CTGAGGACGATCGGCACTATA H 9 
FAM105B oligo 4 SI04330046 AACATCGATCAGTACAAGGAA H 9 
JOSD1 oligo 1 SI03099908 CTGGTGGTACCAGAAGAGGTA H 7 
JOSD1 oligo 2 SI05098051 TGGGATATGCAAAGACGCTTA H 7 
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JOSD1 oligo 3 SI05098058 CAGCGTTGGGTGAGGAAAGTA H 7 
JOSD1 oligo 4 SI02640988 CAACCTCGACTCCAAACTCAA H 7 
JOSD2 oligo 1 SI03075541 CCAGGTGGACGGTGTCTACTA H 8 
JOSD2 oligo 2 SI00150528 CTGCCGCTGCTGCCTCAATAA H 8 
JOSD2 oligo 3 SI00150535 CTGGGAAAGGCCAGCACTTCA H 8 
JOSD2 oligo 4 SI02648009 ACCGGCAACTATGATGTCAAT H 8 
MPND oligo 1 SI02779231 TCAGGTAATAAAGAAACGGAA H 2 
MPND oligo 2 SI02779238 CCGGATGGGCTCAGGTAATAA H 2 
MPND oligo 3 SI00144760 ACGGAGTGAGGTCGTGGGTTA H 2 
MPND oligo 4 SI00144767 CACCTACCTCGACAAGCTTAA H 2 
MYSM1 oligo 1 SI04166358 TATAATCGAAATAATCCCTTA H 4 
MYSM1 oligo 2 SI04170803 AAGACCGGCCATAATCTTCAA H 4 
MYSM1 oligo 3 SI04332846 TGGGATGATTGTTAGTCCCTA H 4 
MYSM1 oligo 4 SI04371409 GAGGCGGATGTGGATATCGAA H 4 
OTUB1 oligo 1 SI00676039 CAGCAGGACCGAATTCAGCAA F 3 
OTUB1 oligo 2 SI00676053 CACTACGATATCCTCTACAAA F 3 
OTUB1 oligo 3 SI00676060 CTGCCAGGCGCTAGACATGTA F 3 
OTUB1 oligo 4 SI04168038 CTCCGACTACCTTGTGGTCTA F 3 
OTUB2 oligo 1 SI03246775 CAGGGAGATCTTCAAGTTCAA F 4 
OTUB2 oligo 2 SI05031740 CAGATGGCCTATTGAGGTCAA F 4 
OTUB2 oligo 3 SI00676074 CAGCCGATAAACATTGATTAA F 4 
OTUB2 oligo 4 SI04250064 AAGGTTCACCGCCATCCGCAA F 4 
OTUD1 oligo 1 SI00676109 AACGGACACTATGATGCTGTA G 4 
OTUD1 oligo 2 SI00676116 ACGAAGAACTTGCCAAATCTA G 4 
OTUD1 oligo 3 SI05150075 CACCCTGGGAATAATTGCATA G 4 
OTUD1 oligo 4 SI05150082 CTGGTGTACCTTCATCTATGA G 4 
OTUD3 oligo 1 SI00453838 CTGGGTCAGCATAGAATGCTA F 8 
OTUD3 oligo 2 SI00488299 TTGAATGTAGTGATTCATCAA F 8 
OTUD3 oligo 3 SI03215821 GACAGTGGACTACATGATAAA F 8 
OTUD3 oligo 4 SI04189934 CAGAAGCGAAGCAGAGGCGAA F 8 
OTUD4 oligo 1 SI00442785 CTGTATGAGAAGGTATTTAAA F 7 
OTUD4 oligo 2 SI05134976 TAGATGCATATTTGTAGAATA F 7 
OTUD4 oligo 3 SI05134983 GTGCCATACAAGGAAAGTTAA F 7 
OTUD4 oligo 4 SI04278610 CAGAGAGAAATTTGAAGCGTT F 7 
OTUD5 oligo 1 SI00368445 CAGGCCGGCTTGGACAATGAA G 3 
OTUD5 oligo 2 SI04153982 TACCACCTACATTAACAGGAA G 3 
OTUD5 oligo 3 SI04245283 TGCCGACTACTTCTCCAACTA G 3 
OTUD5 oligo 4 SI04303754 CCCATTCGTGTTAGCTACCAT G 3 
OTUD6A oligo 1 SI00442792 CAAGACGACAGTAGCATTGAA G 2 
OTUD6A oligo 2 SI04177866 CTACGACGACTTCATGATCTA G 2 
OTUD6A oligo 3 SI04201785 AGGCCCAGATCCGGAGCTTAA G 2 
OTUD6A oligo 4 SI04268285 AAGAGTGAACAGCAGCGCATA G 2 
OTUD6B oligo 1 SI00344939 AGGGTCATTGATAGCAAGTAA G 1 
OTUD6B oligo 2 SI04172420 TTCGGTTACACGGTTGGTAAA G 1 
OTUD6B oligo 3 SI04185034 AAGGAGCGAGAAGAACGGATA G 1 
OTUD6B oligo 4 SI04233915 CAGACCGCTGAGTATATGCAA G 1 
OTUD7A oligo 1 SI04167408 CACGCCGTCGCCCACAGACAA F 6 
OTUD7A oligo 2 SI04211242 CCACGTGGCAAGTGAATGCAA F 6 
OTUD7A oligo 3 SI04298658 CGGGACCTGGTGTTACGGAAA F 6 
OTUD7A oligo 4 SI04349338 CCGCGATTCGGTGTGCAGCAA F 6 
OTUD7B oligo 1 SI04184383 AACCCATCCCTTGGAACGTAA F 5 
OTUD7B oligo 2 SI04210850 ATCCGTTTGTTTAGATGGGAA F 5 
OTUD7B oligo 3 SI04291308 ACCGAGTGGCTGATTCCTATA F 5 
OTUD7B oligo 4 SI00764862 CAGGATGACATCGTTCAAGAA F 5 
PAN2 oligo 1 SI04987066 ACAGATGGTGCTATTAATTGA E 10 
PAN2 oligo 2 SI04987073 TAGAATTGACCCAGATGGAAA E 10 
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PAN2 oligo 3 SI04192237 AAGGTGCTCAAGGGTCTTTAT E 10 
PAN2 oligo 4 SI04196101 AGCCGATATCTTTCATGTGAA E 10 
PRPF8 oligo 1 SI00088543 ACGGGCATGTATCGATACAAA G 12 
PRPF8 oligo 2 SI00088550 ATGGCTTGTCATCCTGAATAA G 12 
PRPF8 oligo 3 SI00088557 CAACGTCGTCATCAACTATAA G 12 
PRPF8 oligo 4 SI03089135 CTCATCGTGGACCACAACATA G 12 
PSMD14 oligo 1 SI00081396 CAGGCATTAATTCATGGACTA G 11 
PSMD14 oligo 2 SI05071101 AAGATCCCATTTAATATTTGA G 11 
PSMD14 oligo 3 SI00081410 TTGGATACTGTCGTATTTAAA G 11 
PSMD14 oligo 4 SI00081417 ACAGACATTATTACTCCATTA G 11 
PSMD7 oligo 1 SI00301483 AAGAATAGTTGGCTGGTACCA G 10 
PSMD7 oligo 2 SI00043596 CCGAATCGGCAAGGTTGGAAA G 10 
PSMD7 oligo 3 SI05062484 GTGGTGCTACGTGGAAGTGAA G 10 
PSMD7 oligo 4 SI05062491 CAGGCTTCAGATTGTATGAGA G 10 
STAMBP oligo 1 SI05008465 CAGAAATTAAGTAGCTCAGAA H 1 
STAMBP oligo 2 SI05008472 AGAAATTAAGTTACTCAGAAA H 1 
STAMBP oligo 3 SI03034717 AAGGAGATTGCATTTCCCAAA H 1 
STAMBP oligo 4 SI03037720 ACAGAGGGTAGCACAACAGAA H 1 
STAMBPL1 oligo 1 SI00127869 CAGGCTGTTCAGTATATGCAA H 3 
STAMBPL1 oligo 2 SI00127876 CCCAAATACTATGGCCAGATA H 3 
STAMBPL1 oligo 3 SI00127883 AACCATCGAGATTACCAGCAA H 3 
STAMBPL1 oligo 4 SI00127890 ACCGTCAACATCAGACACCTA H 3 
TNFAIP3 oligo 1 SI00086989 CCGAGCTGTTCCACTTGTTAA F 12 
TNFAIP3 oligo 2 SI05018608 CACGATGCTCAGGTTTGGTAA F 12 
TNFAIP3 oligo 3 SI00087003 CAGATGTATGGCTAACCGGAA F 12 
TNFAIP3 oligo 4 SI00087010 CTCGGCTATGACAGCCATCAT F 12 
UCHL1 oligo 1 SI00060648 CACGCAGTGGCCAATAATCAA A 1 
UCHL1 oligo 2 SI00060655 CTCCGCGAAGATGCAGCTCAA A 1 
UCHL1 oligo 3 SI00060669 CAGCCACACCCAGGCACTTAA A 1 
UCHL1 oligo 4 SI03030230 AACGTGGATGGCCACCTCTAT A 1 
UCHL3 oligo 1 SI00083545 CAGGGACAAGATGTTACATCA A 2 
UCHL3 oligo 2 SI00083552 TAGAAGTTTGCAAGAAGTTTA A 2 
UCHL3 oligo 3 SI00083559 CTGGCAATTCGTTGATGTATA A 2 
UCHL3 oligo 4 SI03077655 CCCGAGGTCACCAACCAGTTT A 2 
UCHL5 oligo 1 SI05707898 TGCAATCATGTTTGATGGTTA A 3 
UCHL5 oligo 2 SI05707905 TAGAGGATAGTATAACAGGAA A 3 
UCHL5 oligo 3 SI05707912 AACAGACAAACTGGATAGTTA A 3 
UCHL5 oligo 4 SI05707919 CAGAACTTCTCTAGTACTGAA A 3 
USP1 oligo 1 SI04346041 ACAGGCATTAATATTAGTGGA A 5 
USP1 oligo 2 SI04362631 AACCCTATGTATGAAGGATAT A 5 
USP1 oligo 3 SI05099507 CTGCACGATCTGTATATAGTA A 5 
USP1 oligo 4 SI05099514 AACTTAGAGGTGTGACCTTAA A 5 
USP10 oligo 1 SI00302113 AACACAGCTTCTGTTGACTCT B 3 
USP10 oligo 2 SI00072989 TCGCTTTGGATGGAAGTTCTA B 3 
USP10 oligo 3 SI00073003 AAGGGAACTGGTGCTACATTA B 3 
USP10 oligo 4 SI00073010 CAGCTTTGTTCGGCTAATGAA B 3 
USP11 oligo 1 SI02780813 CTGCGTCGGGTACGTGATGAA B 4 
USP11 oligo 2 SI02781156 ACCGATTCTATTGGCCTAGTA B 4 
USP11 oligo 3 SI04437573 AAGCGTTACTATGACGAGGTA B 4 
USP11 oligo 4 SI05127381 CCGCTTCTCTTATTCGTGTTA B 4 
USP12 oligo 1 SI02758224 CCGATCATGGTAGTTGATTTA B 5 
USP12 oligo 2 SI00162512 AAGAAGTTCATCACAAGATTA B 5 
USP12 oligo 3 SI00162526 ATGGATCAACTTCATCGATAT B 5 
USP12 oligo 4 SI00162533 TCACAAGATTACGGAAAGAAA B 5 
USP13 oligo 1 SI00058093 TCGCTTATGAACTAACGAGAA B 6 
USP13 oligo 2 SI05052250 AGACATGTGGATAACGTTATA B 6 
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USP13 oligo 3 SI00058100 AGCGACGATTATGAATATGAA B 6 
USP13 oligo 4 SI03061968 CACTACGAGCAACGAATAATA B 6 
USP14 oligo 1 SI00072961 CAGAGTTGAAATGCCTTTCAA B 7 
USP14 oligo 2 SI00072968 CCCATCCTTTGCCTTATCTAA B 7 
USP14 oligo 3 SI00072975 CCGCTCTACTCCGTTACTGTA B 7 
USP14 oligo 4 SI00072982 TGGCTTCAGCGCAGTATATTA B 7 
USP15 oligo 1 SI00087353 ATGAATAATGTTGTAACTCGA B 8 
USP15 oligo 2 SI00087360 TATGTCGGAATTCTTAATTAA B 8 
USP15 oligo 3 SI00087367 AAGATGATACCAGGCATATAA B 8 
USP15 oligo 4 SI03072909 CAGTCGATACATGAGAGACAA B 8 
USP16 oligo 1 SI05021191 AATGGCTGAAATAACGATAAA B 9 
USP16 oligo 2 SI05021198 AACATTAAATACATGCCAGAA B 9 
USP16 oligo 3 SI04171412 CCAGTGCTTAGAGAACTACTA B 9 
USP16 oligo 4 SI00758135 CAAGGAGAAGTAAATATTAAA B 9 
USP17 oligo 1 SI04389847 TGGAAATTCCTTCAAGAGCAA B 10 
USP17 oligo 2 SI04389854 CCCGACGTACTTGTGATTCAT B 10 
USP17 oligo 3 SI04389861 ATGAAGAACCATCATCCTGAA B 10 
USP17 oligo 4 SI04389868 CACAGGCAACAAGATTGCCAA B 10 
USP17L2 oligo 1 SI04192174 AGCAGGTAGATCATCACTCTA B 12 
USP17L2 oligo 2 SI00374738 GACGTACTTGTGATTCATCAA B 12 
USP17L2 oligo 3 SI03130624 AAGCCTGAGTTCAACGTCAGA B 12 
USP17L2 oligo 4 SI04157237 CGCCGGCCTCCAAGACGTTAA B 12 
USP17L6P oligo 1 SI03660657 GCCCTTGGCTCTGAAGACTAA B 11 
USP17L6P oligo 2 SI03660664 AGCAGGTAGATCATCACTCTA B 11 
USP17L6P oligo 3 SI03660671 TGGGAAATACCTGCTACGTGA B 11 
USP17L6P oligo 4 SI03660678 CGCCGGCCTCCAAGACGTTAA B 11 
USP18 oligo 1 SI00118034 TAAGCGCTTCCTGGAAGTGAA C 1 
USP18 oligo 2 SI05112051 CAGGTCCTGATCAGTCAGAAT C 1 
USP18 oligo 3 SI00118041 AAGATGGAGTGCTAATGGAAA C 1 
USP18 oligo 4 SI03022915 TTCGCTTTCCATTCAGTGGAA C 1 
USP19 oligo 1 SI00758163 TTCAGTGGTGGTGCACGTGTA C 2 
USP19 oligo 2 SI00758170 AACGTGTTCTATCCTCTGGTA C 2 
USP19 oligo 3 SI00758177 CACGAGGACCTGAATCGCATT C 2 
USP19 oligo 4 SI00758184 CTGGCGTGACAAGATCAATGA C 2 
USP2 oligo 1 SI03246698 CAGATTGTGGTTACTGTTCTA A 6 
USP2 oligo 2 SI03247034 CAGGAGAATGGCACACTTTCA A 6 
USP2 oligo 3 SI05094292 ATGGAATTTAGTTGCCTCCAA A 6 
USP2 oligo 4 SI05094299 CTCCAAGAATTGTGCCTTATA A 6 
USP20 oligo 1 SI00090965 CCGGATGATGAAACAGGGATA C 3 
USP20 oligo 2 SI00090972 CAGGCTTGTTGAAACGACCAA C 3 
USP20 oligo 3 SI00090979 ACCGTCGTACGTGCTCAAGAA C 3 
USP20 oligo 4 SI00090986 TCGAGTGACACGGATGAGAAA C 3 
USP21 oligo 1 SI05043465 GAAGCCCTTTAAACACCCTTA C 4 
USP21 oligo 2 SI00100632 CAACCTAATGTGGAAACGTTA C 4 
USP21 oligo 3 SI00100639 GCGGCTACACCTTGAAATCAA C 4 
USP21 oligo 4 SI03072650 CAGTACAAAGATTCCCTCGAA C 4 
USP22 oligo 1 SI03246705 AAGGTGAATTTCATAAATGTA C 5 
USP22 oligo 2 SI03247041 CTGAGTTTATACAGAAATTTA C 5 
USP22 oligo 3 SI00758219 AAGAAGCATATTCACGAGCAT C 5 
USP22 oligo 4 SI00758226 CAGGACTACATCTATGACAAA C 5 
USP24 oligo 1 SI05013610 TGGGTCTAGATGAGAACCCTA C 6 
USP24 oligo 2 SI03031770 AAGAGCAATCAGGAAGCAGTA C 6 
USP24 oligo 3 SI03038399 ACCACAGAGTAATGTCTCTAA C 6 
USP24 oligo 4 SI03058790 CACCGTGTATATTATACGCTT C 6 
USP25 oligo 1 SI03246845 CAAGAGGAGTTTAATAAAGAA C 7 
USP25 oligo 2 SI05013995 CAGCACTGTGTACGATACATA C 7 
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USP25 oligo 3 SI05014002 TTCCATGACTACAGCCATTTA C 7 
USP25 oligo 4 SI04156264 CTGGCAATGATAGATACATCA C 7 
USP26 oligo 1 SI04219453 TACGATGATATGCGGGTGTTA C 8 
USP26 oligo 2 SI04259962 CAGCTTAATAGCAAGGAGGTA C 8 
USP26 oligo 3 SI04346328 AAGATTATCAATAATCGGAGA C 8 
USP26 oligo 4 SI04358186 AACCGTTAGCTCACTTAATGA C 8 
USP27X oligo 1 SI00528122 CAGAATGAATGGACAATTGCA C 9 
USP27X oligo 2 SI00528129 CAGTCTGATGTCACCTGTCAA C 9 
USP27X oligo 3 SI05147898 TACAACTGGCATCGAGATCTA C 9 
USP27X oligo 4 SI05147905 CAGGCCTCAGCTAAGAGTATA C 9 
USP28 oligo 1 SI03246712 AAGGATTAGGTGGGCACATAA C 10 
USP28 oligo 2 SI03247048 CTACAAGAGATTAGAAATATA C 10 
USP28 oligo 3 SI04294759 GAGCGTTGGTTTACAAAGCTA C 10 
USP28 oligo 4 SI04149775 ATGAAGGTGGCTCAAGCGAAA C 10 
USP29 oligo 1 SI05115285 AGCAATCAGATGGAGATTCTA C 11 
USP29 oligo 2 SI04154633 AAGAATAACGAGCAAGTTTAT C 11 
USP29 oligo 3 SI04233131 CAGCTAGGGACTGATTAGAAA C 11 
USP29 oligo 4 SI04241503 CTCAAGGTAGAACCTAATAAT C 11 
USP3 oligo 1 SI00089432 AGCGCTCTAAGAATCAAGAAA A 7 
USP3 oligo 2 SI00089439 CTGGATCGGATAAACTTTAAT A 7 
USP3 oligo 3 SI00089446 CAGAAGTAAGCGCTCTAAGAA A 7 
USP3 oligo 4 SI03071432 CAGGGCGGTTTCAACGGTGTT A 7 
USP30 oligo 1 SI00758394 CACACCAGTATTTATCCTTAA C 12 
USP30 oligo 2 SI03122714 AACAAATTACCTGCCGCACAA C 12 
USP30 oligo 3 SI04286044 CTCCGATGACACTGTCCGCAA C 12 
USP30 oligo 4 SI04287920 CTCACGAATTATTCCATGTCA C 12 
USP31 oligo 1 SI00758415 CCCGAAATATTTAGGCCTGAA D 1 
USP31 oligo 2 SI00758422 CCGAGTTCATGAAGACCTCAA D 1 
USP31 oligo 3 SI00758429 GAGCGTCATCATCAGCCTCAA D 1 
USP31 oligo 4 SI03058272 CACCGAGCTCTTCGCCGAGTA D 1 
USP32 oligo 1 SI05015605 TACAAGCTCTCCGATAGAGAA D 2 
USP32 oligo 2 SI05015612 TAGAGTTTACCATAATCATAA D 2 
USP32 oligo 3 SI03021592 TTCACGAATATCTATCTCAAA D 2 
USP32 oligo 4 SI03023538 TTGAAGTTCGCAACAAAGATA D 2 
USP33 oligo 1 SI05031180 TTGATCTAGGATAAAGATGAA D 3 
USP33 oligo 2 SI05031187 CTGACAATTATCAGAGTTATA D 3 
USP33 oligo 3 SI00109130 CTGCAAGTAGTGGACACTATA D 3 
USP33 oligo 4 SI00109137 AAGAATTCCTTCGATGTTTAA D 3 
USP34 oligo 1 SI05022507 CTCTGCTTGAATGGCAAGATA D 4 
USP34 oligo 2 SI00758450 CTGGATTGAGTCAGATAACAA D 4 
USP34 oligo 3 SI00758464 AAGCCTAGATCTTGCATTTAA D 4 
USP34 oligo 4 SI03042795 AGCAGTGATAATAGCGATACA D 4 
USP35 oligo 1 SI05068924 CAGATATGGAAGTAAGACCTA D 5 
USP35 oligo 2 SI00758478 CCCTTCTAACTTCTAACCGAA D 5 
USP35 oligo 3 SI03022530 TTCCTTCGAATCTGTCAGCAA D 5 
USP35 oligo 4 SI03054373 CAAGGACTTGATGGAAGCCAT D 5 
USP36 oligo 1 SI00138068 TCCGTATATGTCCCAGAATAA D 6 
USP36 oligo 2 SI00138075 CCCGAGTGTGATTCCAGATCA D 6 
USP36 oligo 3 SI00138082 CAAGAGCGTCTCGGACACCTA D 6 
USP36 oligo 4 SI00138089 CCGCATCGAGATGCCATGCAT D 6 
USP37 oligo 1 SI05080026 AAGCAGCTTATGAAACCATAT D 7 
USP37 oligo 2 SI04191873 AAGGATTTACTCAAGAAGGTT D 7 
USP37 oligo 3 SI04196262 ATGGTCCTATCAGAATTCGAA D 7 
USP37 oligo 4 SI04337690 CTCGGACGATTCCTTCTTTGA D 7 
USP38 oligo 1 SI00143612 CAGCATAGTACTAATGGTTTA D 8 
USP38 oligo 2 SI00143619 CAGGAAGTAGCTAGTAAAGCA D 8 
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USP38 oligo 3 SI00143626 ATGGGTAATTGCACTCCTGAA D 8 
USP38 oligo 4 SI00143633 CTGGTCTTATTAACCTAGGAA D 8 
USP39 oligo 1 SI04131869 ACCAAGTTGCCTCCATATCTA D 9 
USP39 oligo 2 SI04157615 CCCGTACCTGGACACCATTAA D 9 
USP39 oligo 3 SI04188513 CAGGCTCTATCTAATGTTCCT D 9 
USP39 oligo 4 SI04226278 CTGGAACCCTCGAAATTTCAA D 9 
USP4 oligo 1 SI00051247 ACCGAGGCGTGGAATAAACTA A 8 
USP4 oligo 2 SI05110952 CTCCGTTGAGTCATCTTGTAA A 8 
USP4 oligo 3 SI00051261 TAGATGAATTAAGACGGTTAA A 8 
USP4 oligo 4 SI02630964 CAGGCAGACCTTGCAGTCAAA A 8 
USP40 oligo 1 SI05100144 CTCAGCGTAATGAAATATTAA D 10 
USP40 oligo 2 SI04161717 AAGGTTCGAATCATCCCTTTA D 10 
USP40 oligo 3 SI04310152 ATGGTGTTTGATATTCGAATT D 10 
USP40 oligo 4 SI04328324 AAAGTCGGCCAAATTACGTAA D 10 
USP41 oligo 1 SI05646774 CAGCCAGATCCTTCCAATGAA D 11 
USP41 oligo 2 SI05646781 CCGGAGTGCTGTGGATGGAAA D 11 
USP41 oligo 3 SI05646788 GCCCAGGGAGTTATCAAGCAA D 11 
USP41 oligo 4 SI05646795 TACGTGCATCCTTGTGTACAT D 11 
USP42 oligo 1 SI05099976 CTGCGTGGTGCTTCTTTAGTA D 12 
USP42 oligo 2 SI05099983 TACCGTGTATATAAATCCCAT D 12 
USP42 oligo 3 SI00758618 TTGGAGGATACCTAAGATCTA D 12 
USP42 oligo 4 SI03048920 ATCTTGATATTCGGCCATATA D 12 
USP43 oligo 1 SI05100690 CCCAAGGTCCATATAACCCAA E 1 
USP43 oligo 2 SI05100697 CCCGTTGTCTTGTAATCTCTA E 1 
USP43 oligo 3 SI00758646 CACCTTTCAGAGAGTCAAATA E 1 
USP43 oligo 4 SI03041836 ACGGTGGAACCGCTTCGAGAA E 1 
USP44 oligo 1 SI05069393 TTGGTCACTAATAGTCTTTCA E 2 
USP44 oligo 2 SI00142268 TTGCATGTGACAACAAATCAA E 2 
USP44 oligo 3 SI00142275 ACGGCAGGAATTGGAGTATCA E 2 
USP44 oligo 4 SI03091473 CTCGCTCAGTCGACCATAATA E 2 
USP45 oligo 1 SI02779273 CAGGAAATTATCGGAACATAA E 3 
USP45 oligo 2 SI02779280 CGGGTGAAAGATCCAACTAAA E 3 
USP45 oligo 3 SI03067988 CAGCTAGTACTTACTTCTGAT E 3 
USP45 oligo 4 SI03071320 CAGGGCCATCTAGTGGTATAT E 3 
USP46 oligo 1 SI02778685 TAGGGAAATGTTTGTACTATA E 4 
USP46 oligo 2 SI04916660 CAGGTTGTCAATTACACGGAT E 4 
USP46 oligo 3 SI04934860 TCCATGAAACTTACGCAGTAA E 4 
USP46 oligo 4 SI00134729 CAGCACGGCATTGTTCCTTAT E 4 
USP47 oligo 1 SI00758716 CAGGATGCTCATAGCTTAATA E 5 
USP47 oligo 2 SI04203262 AGGATTAAACTGAATGATCGA E 5 
USP47 oligo 3 SI04322080 TGGCGTCAAGTCAACATATAT E 5 
USP47 oligo 4 SI04355183 TGGATCGGCATGCAAATACAA E 5 
USP48 oligo 1 SI02779091 ACCAGATGCGTTGGTCCATAA E 6 
USP48 oligo 2 SI04387257 AAGGAACTCATTGCTCTCGAA E 6 
USP48 oligo 3 SI04387264 AAGATCTAGCAGAACCTTCTA E 6 
USP48 oligo 4 SI05001381 CAACACGTAACCGAAGCAATA E 6 
USP49 oligo 1 SI00635068 TCCAGTCAATATCCCACTTAA E 7 
USP49 oligo 2 SI05071997 CAGGACCTAGGCCCTGTGCAA E 7 
USP49 oligo 3 SI05072004 TACCTAGAGGGAAATTACATA E 7 
USP49 oligo 4 SI04195821 CTGGAATTCCCTGAACGCTAT E 7 
USP5 oligo 1 SI00052416 ACCGACGATCCGGGTCCCTAA A 9 
USP5 oligo 2 SI00052423 TACGTCTGCCACATCAAGAAA A 9 
USP5 oligo 3 SI00052430 AGCGAGGAGAAGTTTGAATTA A 9 
USP5 oligo 4 SI03076717 CCCAGCGAGTTGACTACATCA A 9 
USP50 oligo 1 SI00758751 CAGCTCAATTATAGCATCGTA E 8 
USP50 oligo 2 SI05131546 CAGCATCTGGTGGTAGAGTTT E 8 
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USP50 oligo 3 SI00758758 CCCGGAGAAGATCATATGAGA E 8 
USP50 oligo 4 SI03069038 CAGGAAGTGGATTACCACTGA E 8 
USP51 oligo 1 SI05065431 GACAGCTAGTATCTTGATATA E 9 
USP51 oligo 2 SI00758786 GAGGACTTACTCTACAGTGAA E 9 
USP51 oligo 3 SI00758793 CCAGAGACTAGGAAACGTAAA E 9 
USP51 oligo 4 SI00758800 AGGCCTGAGAGGGCTAATCAA E 9 
USP53 oligo 1 SI04133283 TTGTACTATGCTGGTAAACTA E 11 
USP53 oligo 2 SI04197487 CAGATTACGACAAGCAACCTA E 11 
USP53 oligo 3 SI04247614 ACCGAGGTTGGAAACCTATGA E 11 
USP53 oligo 4 SI04282103 CTTCGTCCTGTTAAAGATAAA E 11 
USP54 oligo 1 SI05088692 CTGGATACTAGCCATTCCTTA E 12 
USP54 oligo 2 SI00758870 CAGGGTGCAATCCTCAACTAA E 12 
USP54 oligo 3 SI04170460 CAGCAGAGCCCTAGTCGATAA E 12 
USP54 oligo 4 SI04198236 AAGGGATGTTTGCACCTCGAA E 12 
USP6 oligo 1 SI00064512 CCCAGGATCGTGATAACTGTA A 10 
USP6 oligo 2 SI00064519 TGCGGAGAGGTTCACAACAAA A 10 
USP6 oligo 3 SI02633442 GCGGAAGGACATACTTATGAA A 10 
USP6 oligo 4 SI03032715 AAGCACAGTAGCAAACTCATA A 10 
USP7 oligo 1 SI00052276 CGGGCCGACACCAGTACATAA A 11 
USP7 oligo 2 SI05082133 TAGAATTTCGTTAAAGTGGAA A 11 
USP7 oligo 3 SI00052283 ATGGAGTTGCGTGGGATTCAA A 11 
USP7 oligo 4 SI00052290 CCCAAATTATTCCGCGGCAAA A 11 
USP8 oligo 1 SI00073017 CAGGGTCAATTCAAATCTACA A 12 
USP8 oligo 2 SI00073024 AAGGCTCGTATTCATGCAGAA A 12 
USP8 oligo 3 SI00073031 CAGGTTCAGGCAAGCCATTTA A 12 
USP8 oligo 4 SI03103604 GAGGATACAGACGATACCGAA A 12 
USP9X oligo 1 SI00066584 CCGCCAGATAGCACAACGATA B 1 
USP9X oligo 2 SI00066598 CAGCTAGTATTTAGCCCAAAT B 1 
USP9X oligo 3 SI00066605 CCGCCTGCAGTGGAAAGTGTA B 1 
USP9X oligo 4 SI03101973 GACGATGTATTCTCAATCGTA B 1 
USP9Y oligo 1 SI00066640 ATGACTGGTCCTAATCTGTAA B 2 
USP9Y oligo 2 SI00066647 AACCGATTGCAATATAGTTTA B 2 
USP9Y oligo 3 SI00066654 CACTAAGGTCTTATAGTCCAA B 2 
USP9Y oligo 4 SI03067827 CAGCGTTGGATGCACTTAGTA B 2 
USPL1 oligo 1 SI03156776 CAAGACCAATTTGTGGACATA F 2 
USPL1 oligo 2 SI03181640 CCAGGGACTGATATAGGGATA F 2 
USPL1 oligo 3 SI04251058 AAGGTATAAACCAGAAGGCCA F 2 
USPL1 oligo 4 SI04342625 ATGCCTGCGTTAGAACATTAA F 2 
VCPIP1 oligo 1 SI00759521 CCCGATGATTATACTCCTGTA F 10 
VCPIP1 oligo 2 SI04141543 TACCAGAAGCTTTCCCTATTA F 10 
VCPIP1 oligo 3 SI04227510 CAGGGACAGACTTTAGTAATA F 10 
VCPIP1 oligo 4 SI04327190 CAGCTCCGGTAGAAACCATTA F 10 
YOD1 oligo 1 SI02809576 ATAAGCTATGGTAACCCTAAA F 11 
YOD1 oligo 2 SI02809590 GACCGTCAAATTAGAGCTTTA F 11 
YOD1 oligo 3 SI04270091 CAGCGTAACTTCCCTGATCCA F 11 
YOD1 oligo 4 SI04277420 AAACTGGTATAGGCTATGTAA F 11 
ZRANB1 oligo 1 SI00118846 CAGATCTGTAATGACCCTAAA F 9 
ZRANB1 oligo 2 SI00118853 CAAGGGTGAAATCTTCGTATA F 9 
ZRANB1 oligo 3 SI00118860 CACATATTCTTAGACGACCAA F 9 
ZRANB1 oligo 4 SI00118867 TAGGATAATTCAATGTCGAAA F 9 
DUB siRNA oligos were purchased from Qiagen. Four individual siRNA oligos were 
used to target each DUB. The row and column sections encode the coordinate of 
each of the DUB siRNA in a 96-well plate.
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Supplementary videos are in the CD attached with this thesis.  
Supplementary Video 1. Depletion of PINK1 protects Parkin-overexpressing 
cells from CCCP-induced cell death. hTERT-RPE1-YFP-Parkin cells were 
transfected for 72 hours with either non-targeting (NT1) or PINK1-targeting siRNA 
(40 nM). Cells were treated with CCCP (10µM) and imaged in the presence of the 
membrane impermeable dye DRAQ7 (pink. YFP-Parkin is shown in grey. Frames 
were collected every 30 min interval and saved for playback at 3 frames/sec. 
Supplementary Video 2. Z-VAD-FMK treatment inhibits CCCP-induced cell 
death. hTERT-RPE1-YFP-Parkin cells were treated with CCCP (10µM) in the 
absence or presence of Z-VAD-FMK (20µM) and imaged in the presence of the 
membrane impermeable dye DRAQ7 (pink). YFP-Parkin is shown in grey. Frames 
were collected every 30 min interval and saved for playback at 3 frames/sec. 
Supplementary Video 3. siRNA-mediated depletion of USP30 enhances CCCP- 
induced cell death. hTERT-RPE1-YFP-Parkin cells were transfected for 72 hrs 
with either non-targeting siRNA (NT1, see also Supplementary Movie 2) or USP30- 
targeting siRNA (D1 and D3, 40 nM). Cells were treated with CCCP (10µM) and 
imaged in the presence of the membrane impermeable dye DRAQ7 (pink). YFP- 
Parkin is shown in grey. Frames were collected every 30 min interval and saved for 
playback at 3 frames/sec. 
Supplementary Video 4. USP30 depletion sensitizes Parkin-overexpressing 
cells to cell death induced by the BH3-mimetic ABT-263. hTERT-RPE1-YFP-
Parkin cells were transfected for 72 hrs with either non-targeting siRNA (NT1) or 
USP30-targeting siRNA (D1 and D3, 40 nM). Cells were then treated with ABT-263 
(10µM). Cells were imaged in the presence of the membrane impermeable dye 
DRAQ7 (pink). YFP-Parkin is shown in grey. Frames were collected every 30 min 
interval and saved for playback at 3 frames/sec. 
Supplementary Video 5. USP30 depletion sensitizes Parkin-overexpressing 
cells to cell death induced by the BH3-mimetic ABT-737. hTERT-RPE1-YFP-
Parkin cells were transfected for 72 hrs with either non-targeting siRNA (NT1) or 
USP30-targeting siRNA (D1 and D3, 40 nM). Cells were then treated with ABT-737 
(10µM). Cells were imaged in the presence of the membrane impermeable dye 
DRAQ7 (pink). YFP-Parkin is shown in grey. Frames were collected every 30 min 
interval and saved for playback at 3 frames/sec. 
